

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	533	(514/231.2,546/121,544/11,544/253).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/11/28 07:56
L2	8	l1 and TGF	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/11/28 07:56

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS	6	JUL 16	CAPLUS enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPLUS patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPLUS enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPLUS enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPLUS enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPLUS coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:36:15 ON 28 NOV 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:36:29 ON 28 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 NOV 2007 HIGHEST RN 956075-61-9

DICTIONARY FILE UPDATES: 27 NOV 2007 HIGHEST RN 956075-61-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524577.str



```

chain nodes :
11 12 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-11 9-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 8-11 9-12
exact bonds :
6-9 8-9
isolated ring systems :
containing 1 :
```

G1:C,H,X,Cy,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom  
12:Atom 14:CLASS 15:CLASS




L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,H,X,Cy,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:36:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3534 TO ITERATE

56.6% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 67115 TO 74245

PROJECTED ANSWERS: 1593 TO 2859

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:36:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 70227 TO ITERATE

100.0% PROCESSED 70227 ITERATIONS

2354 ANSWERS

SEARCH TIME: 00.00.01

L3 2354 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 07:36:53 ON 28 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Nov 2007 VOL 147 ISS 23  
FILE LAST UPDATED: 27 Nov 2007 (20071127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full  
L4 93 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:907613 CAPLUS

DOCUMENT NUMBER: 147:269261

TITLE: Methods and compositions using adenosine A1 receptor antagonists for treating disorders associated with increased bone turnover and osteopenia  
INVENTOR(S): Cronstein, Bruce N.; Kara, Firas Mohamed  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 53pp.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007191279	A1	20070816	US 2007-705689	20070213
WO 2007095161	A2	20070823	WO 2007-US3656	20070213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LX, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-773176P P 20060214

AB The invention provides methods and compns. for modulating osteoclastogenesis and for treating bone diseases characterized by bone loss or a decrease in bone mass or d., by administering a compound or agent that modulates the adenosine A1 receptor, in particular, an inhibitor or antagonist of the A1 receptor.

IT 131185-37-0, FK838 171050-45-6, FR166124

171050-45-6D, FR166124, analogs


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(adenosine A1 receptor antagonist for treatment of bone disease, and use with other agents)

RN 131185-37-0 CAPLUS


CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171050-45-6 CAPLUS


CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)

L4 ANSWER 1 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 171050-45-6 CAPLUS

CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:675680 CAPLUS

DOCUMENT NUMBER: 147:64572

TITLE: Control of intraocular pressure using ALK5 modulation agents

INVENTOR(S): Fleenor, Debra L.; Pang, Iok-Hou; Shepard, Allan R.; Hellberg, Mark R.; Clark, Abbot F.; Klimko, Peter G.  
PATENT ASSIGNEE(S): Alcon, Inc., Switz.  
SOURCE: PCT Int. Appl., 31pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070866	A2	20070621	WO 2006-US62151	20061215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LX, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2007142376 A1 20070621 US 2006-611312 20061215

PRIORITY APPLN. INFO.: US 2005-751130P P 20051216

AB The invention discloses an ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity. The invention also discloses a method for treating glaucoma and controlling intraocular pressure, comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.

IT 676344-72-2 942044-99-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(ALK5 modulators for control of intraocular pressure and treatment of glaucoma)

RN 676344-72-2 CAPLUS


CN 1-Propanamine, N,N-dimethyl-3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 942044-99-7 CAPLUS

L4 ANSWER 2 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 2-Pyridinidine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN  
ACCESSION NUMBER: 2007:644426 CAPLUS  
DOCUMENT NUMBER: 147:72788  
TITLE: Preparation of 3-(pyrimidin-4-yl)pyrazolo[1,5-  
a]pyridines as ErbB kinase inhibitors for treating  
neoplasm  
INVENTOR(S): Uheling, David Edward; Hubbard, Robert Dale; Waterson,  
Alex Gregory; Petrov, Kimberly; Bifulco, Neil, Jr.;  
Wilson, Joseph Wendell; Badiang, Jennifer Gabriel;  
Cheung, Muir Yamabe, Mariko  
PATENT ASSIGNEE(S): Smithline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 2005pp.  
CODEN: PIXX2D  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007067506	A2	20070614	WO 2006-0546316	20061204
WO 2007067506	A3	20070616		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SI, SM, SN, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BG, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  
PRIORITY APPL. INFO.: US 2005-742351P P 20051205  
OTHER SOURCE(S): MARPAT 147:72788  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1] = (R1a): a = 0-3; each R1 = independently alk(en)yl, (un)substituted (hetero)aryl, etc.; A = (hetero)aryl, heterocyclyl; R9 = alk(en)ylene, cycloalkylene; Y1 = CO, NHCO, CS, NHCS; R2' = (R2b); R2'' = (R2c); each b, c = independently 0-2; each R2 = independently halo, alkyl, CN, NO2, etc.; R3' = (R3d); d = 0-2; each R3 = independently halo, alk(en)yl, aryl, arylaminocarbonyl, etc.; R4 = (R4e); e = 0-1; each R4 = independently alk(en)ylene; B = (hetero)aryl; Z' = (Z1g); g = 0-4; Z = (Alk)n-(Alk)p-(R5)q; m, n, p = independently 0-1; each Alk = independently alk(en)ylene; Y2 = O, CO, SO, NH, etc.; q = 1-2; R5 = independently CN, NO2, halo, aryl, aryl, etc. and their pharmaceutically acceptable salts, and solvates were prepared as ErbB kinase inhibitors for treating cancer. Thus, acylation of 3-ethynylaniline with trifluoroacetic acid anhydride, Sonogashira coupling of 2,4-dichloropyrimidine with the alkyne, cyclization with N-aminopyridine iodide, amination of the chloride with 5-(3-aminophenyl)oxazole, and cleavage of trifluoroacetyl group gave pyrimidine 11. Selected I showed inhibitory activity vs. EGFR or ErbB-2 protein tyrosine kinases with a pIC50 > 7. Selected I showed


L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
[(Dimethylamino)methyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(3-pyridinyl)acetamide 941318-75-9P, N-[3-[3-[2-[[3-[(Dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-pyridinyl)acetamide 941318-76-9P, N-[3-[3-[2-[[3-[(Dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(3-methyl-5-oxazolyl)acetamide 941318-78-1P, N-[3-[3-[2-[[3-[(Dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(5-methyl-1,3-thiazol-4-yl)acetamide 941318-79-2P, N-[3-[4-Fluoro-3-[2-[(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-81-6P, N-[3-[3-[2-[[3-[(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-82-7P, N-[3-[4-Fluoro-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-83-8P, N-[3-[6-Fluoro-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-85-0P, N-[3-[3-[2-[[3-[(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-86-1P, N-[3-[6-Fluoro-3-[2-[(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-87-2P, N-[5-[3-[2-[[3-[(Dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-89-7P, N-[5-[3-[2-[[3-[(Dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-90-7P, N-[5-[3-[2-[[3-[(Dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-91-8P, N-[5-[3-[2-[[3-[(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-92-9P, N-[3-[3-[2-[[3-[(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-94-1P, N-[3-[3-[2-[[3-[(Dimethylamino)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-95-2P, N-[3-[3-[2-[[3-[[2-(Methylsulfonyl)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-97-4P, N-[3-[3-[2-[[3-[(Aminomethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-99-6P, N-[3-[3-[2-[[3-[(Aminomethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(3-thienyl)acetamide 941319-02-4P, N-[3-[3-[2-[[4-Chloro-3-[2-[(1-pyrrolidinyl)methyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-05-7P, N-[3-[3-[2-[[4-Chloro-3-[2-[(dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-07-9P, N-[3-[3-[2-[[4-Chloro-3-[2-[(methyl(1-methyl-3-pyrrolidinyl)amino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-09-1P, N-[3-[3-[2-[[4-(Methoxy)-3-[4-(2-methylsulfonyl)ethyl]-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-14-8P, N-[5-[3-[2-[[2-[(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide 941319-16-0P, N-[2-Methoxy-5-[3-[2-[[2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl]amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-17-1P, N-[4-[3-[2-[[3-[(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-phenylacetamide 941319-19-3P, N-[3-[3-[2-[[3-[(4-Methyl-1,3-oxazol-5-

L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
antiproliferative activity of less than 100 nM in at least one of BT474, HNS and Colo205 tumor cell lines. I are useful in the treatment of diseases assocd. with inappropriate ErbB family kinase activity.  
IT 895638-09-2P, 2,6-Difluoro-N-[3-[3-[5-fluoro-2-[(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 941318-34-9P, N-[3-[3-[2-[[3-[(1,3-Oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-37-2P, N-[3-[3-[2-[[3-[(Dimethylamino)propyl]amino]-3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-40-7P, 2-Phenyl-N-[3-[3-[2-[(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-44-1P, 2-(2,5-Difluorophenyl)-N-[3-[3-[2-[(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-45-2P, N-[3-[3-[2-[[3-[(Dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-48-5P, N-[3-[3-[2-[[2-Methyl-1,2,3,4-tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-49-6P, N-[3-[3-[2-[[3-[(Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-50-9P, N-[3-[3-[2-[[3-[(1-Pyrrolidinyl)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-52-1P, N-[3-[3-[2-[[3-[(4-Morpholinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-54-3P, N-[3-[3-[2-[[3-[(Dimethylamino)propyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-56-5P, N-[3-[3-[2-[[3-[(1-Pyrrolidinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-58-7P, N-[3-[3-[2-[[3-[(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-60-1P, N-[3-[3-[2-[[3-[(2-Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-62-3P, N-[3-[3-[2-[[1,2,3,4-Tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-64-5P, N-[3-[3-[2-[[3-[(1,3-Oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(3-thienyl)acetamide 941318-66-7P, 2-(1H-Indol-3-yl)-N-[3-[3-[2-[[3-[(1,3-oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-67-8P, 2-(3-Methyl-5-oxazolyl)-N-[3-[3-[2-[[3-[(1,3-oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-68-9P, 2-(2,6-Difluorophenyl)-N-[3-[3-[2-[[3-[(1,3-oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-69-0P, N-[3-[3-[2-[[3-[(1,3-Oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(3-pyridinyl)acetamide 941318-70-3P, N-[3-[3-[2-[[3-[(3-Oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(4-pyridinyl)acetamide 941318-71-4P, N-[3-[3-[2-[[3-[(1,3-Oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-pyridinyl)acetamide 941318-72-5P, N-[3-[3-[2-[[3-[(Dimethylamino)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(3-thienyl)acetamide 941318-73-6P, 2-(2,6-Difluorophenyl)-N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-74-7P, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-75-9P, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-23-9P, N-[3-[3-[2-[[2-Amino-3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-25-1P, N-[3-[3-[2-[[7-Amino-5,6,7,8-tetrahydro-2-naphthalenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-27-3P, N-[2-Methyl-5-[3-[2-[[3-[(1-Pyrrolidinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-34-2P, N-[5-[3-[2-[[5-[(2-(Dimethylamino)ethyl]oxy)-2-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methylphenyl]-2-(2-thienyl)acetamide 941319-36-4P, N-[5-[3-[2-[[3-[[2-(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methylphenyl]-2-(2-thienyl)acetamide 941319-38-6P, N-[2-Methyl-5-[3-[2-[[2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-39-7P, N-[5-[3-[2-[[3-[[2-(Dimethylamino)ethyl]oxy]-2-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2-(2-thienyl)acetamide 941319-43-3P, N-[2-Fluoro-5-[3-[2-[[3-[(1-Pyrrolidinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-44-4P, N-[5-[3-[2-[[5-[(2-(Dimethylamino)ethyl]oxy)-2-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2-(2-thienyl)acetamide 941319-45-5P, N-[2-Fluoro-5-[3-[2-[[2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-46-6P, N-[5-[3-[2-[[3-[[2-(Dimethylamino)ethyl]oxy]-2-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide 941319-48-8P, N-[5-[3-[2-[[3-[[2-(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide 941319-50-2P, N-[3-[3-[2-[[3-[[2-(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]-6-methoxy]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-phenyl-2-propenamide 941319-55-7P 941319-56-8P, 1-[3-[3-[2-[[3-[(2-Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]-6-methoxy]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-(1-pyrrolidinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-57-9P, N-[3-[6-Methyl-3-[2-[[3-[(1-pyrrolidinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-61-5P, N-[3-[3-[2-[[3-[(2-Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]-6-methoxy]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941319-62-6P, N-[3-[3-[2-[[4-(4-Acetyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-6-methoxy]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; prepn. of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)  
RN 895638-09-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[[1,2,3,4-tetrahydro-2-methyl-

L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
7-isoquinoliny]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-  
(CA INDEX NAME)




RN 941318-34-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-37-2 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(dimethylamino)propyl]amino]-3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 941318-40-7 CAPLUS  
CN Benzeneacetamide, N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-42-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-43-0 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 941318-44-1 CAPLUS  
CN Benzeneacetamide, 2,5-difluoro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-45-2 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-48-5 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 941318-49-6 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-50-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-52-1 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-54-3 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[3-(dimethylamino)propoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-56-5 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-58-7 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[2-(diethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-64-5 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[5-oxazolyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-66-7 CAPLUS  
CN 1H-Indole-3-acetamide, N-[3-[3-[2-[[3-[5-oxazolyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-67-8 CAPLUS  
CN 5-isoxazoleacetamide, 3-methyl-N-[3-[3-[2-[[3-[5-oxazolyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-60-1 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-62-3 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[2-(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-68-9 CAPLUS  
CN Benzeneacetamide, 2,6-difluoro-N-[3-[3-[2-[[3-[5-oxazolyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-69-0 CAPLUS  
CN 3-Pyridineacetamide, N-[3-[3-[2-[[3-[5-oxazolyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-70-3 CAPLUS  
CN 4-Pyridineacetamide, N-[3-[3-[2-[[3-[5-oxazolyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-71-4 CAPLUS  
CN 2-Pyridineacetamide, N-[3-[3-[2-[[3-(5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-72-5 CAPLUS  
CN 3-Thiopheneacetamide, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-73-6 CAPLUS  
CN Benzeneacetamide, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 941318-74-7 CAPLUS  
CN 3-Pyridineacetamide, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-75-8 CAPLUS  
CN 2-Pyridineacetamide, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-76-9 CAPLUS  
CN 5-Isoxazoleacetamide, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (CA INDEX NAME)




RN 941318-78-1 CAPLUS  
CN 4-Thiazoleacetamide, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-5-methyl-2-phenyl- (CA INDEX NAME)




RN 941318-79-2 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[4-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-1-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-81-6 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-82-7 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[4-fluoro-3-[2-[[3-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-83-8 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[6-fluoro-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-85-0 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[2-[(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-90-7 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]- (CA INDEX NAME)




RN 941318-91-8 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]- (CA INDEX NAME)




RN 941318-86-1 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[6-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 941318-87-2 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(3-[(dimethylamino)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]- (CA INDEX NAME)




RN 941318-92-9 CAPLUS  
CN 3-Thiopheneacetamide, N-[3-[3-[2-[(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-94-1 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)






RN 941318-95-2 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[(methylsulfonyl)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-97-4 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(aminomethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-99-6 CAPLUS  
CN 3-Thiopheneacetamide, N-[3-[3-[2-[[3-(aminomethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


RN 941319-07-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[4-chloro-3-[2-(methyl(1-methyl-3-pyrrolidinyl)amino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-09-1 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[4-methoxy-3-[2-(methylsulfonyl)ethyl]-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)





RN 941319-14-8 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[[3-(dimethylamino)ethyl]-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 941319-02-4 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[4-chloro-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-05-7 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[4-chloro-3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-16-0 CAPLUS  
CN 2-Thiopheneacetamide, N-[2-methoxy-5-[3-[2-[[1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-17-1 CAPLUS  
CN Benzeneacetamide, N-[4-[3-[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-19-3 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(4-methyl-5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 941319-22-8 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[(2-dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-23-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[(2-amino-2,3-dihydro-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-25-1 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[(7-amino-5,6,7,8-tetrahydro-2-naphthalenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


RN 941319-36-4 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 941319-38-6 CAPLUS  
CN 2-Thiopheneacetamide, N-[2-methyl-5-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)





RN 941319-39-7 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(3-[2-(dimethylamino)ethoxy]-2-methylphenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]- (CA INDEX NAME)




RN 941319-27-3 CAPLUS  
CN 2-Thiopheneacetamide, N-[2-methyl-5-[3-[2-[(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-34-2 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(5-[2-(dimethylamino)ethoxy]-2-methylphenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 941319-43-3 CAPLUS  
CN 2-Thiopheneacetamide, N-[2-fluoro-5-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-44-4 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(5-[2-(dimethylamino)ethoxy]-2-methylphenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]- (CA INDEX NAME)




RN 941319-45-5 CAPLUS  
CN 2-Thiopheneacetamide, N-[2-fluoro-5-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 941319-46-6 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(5-[2-(dimethylamino)ethoxy]-2-methylphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 941319-50-2 CAPLUS  
CN Cyclopropanecarboxamide, N-[3-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]-6-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-phenyl]- (CA INDEX NAME)




RN 941319-54-6 CAPLUS  
CN 2-Propenamide, N-[3-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]-6-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-phenyl-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 941319-48-8 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 941319-49-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[5-[3-[2-[(5-[2-(dimethylamino)ethoxy]-2-methylphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 941319-55-7 CAPLUS  
CN Urea, N-[3-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]-6-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-N'-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 941319-56-8 CAPLUS  
CN Urea, N-[3-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]-6-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-N'-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 941319-57-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[6-methyl-3-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-61-5 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((dimethylamino)methyl)phenyl]-2-pyrimidinamine 941318-53-2P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((4-morpholinyl)propyl)oxy]phenyl]-2-pyrimidinamine 941318-55-4P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((3-(dimethylamino)propyl)oxy)phenyl]-2-pyrimidinamine 941318-57-6P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((1-pyrrolidinyl)propyl)oxy]phenyl]-2-pyrimidinamine 941318-59-8P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((2-(diethylamino)ethyl)oxy)phenyl]-2-pyrimidinamine 941318-61-2P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((2-(dimethylamino)ethyl)oxy)phenyl]-2-pyrimidinamine 941318-63-4P, 2-(2-Thienyl)-N-[3-[3-[2-[[2-(trifluoroacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-65-6P, 2,2,2-Trifluoro-N-[3-[3-[2-[[3-(1,3-oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-80-5P, N-[3-[3-(2-Chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-84-9P, N-[3-[3-(2-Chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-88-3P 941318-89-4P, 4-[2-(3-Amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((dimethylamino)methyl)phenyl]-2-pyrimidinamine 941318-93-0P 941318-96-3P, 2,2,2-Trifluoro-N-[2-(methylsulfonyl)ethyl]-N-[3-[[4-[2-(3-(2-thienylacetyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]methyl]acetamide 941318-98-5P, 2,2,2-Trifluoro-N-[3-[[4-[2-(3-((2-thienylacetyl)amino)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]phenyl]methyl]acetamide 941319-00-2P, N-[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(3-thienyl)acetamide 941319-01-3P, 2,2,2-Trifluoro-N-[3-[[4-[2-(3-((thien-3-yl)acetyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]phenyl]methyl]acetamide 941319-03-5P 941319-04-6P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-chloro-3-[[2-(1-pyrrolidinyl)ethyl]oxy]phenyl]-2-pyrimidinamine 941319-06-8P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-chloro-3-[[2-(dimethylamino)ethyl]oxy]phenyl]-2-pyrimidinamine 941319-08-0P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-chloro-3-[[2-methyl(1-methyl-3-pyrrolidinyl)amino]ethyl]oxy]phenyl]-2-pyrimidinamine 941319-12-6P, 2,2,2-Trifluoro-N-[3-[3-[2-[[4-(methyloxy)-3-[4-[2-(methylsulfonyl)ethyl]-1-piperazinyl]phenyl]-2-pyrimidinamine 941319-15-9P, N-[5-[3-(2-Chloropyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide 941319-24-0P, 2,2,2-Trifluoro-N-[5-[[4-[2-(3-((2-thienylacetyl)amino]phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]-2,3-dihydro-1H-inden-2-yl]acetamide 941319-26-2P, 2,2,2-Trifluoro-N-[7-[[4-[2-(3-((2-thienylacetyl)amino]phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]-1,2,3,4-tetrahydro-2-naphthalenyl]acetamide 941319-31-9P 941319-32-0P, 5-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methylaniline 941319-33-1P, N-[5-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methylphenyl]-2-(2-thienyl)acetamide 941319-40-0P, 5-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluoroaniline 941319-41-1P, N-[5-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2-(2-thienyl)acetamide 941319-47-7P, 5-[3-(2-Chloro-4-


RN 941319-62-6 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[4-(4-acetyl-1-piperazinyl)phenyl]amino]-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




IT 895634-85-2P, 3-[2-(Methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895634-86-3P, 3-[2-(Methylsulfinyl)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895635-03-7P 895635-04-8P, 2,2,2-Trifluoro-N-[3-[3-[2-[[3-(fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895635-05-8P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(3-fluorophenyl)-2-pyrimidinamine 895635-70-8P, [3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amine 895636-50-7P 895636-51-8P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[[2-(1-pyrrolidinyl)ethyl]oxy]phenyl]-2-pyrimidinamine 895636-53-0P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-2-pyrimidinamine 895636-95-0P 895637-03-3P 895637-16-8P 895637-17-9P 895637-18-0P, 3-[3-(2-Chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]aniline 895637-24-8P, 3-[3-(2-Chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]aniline 895637-48-6P 895637-49-7P, [4-[2-(3-Amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl][2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amine 895637-51-1P 895637-52-2P, 4-[2-(3-Amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[[2-(dimethylamino)ethyl]oxy]phenyl]-2-pyrimidinamine 895637-73-7P, 2,2,2-Trifluoro-N-[3-[3-[2-[[2-(methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895637-74-8P, N-[4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-2-methyl-1,2,3,4-tetrahydro-7-isoquinolinamine 895637-97-5P 895638-05-8P, N-[4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-2-pyrimidinyl]-2-methyl-1,2,3,4-tetrahydro-7-isoquinolinamine 895638-07-0P 895638-08-1P, 2,2,2-Trifluoro-N-[3-[3-(5-fluoro-2-[(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 941318-35-0P, 3-[3-[2-[[3-(1,3-oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide monohydrochloride 941318-36-1P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((1,3-oxazol-5-yl)phenyl)-2-pyrimidinamine 941318-38-3P, N-[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide 941318-41-8P, 4-[2-(3-Nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-2-pyrimidinamine 941318-46-3P 941318-47-4P,

pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-(methyloxy)aniline 941319-51-3P 941319-53-5P, 4-[2-(3-Aminophenyl)-6-(methyloxy)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[[2-(dimethylamino)ethyl]oxy]phenyl]-2-pyrimidinamine 941319-58-0P 941319-59-1P, [3-[3-(2-Chloro-4-pyrimidinyl)-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]amine 941319-60-4P, N-[3-[3-(2-Chloro-4-pyrimidinyl)-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(2-thienyl)acetamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
intermediate, prepn. of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasia


RN 895634-85-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 895634-86-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylsulfinyl)-4-pyrimidinyl]-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 895635-03-7 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895635-04-8 CAPLUS  
CN Acetamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895635-05-9 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (CA INDEX NAME)




RN 895635-70-8 CAPLUS  
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 895636-95-0 CAPLUS  
CN Acetamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-03-3 CAPLUS  
CN Acetamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-16-8 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895636-50-7 CAPLUS  
CN Acetamide, N-[3-[3-[2-[(2-chloroethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895636-51-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 895636-53-0 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (CA INDEX NAME)




RN 895637-17-9 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-18-0 CAPLUS  
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 895637-24-8 CAPLUS  
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 895637-48-6 CAPLUS  
CN Acetamide, N-[5-[3-[2-[(2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-49-7 CAPLUS  
CN 1H-Indene-2,5-diamine, N5-[4-[2-(3-amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-2,3-dihydro-N2,N2-dimethyl- (CA INDEX NAME)




RN 895637-51-1 CAPLUS  
CN Acetamide, N-[5-[3-[2-[(3-(2-(dimethylamino)ethoxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-52-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 895637-73-7 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[3-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-74-8 CAPLUS  
CN 7-Isoquinolinamine, N-[4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-1,2,3,4-tetrahydro-2-methyl- (CA INDEX NAME)




RN 895637-97-5 CAPLUS  
CN Acetamide, N-[3-[3-[2-[(3-(3-chloropropoxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895638-05-8 CAPLUS  
CN 7-Isoquinolinamine, N-[4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-2-pyrimidinyl]-1,2,3,4-tetrahydro-2-methyl- (CA INDEX NAME)




RN 895638-07-0 CAPLUS  
CN Acetamide, N-[3-[3-[2-(2-chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895638-08-1 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[3-[3-[5-fluoro-2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-35-0 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[3-[3-[2-[(3-(5-oxazolyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 941318-36-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(5-oxazolyl)phenyl]- (CA INDEX NAME)



RN 941318-38-3 CAPLUS  
 CN 2-Thiopheneacetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-41-8 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (CA INDEX NAME)




RN 941318-46-3 CAPLUS  
 CN Acetamide, N-[3-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)


L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 941318-57-6 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(3-(1-pyrrolidinyl)propoxy)phenyl]- (CA INDEX NAME)




RN 941318-59-8 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(2-(diethylamino)ethoxy)phenyl]- (CA INDEX NAME)




RN 941318-61-2 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(2-(dimethylamino)ethoxy)phenyl]- (CA INDEX NAME)


L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 941318-47-4 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[(dimethylamino)methyl]phenyl]- (CA INDEX NAME)




RN 941318-53-2 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-morpholinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 941318-55-4 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(3-(dimethylamino)propoxy)phenyl]- (CA INDEX NAME)


L4 ANSWER 3 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 941318-63-4 CAPLUS  
 CN 2-Thiopheneacetamide, N-[3-[3-[2-[[1,2,3,4-tetrahydro-2-(2,2,2-trifluoroacetyl)-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-65-6 CAPLUS  
 CN Acetamide, 2,2,2-trifluoro-N-[3-[3-[2-[[3-(5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-80-5 CAPLUS  
 CN 2-Thiopheneacetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)





RN 941318-84-9 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-88-3 CAPLUS  
CN Acetamide, N-[5-[3-[2-[[3-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]- (CA INDEX NAME)




RN 941318-89-4 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[(dimethylamino)methyl]phenyl]- (CA INDEX NAME)




RN 941319-00-2 CAPLUS  
CN 3-Thiopheneacetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941319-01-3 CAPLUS  
CN 3-Thiopheneacetamide, N-[3-[3-[2-[[3-[(2,2,2-trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 941318-93-0 CAPLUS  
CN Acetamide, N-[3-[3-[2-[[3-[(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 941318-96-3 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[(2-(methylsulfonyl)ethyl] (2,2,2-trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 941318-98-5 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-[2-[[3-[(2,2,2-trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


RN 941319-03-5 CAPLUS  
CN Acetamide, N-[3-[3-[2-[[4-chloro-3-(2-chloroethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 941319-04-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-chloro-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)












RN 941319-06-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-chloro-3-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 941319-08-0 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-




CN1CCN(C1)COCc2ccc(Cl)cc2Nc3nc4c(nc5ccccc5n4)c6ccc(N)cc6COc1ccc(Nc2nc3ccccc3n2)cc1N4CCN(CC4)CCOC(=O)C(F)(F)FCOc1ccc(Nc2nc3ccccc3n2)cc1N4CCN(CC4)CCS(=O)(=O)C


RN 941319-51-3 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)





RN 941319-53-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)-6-methoxypyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 941319-58-0 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 941319-59-1 CAPLUS  
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-6-methylpyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 941319-60-4 CAPLUS  
CN 2-Thiopheneacetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



IT 941319-18-2, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-2-pyrimidinamine  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)


RN 941319-18-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-[[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



IT 941319-52-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)

RN 941319-52-4 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-4-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)


ACCESSION NUMBER: 2007:602630 CAPLUS  
DOCUMENT NUMBER: 147:211828  
TITLE: Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors  
AUTHOR(S): Alam, Mahbub; Beevers, Rebekah E.; Ceska, Tom; Davenport, Richard J.; Dickson, Karen M.; Fortunato, Marar; Gowers, Lewis; Haughan, Alan F.; James, Lynwen A.; Jones, Mark W.; Kinsella, Natasha; Lowe, Christopher; Meissner, Johannes W. G.; Nicolas, Anne-Lise; Perry, Benjamin C.; Phillips, David J.; Pitt, William R.; Platt, Adam; Ratcliffe, Andrew J.; Sharpe, Andrew; Tait, Laura J.  
CORPORATE SOURCE: UCB, Granta Park, Great Abington, Cambridge, CB21 6GS, UK  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(12), 3463-3467  
CODEN: BMCLEB; ISSN: 0960-894X  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB The development of a series of aminopyrimidines, e.g., I, as inhibitors of c-Jun N-terminal kinases is described. The synthesis, in vitro inhibitory values for JNK1, JNK2 and CDK2, and the in vitro inhibitory value for a c-Jun cellular assay were discussed.


IT 945016-61-5P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)

RN 945016-61-5 CAPLUS  
CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



L4 ANSWER 4 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 131185-56-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)  
 RN 131185-56-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(2-chloro-4-pyrimidinyl)-2-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:478006 CAPLUS  
 DOCUMENT NUMBER: 147:109062  
 TITLE: Pyrazolo[1,5-a]pyridine antiherpetic: Effects of the C3 substituent on antiviral activity  
 AUTHOR(S): Johns, Brian A.; Gudmundsson, Kristjan S.; Allen, Scott H.  
 CORPORATE SOURCE: Department of Medicinal Chemistry, Infectious Diseases CEOD, GlaxoSmithKline Research & Development, Research Triangle Park, NC, 27709-3398, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2858-2862  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A recently disclosed series of pyrazolo[1,5-a]pyridine inhibitors of herpes virus replication has been closely examined herein for effects of the C3 substituent on antiviral activity. Significant changes in activity are observed by alterations of the heteroatom basicity and orientation of the group at C3. These results in combination with previous studies have served to further elaborate the minimal pharmacophore required for potency of this novel series of antiviral agents. During the course of these studies, several novel synthetic approaches were developed and are described.


IT 942937-53-3P  
 RL: BYP (Byproduct); PREP (Preparation)  
 (pyrazolopyridine antiherpetic)  
 RN 942937-53-3 CAPLUS  
 CN 1(6H)-Pyridazinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)




IT 437612-24-3P 437612-25-4P 437612-26-5P  
 437612-80-1P 437613-02-0P 942937-35-1P  
 942937-40-8P 942937-42-0P 942937-44-2P  
 942937-46-4P 942937-48-6P 942937-57-7P  
 942937-83-9P 942937-85-1P 942937-95-3P  
 942938-00-3P 942938-02-5P 942938-04-7P  
 942938-06-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (pyrazolopyridine antiherpetic)  
 RN 437612-24-3 CAPLUS

L4 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 437612-25-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-26-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-hydrazinyl-4-pyridinyl)- (CA INDEX NAME)




RN 437612-80-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[6-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)


L4 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 437613-02-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)




RN 942937-35-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-azido-4-pyridinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 942937-40-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(3-pyridinyl)- (CA INDEX NAME)




RN 942937-42-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-fluoro-3-pyridinyl)- (CA INDEX NAME)




RN 942937-44-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-3-pyridinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)


RN 942937-57-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(4-pyridazinyl)- (CA INDEX NAME)




RN 942937-83-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(1H-pyrazol-3-yl)- (CA INDEX NAME)





RN 942937-85-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(4-isoxazolyl)- (CA INDEX NAME)




RN 942937-46-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(6-fluoro-3-pyridinyl)- (CA INDEX NAME)




RN 942937-48-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[6-(cyclopentylamino)-3-pyridinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 942937-95-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(4-amino-1H-pyrazol-3-yl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 942938-00-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-thiazolyl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 942938-02-5 CAPLUS


L4 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-1H-imidazol-5-yl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 942938-04-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-1H-imidazol-5-yl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 942938-06-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-methyl-4-oxazolyl)- (CA INDEX NAME)




L4 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 indol-5-yl)- (CA INDEX NAME)



RN 942937-75-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(3-furanyl)- (CA INDEX NAME)



RN 942937-77-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-furanyl)- (CA INDEX NAME)




RN 942937-79-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(1H-pyrazol-4-yl)- (CA INDEX NAME)

L4 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 437611-97-7, GW3733 437612-08-3 942937-68-0  
 942937-71-5 942937-75-9 942937-77-1  
 942937-79-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pyrazolopyridine antihypertensives)


RN 437611-97-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 437612-08-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 942937-68-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(3-aminophenyl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 942937-71-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(1H-

L4 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 437612-79-8P 468063-51-6P 942937-51-1P  
 942937-55-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (pyrazolopyridine antihypertensives)


RN 437612-79-8 CAPLUS  
 CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-51-6 CAPLUS  
 CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 942937-51-1 CAPLUS  
 CN 1(4H)-Pyridazinecarboxylic acid, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)




RN 942937-55-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridazinyl)-  
(CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2007:35679 CAPLUS  
DOCUMENT NUMBER: 146:330260  
TITLE: FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice  
AUTHOR(S): Ohori, Makoto; Takeuchi, Mikio; Maruki, Riyo; Nakajima, Hidenori; Miyake, Hiroshi  
CORPORATE SOURCE: Lead Discovery Research Labs, Astellas Pharma Inc., Tsukuba, 305-8585, Japan  
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (2007), 374(4), 311-316  
CODEN: NSAPCC; ISSN: 0028-1298  
PUBLISHER: Springer  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Extracellular signal-regulated kinase (ERK), a serine/threonine protein kinase of the mitogen-activated protein kinase superfamily, is activated by various stimuli in inflammatory cells. We recently described FR180204 (5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine), a novel selective ERK inhibitor. In this paper, we investigated the effect of FR180204 on collagen-induced arthritis (CIA) in DBA/1 mice, an animal model of rheumatoid arthritis (RA) mediated by type II collagen (CII)-reactive T cells and anti-CII antibodies. Preventive administration of FR180204 (100 mg/kg, i.p., b.i.d.) significantly ameliorated the clinical arthritis and body weight loss occurring in the CIA mice. Further, FR180204-treated mice showed a significant decrease in plasma anti-CII antibody levels (62%). FR180204 also attenuated delayed-type hypersensitivity in CII-immunized DBA/1 mice, an inflammatory response elicited by CII-reactive T cells, in a dose-dependent manner (52 and 62% inhibition at 32 and 100 mg/kg, resp.). Moreover, FR180204 inhibited in vitro CII-induced proliferation of lymph node cells prepared from CII-immunized mice, in which CII-specific T cells are known to undergo specific proliferation. In conclusion, our results suggest that ERK regulates both the cell-mediated and humoral immune responses in the development of CIA. ERK inhibitors may be useful as therapeutic reagents for the treatment of RA.  
IT 865362-74-9, FR 180204  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice)  
RN 865362-74-9 CAPLUS  
CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2006:952415 CAPLUS  
DOCUMENT NUMBER: 145:342443  
TITLE: Compositions comprising NEP inhibitors, endogenous endothelin inhibitors and diuretics for treatment of cardiovascular disease  
INVENTOR(S): Straub, Matthias; Witte, Klaus; Ziegler, Dieter; Fischer, Yvan  
PATENT ASSIGNEE(S): Solvay Pharmaceuticals GmbH, Germany  
SOURCE: U.S. Pat. Appl. Publ., 15pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006205625	A1	20060914	US 2006-356088	20060217
PRIORITY APPLN. INFO.:			US 2005-653956P	P 20050218
OTHER SOURCE(S): MARPAT 145:342443				

AB A novel combination therapy for cardiovascular diseases or conditions, including administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist. For example, capsule was formulated containing daglutril calcium 250 mg and hydrochlorothiazide 50 mg.  
IT 131185-37-0, FK-838 171050-45-6, FR-166124  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compos. comprising NEP inhibitors, endogenous endothelin inhibitors and diuretics for treatment of cardiovascular disease)  
RN 131185-37-0 CAPLUS  
CN 1-(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171050-45-6 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




L4 ANSWER 8 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:847629 CAPLUS  
DOCUMENT NUMBER: 145:278270  
TITLE: Pharmaceutical compositions comprising inhibitors of neutral endopeptidase and inhibitors of the endogenous endothelin and diuretics for the treatment of cardiovascular diseases  
INVENTOR(S): Witte, Klaus; Ziegler, Dieter; Straub, Matthias; Fischer, Yvan  
PATENT ASSIGNEE(S): Solvay Pharmaceuticals GmbH, Germany  
SOURCE: PCT Int. Appl., 39pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006087371	A1	20060824	WO 2006-EP60057	20060217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
AU 2006215583	A1	20060824	AU 2006-215583	20060217
CA 2596922	A1	20060824	CA 2006-2596922	20060217
EP 1853270	A1	20071114	EP 2006-708348	20060217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: EP 2005-101235 A 20050218 WO 2006-EP60057 W 20060217				

OTHER SOURCE(S): MARPAT 145:278270  
AB A novel combination therapy is described for cardiovascular diseases or conditions, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist. For example, capsules contained daglutril calcium, and hydrochlorothiazide, corn starch, lactose and Et acetate.  
IT 131185-37-0, FK 838 171050-45-6, FR 166124  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. comprising inhibitors of neutral endopeptidase and inhibitors of the endogenous endothelin and diuretics for the treatment of cardiovascular diseases)  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

L4 ANSWER 8 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 171050-45-6 CAPLUS  
CN 1-cyclohexene-1-acetic acid, 2-[(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2006:634999 CAPLUS  
DOCUMENT NUMBER: 145:103711  
TITLE: Preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm  
INVENTOR(S): Uehling, David Edward; Stevens, Kirk Lawrence; Dickerson, Scott Howard; Waterson, Alex Gregory; Harris, Philip Anthony; Sammond, Douglas McCord; Hubbard, Robert Dale; Emerson, Holly Kathleen; Wilson, Joseph W.  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 255 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006068826	A2	20060629	WO 2005-US44166	20051206
WO 2006068826	A3	20061005		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
EP 1828185	A2	20070905	EP 2005-853157	20051206
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
PRIORITY APPLN. INFO.: US 2004-637928P P 20041221 US 2005-709079P P 20050817 WO 2005-US44166 W 20051206				

OTHER SOURCE(S): MARPAT 145:103711  
GI

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)







IT 895636-34-7P 895636-35-8P  
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)  
RN 895636-34-7 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-, (+)- (CA INDEX NAME)

Rotation (+).

PAGE 1-A




L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
N-[3-[3-[2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895634-94-3P,  
N-[3-[3-[2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxybenzamide  
895634-96-5P 895635-68-4P, N-[3-[3-[2-[(1,2,3,4-tetrahydro-7-isoquinoliny]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-95-7P, N-[3-[3-[2-[(3-chloro-4-hydroxyphenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-68-7P, N-[3-[3-[2-[(2-chloro-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl-1H-pyrrole-2-carboxamide 895636-76-7P 895637-12-4P,  
2,6-Difluoro-N-[3-[3-[2-[(3-hydroxy-4-(methoxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895637-83-9P, 4-[2-[(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)-2-pyrimidinamine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; prepn. of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)  
RN 895634-90-9 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (CA INDEX NAME)



RN 895634-92-1 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


PAGE 2-A




RN 895636-35-8 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-, (-)- (CA INDEX NAME)

Rotation (-).

PAGE 1-A




PAGE 2-A




IT 895634-90-9P, 1-Methyl-1H-pyrrole-2-carboxylic acid  
N-[3-[3-[2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amide 895634-92-1P,


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 895634-94-3 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 895634-96-5 CAPLUS  
CN Benzamide, 2-chloro-N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-68-4 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(1,2,3,4-tetrahydro-7-isoquinoliny]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)






RN 895635-95-7 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(3-chloro-4-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-68-7 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (CA INDEX NAME)




RN 895636-76-7 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[7-(trifluoromethyl)-3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


yl]phenyl]benzamide 895634-97-6P, N-[3-[3-[2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]thiobenzamide 895634-98-7P, 2-Chloro-N-[3-[3-[2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]thiobenzamide 895634-99-8P, N-[3-[3-[2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxythiobenzamide 895635-00-4P, 1-Methyl-1H-pyrrole-2-carboxylic acid N-[3-[3-[2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amide 895635-01-5P, 2-Chloro-5-fluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-06-0P, 2-Fluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-07-1P, 2-Fluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-6-trifluoromethylbenzamide 895635-08-2P, 2,3-Difluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-09-3P, 4-Fluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-10-6P, N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-trifluoromethylbenzamide 895635-11-7P, 3-Fluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-12-8P, N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methylbenzamide 895635-13-9P, 2,4-Difluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-14-0P, 2-Chloro-4-fluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-15-1P, 2-Chloro-3,6-difluoro-N-[3-[3-[2-[(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-16-2P 895635-17-3P, N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide 895635-18-4P, N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-quinoxalinecarboxamide 895635-19-5P, N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-thiophenecarboxamide 895635-20-8P, N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl-1H-1,2,3-benzotriazole-5-carboxamide 895635-21-9P, 2,6-Difluoro-N-[3-[3-[2-[(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-23-1P 895635-26-4P, 2,6-Difluoro-N-[3-[3-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-27-5P, 2,6-Difluoro-N-[3-[3-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-28-6P, N-[3-[3-[2-[(3-Cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-31-1P, 2,6-Difluoro-N-[3-[3-[2-[(3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-32-2P, 2,6-Difluoro-N-[3-[3-[2-[(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-33-3P, 2,6-Difluoro-N-[3-[3-[2-[(1,3-oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-



RN 895637-12-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-hydroxy-4-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895637-83-9 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (CA INDEX NAME)



IT 895634-81-8P, 1-[3-[3-[2-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-phenylurea 895634-89-6P, 1-(2-Chlorophenyl)-3-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-

yl]phenyl]benzamide 895635-34-4P, N-[3-[3-[2-[(3-Acetylaminophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-35-5P, 2-Chloro-6-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3,5-dimethylisoxazole-4-carboxamide 895635-38-8P, 2,5-Difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-39-9P, 2,5-Difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-41-3P, N-[3-[3-[2-[(4-(3-(Dimethylamino)propyl)amino]-3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-43-5P, 2,6-Difluoro-N-[3-[3-[2-[(3-fluoro-4-[(3-(4-methyl-1-piperazinyl)propyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-45-7P, 2,5-Difluoro-N-[3-[3-[2-[(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-48-0P, 2,5-Difluoro-N-[3-[3-[2-[(3-(1,3-oxazol-5-yl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-49-1P, 2,5-Difluoro-N-[3-[3-[2-[(4-(4-morpholinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-50-4P, 2,5-Difluoro-N-[3-[3-[2-[(3-fluoro-4-(methoxyphenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-51-5P, N-[3-[3-[2-[(3-(Acetylaminophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluorobenzamide 895635-52-6P, N-[3-[3-[2-[(3-Cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluorobenzamide 895635-53-7P, 2,5-Difluoro-N-[3-[3-[2-[(2-oxo-1-pyrrolidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-55-9P, N-[3-[3-[2-[(4-[(Ethylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluorobenzamide 895635-56-0P, N-[3-[3-[2-[(3-(Aminomethyl)amino)-4-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluorobenzamide 895635-57-1P, 2,5-Difluoro-N-[3-[3-[2-[(4-(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-58-2P, 2,6-Difluoro-N-[3-[3-[2-[(3-[2-(4-morpholinyl)ethyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-59-3P, 2,6-Difluoro-N-[3-[3-[2-[(3-[2-(4-morpholinyl)ethyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-62-8P, 2,6-Difluoro-N-[3-[3-[2-[(4-[2-(4-methylphenyl)ethyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-63-9P, 2,6-Difluoro-N-[3-[3-[2-[(1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-64-0P, 2,6-Difluoro-N-[3-[3-[2-[(3-[(2-hydroxyethyl)sulfonyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-65-1P, 2,6-Difluoro-N-[3-[3-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-66-2P, 2,6-Difluoro-N-[3-[3-[2-[(4-morpholinyl)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-67-3P, N-[3-[3-[2-[(3-[(2-(Dimethylamino)ethyl)oxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-72-0P, N-[3-[3-[2-[(2-Methyl-1,2,3,4-tetrahydro-7-isquinolinyl)amino]-4-

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895635-73-1P, 2,6-Difluoro-N-[3-[3-[2-[(1,2,3,4-tetrahydro-7-  
isouquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895635-75-3P, 2,6-Difluoro-N-[3-[3-[2-[(6-  
isouquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895635-76-4P, N-[3-[3-[2-[(3-  
Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-  
pyridinecarboxamide 895635-77-5P, N-[3-[3-[2-[(3-  
Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]isoxazole-5-carboxamide 895635-78-6P,  
N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2-[(trifluoromethyl)oxy]benzamide 895635-79-7P,  
N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2-methoxybenzamide 895635-80-0P,  
2-Chloro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-3-methylbenzamide 895635-81-1P,  
3-Fluoro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2-methylbenzamide 895635-82-2P,  
2,6-Difluoro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-3-methylbenzamide 895635-83-3P,  
2-Chloro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-4-pyridinecarboxamide 895635-84-4P,  
6-Chloro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2-thiophenecarboxamide 895635-85-5P,  
N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-4-pyridinecarboxamide 895635-86-6P,  
N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-3-methyl-2-thiophenecarboxamide 895635-87-7P,  
3-Chloro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2-thiophenecarboxamide 895635-88-8P,  
3-Bromo-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2-thiophenecarboxamide 895635-89-9P,  
N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-3-thiophenecarboxamide 895635-90-2P,  
N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-1-methyl-1H-pyrrole-2-carboxamide 895635-91-3P,  
5-Fluoro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2-methylbenzamide 895635-92-4P,  
N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-1-methyl-1H-imidazole-5-carboxamide 895635-93-5P,  
2,6-Difluoro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]benzamide 895635-96-8P,  
N-[3-[3-[2-[(3-Chloro-4-(methyloxy)phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895635-97-9P, N-[3-[3-[2-[(3-Cyano-4-fluorophenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895635-98-0P, N-[3-[3-[2-[(3-Trifluoromethyl-4-chlorophenylamino)-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895635-99-1P, N-[3-[3-[2-[(3-Cyano-4-(pyrrol-1-yl)phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-00-7P, N-[3-[3-[2-[(4-Methyl-1-piperazinyl)phenyl]amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-01-8P, N-[3-[3-[2-[(4-Chlorophenylamino)-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-02-9P, N-[3-[3-[2-[(4-Cyanophenyl)phenyl]amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-03-0P, N-[3-[3-[2-[(4-(4-Pyridinyl)methyl]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-04-1P, N-[3-[3-[2-[(3-Methyl-4-cyanophenylamino)-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
morpholinyl]ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2,6-difluorobenzamide 895636-39-2P,  
N-[3-[3-[2-[(3-Chloro-4-[(2-dimethylamino)ethyl]oxy]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-41-6P 895636-42-7P, N-[3-[3-[2-[(3-[(4-Amino-2-  
fluorophenyl)oxy]propyl)-(methyloxy)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-43-8P,  
N-[3-[3-[2-[(4-[(3-(4-Amino-2-fluorophenyl)oxy]-3-fluorophenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-45-0P, 2,6-Difluoro-N-[3-[3-[2-[(3-fluoro-4-[(2-oxo-1-  
pyrrolidinyl)ethyl]oxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-  
2-yl]phenyl]benzamide 895636-47-2P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
fluoro-4-[(2-1-piperidinyl)ethyl]oxy]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-48-3P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
(methanesulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-  
2-yl]phenyl]benzamide 895636-49-4P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
[(2-1-pyrrolidinyl)ethyl]oxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]benzamide 895636-52-9P, Furan-2-carboxylic  
acid N-[3-[3-(2-phenylaminopyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]amide 895636-54-1P, N-[3-[3-(2-Phenylaminopyrimidin-4-  
yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]nicotinamide 895636-55-2P,  
N-[3-[3-(2-Phenylaminopyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-  
thiophenecarboxamide 895636-56-3P, N-[3-[3-(2-  
Phenylaminopyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-  
pyridinecarboxamide 895636-57-4P, 3-Methyl-N-[3-[3-[2-  
(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-58-5P, 4-Chloro-N-[3-[3-(2-phenylamino)-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-59-6P, 3-Amino-N-[3-[3-(2-phenylamino)-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-60-9P, 4-Amino-N-[3-[3-(2-phenylamino)-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-61-0P, 3-Methyl-N-[3-[3-(2-phenylamino)-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-thiophenecarboxamide  
895636-62-1P, 2,6-Difluoro-N-[3-[3-[2-[(3-fluoro-4-(1-  
piperidinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-64-3P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
fluoro-4-(1-pyrrolidinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]benzamide 895636-65-4P,  
N-[3-[3-(2-Phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-  
1-methyl-1H-pyrrole-2-carboxamide 895636-69-8P,  
N-[3-[3-[2-[(3-Cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-1-methyl-1H-pyrrole-2-carboxamide 895636-82-5P,  
N-[3-[3-(2-Phenylamino)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-83-6P,  
N-[3-[3-[2-[(3-Fluorophenylamino)-4-pyrimidinyl]-7-  
(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-84-7P, N-[3-[3-[2-[(3-Fluoro-4-methoxyphenyl)amino]-4-  
pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-  
difluorobenzamide 895636-85-8P, 2,6-Difluoro-N-[3-[7-methyl-3-[2-  
[(3-(trifluoromethyl)phenyl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-87-0P  
2,6-Difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]pyrimidin-4-yl]-7-  
methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895636-88-1P,  
2,6-Difluoro-N-[3-[3-[2-[(3-fluoro-4-methoxyphenyl)amino]pyrimidin-4-yl]-7-  
methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895636-89-2P,  
2,6-Difluoro-N-[3-[7-methoxy-3-[2-[(3-(trifluoromethyl)phenyl)amino]pyrimi-  
din-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895636-91-6P  
2,6-Difluoro-N-[2-(methyloxy)-5-[3-[2-[(1,2,3,4-tetrahydro-7-

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
895636-05-2P, N-[3-[3-[2-[(4-Anilino)phenylamino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-06-3P, N-[3-[3-[2-[(2,3-Dimethyl-6-quinoloxalyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-07-4P, 2,6-Difluoro-N-[3-[3-[2-[(4-  
(phenylcarbamoyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-08-5P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
fluoro-4-(4-morpholinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-  
2-yl]phenyl]benzamide 895636-09-6P, 2,6-Difluoro-N-[3-[3-[2-[(4-  
(4-morpholinyl)carbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]benzamide 895636-10-9P,  
2,6-Difluoro-N-[3-[3-[2-[(4-1H-pyrazol-3-yl)phenyl]amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-11-0P, 2,6-Difluoro-N-[3-[3-[2-[(4-  
(phenylacetyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-12-1P, N-[3-[3-[2-[(4-  
(Cyclopropylamino)carbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-13-2P,  
N-[3-[3-[2-[(4-(Aminocarbonyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-14-3P,  
N-[3-[3-[2-[(4-[(2-Dimethylamino)ethyl]oxy]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-15-4P, 2,6-Difluoro-N-[3-[3-[2-[(4-[(2-methyl-1-  
piperazinyl)ethyl]oxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-16-5P, N-[3-[3-[2-[(4-4-Ethyl-1-  
piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2,6-difluorobenzamide 895636-17-6P,  
N-[3-[3-[2-[(4-[(Dimethylamino)methyl]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-18-7P, 2,6-Difluoro-N-[3-[3-[2-[(3-(4-methyl-1-  
piperazinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-19-8P 895636-20-1P,  
2,6-Difluoro-N-[3-[3-[2-[(4-(methyloxy)-3-(1-piperazinyl)phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-21-2P, N-[3-[3-[2-[(4-[(3-Dimethylamino)propyl]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-22-3P 895636-23-4P, N-[3-[3-[2-[(3-Dihydro-1-  
benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-  
2,6-difluorobenzamide 895636-24-5P,  
2,6-Difluoro-N-[3-[3-[2-[(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]benzamide 895636-25-6P,  
2,6-Difluoro-N-[3-[3-[2-[(4-(methanesulfonyl)methyl]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-26-7P, N-[3-[3-[2-[(3-(Aminomethyl)phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-27-8P, N-[3-[3-[2-[(3-(2-Aminomethyl)ethyl]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-29-0P, 2,6-Difluoro-N-[3-[3-[2-[(3,4,5-  
trifluoromethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-30-3P, N-[3-[3-[2-[(5-(Ethylsulfonyl)-  
2-(methyloxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2,6-difluorobenzamide 895636-31-4P,  
2,6-Difluoro-N-[3-[3-[2-[(2-(methyloxy)-4-[(methanesulfonyl)methyl]phenyl)a-  
mino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895636-36-9P, N-[3-[3-[2-[(3-Chloro-4-[(2-  
(methyloxy)ethyl]oxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2,6-difluorobenzamide 895636-37-0P,  
N-[3-[3-[2-[(3-Chloro-4-[(3-dimethylamino)propyl]oxy]phenyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-38-1P, N-[3-[3-[2-[(3-Chloro-4-[(2-4-


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
isouquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895636-99-4P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
-[(1,2,3,4-tetrahydro-7-isouquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]benzamide 895637-06-6P,  
3-[(2-Chloro-4-[(4-2-3-[(2,6-difluorophenyl)carbonyl]amino)phenyl]pyraz-  
olo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]phenyl]oxy]-1-propanesulfonic  
acid 895637-07-7P, Methyl 4-[(2-chloro-4-[(4-2-3-[(2,6-  
difluorophenyl)carbonyl]amino)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-  
pyrimidinyl]amino]ethylbutanoate 895637-08-8P,  
N-[3-[3-[2-[(3-Chloro-4-[(2-(methanesulfonyl)amino)ethyl]oxy]phenyl]amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895637-09-9P, N-[3-[3-[2-[(3-Chloro-4-[(4-methyl-1-  
piperazinyl)propyl]oxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-  
2-yl]phenyl]-2,6-difluorobenzamide 895637-11-3P  
895637-13-5P, N-[3-[3-[2-[(3-[(2-Dimethylamino)ethyl]oxy)-4-  
(methyloxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-  
2,6-difluorobenzamide 895637-14-6P, N-[3-[3-[2-[(3-[(2-  
(Dimethylamino)ethyl]oxy]phenyl)amino]-4-pyrimidinyl]-4-fluoropyrazolo[1,5-  
a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895637-20-4P,  
2,6-Difluoro-N-[3-[4-fluoro-3-[2-[(2-methyl-1,2,3,4-tetrahydro-7-  
isouquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895637-21-5P, 2,6-Difluoro-N-[3-[4-fluoro-3-  
-[2-[(3-(1-pyrrolidinyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-  
a]pyridin-2-yl]phenyl]benzamide 895637-22-6P,  
N-[3-[3-[2-[(3-[(2-Dimethylamino)ethyl]oxy]phenyl)amino]-4-pyrimidinyl]-6-  
fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895637-25-9P, 2,6-Difluoro-N-[3-[6-fluoro-3-[2-[(3-[(1-  
pyrrolidinyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895637-26-0P, 2,6-Difluoro-N-[3-[6-fluoro-3-  
-[2-[(2-methyl-1,2,3,4-tetrahydro-7-isouquinolinyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895637-27-1P, N-[3-[3-[2-[(7-Amino-5,6,7,8-tetrahydro-2-  
naphthalenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-  
difluorobenzamide 895637-30-6P 895637-33-9P,  
N-[3-[3-[2-[(2-Dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895637-36-2P, N-[3-[3-[2-[(2-Amino-2,3-dihydro-1H-inden-5-  
yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-  
difluorobenzamide 895637-38-4P, 2,6-Difluoro-N-[3-[3-[2-[(3-4-  
methyl-1,3-oxazol-5-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-  
2-yl]phenyl]benzamide 895637-41-9P, 2,6-Difluoro-N-[3-[3-[2-  
[(2,4,4-trimethyl-1,2,3,4-tetrahydro-7-isouquinolinyl)amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide  
895637-42-0P, 2,6-Difluoro-N-[3-[3-[2-[(2-methyl-1,2,3,4-  
tetrahydro-7-isouquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895637-43-1P, N-[3-[3-[2-[(3-  
(Aminomethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2,6-difluorobenzamide 895637-47-5P  
895637-50-0P, N-[5-[3-[2-[(3-[(2-Dimethylamino)ethyl]oxy]phenyl)a-  
mino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-  
difluorobenzamide 895637-53-3P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
(methylanilino)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]benzamide 895637-56-6P, N-[3-[3-[2-[(3-  
(Aminomethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-  
yl]phenyl]-2,5-difluorobenzamide 895637-58-8P,  
N-[3-[3-[2-[(3-[(2-Dimethylamino)ethyl]amino)methyl]phenyl]amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895637-62-4P 895637-65-7P, 2,6-Difluoro-N-[3-[3-[2-[(3-  
[[2-(methanesulfonyl)ethyl]amino]amino]methyl]phenyl]amino]-4-  
pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide




L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-6-(trifluoromethyl)- (CA INDEX NAME)



RN 895635-08-2 CAPLUS  
 CN Benzamide, 2,3-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-09-3 CAPLUS  
 CN Benzamide, 4-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-10-6 CAPLUS


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Benzamide, 2,4-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-14-0 CAPLUS  
 CN Benzamide, 2-chloro-4-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-15-1 CAPLUS  
 CN Benzamide, 2-chloro-3,6-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Benzamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 895635-11-7 CAPLUS  
 CN Benzamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 895635-12-8 CAPLUS  
 CN Benzamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (CA INDEX NAME)




RN 895635-13-9 CAPLUS

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 895635-16-2 CAPLUS  
 CN 2-Pyridinecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-17-3 CAPLUS  
 CN 1H-Pyrazole-5-carboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1,3-dimethyl- (CA INDEX NAME)




RN 895635-18-4 CAPLUS  
 CN 2-Quinoxalinecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-19-5 CAPLUS  
 CN 2-Thiophenecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895635-20-8 CAPLUS  
CN 1H-Benzotriazole-5-carboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,3-dihydro-1-methyl- (CA INDEX NAME)




RN 895635-21-9 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-23-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-[(2S)-1-methyl-2-pyrrolidinylmethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




Absolute stereochemistry.



RN 895635-27-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-28-6 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[3-cyanophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895635-26-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


RN 895635-29-7 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(1H-benzotriazol-5-ylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-30-0 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895635-31-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-32-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (CA INDEX NAME)




RN 895635-33-3 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[[3-(5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (CA INDEX NAME)




RN 895635-34-4 CAPLUS  
CN Benzamide, N-[3-{3-[2-[[3-(acetylamino)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895635-38-8 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[3-{3-[2-[[3-(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (CA INDEX NAME)




RN 895635-39-9 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[3-{3-[2-[[3-(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-6-methyl- (CA INDEX NAME)




RN 895635-35-5 CAPLUS  
CN Benzamide, 2-chloro-6-fluoro-N-[3-{3-[2-[[3-(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (CA INDEX NAME)




RN 895635-37-7 CAPLUS  
CN 4-Isoxazolecarboxamide, N-[3-{3-[2-[[3-(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-3,5-dimethyl- (CA INDEX NAME)



RN 895635-41-3 CAPLUS  
CN Benzamide, N-[3-{3-[2-[[4-[[3-(dimethylamino)propyl]amino]-3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895635-43-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl- (CA INDEX NAME)




RN 895635-45-7 CAPLUS


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Benzamide, 2,5-difluoro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895635-48-0 CAPLUS  
 CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[3-(5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-49-1 CAPLUS  
 CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-50-4 CAPLUS  
 CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[3-(fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 895635-53-7 CAPLUS  
 CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[3-(2-oxo-1-pyrrolidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-54-8 CAPLUS  
 CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[4-(2-oxo-1-pyrrolidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 895635-51-5 CAPLUS  
 CN Benzamide, N-[3-[3-[2-[[3-(acetylamino)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (CA INDEX NAME)




RN 895635-52-6 CAPLUS  
 CN Benzamide, N-[3-[3-[2-[[3-(cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (CA INDEX NAME)

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 895635-55-9 CAPLUS  
 CN Benzamide, N-[3-[3-[2-[[4-[(ethylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (CA INDEX NAME)




RN 895635-56-0 CAPLUS  
 CN Benzamide, N-[3-[3-[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (CA INDEX NAME)




RN 895635-57-1 CAPLUS  
 CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-58-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-59-3 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[3-(4-morpholinyl)propyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)





RN 895635-62-8 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-66-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-67-3 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)



RN 895635-63-9 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-64-0 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(2-hydroxyethyl)sulfonyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-65-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(3-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


RN 895635-72-0 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[3-[2-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895635-73-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-75-3 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[2-(6-isoquinolinylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)






RN 895635-76-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-77-5 CAPLUS

CN 5-Isoxazolecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)





RN 895635-78-6 CAPLUS

CN Benzamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 895635-79-7 CAPLUS

CN Benzamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 895635-83-3 CAPLUS

CN 4-Pyridinecarboxamide, 2-chloro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-84-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-85-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-80-0 CAPLUS

CN Benzamide, 2-chloro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (CA INDEX NAME)





RN 895635-81-1 CAPLUS

CN Benzamide, 3-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-methyl- (CA INDEX NAME)




RN 895635-82-2 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (CA INDEX NAME)



RN 895635-86-6 CAPLUS


CN 2-Thiophenecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (CA INDEX NAME)




RN 895635-87-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)








RN 895635-88-8 CAPLUS  
CN 2-Thiophenecarboxamide, 3-bromo-N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895635-89-9 CAPLUS  
CN 3-Thiophenecarboxamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-93-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-isoxazolylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RN 895635-96-8 CAPLUS  
CN Benzamide, N-[3-{3-[2-[(3-chloro-4-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)


RN 895635-90-2 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (CA INDEX NAME)




RN 895635-91-3 CAPLUS  
CN Benzamide, 5-fluoro-N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-methyl- (CA INDEX NAME)




RN 895635-92-4 CAPLUS  
CN 1H-Imidazole-5-carboxamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (CA INDEX NAME)




RN 895635-97-9 CAPLUS  
CN Benzamide, N-[3-{3-[2-[(3-cyano-4-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895635-98-0 CAPLUS  
CN Benzamide, N-[3-{3-[2-[(4-chloro-3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895635-99-1 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[3-cyano-4-(1H-pyrrol-1-yl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-00-7 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-03-0 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(4-pyridinylmethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-04-1 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4-cyano-3-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-01-8 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4-chlorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-02-9 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4'-cyano[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-05-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(phenylamino)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)





RN 895636-06-3 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[2,3-dimethyl-6-quinoxalyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-07-4 CAPLUS  
CN Benamide, N-[3-[3-[2-[(4-benzoylphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)



RN 895636-08-5 CAPLUS  
CN Benamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluoro-4-(4-morpholinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-12-1 CAPLUS  
CN Benamide, N-[3-[3-[2-[(4-(cyclopropylamino)carbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-13-2 CAPLUS  
CN Benamide, N-[3-[3-[2-[(4-(aminocarbonyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)


RN 895636-09-6 CAPLUS  
CN Benamide, 2,6-difluoro-N-[3-[3-[2-[(4-(4-morpholinylcarbonyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-10-9 CAPLUS  
CN Benamide, 2,6-difluoro-N-[3-[3-[2-[(4-(1H-pyrazol-3-yl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-11-0 CAPLUS  
CN Benamide, 2,6-difluoro-N-[3-[3-[2-[(4-(phenylacetyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-14-3 CAPLUS  
CN Benamide, N-[3-[3-[2-[(4-(2-(dimethylamino)ethoxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)



RN 895636-15-4 CAPLUS  
CN Benamide, 2,6-difluoro-N-[3-[3-[2-[(4-(2-(4-methyl-1-piperazinyl)ethoxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-16-5 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-17-6 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4-(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)


RN 895636-20-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-methoxy-3-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-21-2 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4-(3-(dimethylamino)propyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-22-3 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[4-[(dimethylamino)acetyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-18-7 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-19-8 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[3-[[dimethylamino]acetyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895636-23-4 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[2,3-dihydro-1,4-benzodioxin-6-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-24-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-25-6 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895636-26-7 CAPLUS

CN Benzamide, N-[3-[3-[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-27-8 CAPLUS

CN Benzamide, N-[3-[3-[2-[[3-(2-(aminosulfonyl)ethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)


RN 895636-31-4 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[2-methoxy-4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-36-9 CAPLUS

CN Benzamide, N-[3-[3-[2-[[3-chloro-4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-37-0 CAPLUS

CN Benzamide, N-[3-[3-[2-[[3-chloro-4-[3-(dimethylamino)propoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)





RN 895636-29-0 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-30-3 CAPLUS

CN Benzamide, N-[3-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-38-1 CAPLUS

CN Benzamide, N-[3-[3-[2-[[3-chloro-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)



RN 895636-39-2 CAPLUS


CN Benzamide, N-[3-[3-[2-[[3-chloro-4-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-41-6 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-(2-

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)  
methoxyethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-42-7 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[[3-(4-amino-2-fluorophenoxy)propyl]methylamino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-43-8 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[[3-(diethylamino)propoxy]-3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)  
o]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895636-49-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[[3-(2-(1-pyrrolidinylethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-52-9 CAPLUS  
CN 2-Furancarboxamide, N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-54-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)



RN 895636-45-0 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[[3-fluoro-4-[2-(2-oxo-1-pyrrolidinylethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-47-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[[3-fluoro-4-[2-(1-piperidinylethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-48-3 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[[3-[(methylsulfonyl)methyl]phenyl]amin


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)




RN 895636-55-2 CAPLUS  
CN 2-Thiophenecarboxamide, N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-56-3 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-57-4 CAPLUS  
CN Benzamide, 3-methyl-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 895636-58-5 CAPLUS  
 CN Benzamide, 4-chloro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895636-59-6 CAPLUS  
 CN Benzamide, 3-amino-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-60-9 CAPLUS  
 CN Benzamide, 4-amino-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-61-0 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-methyl-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 895636-62-1 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-64-3 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-(1-pyrrolidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-65-4 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 895636-69-8 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, N-[3-[3-[2-[[3-cyanophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (CA INDEX NAME)




RN 895636-82-5 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-83-6 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluorophenyl]amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 895636-84-7 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-methoxyphenyl]amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-85-8 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-[7-methyl-3-[2-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)








RN 895636-87-0 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-88-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895637-06-6 CAPLUS  
CN 1-Propanesulfonic acid, 3-[2-chloro-4-[(4-[2-[(2,6-difluorobenzoyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl)amino]phenoxy]- (CA INDEX NAME)




RN 895637-07-7 CAPLUS  
CN Butanoic acid, 4-[2-chloro-4-[(4-[2-[(2,6-difluorobenzoyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl)amino]phenoxy]-, methyl ester (CA INDEX NAME)




RN 895637-08-8 CAPLUS

RN 895636-89-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-{7-methoxy-3-[2-[(3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-91-6 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[2-methoxy-5-[3-[2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-99-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[2-fluoro-5-[3-[2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Benzamide, N-[3-[3-[2-[(3-chloro-4-[2-[(methylsulfonyl)amino]ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-09-9 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(3-chloro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)



RN 895637-11-3 CAPLUS  
CN Formic acid, Compd. with N-[3-[3-[2-[(3-[3-(dimethylamino)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide (9C1) (CA INDEX NAME)

CM 1

CRN 895637-10-2  
CMF C36 H33 F2 N7 O3




CM 2

CRN 64-18-6  
CMF C H2 O2

O=CH-OH

RN 895637-13-5 CAPLUS


CN Benzamide, N-[3-[3-[2-[[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)



RN 895637-14-6 CAPLUS


CN Benzamide, N-[3-[3-[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)

CN Benzamide, N-[3-[3-[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-25-9 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[6-fluoro-3-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-26-0 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[6-fluoro-3-[2-[[1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-20-4 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[4-fluoro-3-[2-[[1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-21-5 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[4-fluoro-3-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-22-6 CAPLUS



RN 895637-27-1 CAPLUS

CN Benzamide, N-[3-[3-[2-[[7-amino-5,6,7,8-tetrahydro-2-naphthalenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-30-6 CAPLUS

CN Benzamide, N-[3-[7-(dimethylamino)-3-[2-[[3-(fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 895637-29-3  
CMF C32 H24 F3 N7 O



CH 2


CRN 76-05-1

CMF C2 H F3 O2




RN 895637-33-9 CAPLUS

CN Benzamide, N-[3-[3-[2-[(2-dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-36-2 CAPLUS

CN Benzamide, N-[3-[3-[2-[(2-amino-2,3-dihydro-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)



RN 895637-43-1 CAPLUS

CN Benzamide, N-[3-[3-[2-[(3-(aminomethyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-47-5 CAPLUS

CN Benzamide, N-[5-[3-[2-[(2-dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 895637-46-4

CMF C35 H28 F3 N7 O




RN 895637-38-4 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-(4-methyl-5-oxazolyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-41-9 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(1,2,3,4-tetrahydro-2,4,4-trimethyl-7-isoquinolinyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895637-42-0 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



CH 2


CRN 76-05-1

CMF C2 H F3 O2




RN 895637-50-0 CAPLUS

CN Benzamide, N-[5-[3-[2-[(3-(2-(dimethylamino)ethoxy)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-53-3 CAPLUS


CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-(methylamino)methyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-56-6 CAPLUS  
CN Benzanide, N-[3-[3-[2-[[3-(aminomethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (CA INDEX NAME)




RN 895637-58-8 CAPLUS  
CN Benzanide, N-[3-[3-[2-[[3-((dimethylamino)ethyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-62-4 CAPLUS



RN 895637-70-4 CAPLUS  
CN Benzanide, 2,6-difluoro-N-[3-[3-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895637-72-6 CAPLUS  
CN Benzanide, 2,5-difluoro-N-[3-[3-[2-[[1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-75-9 CAPLUS  
CN Benzanide, N-[5-[3-[2-[[3-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl-

CN Benzanide, N-[3-[3-[2-[[3-chloro-4-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 895637-61-3  
CMF C35 H30 Cl F2 N7 O2




CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 895637-65-7 CAPLUS  
CN Benzanide, 2,5-difluoro-N-[3-[3-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-76-0 CAPLUS  
CN Benzanide, 2,6-difluoro-N-[3-[3-[2-[[3-(fluorophenyl)amino]-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-84-0 CAPLUS  
CN Benzanide, N-[5-[3-[2-[[3-(dimethylamino)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl-




RN 895637-85-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-90-8 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-96-4 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(3-[3-(dimethylamino)propoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-98-6 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(2-methyl-5-benzothiazolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-99-7 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895637-92-0 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-[2-(methyl-2-propenylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-93-1 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[(3-[2-(methyl-2-propenylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-95-3 CAPLUS  
CN Benzamide, N-[3-[3-[2-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895638-00-3 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895638-01-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895638-09-2 CAPLUS  
CN Benzanide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[(1,2,3,4-tetrahydro-2-methyl-7-isquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895638-10-5 CAPLUS  
CN Benzanide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-[(1-methyl-2-pyrrolidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)

895636-70-1P, N-[3-[5-(Hydroxymethyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide  
895636-71-2P, 5-[[[(1,1-Dimethylethyl)dimethylsilyl]oxy]methyl]-3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine  
895636-72-3P, 3-[2-(Methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)-5-[(phenylethyl)oxy]pyrazolo[1,5-a]pyridine 895636-73-4P, 5-[[[(1,1-Dimethylethyl)dimethylsilyl]oxy]methyl]-3-[2-(methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895636-74-5P, 5-[[[(1,1-Dimethylethyl)dimethylsilyl]oxy]methyl]-2-(3-nitrophenyl)-3-[4-pyrimidinyl]pyrazolo[1,5-a]pyridine 895636-75-6P, [2-(3-Aminophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridin-5-yl]methanol  
895636-80-3P, N-[3-[3-(2-Methylsulfonyl-4-pyrimidinyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-81-4P, N-[3-[3-(2-Methylsulfonyl-4-pyrimidinyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-86-9P, N-[3-[3-(2-Chloropyrimidin-4-yl)-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-90-5P, N-[3-[3-(2-Chloropyrimidin-4-yl)-7-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide  
895636-95-0P, 2,2,2-Trifluoro-N-[5-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-(methoxy)phenyl]acetamide  
895636-96-1P, N-[5-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-(methoxy)phenyl]-2,6-difluorobenzamide  
895636-97-2P, 2,6-Difluoro-N-[2-(methoxy)-5-[3-[2-[[2-(trifluoroacetyl)-1,2,3,4-tetrahydro-7-isquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide  
895637-03-3P 895637-04-4P, N-[5-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-difluorobenzamide 895637-05-5P, 2,6-Difluoro-N-[2-fluoro-5-[3-[2-[[2-(trifluoroacetyl)-1,2,3,4-tetrahydro-7-isquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide  
895637-16-8P 895637-18-0P, 3-[3-(2-Chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]aniline 895637-19-1P, N-[3-[3-(2-Chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895637-23-7P, N-[3-[3-(2-Chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895637-28-2P, 2,6-Difluoro-N-[3-[2-[[7-[(trifluoroacetyl)amino]-5,6,7,8-tetrahydro-2-naphthalenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide 895637-31-7P, 2-(3-Bromophenyl)-3-[2-[[3-(fluorophenyl)amino]-4-pyrimidinyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-7-amine 895637-37-3P, 2,6-Difluoro-N-[3-[2-[[2-[[2-(trifluoroacetyl)amino]-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide 895637-45-3P, 2,6-Difluoro-N-[3-[2-[[3-[[[(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide 895637-48-6P, 2,2,2-Trifluoro-N-[5-[3-[2-[[2-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]acetamide 895637-49-7P, [4-[2-(3-Amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl][2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amine 895637-51-1P, 2,2,2-Trifluoro-N-[5-[3-[2-[[3-[[2-(Dimethylamino)ethyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]acetamide 895637-52-2P, 4-[2-(3-Amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[[2-(dimethylamino)ethyl]oxy]phenyl]-2-pyrimidinamine 895637-55-5P, 2,6-Difluoro-N-[3-[3-[2-[[3-[[methyl(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide



RN 895638-11-6 CAPLUS  
CN Benzanide, 2,6-difluoro-N-[3-[3-[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




IT 895634-85-2P, 3-[2-(Methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895634-86-3P, 3-[2-(Methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895634-87-4P, N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-4-[2-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 895634-88-5P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-pyrimidinamine 895635-03-7P 895635-04-8P, 2,2,2-Trifluoro-N-[3-[2-[[3-(fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895635-05-9P, N-[4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl](3-fluorophenyl)amine 895635-25-3P, N-[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-46-8P, N-[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluorobenzamide 895635-69-5P, N-[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide 895635-71-9P, N-[3-[3-[2-[[2-(2,2,2-Trifluoroacetyl)-1,2,3,4-tetrahydro-7-isquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide 895635-74-2P 895636-50-7P 895636-51-8P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-

895637-57-7P, 2,5-Difluoro-N-[3-[3-[2-[[3-[[[(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide 895637-69-1P, 2,5-Difluoro-N-[3-[3-[2-[[3-[[[(2-methylsulfonyl)ethyl](trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzanide 895637-71-5P, 2,6-Difluoro-N-[3-[2-[[3-[[[(2-methylsulfonyl)ethyl](trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[[2-(methyl(2-propen-1-yl)amino)ethyl]oxy]phenyl]-2-pyrimidinamine 895637-97-5P, 2,2,2-Trifluoro-N-[3-[3-[2-[[3-[[3-(Chloropropyl)oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895637-74-8P, N-[4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-2-methyl-1,2,3,4-tetrahydro-7-isquinolinamine 895637-89-5P, 4-[2-(3-Bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-(3-fluorophenyl)-2-pyrimidinamine 895637-94-2P, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[[2-(methyl(2-propen-1-yl)amino)ethyl]oxy]phenyl]-2-pyrimidinamine 895637-97-5P, 2,2,2-Trifluoro-N-[3-[3-[2-[[3-[[3-(Chloropropyl)oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895638-03-6P, 2-(3-Bromophenyl)-3-(2-chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridine 895638-04-7P, 4-[2-(3-Bromophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-(3-fluorophenyl)-2-pyrimidinamine 895638-05-8P, N-[4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-2-pyrimidinyl]-2-methyl-1,2,3,4-tetrahydro-7-isquinolinamine 895638-07-0P, 2,2,2-Trifluoro-N-[3-[3-(2-Chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895638-08-1P, 2,2,2-Trifluoro-N-[3-[3-[5-fluoro-2-[[2-methyl-1,2,3,4-tetrahydro-7-isquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; prepn. of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)


RN 895634-85-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 895634-86-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 895634-87-4 CAPLUS  
CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 895634-88-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)




RN 895635-03-7 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895635-46-8 CAPLUS  
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (CA INDEX NAME)




RN 895635-69-5 CAPLUS  
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-71-9 CAPLUS  
CN Benzamide, N-[3-[3-[2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-04-8 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895635-05-9 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (CA INDEX NAME)




RN 895635-25-3 CAPLUS  
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895635-74-2 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-50-7 CAPLUS  
CN Acetamide, N-[3-[3-[2-[[3-(2-chloroethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895636-51-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-




RN 895636-70-1 CAPLUS  
CN Benzamide, N-[3-[5-(hydroxymethyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-71-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 895636-72-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)-5-(phenylmethoxy)- (CA INDEX NAME)




RN 895636-80-3 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-(methylthio)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-81-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-(methylsulfonyl)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 895636-86-9 CAPLUS  
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-73-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-[2-(methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 895636-74-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-(3-nitrophenyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 895636-75-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-methanol, 2-(3-aminophenyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)



RN 895636-90-5 CAPLUS  
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-7-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895636-95-0 CAPLUS  
CN Acetamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895636-96-1 CAPLUS  
CN Benzamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,6-difluoro- (CA INDEX NAME)






RN 895636-97-2 CAPLUS

CN Benzamide, 2,6-difluoro-N-[2-methoxy-5-[3-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-03-3 CAPLUS

CN Acetamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-04-4 CAPLUS

CN Benzamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-19-1 CAPLUS

CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-23-7 CAPLUS

CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (CA INDEX NAME)




RN 895637-28-2 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[5,6,7,8-tetrahydro-7-((trifluoroacetyl)amino)-2-naphthalenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-05-5 CAPLUS

CN Benzamide, 2,6-difluoro-N-[2-fluoro-5-[3-[2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-16-8 CAPLUS

CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-18-0 CAPLUS

CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 895637-31-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[(3-bromophenyl)-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-N,N-dimethyl]- (CA INDEX NAME)




RN 895637-37-3 CAPLUS

CN Benzamide, N-[3-[3-[2-[[2,3-dihydro-2-((trifluoroacetyl)amino)-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-45-3 CAPLUS


CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[[[(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-48-6 CAPLUS  
CN Acetamide, N-[5-[3-[2-[[2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-49-7 CAPLUS  
CN 1H-indene-2,5-diamine, N5-[4-{2-[(3-amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-2-yl]-2-pyrimidinyl}-2,3-dihydro-N2,N2-dimethyl-1H-indene-5-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-51-1 CAPLUS  
CN Acetamide, N-[5-[3-[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895637-52-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 895637-55-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[[methyl(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-57-7 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[[methyl(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-69-1 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[3-[[methyl(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-71-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-[[methyl(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-73-7 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[3-[3-[2-[[3-[[methyl(trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 895637-74-8 CAPLUS  
CN 7-Isoquinolinamine, N-[4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-1,2,3,4-tetrahydro-2-methyl- (CA INDEX NAME)




RN 895637-89-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-(3-fluorophenyl)- (CA INDEX NAME)




RN 895637-94-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
(methyl-2-propenylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 895637-97-5 CAPLUS  
CN Acetamide, N-[3-[3-[2-[(3-(3-chloropropoxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895638-03-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(3-bromophenyl)-3-(2-chloro-5-fluoro-4-pyrimidinyl)- (CA INDEX NAME)




RN 895638-04-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-(3-fluorophenyl)- (CA INDEX NAME)

L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 895635-36-6, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-1-(3-fluorophenyl)-2-pyrimidinamine 895635-40-2 895635-70-8, [3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amine 895636-53-0, N-[4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]phenylamine 895636-63-2, 3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-N-(2,6-difluorophenyl)benzamide 895637-24-8, 3-[3-(2-Chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]aniline 895637-63-5, N-[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methylbenzamide  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasms)  
RN 895635-36-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-1-(3-fluorophenyl)-1,2-dihydro- (CA INDEX NAME)




RN 895635-40-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (CA INDEX NAME)


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 895638-05-8 CAPLUS  
CN 7-Isoquinolinamine, N-[4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-2-pyrimidinyl]-1,2,3,4-tetrahydro-2-methyl- (CA INDEX NAME)




RN 895638-07-0 CAPLUS  
CN Acetamide, N-[3-[3-(2-chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 895638-08-1 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[3-[3-[5-fluoro-2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)


L4 ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 895635-70-8 CAPLUS  
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 895636-53-0 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (CA INDEX NAME)




RN 895636-63-2 CAPLUS  
CN Benzamide, 3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-N-(2,6-difluorophenyl)- (CA INDEX NAME)




L4: ANSWER 9 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 895637-24-8 CAPLUS  
 CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 895637-63-5 CAPLUS  
 CN Benzanide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl- (CA INDEX NAME)




IT 895637-17-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors  
 for treating neoplasm)  
 RN 895637-17-9 CAPLUS  
 CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




L4: ANSWER 10 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 pyrimidinyl]- (CA INDEX NAME)



RN 888021-52-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(4-methylphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)



RN 888021-53-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(3-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)



RN 888021-54-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(3-pyridinyl)- (CA INDEX NAME)

L4: ANSWER 10 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2006:496072 CAPLUS  
 DOCUMENT NUMBER: 145:8184  
 TITLE: Process for preparing pyrazolopyridine compounds  
 INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006055245	A2	20060526	WO 2005-US39571	20051101
WO 2006055245	A3	20060817		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BU, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPL. INFO.:			US 2004-628820P P 20041117	
OTHER SOURCE(S):			CASREACT 145:8184; MARPAT 145:8184	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The present invention provides a process for preparing pyrazolopyridine compds. I [R1 = (hetero)aryl; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, cycloalkyl, etc.; p = 0-3; R6 = halo, alkyl, cycloalkyl, etc.] comprising the steps of (a) reacting II with a hindered amide base to produce an anion and (b) reacting the anion with 9-methoxy-9-borabicyclo[3.3.1]nonane; (c) adding a compound RIX (wherein X = halo or triflate) in the presence of a palladium catalyst to prepare a compound of formula I wherein R2 = SMe; (c) optionally converting I into its pharmaceutically acceptable salt or solvate; and (d) optionally converting I or a pharmaceutically its salt into a different compound I. Thus, treating 2-(4-fluorophenyl)-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine (2-step synthesis given) with lithium diisopropylamide in THF followed by addition of 9-methoxy-9-borabicyclo[3.3.1]nonane, and after 1 h K3PO4, DMF, 4-iodotoluene and PdCl2(dppf):CH2Cl2 afforded 67% III.

IT 401816-34-0P 888021-52-1P 888021-53-2P 888021-54-3P 888021-55-4P 888021-69-0P 888021-71-4P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (process for preparing pyrazolopyridine compds.)  
 RN 401816-34-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-


L4: ANSWER 10 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 888021-55-4 CAPLUS  
 CN Ethanone, 1-[4-[2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-7-yl]phenyl]- (CA INDEX NAME)




RN 888021-69-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 888021-71-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




IT 888021-56-5P 888021-57-6P 888021-58-7P  
 888021-59-8P 888021-60-1P 888021-61-2P  
 888021-62-3P 888021-63-4P 888021-64-5P  
 888021-65-6P 888021-66-7P 888021-67-8P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
 (process for preparing pyrazolopyridine compds.)  
 RN 888021-56-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-(4-fluorophenyl)-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 888021-57-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-(3-methoxyphenyl)-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 888021-58-7 CAPLUS  
 CN Benzenamine, 4-[2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-7-yl]- (CA INDEX NAME)




RN 888021-62-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 888021-63-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(3-methylphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 888021-64-5 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(3-




RN 888021-59-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(3-thienyl)- (CA INDEX NAME)




RN 888021-60-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(4-methylphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 888021-61-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 888021-65-6 CAPLUS  
 CN Ethanone, 1-[4-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]- (CA INDEX NAME)



RN 888021-66-7 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 888021-67-8 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




ACCESSION NUMBER: 2006:440458 CAPLUS  
 DOCUMENT NUMBER: 144:468186  
 TITLE: Preparation of (halopyrazolopyridinyl)pyridazinones and their use as phosphodiesterase (PDE) inhibitors and pharmaceuticals  
 INVENTOR(S): Kono, Yasushi; Ando, Naoki; Iwase, Kazuhiko; Yasue, Tokutarō; Kishi, Tetsuya; Nagasawa, Michiaki; Hori, Wataru  
 PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 66 pp.  
 DOCUMENT TYPE: CODEN: JXXXXF  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: Japanese  
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006117647	A	20060511	JP 2005-271518	20050920
PRIORITY APPLN. INFO.:			JP 2004-274779	A 20040922
OTHER SOURCE(S):			MARPAT 144:468186	
GI				




AB Title compds. I [R1 = halo, C1-4 alkoxy; R2 = H, halo, OH, C1-4 alkoxy; R3 = H, halo, (un)substituted C1-4 alkyl, C3-8 cycloalkyl, C2-4 alkenyl, C1-4 alkoxy, CO2H, etc.; R4 = C1-4 alkyl; R5 = H, R6(CH2)<sub>m</sub>; R6 = C3-8 cycloalkyl, aromatic or saturated heterocyclyl; m = 1, 2; the broken line may be single or double bond] are prepared. They are useful for treatment of angina pectoris, heart failure, hypertension, asthma, COPD, atopic dermatitis, multiple sclerosis, Alzheimer's disease, schizophrenia, etc. Thus, refluxing NH2NH2.H2O with 4-(6-chloro-2-methylpyrazolo[1,5-a]pyridin-3-yl)-3-methyl-4-oxobutyric acid in EtOH gave I (R1 = Cl, R2 = R5 = H, R3 = R4 = Me, the broken line is single bond), which inhibited human PDE3, PDE4, PDE5, and PDE10 with IC50 values of 1.46, 16.5, 55.7, and 8.44 μmol/L, resp.  
 IT 886222-87-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of (halopyrazolopyridinyl)pyridazinones as phosphodiesterase inhibitors for treatment of diseases)  
 RN 886222-87-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(6-chloro-2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-4,5-dihydro-5-methyl- (CA INDEX NAME)




ACCESSION NUMBER: 2006:386432 CAPLUS  
 DOCUMENT NUMBER: 144:425692  
 TITLE: Methods using TGF-β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries  
 INVENTOR(S): Ling, Leona E.; Fu, Kai; Gill, Alan; Gotwals, Philip J.  
 PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA  
 SOURCE: PCT Int. Appl., 228 pp.  
 DOCUMENT TYPE: CODEN: PIXX02  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044509	A2	20060427	WO 2005-US36770	20051013
WO 2006044509	A3	20060817		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW:				
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BV, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005295734	A1	20060427	AU 2005-295734	20051013
CA 2584248	A1	20060427	CA 2005-2584248	20051013
EP 1804801	A2	20070711	EP 2005-813747	20051013
R:				
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-619116P	P 20041015
			WO 2005-US36770	W 20051013
OTHER SOURCE(S):			MARPAT 144:425692	


AB The invention discloses the use of TGF-β type I receptor inhibitors and Alk4 inhibitors and implantable devices including these compds. in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).  
 IT 672932-46-6 672932-50-2 672932-51-3  
 RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (TGF-β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries)  
 RN 672932-46-6 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 672932-50-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 672932-51-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




L4 ANSWER 13 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
(drug candidate; prepn. of pyridazinones as inhibitors of the prodn. and transduction of cytokines)  
RN 882975-01-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-hydroxycyclohexyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 882974-78-9P, 2-(2,6-Dichlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone 882975-12-4P, 2-(2-Chlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone 882975-13-5P, 2-(2-Methylphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridazinones as inhibitors of the production and transduction of cytokines)

RN 882974-78-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2,6-dichlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 882975-12-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-chlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 882975-13-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-methylphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

ACCESSION NUMBER: 2006:342780 CAPLUS  
DOCUMENT NUMBER: 144:390930  
TITLE: Preparation of pyridazinone derivatives as inhibitors of the production and transduction of cytokines  
INVENTOR(S): Yamazaki, Hitoshi; Kasahara, Chiyoishi; Shigenaga, Shinji; Higuchi, Koichi; Mizuhara, Hidekazu; Yasuda, Minoru; Yokomoto, Masaharu; Misumi, Keiji; Kinoshita, Tomohiko; Katayama, Kimiko  
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan; Wakunaga Pharmaceutical Co., Ltd.  
SOURCE: PCT Int. Appl., 124 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006038734	A1	20060413	WO 2005-JP18901	20051007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HN, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: AU 2004-905844 A 20041008				
OTHER SOURCE(S): MARPAT 144:390930				
G1				


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I and II [R1 = (un)substituted lower alkyl, aryl; R2 = (un)substituted aryl or thienyl; R3 = H, lower alkyl; A = O, S; R4 = H, (un)substituted amino, piperazin-1-yl, etc.; R5 = H, lower alkyl, hydroxy(lower)alkyl; R6 = H, (un)substituted amino, N-lower alkoxycarbonyl/piperazinyl; or R5R6 = -Y-CH-CH-, -2-(CH2)3-, Y = CH, N; Z = CH2, NH; with provisos; and their salts] were prepared as inhibitors of the production and transduction of cytokines. Thus, reacting 6-[2-amino-4-(4-fluorophenyl)-1,3-thiazol-5-yl]-3(2H)-pyridazinone (preparation given) with 1-oxaspiro[2.5]octane in dioxane in the presence of NaOH gave pyridazinone III. Pyridazinone III inhibited TNF- $\alpha$  production in THP-1 cells at 100 nM. I and II are useful for treating cytokines mediated diseases, such as pain, rheumatoid arthritis, inflammation, psoriasis, etc.  
IT 882975-01-1P, 2-[(1-Hydroxycyclohexyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



IT 131185-06-3, 6-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyridazinones as inhibitors of the production and transduction of cytokines)

RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:19715 CAPLUS

DOCUMENT NUMBER: 144:163524

TITLE: Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses  
 AUTHOR(S): Allen, Scott H.; Johns, Brian A.; Gudmundsson, Kristjan S.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie H.; Selleseth, Dean W.; Creech, Katrina L.; Moniri, Kelly R.

CORPORATE SOURCE: Department of Medicinal Chemistry, GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA

SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(4), 944-954

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:163524

AB A novel series of potent C-6 substituted pyrazolo[1,5-a]pyridine inhibitors of herpes simplex viruses has been identified. A synthetic methodol. was developed involving functionalization of a C-6 trifluoromethyl pyrazolo[1,5-a]pyridine to allow facile access to a diverse set of analogs from common late stage intermediates. The expansion of the SAR of this series at the 6 position allows for modifications to developability parameters such as clog P, while maintaining potency comparable to acyclovir.

IT 468062-75-1P 473712-17-3P 474304-08-0P


874668-24-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)

RN 468062-75-1 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 473712-17-3 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)


RN 468062-82-0 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-84-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-methanamine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 468063-30-1 CAPLUS


CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)



RN 473711-98-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)


L4 ANSWER 14 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl


RN 474304-08-0 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 874668-24-3 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 468062-82-0P 468062-84-2P 468063-30-1P


473711-98-7P 473711-99-8P 474303-58-7P

474303-60-1P 474303-61-2P 474303-62-3P

474303-63-4P 474303-64-5P 474303-65-6P


474303-66-7P

L4 ANSWER 14 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 473711-99-8 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (CA INDEX NAME)



RN 474303-58-7 CAPLUS


CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)




RN 474303-60-1 CAPLUS

CN Pyrrolidine, 1-[[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]carbonyl]- (9CI) (CA INDEX NAME)







RN 474303-61-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 474303-62-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-hydroxy- (CA INDEX NAME)




RN 474303-63-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




IT 437611-97-7, GW 3733  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)  
RN 437611-97-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-81-9P  
468062-83-1P 468063-25-4P 468063-27-6P  
468063-28-7P 468063-29-8P 473712-18-4P  
474304-05-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)  
RN 468062-79-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-80-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 474303-64-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 474303-65-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (CA INDEX NAME)




RN 474303-66-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-methanol, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 468062-81-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 468062-83-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[6-(bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468063-25-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (CA INDEX NAME)



L4 ANSWER 14 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 468063-27-6 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468063-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 468063-29-8 CAPLUS


CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)



RN 473712-18-4 CAPLUS


CN Carbamic acid, [3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 474304-05-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(triethoxymethyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1241434 CAPLUS

DOCUMENT NUMBER: 144:63899

TITLE: Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative

AUTHOR(S): Kinoshita, Takayoshi; Warizaya, Masaichi; Ohori, Makoto; Sato, Kentaro; Neya, Masahiro; Fujii, Takashi  
Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, Tsukuba, Ibaraki, 300-2698, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(1), 55-58


CODEN: BMCLEB; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A series of pyrazolopyridazine compds. were briefly investigated as ERK2 inhibitors. The crystal structure of ERK2 complexed with the allyl derivative

(I) was determined. The compound induces structural change including movement of


the glycine-rich loop and peptide flip between Met108-Glu109. As a result, the newly formed subsite can recognize small hydrophobic substituents but not hydrophilic ones.

IT 871568-25-1

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative)

RN 871568-25-1 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(2-propenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 865362-74-9 871568-24-0 871568-26-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative)


RN 865362-74-9 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 871568-24-0 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 1-methyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 871568-26-2 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazine-1-ethanol, 3-amino-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1162315 CAPLUS

DOCUMENT NUMBER: 144:345937

TITLE: Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain

AUTHOR(S): Matsuya, Takahiro; Takamatsu, Hiroyuki; Murakami, Yoshihiro; Noda, Akihiro; Ichise, Rikiya; Awaga, Yuji; Nishimura, Shintaro

CORPORATE SOURCE: Basic Research Division, The Medical and Pharmacological Research Center Foundation, Ishikawa, 925-0613, Japan

SOURCE: Nuclear Medicine and Biology (2005), 32(8), 837-844

CODEN: NMBIED; ISSN: 0969-8051

PUBLISHER: Elsevier Inc.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB This report describes the synthesis of [11C]2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone ([11C]FR194921), a highly selective, nonxanthine-type adenosine A1 receptor antagonist, used in brain imaging in rats and conscious monkeys as a potential novel PET tracer. [11C]FR194921 was successfully synthesized in 19 min after [11C]CH3I formation. The radiochem. yield was 38±3%, and radioactivity was 4.1±0.4 GBq, calculated from end of synthesis; radiochem. purity was higher than 99%, and the specific radioactivity was 25.0±8.1 GBq μmol<sup>-1</sup> (n=5). In a rat experiment, the distribution of [11C]FR194921 was higher in the hippocampus, striatum and cerebellum regions. This accumulation was significantly decreased by approx. 50% by pretreatment with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), an adenosine A1 receptor antagonist, which indicated specific binding of the radioligand to adenosine A1 receptors. In conscious monkey PET expts., [11C]FR194921 accumulated in several regions of the brain, especially in the occipital cortex, thalamus and striatum. These results suggest that [11C]FR194921 can be used as an agent for imaging adenosine A1 receptors in vivo by positron emission tomog. (PET).

IT 881030-50-8P  
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis and evaluation of [11C]FR194921 as nonxanthine-type PET tracer for adenosine A1 receptors in brain)

RN 881030-50-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-[1-(methyl-11C)-4-piperidinyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 202646-90-0, Desmethyl-FR194921


RL: RCT (Reactant); RACT (Reactant or reagent) (synthesis and evaluation of [11C]FR194921 as nonxanthine-type PET tracer for adenosine A1 receptors in brain)

RN 202646-90-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-

L4 ANSWER 16 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

piperidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 34

THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1024651 CAPLUS

DOCUMENT NUMBER: 143:460071

TITLE: Pyrazolo[1,5-a]pyridines as p38 Kinase Inhibitors

AUTHOR(S): Stevens, Kirk L.; Jung, David K.; Alberti, Michael J.; Badiang, Jennifer G.; Peckham, Gregory E.; Veal, Jim M.; Cheung, Mui; Harris, Philip A.; Chamberlain, Stanley D.; Peel, Michael R.

CORPORATE SOURCE: Research and Development, Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA

SOURCE: Organic Letters (2005), 7(21), 4753-4756

CODEN: ORLEF7; ISSN: 1523-7060


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:460071

GI




AB A convergent synthesis of substituted pyrazolo[1,5-a]pyridines, e.g., 1, has been achieved either via a regioselective [3 + 2]-cycloaddn. of N-aminopyridines with alkynes or by thermal cyclization of disubstituted azirines. Subsequent palladium-catalyzed introduction of pyridines or de novo synthesis of pyrimidines afforded inhibitors of p38 kinase.

IT 401816-10-2P 401816-13-5P 401816-14-6P 401816-32-8P 401816-41-9P 401816-44-2P 401816-51-1P 401816-54-4P 401816-57-7P 401816-61-3P 401816-62-4P 401816-67-9P 401816-68-0P 401816-79-3P 401816-80-6P 401816-89-5P 468062-94-4P 468062-95-5P 468062-99-9P 468063-20-9P 468063-23-2P 468063-44-7P 869334-80-5P 869334-81-6P 869334-82-7P 869334-83-8P 869334-84-9P 869334-85-0P 869334-86-1P 869334-87-2P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (regioselective preparation, p38 kinase inhibitory activity, and structure-activity relationship of pyrazolopyridines using a [3 + 2]-cycloaddn. or thermal cyclization as the key reaction)

RN 401816-10-2 CAPLUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (CA INDEX NAME)

L4 ANSWER 17 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-13-5 CAPLUS

CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 401816-14-6 CAPLUS

CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 401816-32-8 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 401816-41-9 CAPLUS


L4 ANSWER 17 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 401816-44-2 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-51-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 401816-54-4 CAPLUS  
 CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)


L4 ANSWER 17 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 401816-67-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 401816-68-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 401816-79-3 CAPLUS  
 CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-80-6 CAPLUS  
 CN 1,3-Propanediamine, N,N-dimethyl-N'-[4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-57-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 401816-61-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 401816-62-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




L4 ANSWER 17 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-89-5 CAPLUS  
 CN 1,3-Propanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468062-94-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 468062-95-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 468062-99-9 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-20-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)-  
(CA INDEX NAME)




RN 468063-23-2 CAPLUS  
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)





RN 869334-82-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(1-methylethyl)amino]-4-pyridinyl]- (CA INDEX NAME)




RN 869334-83-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-(2-(cyclopropylamino)-4-pyridinyl)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 869334-84-9 CAPLUS  
CN 2-Pyrimidinamine, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 468063-44-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 869334-80-5 CAPLUS  
CN 2-Pyridinamine, N-butyl-4-[4-fluoro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 869334-81-6 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


RN 869334-85-0 CAPLUS  
CN 1-Propanol, 3-[[4-[6-(trifluoromethyl)-2-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 869334-86-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N,N-dimethyl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 869334-87-2 CAPLUS  
CN 1-Propanol, 3-[[4-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




IT	401815-97-2P 401816-29-3P 401816-55-5P
	RL: RCT (Reactant); SFN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
	(regioselective preparation, p38 kinase inhibitory activity, and structure-activity relationship of pyrazolopyridines using a [3 + 2]-cycloaddn, or thermal cyclization as the key reaction)
RN	401815-97-2 CA
CN	Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)



RN 401816-29-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)



RN 401816-55-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((4-methoxyphenyl)methoxy)propyl]- (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:777994 CAPLUS  
DOCUMENT NUMBER: 143:367266  
TITLE: Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses  
AUTHOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.; Wang, Zhicheng; Turner, Elizabeth M.; Allen, Scott H.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie J.; Selleseth, Dean W.; Moniri, Kelly R.; Creech, Katrina L.  
CORPORATE SOURCE: GlaxoSmithKline Research and Development, Department of Medicinal Chemistry, Research Triangle Park, NC, 27709-3398, USA  
SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(18), 5346-5361  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 143:367266

AB Herpesviruses are a significant source of human disease; amongst these herpes simplex virus 1 (HSV-1) and HSV-2 are very prevalent and cause recurrent infections. A pyrazolo[1,5-a]pyridine scaffold that showed promising activity against HSV-1 and HSV-2 in Vero cell antiviral assays was recently reported. Here, the synthesis and anti-herpetic activity of several 3-pyrimidinyl-2-(phenyl)pyrazolo[1,5-a]pyridine derivs. with differing 2-Ph substitution patterns is described. Approaches to rapidly access a number of analogs with different 2-Ph substitution patterns are outlined. Several of the compds. described have comparable activity to acyclovir against HSV-1 and HSV-2.

IT 437611-97-7  
RL: PAC (Pharmacological activity); BIOL (Biological study) (preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and study of antiviral activity of N-cyclopentyl[(cyclopentylamino)pyrimidinyl](4-fluorophenyl)pyrazolo[1,5-a]pyridinamine)  
RN 437611-97-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




IT 437611-98-8P 460078-20-0P 460078-26-6P 460078-37-9P 460078-45-9P 460078-46-0P 460078-55-1P 460078-60-8P 460078-71-1P 460078-74-4P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and

ACCESSION NUMBER: 2005:993256 CAPLUS  
DOCUMENT NUMBER: 143:318600  
TITLE: Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex  
AUTHOR(S): Otori, Makoto; Kinoshita, Takayoshi; Okubo, Mitsuru; Sato, Kentaro; Yamazaki, Akiko; Arakawa, Hiroyuki; Nishimura, Shintaro; Inamura, Noriaki; Nakajima, Hidenori; Meya, Masahiro; Miyake, Hiroshi; Fujii, Takashi  
CORPORATE SOURCE: Lead Discovery Research Laboratories, Astellas Pharma Inc., Tsukuba, Ibaraki, 300-8585, Japan  
SOURCE: Biochemical and Biophysical Research Communications (2005), 336(1), 357-363  
CODEN: BBRCAS; ISSN: 0006-291X  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB Selective inhibition of extracellular signal-regulated kinase (ERK) represents a potential approach for the treatment of cancer and other diseases; however, no selective inhibitors are currently available. Here, the authors describe an ERK-selective inhibitor, FR180204, and determine the structural basis of its selectivity. FR180204 inhibited the kinase activity of ERK1 and ERK2, with  $K_i$  values 0.31 and 0.14  $\mu$ M, resp. Lineaver-Burk anal. of the binding interaction revealed that FR180204 acted as competitive inhibitor of ATP. In mink lung epithelial Mv1Lu cells, FR180204 inhibited TGF $\beta$ -induced luciferase-expression. X-ray crystal structure anal. of the human ERK2/FR180204 complex revealed that Q105, D106, L156, and C166, which form the ATP-binding pocket on ERK, play important roles in the drug/protein interaction. These results suggest that FR180204 is an ERK-selective and cell-permeable inhibitor, and could be useful for elucidating the roles of ERK as well as for drug development.

IT 865362-74-9, FR 180204  
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (identification of a selective ERK inhibitor and structural determination of inhibitor-ERK2 complex)  
RN 865362-74-9 CAPLUS  
CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


study of their activity against herpesvirus)  
RN 437611-98-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-20-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460078-26-6 CAPLUS  
CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-37-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-aminophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-45-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(2-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-46-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-55-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-aminophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




IT 437611-99-9P 437612-02-7P 437612-76-5P  
460078-29-9P 460078-30-2P 460078-31-3P  
460078-33-5P 460078-34-6P 460078-35-7P  
460078-36-8P 460078-38-0P 460078-44-8P  
460078-50-6P 460078-56-2P 460078-57-3P  
460078-59-5P 460078-61-9P 460078-62-0P  
460078-66-4P 460078-75-5P 460078-76-6P  
460078-77-7P 460079-24-7P 866393-63-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and  
study of their activity against herpesvirus)  
RN 437611-99-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-02-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-76-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-60-8 CAPLUS  
CN Benzonitrile, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-71-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 460078-74-4 CAPLUS  
CN Phenol, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-29-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-30-2 CAPLUS  
CN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460078-31-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-33-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 460078-34-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-(cyclobutylmethoxy)phenyl]-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-35-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 460078-50-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[1,1'-biphenyl]-3-yl-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-56-2 CAPLUS  
CN Acetamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 460078-57-3 CAPLUS  
CN Methanesulfonamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 460078-36-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[1,1'-biphenyl]-4-yl-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-38-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(cyclohexylamino)phenyl]- (CA INDEX NAME)




RN 460078-44-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 460078-59-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (CA INDEX NAME)




RN 460078-61-9 CAPLUS  
CN Benzamide, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-62-0 CAPLUS




L4 ANSWER 19 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Benzoic acid, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)



RN 460078-66-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (CA INDEX NAME)




RN 460078-75-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 460078-76-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)- (CA INDEX NAME)


L4 ANSWER 19 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 460078-70-0P 460079-65-6P 866393-64-8P  
 866393-65-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (Preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and study of their activity against herpesvirus)  
 RN 460078-70-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 460079-65-6 CAPLUS  
 CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 866393-64-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-[(diphenylmethyl)amino]phenyl]- (CA INDEX NAME)


L4 ANSWER 19 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 460078-77-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460079-24-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 866393-63-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(1-methylpropoxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 19 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 866393-65-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-[(diphenylmethyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2005:202833 CAPLUS  
DOCUMENT NUMBER: 142:430228  
TITLE: Pyrazolopyridine antiherpetic: SAR of C2' and C7 amine substituents  
AUTHOR(S): Johns, Brian A.; Gudmundsson, Kristjan S.; Turner, Elizabeth M.; Allen, Scott H.; Samano, Vicente A.; Ray, John A.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie J.; Selleseth, Dean W.; Creech, Katrina L.; Moniri, Kelly A.  
CORPORATE SOURCE: GlaxoSmithKline Research and Development, Department of Medicinal Chemistry, Research Triangle Park, NC, 27709-3398, USA  
SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(7), 2397-2411  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 142:430228  
GI




I

AB A series of potent pyrimidinylpyrazolo[1,5-a]pyridine inhibitors, e.g., I, of herpes simplex virus 1 replication have been identified. Several complimentary synthetic methods were developed to allow facile access to a diverse set of analogs from common late stage intermediates. Detailed examination of the amine substituents at the C2' position of the pyrimidine and C7 position of the core pyrazolopyridine is described. The antiviral data suggested that non-polar amines were preferred for optimal activity. Addnl., the 2' position has been shown to require an NH group to retain activity levels similar to that of the gold standard acyclovir.  
IT 437384-04-8P 437384-12-8P 437384-13-9P  
437611-97-7P 437611-99-9P 437612-00-5P  
437612-01-6P 437612-02-7P 437612-07-2P  
437612-08-3P 437612-09-4P 437612-17-4P  
437612-19-6P 437612-27-6P 437612-28-7P  
437612-29-8P 437612-30-1P 437612-31-2P  
437612-32-3P 437612-34-5P 437612-36-7P  
437612-39-0P 437612-40-3P 437612-41-4P  
437612-43-6P 437612-44-7P 437612-45-8P  
437612-50-5P 850999-17-6P 850999-18-7P


L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437611-99-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-00-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-01-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (CA INDEX NAME)

L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


850999-30-3P 850999-31-4P 850999-44-9P  
850999-51-8P 850999-52-9P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn., antiherpetic activity, and structure-activity relationship of (aminopyrimidinyl)aminopyrazolopyridines)  
RN 437384-04-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 437384-12-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437384-13-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437611-97-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)


L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 437612-02-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-07-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-08-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-09-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl- (CA INDEX NAME)




RN 437612-17-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-19-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 437612-27-6 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437612-28-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 437612-29-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-30-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 437612-31-2 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437612-32-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437612-34-5 CAPLUS  
CN 1-Propanol, 3-[[4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 437612-36-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-39-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 437612-40-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 437612-41-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-43-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 437612-44-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (CA INDEX NAME)

L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 850999-18-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-4-morpholinyl- (CA INDEX NAME)




RN 850999-30-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N,2-bis(4-fluorophenyl)-3-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 850999-31-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N,2-bis(4-fluorophenyl)- (CA INDEX NAME)




L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 437612-45-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)



RN 437612-50-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 850999-17-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-1-pyrrolidinyl- (CA INDEX NAME)




L4 ANSWER 20 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 850999-44-9 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 850999-51-8 CAPLUS  
CN 1-Piperazineethanol, 4-[[[4-(7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 850999-52-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[4-(2-methoxyethyl)-1-piperazinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




IT 401816-34-0P 401816-35-1P 437612-22-1P  
437612-33-4P 437613-05-3P 437613-07-5P  
437613-08-6P 468062-98-8P 850999-40-5P  
850999-41-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation, antihypertensive activity, and structure-activity relationship

of (aminopyrimidinyl)aminopyrazolopyridines)

RN 401816-34-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 401816-35-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




```

RN  437612-22-1  CAPLUS
CN  2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)


```




RN 437612-33-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)





RN 468062-98-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 850999-40-5 CAPLUS  
CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 850999-41-6 CAPLUS  
CN 2-Pyrimidinamine, 4-(7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 437613-05-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437613-07-5 CAPLUS  
CN 2(1H)-Pyrimidinethione, 4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 437613-08-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)


L4 ANSWER 21 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:1068075 CAPLUS  
 DOCUMENT NUMBER: 142:168975  
 TITLE: "Lead Hopping". Validation of Topomer Similarity as a Superior Predictor of Similar Biological Activities  
 AUTHOR(S): Cramer, Richard D.; Jilek, Robert J.; Guessregen, Stefan; Clark, Stephanie J.; Wendt, Bernd; Clark, Robert D.  
 CORPORATE SOURCE: Tripos Discovery Research, Cornwall, EX23 8LY, UK  
 SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6777-6791  
 CODEN: JMCHAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Two extensive studies quantifying the ability of topomer shape similarity to forecast a variety of biol. similarities are described. In a prospective trial of "lead hopping", using topomer similarity for virtual screening and queries from the patent literature, biol. assays of 308 selected compds. (representing 0.03% of those available, per assay type) yielded 11 successful "lead hops" in the 13 assays attempted. The hit rate averaged over all assays was 39% ("activity" defined as inhibition  $\geq 20\%$  at 10  $\mu\text{M}$ ), significantly greater than an unexpectedly high neg. control hit rate of 15%. The average "Tanimoto 2D fingerprint similarity" between query and "lead hop" structures (0.36) was little more than the Tanimoto similarity between random drug-like structures. Topomer shape and Tanimoto 2D fingerprint similarities were also compared retrospectively, in their tendencies to concentrate together potential and actual drugs reported to belong to the same "activity class", for twenty classes. Among the most similar 3% of structures (corresponding to " $\geq 0.85$  Tanimoto" for these structures), an average of 62% of the topomer similar selection possessed a near neighbor belonging to the same activity class, roughly a one-third superiority over the "Tanimoto  $\geq 0.85$ " selection containing 48% actives in avoiding false positives. Conversely, the least similar 75% of structures contained 0.3% actives for topomer similarity vs. 1.0% actives for Tanimoto 2D fingerprint similarity, a 3-fold superiority for topomers in avoiding false negatives.  
 IT 202646-80-8  
 RL: PAC (Pharmacological activity); BIOL (Biological study) (validation of topomer similarity as a superior predictor of similar biol. activities of "Lead hopping")  
 RN 202646-80-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 22 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L4 ANSWER 22 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:798011 CAPLUS  
 DOCUMENT NUMBER: 142:148488  
 TITLE: Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors  
 AUTHOR(S): Maemoto, Takuya; Tada, Miho; Mihara, Takuma; Ueyama, Noriko; Matsukawa, Hideaki; Harada, Katsuya; Yamaji, Takayuki; Shirakawa, Kiyoharu; Kuroda, Satoru; Akahane, Atsushi; Iwashita, Akinori; Matsukawa, Nobuya; Mutoh, Seitaro  
 CORPORATE SOURCE: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan  
 SOURCE: Journal of Pharmacological Sciences (Tokyo, Japan) (2004), 96(1), 42-52  
 CODEN: JPSTGJ; ISSN: 1347-8613  
 PUBLISHER: Japanese Pharmacological Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Adenosine A1 receptors in the brain are believed to play an important role in brain functioning. We have discovered a novel adenosine A1 receptor antagonist, FR194921 (2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone), and characterized the pharmacol. activity in the present study. FR194921 showed potent and selective affinity for the adenosine A1 receptor without affinity for A2A and A3 receptors and did not show any species differences in binding affinity profile among human, rat, and mouse. Pharmacokinetic study in rats revealed that FR194921 was orally active and highly brain penetrable. Oral administration of FR194921 dose-dependently ameliorated the hypolocomotion induced by the A1 receptor agonist N6-cyclopentyladenosine in rats, indicating this compound exerts A1-antagonistic action in vivo. In the passive avoidance test, scopolamine (1 mg/kg)-induced memory deficits were significantly ameliorated by FR194921 (0.32, 1 mg/kg). In two animal models of anxiety, the social interaction test and elevated plus maze, FR194921 showed specific anxiolytic activity without significantly influencing general behavior. In contrast, FR194921 did not show antidepressant activity even at a dose of 32 mg/kg in the rat forced swimming test. These results indicate that the novel, potent, and selective adenosine A1 receptor antagonist FR194921 exerts both cognitive-enhancing and anxiolytic activity, suggesting the therapeutic potential of this compound for dementia and anxiety disorders.  
 IT 202646-80-8, FR 194921  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacol. characterization of FR194921)  
 RN 202646-80-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 23 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:343857 CAPLUS  
 DOCUMENT NUMBER: 141:058831  
 TITLE: Effects of the adenosine A1 receptor inhibitor FK 838 on proximal tubular fluid output in rats  
 AUTHOR(S): Bak, Martin; Thomsen, Klaus  
 CORPORATE SOURCE: Institute for Basic Psychiatric Research, Department of Biological Psychiatry, Aarhus University Hospital, Risskov, DK-8240, Den.  
 SOURCE: Nephrology, Dialysis, Transplantation (2004), 19(5), 1077-1082  
 CODEN: NDTREA; ISSN: 0931-0509  
 PUBLISHER: Oxford University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Background. Adenosine A1 receptor blockade has been suggested as a treatment in conditions with sodium and fluid retention because it increases urinary Na<sup>+</sup> excretion and increases proximal tubular fluid output. In the present study, we examine the time course for the renal responses to adenosine A1 receptor blockade in order to investigate whether the effects may be prolonged and not just temporary. Methods. The acute effects of the adenosine A1 receptor inhibitor FK 838 on segmental tubular Na<sup>+</sup> handling were examined by a renal clearance technique in conscious chronically instrumented rats. Lithium clearance (CL<sub>Li</sub>) was used as a clearance marker of proximal tubular fluid output. Results. Acute adenosine A1 receptor inhibition did not affect the glomerular filtration rate (GFR) significantly. In contrast, the inhibition led to significant increases in CL<sub>Li</sub> (from 290 $\pm$ 28 to 431 $\pm$ 28  $\mu\text{L}/\text{min}/100$  g), fractional Li<sup>+</sup> excretion (FELi) (from 33 $\pm$ 2 to 47 $\pm$ 3%) and fractional Na<sup>+</sup> excretion (FENa) (from 0.44 $\pm$ 0.07 to 2.03 $\pm$ 0.42%). Sodium excretion, expressed as a fraction of proximal tubular fluid output (CNa/CL<sub>Li</sub>), rose from 1.3 $\pm$ 0.2 to 4.2 $\pm$ 0.4%, suggesting that the natriuretic effect was supported by inhibition of distal nephron Na<sup>+</sup> reabsorption. All values returned to baseline values during the clearance study and thereby indicated that neither proximal tubular fluid output nor urinary sodium excretion remained elevated for a prolonged time. Conclusion. It is concluded that in conscious unstressed rats, acute adenosine A1 receptor inhibition by FK 838 led to a significant natriuresis that was caused by inhibition of proximal tubular Na<sup>+</sup> reabsorption, possibly with a contribution from inhibition of distal nephron Na<sup>+</sup> reabsorption. The increased proximal tubular fluid output and the increased urinary Na<sup>+</sup> excretion returned to baseline values during the clearance study, indicating that none of these effects of adenosine A1 blockade were long lasting.  
 IT 131185-37-0, FK 838  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (diuretic FK 838 increased CL<sub>Li</sub>, FELi, CNa/CL<sub>Li</sub> and FENa without causing any significant change in GFR in conscious rat showing that natriuretic effect was due to combined effect on proximal tubules and distal nephron)  
 RN 131185-37-0 CAPLUS  
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:333716 CAPLUS  
DOCUMENT NUMBER: 140:357367  
TITLE: Preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection  
INVENTOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 80 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033454	A1	20040422	WO 2003-US30334	20030924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003275266	A1	20040504	AU 2003-275266	20030924
EP 1546148	A1	20050629	EP 2003-759640	20030924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006504728	T	20060209	JP 2004-543022	20030924
US 2005282842	A1	20051222	US 2005-530101	20050401
US 7153863	B2	20061226		
US 2007112014	A1	20070517	US 2006-554615	20061031
PRIORITY APPLN. INFO.:			US 2002-415939P	P 20021003
			WO 2003-US30334	W 20030924
			US 2005-530101	A3 20050401
OTHER SOURCE(S):		MARPAT 140:357367		
GI				



AB The title compds. [1; p = 0-4; R1 = halo, alkyl, cycloalkyl, etc.; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; R5 = H, halo, alkyl, etc.] were prepared. Thus, coupling 2-fluoro-4-iodopyridine with pentyne followed by reacting 2-fluoro-4-(pent-1-ynyl)pyridine with 1-aminopyridinium iodide afforded


L4 ANSWER 24 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
3-(2-fluoropyridin-4-yl)-2-propylpyrazolo[1,5-a]pyridine which showed IC50 of >40  $\mu$ M against HSV-1. The pharmaceutical compns. comprising the compd. I are claimed.

IT 681262-20-4P, 2-Cyclopropyl-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 681262-21-5P, N-Cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681262-22-6P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-cyclopropylpyrazolo[1,5-a]pyridin-7-amine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection)


RN 681262-20-4 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-cyclopropyl-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 681262-21-5 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 681262-22-6 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-cyclopropyl- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:267334 CAPLUS  
 DOCUMENT NUMBER: 140:303661  
 TITLE: Preparation of pyrazolopyridines as TGF- $\beta$  signal transduction inhibitors useful against cancer and other diseases  
 INVENTOR(S): Beight, Douglas Wade; Bonjouklian, Rosanne; Liao, Junkai; McMillen, William Thomas; Parkhurst, Brandon Lee; Sawyer, Jason Scott; Yingling, Jonathan Michael; York, Jeremy Schulenburg  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 98 pp.  
 CODEN: P1XXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026871	A1	20040401	WO 2003-US26297	20030916
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003268156	A1	20040408	AU 2003-268156	20030916
EP 1543001	A1	20050622	EP 2003-749105	20030916
EP 1543001	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 370139	T	20070915	AT 2003-749105	20030916
US 2005222197	A1	20051006	US 2005-524577	20050215
PRIORITY APPLN. INFO.:			US 2002-411560P	P 20020917
			WO 2003-US26297	W 20030916
OTHER SOURCE(S):	MARPAT 140:303661			
GI				




L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Quinoline, 7-methoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-52-5 CAPLUS  
 CN Quinoline, 7-methoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 676343-74-1 CAPLUS  
 CN Benzaldehyde, 2-fluoro-5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 676343-84-3 CAPLUS  
 CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-03-9 CAPLUS

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 AB Novel pyrazolopyridines (shown as I; variables defined below; e.g. II) are disclosed and their use as pharmaceutical agents, in particular their use as TGF- $\beta$  signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF  $\beta$ . Inhibitory activities (IC50 in  $\mu$ M) for >100 examples of I against TGF- $\beta$  type I receptor kinase, TGF- $\beta$  type II receptor kinase, p38 $\alpha$ /SAPK2 $\alpha$ , and TGF- $\beta$  dependent luciferase production was at least 10, 20, and 20, resp.; several specific values in each case are reported, e.g. 0.102  $\mu$ M for 4-[2-(5-butylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline in the TGF- $\beta$  type I receptor kinase test. Although the methods of preparation are not claimed, .apprx.130 I and .apprx.90 intermediate example preps. and/or characterization data are included. For example, II was prepared (62 %) by coupling


3-bromo-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine with p-fluorophenylboronic acid. The pyridine reactant was prepared by action of N-bromosuccinimide on 2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid, which was prepared by base hydrolysis of 2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid Et ester, which was prepared by cyclization of 1-aminopyridinium iodide with (6-methylpyridin-2-yl)propynoic acid Et ester, which was prepared by reaction of Et chloroformate and BuLi with 2-ethynyl-6-methylpyridine, which was prepared from 2-bromo-6-methylpyridine and trimethylsilylacetylene. For I: R1 is (un)substituted pyridine, furyl or thiophenyl; R2 is (un)substituted quinoline, Ph, naphthalene, pyridine, quinazoline, cinnoline, indole, imidazo[1,2-a]pyridin-2-yl, benzofuran, dihydrobenzofuran, dihydrobenzo[1,4]dioxane, benzodioxolane, benzothienophene, 2-aminobenzimidazole, imidazo[1,2-a]pyridine. R7 is H, benzyl, aryl, C1-C4 alkyl, halogen, -CO2(C1-C4 alkyl), -CONR6R6, -C1-C4 alc., -SO2(C1-C4 alkyl), or -COR8, wherein R5 is (C1-C4 alkyl)R9, R8 is (C1-C4 alkyl) or (C2-C4 alkenyl), and R9 is NR3R4, wherein R3 and R4 = (C1-C4 alkyl); addnl. details are given in the claims.

IT 676343-50-3P, 7-Methoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-52-5P, 7-Methoxy-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-74-1P, 2-Fluoro-5-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzaldehyde 676343-84-3P, 4-[2-(6-chloropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-03-9P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid ethyl ester 676344-04-0P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-4-carboxylic acid ethyl ester 676344-14-2P, 7-Bromo-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-19-7P, 2-(6-Chloropyridin-2-yl)-3-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine 676344-23-3P, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-bromoquinoline 676344-24-4P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid ethyl ester 676344-25-5P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid ethyl ester 676344-29-9P, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid methyl ester 676344-40-4P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]acrylic acid methyl ester 676344-54-0P, [3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-6-yl]methanol  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Drug candidate: preparation of pyrazolopyridines as TGF- $\beta$  signal transduction inhibitors useful against cancer and other diseases)  
 RN 676343-50-3 CAPLUS


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (CA INDEX NAME)




RN 676344-04-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 676344-14-2 CAPLUS  
 CN Quinoline, 7-bromo-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-19-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(6-chloro-2-pyridinyl)-3-(4-fluorophenyl)- (CA INDEX NAME)







L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 RN 676344-23-3 CAPLUS  
 CN Quinoline, 7-bromo-4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 676344-24-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 2-(2-pyridinyl)-3-(4-quinolinyl)-, ethyl ester (CA INDEX NAME)




RN 676344-25-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(2-pyridinyl)-3-(4-quinolinyl)-, ethyl ester (CA INDEX NAME)




RN 676344-29-9 CAPLUS  
 CN 7-Quinolincarboxylic acid, 4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 676344-40-4 CAPLUS  
 CN 2-Propenoic acid, 3-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]-, methyl ester (CA INDEX NAME)



RN 676344-54-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




IT 676343-55-8P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-58-1P, Dimethyl[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]amine 676343-59-2P, 3-(4-Methoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-60-5P, 3-[4-(Methanesulfonyl)phenyl]-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-61-6P, 2-(6-Methylpyridin-2-yl)-3-phenylpyrazolo[1,5-a]pyridine 676343-62-7P, 2-(6-Methylpyridin-2-yl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyridine 676343-63-8P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-6-phenylpyrazolo[1,5-a]pyridine 676343-64-9P, 3-(4-Fluorophenyl)-6-methanesulfonyl-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-65-0P, 2-(6-Methylpyridin-2-yl)-3-(4-trifluoromethylphenyl)pyrazolo[1,5-a]pyridine 676343-66-1P, 3-(6-Methoxypyridin-3-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-67-2P, 3-(Benzodioxol-5-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-68-3P,

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 3-(3,5-Difluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-69-4P, 2-(6-Methylpyridin-2-yl)-3-(p-tolyl)pyrazolo[1,5-a]pyridine 676343-70-7P, 3-(1H-Indol-5-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-71-8P, 3-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzamide 676343-72-9P, 3-(3,4-Dimethoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-73-0P, N,N-Dimethyl-3-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzamide 676343-75-2P, [4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]amine 676343-76-3P, N-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]acetamide 676343-77-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenol 676343-78-5P, 3-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-79-6P, 3-(3-Methoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-80-9P, 3-(3-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-81-0P, 2-(6-Ethylpyridin-2-yl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine 676343-82-1P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenol 676343-83-2P, N'-[2-Fluoro-5-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzyl]-N,N-dimethylethane-1,2-diamine 676343-85-4P, 3-(4-Fluorophenyl)-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-86-5P, 7-Ethoxy-4-[4-phenyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-87-6P, 7-Ethoxy-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-88-7P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-89-8P, 7-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-90-1P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-91-2P, 6,7-Dimethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-92-3P, 7-Chloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-93-4P, 6-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-94-5P, 3-(4-Fluoronaphthalen-1-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-95-6P, 4-[2-(Furan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-96-7P, 4-[2-(Thiophen-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-97-8P, 6,7-Difluoro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-98-9P, 6,7-Dichloro-4-[2-(6-ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-99-0P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-6,7-dimethoxyquinoline 676344-00-6P, 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-01-7P, 7-Ethoxy-4-[2-(6-ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-02-8P, 2-(6-Ethylpyridin-2-yl)-3-(4-Fluoronaphthalen-1-yl)pyrazolo[1,5-a]pyridine 676344-05-1P, 3-(4-Fluorophenyl)-4-iodo-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-06-2P, 3-(4-Fluorophenyl)-2-(6-propylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-07-3P, 2-(6-Ethylpyridin-2-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 676344-08-4P, 3-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-09-5P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-10-8P, 4-[2-(6-Fluoropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-11-9P, 4-[2-(5-Butylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-12-0P, 8-Fluoro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-13-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-6-trifluoromethylquinoline 676344-15-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-trifluoromethylquinoline 676344-16-4P, 3-(3-Chloro-4-Fluorophenyl)-2-(6-methylpyridin-2-


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 yl)pyrazolo[1,5-a]pyridine 676344-17-5P, 2-(6-Methylpyridin-2-yl)-3-[2-(4,5-Trifluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]phenylamine 676344-18-6P, 3-(4-Fluoro-2-methylphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-20-0P, 4-[2-(5-Bromopyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-21-1P, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-22-2P, 4-[5-Benzyl-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-bromoquinoline 676344-26-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid methyl ester 676344-27-7P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-6-carboxylic acid methyl ester 676344-30-2P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylaminoethyl)amide 676344-31-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 676344-32-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (2-dimethylaminoethyl)amide 676344-33-5P, 5-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzofuran-2-carboxylic acid (2-dimethylaminoethyl)amide 676344-34-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide 676344-35-7P, 4-[2-(6-Methoxypyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-36-8P, 4-[2-(6-Ethoxypyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-37-9P, 3-(4-Fluorophenyl)-2-(6-methoxypyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-38-0P, 2-(6-Ethoxypyridin-2-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 676344-39-1P, 7-Benzyl-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-41-5P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]acrylic acid 676344-42-6P, 4-[2-(6-Ethylsulfanylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-43-7P, 4-[2-(6-Phenylsulfanylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-44-8P, 4-[2-(6-Morpholin-4-yl)pyridin-2-yl]pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-45-9P, 3-(4-Fluorophenyl)-2-(6-methylsulfanylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-46-0P, 3-(4-Methylsulfanylphenyl)-2-(6-methylsulfanylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-47-1P, Dimethyl[2-[(4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)sulfanyl]ethyl]amine 676344-48-2P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid dimethylamide 676344-49-3P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid dimethylamide 676344-50-6P, 4-[2-(6-Vinylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-51-7P, [6-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]aminodiazol-1,2-yl]pyridine 676344-52-8P, [6-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-1H-benzimidazol-2-yl]amine 676344-55-1P, 6-[(Allyloxy)methyl]-3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-56-2P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(pyrrolidin-1-yl)propyl]amide 676344-57-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]propionamide 676344-58-4P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]-N-[3-(pyrrolidin-1-yl)propyl]propionamide 676344-59-5P, N-(2-Dimethylaminoethyl)-3-[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]propionamide 676344-60-8P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid (3-dimethylaminopropyl)amide 676344-61-9P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (2-hydroxyethyl)amide 676344-62-0P

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 , 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic hydrazide 676344-63-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-hydroxypropyl)amide 676344-64-2P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid methylamide 676344-65-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-ethoxypropyl)amide 676344-66-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(morpholin-4-yl)propyl]amide 676344-67-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(imidazol-1-yl)propyl]amide 676344-68-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-dimethylaminopropyl)amide 676344-69-7P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [2-(2-methoxyphenyl)ethyl]amide 676344-70-0P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [2-(morpholin-4-yl)ethyl]amide 676344-71-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid amide 676344-72-2P, Dimethyl[3-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-73-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(morpholin-4-yl)ethoxy]quinoline 676344-74-4P, Diisopropyl[2-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-75-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(pyrrol-1-yl)ethoxy]quinoline 676344-76-6P, Dimethyl[1-methyl-2-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-77-7P, Methyl[3-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-78-8P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(piperidin-1-yl)ethoxy]quinoline 676344-79-9P, Diethyl[2-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-80-2P, Dimethyl[3-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-81-3P, 7-[2-(Morpholin-4-yl)ethoxy]-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-82-4P, Diisopropyl[2-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-83-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(morpholin-4-yl)propoxy]quinoline 676344-84-6P, 1-[3-[[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]-1,3-dihydrobenzimidazol-2-one 676344-85-7P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]propionic acid methyl ester 676344-86-8P, Diethyl[3-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-87-9P, (Ethyl)(methyl)[3-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-88-0P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinoline 676344-89-1P, 7-[3-(Piperidin-1-yl)propoxy]-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-90-4P, Diethyl[2-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-91-5P, Dimethyl[2-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; prepn. of pyrazolopyridines as TGF- $\beta$  signal transduction inhibitors useful against cancer and other diseases)  
 RN 676343-55-8 CAPLUS


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 676343-62-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 676343-63-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-phenyl- (CA INDEX NAME)




RN 676343-64-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-(methylsulfonyl)- (CA INDEX NAME)




RN 676343-65-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-58-1 CAPLUS  
 CN Benzenamine, N,N-dimethyl-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 676343-59-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(4-methoxyphenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-60-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676343-61-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-phenyl- (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 676343-66-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridinyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-67-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(1,3-benzodioxol-5-yl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-68-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(3,5-difluorophenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-69-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(4-methylphenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-70-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(1H-indol-5-yl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-71-8 CAPLUS  
CN Benzamide, 3-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-72-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3,4-dimethoxyphenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-73-0 CAPLUS  
CN Benzamide, N,N-dimethyl-3-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-79-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3-methoxyphenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-80-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-81-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)




RN 676343-82-1 CAPLUS  
CN Phenol, 4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-75-2 CAPLUS  
CN Benzenamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-76-3 CAPLUS  
CN Acetamide, N-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]- (CA INDEX NAME)




RN 676343-77-4 CAPLUS  
CN Phenol, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-78-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-83-2 CAPLUS  
CN 1,2-Ethanediamine, N'-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]methyl-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 676343-85-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 676343-86-5 CAPLUS  
CN Quinoline, 7-ethoxy-4-[4-phenyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-87-6 CAPLUS  
CN Quinoline, 7-ethoxy-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-88-7 CAPLUS  
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-89-8 CAPLUS  
CN Quinoline, 7-ethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-90-1 CAPLUS  
CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-91-2 CAPLUS  
CN Quinoline, 6,7-dimethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-95-6 CAPLUS  
CN Quinoline, 4-[2-(2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-96-7 CAPLUS  
CN Quinoline, 4-[2-(2-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-97-8 CAPLUS  
CN Quinoline, 6,7-difluoro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-98-9 CAPLUS  
CN Quinoline, 6,7-dichloro-4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-92-3 CAPLUS  
CN Quinoline, 7-chloro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-93-4 CAPLUS  
CN Quinoline, 6-ethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-94-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluoro-1-naphthalenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676343-99-0 CAPLUS  
CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 676344-00-6 CAPLUS  
CN Quinoline, 6,7-dichloro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-01-7 CAPLUS  
CN Quinoline, 7-ethoxy-4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)





RN 676344-02-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-fluoro-1-naphthalenyl)- (CA INDEX NAME)




RN 676344-05-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-4-iodo-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676344-06-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-propyl-2-pyridinyl)- (CA INDEX NAME)



RN 676344-12-0 CAPLUS  
CN Quinoline, 8-fluoro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-13-1 CAPLUS  
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 676344-15-3 CAPLUS  
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-(trifluoromethyl)- (CA INDEX NAME)


RN 676344-07-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 676344-08-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(2-pyridinyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 676344-09-5 CAPLUS  
CN Quinoline, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-10-8 CAPLUS  
CN Quinoline, 4-[2-(6-fluoro-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-11-9 CAPLUS  
CN Quinoline, 4-[2-(5-butyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-16-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3-chloro-4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676344-17-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(2,4,5-trifluorophenyl)- (CA INDEX NAME)




RN 676344-18-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[4-fluoro-3-(trifluoromethyl)phenyl]-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676344-20-0 CAPLUS  
CN Quinoline, 4-[2-(5-bromo-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 676344-21-1 CAPLUS  
CN Quinoline, 4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-22-2 CAPLUS  
CN Quinoline, 7-bromo-4-[2-(6-methyl-2-pyridinyl)-5-(phenylmethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-26-6 CAPLUS  
CN 7-Quinolinecarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (CA INDEX NAME)


RN 676344-32-4 CAPLUS  
CN 7-Quinolinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-33-5 CAPLUS  
CN 2-Benzofurancarboxamide, N-[2-(dimethylamino)ethyl]-5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-34-6 CAPLUS  
CN 7-Quinolinecarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-35-7 CAPLUS  
CN Quinoline, 4-[2-(6-methoxy-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)





RN 676344-27-7 CAPLUS  
CN 6-Quinolinecarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (CA INDEX NAME)




RN 676344-30-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 676344-31-3 CAPLUS  
CN 6-Quinolinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-36-8 CAPLUS  
CN Quinoline, 4-[2-(6-ethoxy-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-37-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methoxy-2-pyridinyl)- (CA INDEX NAME)




RN 676344-38-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethoxy-2-pyridinyl)-3-(4-fluorophenyl)- (CA INDEX NAME)




L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 676344-39-1 CAPLUS  
 CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-(phenylmethyl)- (CA INDEX NAME)



RN 676344-41-5 CAPLUS  
 CN 2-Propenoic acid, 3-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 676344-42-6 CAPLUS  
 CN Quinoline, 4-[2-[6-(ethylthio)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-43-7 CAPLUS  
 CN Quinoline, 4-[2-[6-(phenylthio)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 676344-47-1 CAPLUS  
 CN Ethanamine, N,N-dimethyl-2-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]thio]- (CA INDEX NAME)




RN 676344-48-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N,N-dimethyl-2-(2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)




RN 676344-49-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N,N-dimethyl-2-(2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)




L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676344-44-8 CAPLUS  
 CN Quinoline, 4-[2-[6-(4-morpholinyl)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-45-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-[6-(methylthio)-2-pyridinyl]- (CA INDEX NAME)




RN 676344-46-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylthio)phenyl]-2-[6-(methylthio)-2-pyridinyl]- (CA INDEX NAME)

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 676344-50-6 CAPLUS  
 CN Quinoline, 4-[2-(6-ethenyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-51-7 CAPLUS  
 CN Imidazo[1,2-a]pyridin-2-amine, 6-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 676344-52-8 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-55-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-[(2-propenyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 676344-56-2 CAPLUS


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 7-Quinolinescarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 676344-57-3 CAPLUS  
 CN 7-Quinolinespropanamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-58-4 CAPLUS  
 CN 7-Quinolinespropanamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 676344-59-5 CAPLUS  
 CN 7-Quinolinespropanamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676344-63-1 CAPLUS  
 CN 7-Quinolinescarboxamide, N-(3-hydroxypropyl)-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-64-2 CAPLUS  
 CN 7-Quinolinescarboxamide, N-methyl-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-65-3 CAPLUS  
 CN 7-Quinolinescarboxamide, N-(3-ethoxypropyl)-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676344-60-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[3-(dimethylamino)propyl]-2-(2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)




RN 676344-61-9 CAPLUS  
 CN 7-Quinolinescarboxamide, N-(2-hydroxyethyl)-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-62-0 CAPLUS  
 CN 7-Quinolinescarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrazide (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676344-66-4 CAPLUS  
 CN 7-Quinolinescarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 676344-67-5 CAPLUS  
 CN 7-Quinolinescarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-68-6 CAPLUS  
 CN 7-Quinolinescarboxamide, N-[3-(dimethylamino)propyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 676344-69-7 CAPLUS  
CN 7-Quinolincarboxamide, N-[2-(2-methoxyphenyl)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-70-0 CAPLUS  
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 676344-71-1 CAPLUS  
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(1H-pyrrol-1-yl)ethoxy]- (CA INDEX NAME)





RN 676344-76-6 CAPLUS  
CN 2-Propanamine, N,N-dimethyl-1-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 676344-77-7 CAPLUS  
CN 1-Propanamine, N-methyl-3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 676344-78-8 CAPLUS  
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 676344-72-2 CAPLUS  
CN 1-Propanamine, N,N-dimethyl-3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 676344-73-3 CAPLUS  
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 676344-74-4 CAPLUS  
CN 2-Propanamine, N-(1-methylethyl)-N-[2-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 676344-75-5 CAPLUS

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


RN 676344-79-9 CAPLUS  
CN Ethanamine, N,N-diethyl-2-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 676344-80-2 CAPLUS  
CN 1-Propanamine, N,N-dimethyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 676344-81-3 CAPLUS  
CN Quinoline, 7-[2-(4-morpholinyl)ethoxy]-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-82-4 CAPLUS  
CN 2-Propanamine, N-(1-methylethyl)-N-[2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 676344-83-5 CAPLUS

CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)




RN 676344-84-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 676344-85-7 CAPLUS


CN 7-Quinolonepropanoic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (CA INDEX NAME)



RN 676344-86-8 CAPLUS


CN 1-Propanamine, N,N-diethyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676344-91-5 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




IT 676344-28-8, 6-Bromo-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline


RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrazolopyridines as TGF-β signal transduction inhibitors useful against cancer and other diseases)

RN 676344-28-8 CAPLUS

CN Quinoline, 6-bromo-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




IT 676343-49-0P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-ol 676343-51-4P, 4-[2-(2-pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-ol 676343-53-6P, 7-(3-Chloropropoxy)-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-54-7P, 7-(2-Chloroethoxy)-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-53-9P, [6-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-1-(propan-2-ylsulfonyl)-1H-benzimidazol-2-yl]amine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)




RN 676344-87-9 CAPLUS

CN 1-Propanamine, N-ethyl-N-methyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 676344-88-0 CAPLUS

CN Quinoline, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 676344-89-1 CAPLUS

CN Quinoline, 7-[3-(1-piperidinyl)propoxy]-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 676344-90-4 CAPLUS


CN Ethanamine, N,N-diethyl-2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)

L4 ANSWER 25 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(prepn. of pyrazolopyridines as TGF-β signal transduction inhibitors useful against cancer and other diseases)


RN 676343-49-0 CAPLUS

CN 7-Quinololinol, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-51-4 CAPLUS

CN 7-Quinololinol, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-53-6 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676343-54-7 CAPLUS

CN Quinoline, 7-(2-chloroethoxy)-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 676344-53-9 CAPLUS  
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:220201 CAPLUS  
DOCUMENT NUMBER: 140:270867  
TITLE: Preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4  
INVENTOR(S): Lee, Wen-chen; Carter, Mary Beth; Sun, Lihong; Lyne, Paul; Chuaqui, Claudio; Zheng, Zhongli; Singh, Juswinder; Borlack-Sjodin, Paula  
PATENT ASSIGNEE(S): Biogen, Inc., USA  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022054	A1	20040318	WO 2003-US27722	20030905
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2497970	A1	20040318	CA 2003-2497970	20030905
AU 2003268447	A1	20040329	AU 2003-268447	20030905
EP 1551398	A1	20050713	EP 2003-749412	20030905
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014053	A	20050719	BR 2003-14053	20030905
CN 1694698	A	20051109	CN 2003-824867	20030905
JP 2006502165	T	20060119	JP 2004-534571	20030905
NZ 539069	A	20070330	NZ 2003-539069	20030905
IN 2005000810	A	20070302	IN 2005-00810	20050302
MX 2005PA02443	A	20050930	MX 2005-PA2443	20050303
ZA 2005001856	A	20060426	ZA 2005-1856	20050303
NO 2005001503	A	20050321	NO 2005-1503	20050321
US 2006106033	A1	20060518	US 2005-526839	20051101
PRIORITY APPLN. INFO.:			US 2002-408811P	P 20020906
			WO 2003-US27722	W 20030905
OTHER SOURCE(S):		HARPAT 140:270867		
GI				




AB The title compds. (I) wherein each of X1-X4 is independently CRM or N; provided that only two of X1-X4 can be W simultaneously; each of Y1 and Y2 is independently CRY or N; provided that at least one of Y1 and Y2 must be N; R1 = alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfenyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, etc.; R2 = alkyl, alkenyl, alkynyl, acyl, halo, hydroxy, NH2, NH(alkyl), N(alkyl)2, NH(cycloalkyl), N(alkyl)(cycloalkyl), NH(heterocycloalkyl), NH(heteroaryl), NH-alkylheteroaryl, NH(aralkyl), cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, aroyl, heterocycloalkyl, (heterocycloalkyl)alkyl, etc.; m = an integer of 0-4; n = an integer of 0-3; provided that when m > 2, two adjacent R1 or R2 groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety; Rx, Ry = H, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfenyl, alkylsulfonyl, cycloalkylcarbonyl, (cycloalkyl)alkylcarbonyl, aroyl, aralkylcarbonyl, etc.] or pharmaceutically acceptable salts or N-oxides thereof. These compds. possess unexpectedly high affinity for transforming growth factor  $\beta$  (TGF $\beta$ ) type I receptor (Alk 5) and/or activin receptor type I (Alk 4), and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders or diseases or disorders mediated by an overexpression of TGF $\beta$ . The fibrotic condition is selected from the group consisting of scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis, restenosis, cardiac fibrosis, ophthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, and keloid. The diseases or disorders mediated by an overexpression of TGF $\beta$  are selected from the group consisting of demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.


IT 672932-46-6P, [4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 672932-50-2P, [4-(2-Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 672932-51-3P, 2-(6-Methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)pyrazolo[1,5-a]pyridine  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4 for treating fibrotic disorders or diseases or disorders mediated by an overexpression of TGF $\beta$ )


RN 672932-46-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 672932-50-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 672932-51-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:827761 CAPLUS

DOCUMENT NUMBER: 140:59556

TITLE: Pyrazolo[1,5-a]pyridines: synthetic approaches to a novel class of antiherpetics  
 AUTHOR(S): Johns, Brian A.; Gudmundsson, Kristjan S.; Turner, Elizabeth M.; Allen, Scott H.; Jung, David K.; Sexton, Connie J.; Boyd, F. Leslie; Peel, Michael R.

CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Virology, GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709-3398, USA

SOURCE: Tetrahedron (2003), 59(45), 9001-9011

CODEN: TETRAH; ISSN: 0040-4020

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:59556

AB Synthesis of a novel class of 7-amino-3-pyrimidinylpyrazolo[1,5-a]pyridine antiherpetic compds. is described. The synthetic methodol. is designed to allow for rapid analog synthesis around the C-3 and C-7 positions of the pyrazolo[1,5-a]pyridine. 7-Chloropyrazolo[1,5-a]pyridine, produced through an azirine rearrangement, served as a key building block. Two complementary methodologies for construction of the C-3 pyrimidine are described. These methods include the development of a novel cyclization utilizing alkynyl ketones or enones to give highly substituted pyrimidines. The outlined strategies facilitated late stage manipulation of either the C-3 or C-7 positions providing flexibility for rapid analog synthesis. Comps. thus prepared included N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-1,2-ethanediamine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]glycine Me ester, etc. Only the preparation of these compds. was reported; pharmacol. data were not given.


IT 437612-03-8P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl-2-pyrimidinamine 437612-22-1P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 437612-48-1P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl-2-pyrimidinamine 437612-94-7P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-2-pyrimidinamine 437612-97-0P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl-2-pyrimidinamine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolo[1,5-a]pyridine derivs.)


RN 437612-03-8 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl- (CA INDEX NAME)




RN 437612-97-0 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl- (CA INDEX NAME)




IT 437611-97-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-04-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-10-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl-2-pyrimidinamine 437612-11-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl-2-pyrimidinamine 437612-12-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-15-2P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-2-pyrimidinamine hydrochloride 437612-16-3P, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]glycine methyl ester 437612-49-2P, N-Cyclopentyl-3-[2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-78-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine




RN 437612-22-1 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 437612-48-1 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl- (CA INDEX NAME)




RN 437612-94-7 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-2-pyrimidinamine (CA INDEX NAME)

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of pyrazolo[1,5-a]pyridine derivs.)


RN 437611-97-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-04-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-10-7 CAPLUS


CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 437612-11-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (CA INDEX NAME)




RN 437612-12-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-[[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-15-2 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (CA INDEX NAME)




RN 437612-49-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-78-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-16-3 CAPLUS  
CN 1,2-Ethanediamine, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 437612-19-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 437612-20-9 CAPLUS



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:740795 CAPLUS

DOCUMENT NUMBER: 139:301697

TITLE: An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats

AUTHOR(S): Schnackenberg, Christine G.; Merz, Emily; Brooks, David P.

CORPORATE SOURCE: Department of Renal Biology, UW 2521, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA

SOURCE: British Journal of Pharmacology (2003), 139(8), 1383-1388

CODEN: BJPCRM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 1 Loop and thiazide diuretics are common therapeutic agents for the treatment of sodium retention and edema. However, resistance to diuretics and decreases in renal function can develop during diuretic therapy. Adenosine causes renal vasoconstriction, sodium resorption, and participates in the tubuloglomerular feedback mechanism for the regulation of glomerular filtration rate. 2 We tested the hypothesis that the selective adenosine A1 receptor antagonist FK838 is orally active and causes diuresis and natriuresis, but maintains glomerular filtration rate in normal rats or in rats with furosemide resistance. 3 In normal male Sprague-Dawley rats, FK838 dose-dependently increased urine flow and sodium and chloride excretion while sparing potassium. In combination with furosemide, FK838 enhanced the diuretic and natriuretic actions of furosemide to the same extent as hydrochlorothiazide and did not increase the potassium loss in normal rats. In furosemide-resistant rats, FK838 increased urine flow and electrolyte excretion to a greater extent than hydrochlorothiazide. In addition, hydrochlorothiazide significantly decreased glomerular filtration rate, whereas FK838 maintained glomerular filtration rate in furosemide-resistant rats. 4 This study shows that the adenosine A1 receptor antagonist FK838 is orally active and causes potent diuresis and natriuresis and maintains glomerular filtration rate in normal or furosemide-resistant rats. Adenosine A1 receptor antagonists may be novel therapeutics for the treatment of edema in normal or otherwise diuretic-resistant patients.


IT 131185-37-0, FK838

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 28 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:652131 CAPLUS

DOCUMENT NUMBER: 139:214237

TITLE: Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

INVENTOR(S): Scaramuzzino, Giovanni

PATENT ASSIGNEE(S): Italy

SOURCE: Brit. Pat. Appl., 313 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-425075	20020213

GI



AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as 5-tocopherol, clidanac, diethylhomoserpine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thionitrite, SNO, etc.; T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc.; R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OPO3H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, OZ-M2, NR22-M2, R12-M2, OR1-M2, OR12-M2, M2 = H, R1-M, OR1-M, SR1-M, NR2R1-M; ZM2 = COCH2CH2CH2M3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared For example, a-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines

L4 ANSWER 29 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT 586347-52-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)


RN 586347-52-6 CAPLUS

CN Benzenesulfonamide, 4-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-, mononitrate (9CI) (CA INDEX NAME)

CH 1

CRN 340321-70-2

CHF C20 H17 N3 O3 S



CH 2

CRN 7697-37-2




CHF H N O3




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:472515 CAPLUS  
 DOCUMENT NUMBER: 139:53015  
 TITLE: Preparation of pyrazolopyridine derivatives as antiherpes agents  
 INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 138 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050120	A1	20030619	WO 2002-0537052	20021120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, NE, SN, TD, TG				
AU 2002357740	A1	20030623	AU 2002-357740	20021120
EP 1453830	A1	20040908	EP 2002-792278	20021120
EP 1453830	B1	20070912		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516916	T	20050609	JP 2003-551144	20021120
AT 373000	T	20070915	AT 2002-792278	20021120
US 2004248903	A1	20041209	US 2004-496358	20040520
US 7199120	B2	20070403		
US 2007161653	A1	20070712	US 2006-558005	20061109
PRIORITY APPLN. INFO.:				
US 2001-339585P F 20011211				
WO 2002-0537052 W 20021120				
US 2004-496358 A3 20040520				
OTHER SOURCE(S): MARPAT 139:53015				
GI				



RN 544675-22-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-pyridinyl)- (CA INDEX NAME)



RN 544675-28-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2,3-bis[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-31-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2,3-bis[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)

AB Pyrazolopyridines I [R = (un)substituted aryl, heteroaryl; R1 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted OH, CO2H, CONH2, C(=NH)NH2, SH, S(O)H, SO2H, NH2, acyl, CN, NO2, N3; p = 0-4; R2 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, (un)substituted OH, SH, S(O)H, SO2H, NH2; R3, R4 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, (un)substituted OH, CO2H, CONH2, C5NH2, SH, S(O)H, SO2H, NH2, acyl] were prepared. Thus, 7-chloro-2-(4-pyridinyl)pyrazolo[1,5-a]pyridine was obtained from 6-chloro-2-picolone and Et isonicotinate in 3 steps and was acetylated, treated with cyclopentylamine, and cyclized with N-cyclopentylguanidine to give the pyrazolopyridine II which had IC50 against HSV-1 of 1.5 µM.


IT 544675-24-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 RN (preparation of pyrazolopyridine derivs. as antiherpes agents)

CN 544675-24-3 CAPLUS  
 2-Pyrimidinamine, 4,4'-pyrazolo[1,5-a]pyridine-2,3-diylbis[N-cyclopentyl- (SCI) (CA INDEX NAME)




IT 544675-20-9P 544675-22-1P 544675-28-7P  
 544675-31-2P 544675-32-3P 544675-33-4P  
 544675-34-5P 544675-35-6P 544675-36-7P  
 544675-40-3P 544675-41-4P 544675-42-5P  
 544675-43-6P 544675-44-7P 544675-45-8P  
 544675-46-9P 544675-47-0P 544675-48-1P  
 544675-49-2P 544675-50-5P 544675-51-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 RN (preparation of pyrazolopyridine derivs. as antiherpes agents)


RN 544675-20-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 544675-32-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-2,3-bis[2-(cyclopropylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-33-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-(4-morpholinyl)-2,3-bis[2-(4-morpholinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-34-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-methylpropyl)-2,3-bis[2-[(2-methylpropyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-35-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(phenylmethyl)-2,3-bis[2-[(phenylmethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-36-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(1-methylethyl)-2,3-bis[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 544675-40-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 544675-44-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(2-furanyl)- (CA INDEX NAME)




PAGE 1-A




PAGE 2-A


RN 544675-45-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (CA INDEX NAME)




RN 544675-41-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-[2-(cyclopentylamino)-4-pyrimidinyl]-3-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-42-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-43-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 544675-46-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (CA INDEX NAME)




RN 544675-47-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (CA INDEX NAME)



RN 544675-48-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(2-furanyl)- (CA INDEX NAME)




PAGE 1-A




PAGE 2-A




RN 544675-49-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(2-furanyl)- (CA INDEX NAME)



RN 544675-50-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(5-bromo-2-furanyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 544675-51-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(2-methyl-4-thiazolyl)- (CA INDEX NAME)




IT 544675-66-3P 544675-67-4P 544675-68-5P  
544675-70-9P 544675-71-0P 544675-72-1P  
544675-73-2P 544675-74-3P 544675-75-4P  
544675-76-5P 544675-77-6P 544675-83-4P  
544675-90-3P 544675-91-4P 544675-95-8P  
544675-99-2P 544676-06-4P 544676-07-5P  
544676-08-6P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrazolopyridine derivs. as antiherpes agents)


RN 544675-66-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2,3-bis[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-67-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2,3-bis[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-68-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2,3-bis[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-70-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluoro-4-pyridinyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-71-0 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 544675-72-1 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-[2-[(1-methylethyl)amino]-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 544675-73-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-[2-(cyclopentylamino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 544675-74-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-[(1-methylethyl)amino]-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl-N-(1-methylethyl)- (CA INDEX NAME)




RN 544675-75-4 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-[(1-methylethyl)amino]-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl-N-(1-methylethyl)- (CA INDEX NAME)




RN 544675-76-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)


RN 544675-90-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methyl-2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 544675-91-4 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methyl-2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 544675-95-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 544675-99-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(5-bromo-2-furanyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 544675-77-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-[(1-methylethyl)amino]-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl-N-cyclopentyl- (CA INDEX NAME)



RN 544675-83-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-(2-fluoro-4-pyridinyl)-2-(2-furanyl)- (CA INDEX NAME)




PAGE 1-A




PAGE 2-A




RN 544676-06-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-fluoro-4-pyridinyl)-2-(2-methyl-4-thiazolyl)- (CA INDEX NAME)




RN 544676-07-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methyl-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 544676-08-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(2-methyl-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




IT 544675-26-5P 544675-37-8P 544675-38-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
 USES (Uses)  
 (preparation of pyrazolopyridine derivs. as antiherpes agents)  
 RN 544675-26-5 CAPLUS  
 CN 2-Pyrimidinamine, 4,4'-(7-chloropyrazolo[1,5-a]pyridine-2,3-diyl)bis(N-cyclopentyl)- (9CI) (CA INDEX NAME)




RN 544675-37-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(2-fluoro-4-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 544675-38-9 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



IT 544675-21-0P 544675-30-1P 544675-39-0P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazolopyridine derivs. as antiherpes agents)  
 RN 544675-21-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(methylamino)-4-pyrimidinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 544675-30-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-methoxyethyl)-2,3-bis[2-[(2-methoxyethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 544675-39-0 CAPLUS  
 CN 2-Pyrimidinamine, N-(1-methylethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


ACCESSION NUMBER: 2003:434561 CAPLUS  
 DOCUMENT NUMBER: 139:22210  
 TITLE: Preparation of pyrazolopyridine derivatives as adenosine antagonists  
 INVENTOR(S): Tanaka, Akira; Minagawa, Masatoshi; Akahane, Atsushi  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045950	A1	20030605	WO 2002-JP12381	20021127
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GI, GR, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347633	A1	20030610	AU 2002-347633	20021127
PRIORITY APPLN. INFO.:			AU 2001-9163	A 20011129
OTHER SOURCE(S):		MARPAT 139:22210	WO 2002-JP12381	W 20021127
GI				




AB Pyrazolopyridine compds. of formula I [R1 = H, alkyl, cycloalkyl; R2 = H, (substituted) OH, acyl, (substituted) amino; R3 = H, halo] are prepared. The pyrazolopyridine compds. and salts thereof are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like. Thus, II was prepared and showed adenosine antagonist activity and anticatalepsy activity.  
 IT 537047-93-1P 537047-96-4P 537047-97-5P  
 537047-98-6P 537048-06-9P 537048-11-6P  
 537048-15-0P 537048-16-1P 537048-17-2P


L4 ANSWER 31 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of pyrazolopyridine derivs. as adenosine antagonists)  
 RN 537047-93-1 CAPLUS  
 CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)- (CA INDEX NAME)




RN 537047-96-4 CAPLUS  
 CN 2(1H)-Pyridinone, 5-(5-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 537047-97-5 CAPLUS  
 CN Acetic acid, [[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 537047-98-6 CAPLUS  
 CN Acetic acid, [[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 537048-06-9 CAPLUS  
 CN Carbamic acid, [2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl]-, 1,1-dimethylethyl ester


L4 ANSWER 31 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 537047-87-3P 537047-88-4P 537047-89-5P  
 537047-90-8P 537047-91-9P 537047-92-0P  
 537047-94-2P 537047-95-3P 537047-99-7P  
 537048-00-3P 537048-01-4P 537048-02-5P  
 537048-03-6P 537048-04-7P 537048-05-8P  
 537048-07-0P 537048-08-1P 537048-09-2P  
 537048-10-5P 537048-12-7P 537048-13-8P  
 537048-14-9P 537048-18-3P 537048-19-4P  
 537048-20-7P 537048-21-8P 537048-22-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazolopyridine derivs. as adenosine antagonists)  
 RN 537047-87-3 CAPLUS  
 CN 2(1H)-Pyridinone, 1-methyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 537047-88-4 CAPLUS  
 CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 537047-89-5 CAPLUS  
 CN 2(1H)-Pyridinone, 1-ethyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 31 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 (9CI) (CA INDEX NAME)




RN 537048-11-6 CAPLUS  
 CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[5-[(5-nitro-2-pyridinyl)oxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 537048-15-0 CAPLUS  
 CN Methanesulfonic acid, trifluoro-, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX NAME)




RN 537048-16-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenyl-, methyl ester (CA INDEX NAME)




RN 537048-17-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenyl- (CA INDEX NAME)

L4 ANSWER 31 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 537047-90-8 CAPLUS  
 CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-propyl- (CA INDEX NAME)




RN 537047-91-9 CAPLUS  
 CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 537047-92-0 CAPLUS  
 CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methyl- (CA INDEX NAME)




RN 537047-94-2 CAPLUS  
 CN 2(1H)-Pyridinone, 1-ethyl-5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 537047-95-3 CAPLUS  
 CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-propyl- (CA INDEX NAME)




RN 537047-99-7 CAPLUS  
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)





RN 537048-00-3 CAPLUS  
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 537048-01-4 CAPLUS  
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-ethyl- (CA INDEX NAME)




RN 537048-02-5 CAPLUS  
CN 2(1H)-Pyridinone, 5-[5-(2-(dimethylamino)ethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-1-(1-methylethyl)- (CA INDEX NAME)




RN 537048-09-2 CAPLUS  
CN 2(1H)-Pyridinone, 5-[5-(2-(methylamino)ethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 537048-10-5 CAPLUS  
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[2-phenyl-5-[(tetrahydro-2H-pyran-2-yl)methoxy]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 537048-12-7 CAPLUS  
CN 2(1H)-Pyridinone, 5-[5-[(5-amino-2-pyridinyl)oxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-1-(1-methylethyl)- (CA INDEX NAME)




RN 537048-13-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


RN 537048-03-6 CAPLUS  
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[5-[2-(4-morpholinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 537048-04-7 CAPLUS  
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[2-phenyl-5-(2-pyridinyloxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 537048-05-8 CAPLUS  
CN 2(1H)-Pyridinone, 5-[5-(2-methoxyethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-1-(1-methylethyl)- (CA INDEX NAME)




RN 537048-07-0 CAPLUS  
CN 2(1H)-Pyridinone, 5-[5-(2-aminoethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-1-(1-methylethyl)- (CA INDEX NAME)




RN 537048-08-1 CAPLUS  
CN Carbamic acid, [2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-14-9 CAPLUS  
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[2-phenyl-5-(4-piperidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 537048-18-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 537048-19-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-N-methyl-2-phenyl- (CA INDEX NAME)




RN 537048-20-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-N-ethyl-2-phenyl- (CA INDEX NAME)




RN 537048-21-8 CAPLUS  
CN Carbamic acid, [3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-22-9 CAPLUS  
CN 2-(1H)-Pyridinone, 5-(2-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)- (CA INDEX NAME)




IT 131185-46-1P 537048-24-1P 537048-25-2P  
537048-26-3P 537048-27-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrazolopyridine derivs. as adenosine antagonists)  
RN 131185-46-1 CAPLUS  
CN 2-(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 537048-24-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[6-(methylsulfonyl)-3-pyridinyl]-2-phenyl- (CA INDEX NAME)




RN 537048-25-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridinyl)-2-phenyl- (CA INDEX NAME)



RN 537048-26-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridinyl]- (CA INDEX NAME)



RN 537048-27-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-3-(6-methoxy-3-pyridinyl)-2-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:251382 CAPLUS  
DOCUMENT NUMBER: 139:223688  
TITLE: Allosteric interactions and QSAR: on the role of ligand hydrophobicity  
AUTHOR(S): Hansch, Corwin; Garg, Rajni; Kurup, Alka; Mekapati, Suresh Babu  
CORPORATE SOURCE: Department of Chemistry, Pomona College, Claremont, CA, 91711, USA  
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(9), 2075-2084  
CODEN: BWCEEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A study of a very large database of QSAR (9100) has uncovered a few unusual examples where as one increases the hydrophobicity of the members of a set of congeners, activity decreases until at a certain point, activity begins to increase. Obviously a change in mechanism is involved. The only way we have found to rationalize this unusual event is by a change in the structure of the receptor. We have found this to occur with Hb, a substance first used to define allosteric reactions.


IT 131185-37-0 171050-45-6 171050-95-6  
171050-96-7 171050-97-8 171051-01-7  
171051-02-8 171051-08-4 171051-34-6  
171051-47-1 171051-52-8  
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(A2A adenosine receptor antagonist activity: parabolic relationship between ligand hydrophobicity and activity in QSAR studies in relation to allosteric interactions)

RN 131185-37-0 CAPLUS  
CN 1-(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-45-6 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-95-6 CAPLUS

CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-96-7 CAPLUS  
CN 1-Cyclohexene-1-butanolic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-97-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-01-7 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




L4 ANSWER 32 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 RN 171051-02-8 CAPLUS  
 CN Acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-08-4 CAPLUS  
 CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



RN 171051-34-6 CAPLUS  
 CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 171051-47-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[2-(2-hydroxyethyl)-1-cyclohexen-1-yl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 33 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN  
 ACCESSION NUMBER: 2003:221686 CAPLUS  
 DOCUMENT NUMBER: 138:238180  
 TITLE: Preparation of pyrazolopyridines for treatment of herpes infections  
 INVENTOR(S): Johns, Brian A.; Gudmundsson, Kristjan  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 124 pp.  
 CODEN: P1XXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022845	A1	20030320	WO 2002-0527251	20020827
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002324798	A1	20030324	AU 2002-324798	20020827
EP 1423389	A1	20040602	EP 2002-759464	20020827
EP 1423389	B1	20070606		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005507878	T	20050324	JP 2003-526920	20020827
AT 364043	T	20070615	AT 2002-759464	20020827
US 2004214834	A1	20041028	US 2004-487968	20040226
PRIORITY APPLN. INFO.:			US 2001-318203P	P 20010907
			WO 2002-0527251	W 20020827
OTHER SOURCE(S):	MARPAT 138:238180			
GI				



AB The present invention provides pyrazolopyridines (shown as I; variables defined below; e.g. N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-

L4 ANSWER 32 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 RN 171051-52-8 CAPLUS  
 CN 1-Cyclohexene-1-acetonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 33 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 (ethylsulfanyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-amine (II) ), pharmaceutical compns. contg. the same, processes for prepg. the same and their use as pharmaceutical agents against herpes infections. IC50 values are reported for 10 examples of I against HSV-1, e.g. 0.074 µM for II. Thirteen example prepgs. of I are included. For example, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-amine was prepd. in 7 steps starting from 4-chloro-2-picoline and Et 4-fluorobenzoate and involving the following intermediates: 2-(4-chloro-2-pyridinyl)-1-(4-fluorophenyl)ethanone, 2-(4-chloro-2-pyridinyl)-1-(4-fluorophenyl)ethanone, 5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine, 5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxaldehyde, 1-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-butyne-1-one, and 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine. For I: R1 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -OR7, -OAr, -OR10Ar, -OR10Het, -C(O)R9, -C(O)Ar, -C(O)Het, -CO2R9, -C(O)NR7Ar, -C(O)NR10Ar, -C(S)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ar, -S(O)NR9, -S(O)NAr, -S(O)NR10Ar, -S(O)NR7R8, -S(O)NR7Ar, -R10cycloalkyl, -R10Ar, -R10Het, -R10OR9, -R10OC(O)R9, -R10OC(O)Ar, -R10OC(O)Het, -R10OC(O)NR9, -R10OC(O)NR10Ar, -R10OC(O)NR9R11, -R10OC(S)NR9R11, -R10C(NH)NR9R11, -R10SO2R9, -R10SO2NR9R11, -R10SO2NHCOR9, -R10NR7R8, -R10NR7Ar, -R10NHCOR9, -R10NHSO2R9, -R10NHC(NH)NR9R11, cyano, azido and nitro; Ar is aryl, R2 = halo, alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ar, Het, -OR7, -OAr, -OHet, -OR10Het, -S(O)NR9, -S(O)NAr, -NR7R8, -NHHet, -NHR10Ar, -NHR10Het, -R10NR7R8 and -R10NR7Ar; Y is N or CH; R3 and R4 = H, halo, alkyl, alkenyl, cycloalkyl, Ar, Het, -OR7, -OAr, -C(O)R7, C(O)Ar, -CO2R7, -CO2Ar, -SO2NHR9, -NR7R8, -NR7Ar, -NHHet, -NHR10Het, -R10OR7, -R10OAr, -R10NR7R8 and -R10NR7Ar; q is 0-5. Each R5 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ar, Het, -OR7, -OAr, -OHet, -C(O)R9, -C(O)Ar, -C(O)Het, -C(O)NR7R8, -C(S)NR9R11, -C(O)NR7Ar, -C(O)NHR10Het, -CO2R9, -C(NH)NR7R8, -C(NH)NR7Ar, -S(O)NR9, -S(O)NAr, -S(O)NR10Ar, -S(O)NR7R8, -S(O)NR7Ar, -NR7R8, -NR7Ar, -NHHet, -NHR10Ar, -NHR10Het, -R10cycloalkyl, -R10OR9, -R10OC(O)R9, -R10OCO2R9, -R10C(O)NR9R11, -R10C(S)NR9R11, -R10C(NH)NR9R11, -R10SO2R9, -R10SO2NR9R11, -R10SO2NHCOR9, -R10NR7R8, -R10NR7Ar, -R10NHC(NH)NR9R11, cyano, azido and nitro; or two adjacent R5 groups together with the atoms to which they are bonded form a C5-6-cycloalkyl or aryl. R = 1-3; each R13 and R14 = H, alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ar, Het, -C(O)R9, -CO2R9, -C(O)NR9R11, -C(S)NR9R11, -C(NH)NR9R11, -SO2R10, -SO2NR9R11, -R10cycloalkyl, -R10OR9, -R10OC(O)R9, -R10OCO2R9, -R10C(O)NR9R11, -R10C(S)NR9R11, -R10C(NH)NR9R11, -R10SO2R10, -R10SO2NR9R11, -R10NHCOR9, -R10NHC(NH)NR9R11, -R10NHSO2R9 and -R10SO2NHCOR9; p is 0, 1 or 2, wherein p + r < 3. Each R6 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ar, Het, -OR7, -OAr, -OHet, -OR10Ar, -OR10Het, -C(O)R9, -C(O)Ar, -C(O)Het, -CO2R9, -C(O)NR7R8, -C(O)NR7Ar, -C(O)NHR10Het, -C(S)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ar, -S(O)NR9, -S(O)NAr, -S(O)NR10Ar, -S(O)NR7R8, -S(O)NR7Ar, -R10cycloalkyl, -R10Ar, -R10Het, -R10OR9, -R10OC(O)R9, -R10OCO2R9, -R10C(O)NR9R11, -R10C(S)NR9R11, -R10C(NH)NR9R11, -R10SO2R9, -R10SO2NR9R11, -R10SO2NHCOR9, -R10NR7R8, -R10NR7Ar, -R10NHC(NH)NR9R11, cyano, azido and nitro; or two adjacent R6 groups together with the atoms to which they are bonded form a C5-6-cycloalkyl or 5- or 6-membered heterocyclic group contg. 1 or 2 heteroatoms; wherein when Y is CH, R3 is not -NR7Ar. Variables used above but not defined are defined in the claims.

IT 473711-94-3P, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-amine 473712-02-6P, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-amine 501953-11-3P, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethylsulfanyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-amine 501953-14-6P,


L4 ANSWER 33 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(methylsulfanyl)pyrazolo[1,5-a]pyridin-5-amine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; prepn. of pyrazolopyridines for treatment of herpes infections)  
 RN 473711-94-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 473712-02-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 501953-11-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethylthio)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 501953-14-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(methylthio)- (CA INDEX NAME)


L4 ANSWER 33 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 501953-15-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 501953-16-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(methylthio)- (CA INDEX NAME)



RN 501953-17-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethylthio)-2-(4-methoxyphenyl)- (CA INDEX NAME)




L4 ANSWER 33 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



IT 501953-12-4P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-5-amine  
 501953-13-5P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-ethoxy-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-amine  
 501953-15-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(2-methoxyethoxy)pyrazolo[1,5-a]pyridin-5-amine  
 501953-16-8P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(methylsulfanyl)pyrazolo[1,5-a]pyridin-5-amine  
 501953-17-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(methylsulfanyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-amine  
 501953-18-0P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(isopropylsulfanyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-amine  
 501953-19-1P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(phenylsulfanyl)pyrazolo[1,5-a]pyridin-5-amine  
 501953-20-4P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(isopropylsulfanyl)pyrazolo[1,5-a]pyridin-5-amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrazolopyridines for treatment of herpes infections)


RN 501953-12-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 501953-13-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-ethoxy-2-(4-fluorophenyl)- (CA INDEX NAME)

L4 ANSWER 33 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


RN 501953-18-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-[(1-methylethyl)thio]- (CA INDEX NAME)



RN 501953-19-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(phenylthio)- (CA INDEX NAME)




RN 501953-20-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-[(1-methylethyl)thio]- (CA INDEX NAME)




IT 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-87-5P, 4-[5-Chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrazolopyridines for treatment of herpes infections)  
 RN 468062-85-3 CAPLUS  
 CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)





RN 468062-87-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 34 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:221519 CAPLUS  
DOCUMENT NUMBER: 138:231748  
TITLE: Methods using adenosine A1 receptor antagonists for treating pulmonary disease  
INVENTOR(S): Smits, Glenn J.; Spinale, Francis G.  
PATENT ASSIGNEE(S): Biogen, Inc., USA; Musc Foundation for Research Development  
SOURCE: PCT Int. Appl., 81 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022284	A1	20030320	WO 2002-US28580	20020906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2459533	A1	20030320	CA 2002-2459533	20020906
AU 2002341618	A1	20030324	AU 2002-341618	20020906
EP 1429775	A1	20040623	EP 2002-775769	20020906
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012329	A	20040921	BR 2002-12329	20020906
HU 2004001805	A2	20041228	HU 2004-1805	20020906
HU 2004001805	A3	20070502		
CN 1564688	A	20050112	CN 2002-819526	20020906
JP 2005501915	T	20050120	JP 2003-526413	20020906
NZ 532083	A	20051028	NZ 2002-532083	20020906
IN 2004XN00276	A	20060331	IN 2004-XN276	20040301
ZA 2004001765	A	20050405	ZA 2004-1765	20040303
NO 2004000982	A	20040603	NO 2004-982	20040305
MX 2004PA02135	A	20050307	MX 2004-PA2135	20040305
US 2004259889	A1	20041223	US 2004-488573	20040817
PRIORITY APPLN. INFO.:			US 2001-317908P	P 20010906
			WO 2002-US28580	W 20020906

OTHER SOURCE(S): MARPAT 138:231748  
AB Methods useful for reducing pulmonary vasoconstriction or improving pulmonary hemodynamics in a patient are disclosed. More particularly, the invention discloses administering adenosine A1 receptor antagonists to reduce pulmonary vasoconstriction and improve pulmonary hemodynamics.  
IT 131185-37-0 141060-57-3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(adenosine A1 receptor antagonists for treating pulmonary disease)  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-57-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:177128 CAPLUS  
DOCUMENT NUMBER: 139:276830  
TITLE: Manufacturing process development of new adenosine antagonist FR120838  
AUTHOR(S): Hashimoto, Norio  
CORPORATE SOURCE: Lab. for Synthetic Technology, Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Purosesu Kemisutori no Shintenkai (2003), 228-237. Shi Emu Shi Shuppan: Tokyo, Japan.  
CODEN: 69DQ2N; ISBN: 4-88231-384-7  
DOCUMENT TYPE: Conference: General Review  
LANGUAGE: Japanese  
AB A review on development of synthetic process for a new adenosine antagonist FR 120838 (FK 838).  
IT 131185-37-0P, FK838  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(development of synthetic process for a new adenosine antagonist FR 120838 (FK 838))  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



ACCESSION NUMBER: 2003:42271 CAPLUS

DOCUMENT NUMBER: 138:106706

TITLE: Preparation of pyridazinones as adenosine receptor antagonists

INVENTOR(S): Tsutsumi, Hideo; Akahane, Atsushi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004494	A1	20030116	WO 2002-JP6671	20020702

W:	JP, US	CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU,
RW:	AT, BE, BG, NL, PT, SE, SK	

PRIORITY APPL. INFO.: MARPAT 138:106706 AU 2001-6064 A 20010702

OTHER SOURCE(S): GI



AB Title compds. [1: R1-R4 = H, suitable substituent; R1R2, R2R3 = (substituted) (heteroatom-interrupted) (CH2)<sub>n</sub> n = 1-12; W = CH:CHCH:CH, CH:NCH:CH2, etc.], were prepared. Thus, 6-[2-(1-hydroxycyclopentyl)pyrazolo[1,5-a]pyridin-3-yl]-2-isopropyl-3(2H)-pyridazinone was refluxed 14 h with Nafion NR50 in HOAc.


6-[2-(1-cyclopenten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-isopropyl-3(2H)-pyridazinone. This showed adenosine A1 receptor binding activity with K<sub>i</sub> = 0.19 nM.

IT 487062-21-5P 487062-24-8P 487062-27-1P  
487062-28-2P 487062-29-3P 487062-30-6P  
487062-31-7P 487062-32-8P 487062-33-9P  
487062-34-0P 487062-35-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridazinones as adenosine receptor antagonists)


RN 487062-21-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487062-24-8 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-cyclopenten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487062-27-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-cyclobuten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)





RN 487062-28-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-cyclohepten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487062-29-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-cycloocten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487062-30-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(6-methyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487062-31-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-methyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487062-32-8 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4,4-dimethyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487062-33-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2,5-dihydro-2-methyl-3-furanyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)





RN 487062-34-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)



RN 487062-35-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3,6-dihydro-2H-thiopyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




IT 487062-98-6P 487063-04-7P 487063-29-6P  
487063-30-9P 487063-31-0P 487063-32-1P  
487063-33-2P 487063-34-3P 487063-35-4P  
487063-36-5P 487063-37-6P 487063-38-7P  
487063-39-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyridazinones as adenosine receptor antagonists)  
RN 487062-98-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487063-32-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-[(1R,2S)-1-hydroxy-2-methylcyclohexyl]pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 487063-33-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-[(1R,2R)-1-hydroxy-2-methylcyclohexyl]pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 487063-34-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(cis-1-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)


RN 487063-04-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclopentyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487063-29-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclobutyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)



RN 487063-30-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycycloheptyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487063-31-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclooctyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487063-35-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(trans-1-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)


Relative stereochemistry.




RN 487063-36-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxy-4,4-dimethylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 487063-37-6 CAPLUS  
CN Pentitol, 1,4-anhydro-2,5-dideoxy-3-C-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 487063-38-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(tetrahydro-4-hydroxy-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 487063-39-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(tetrahydro-4-hydroxy-2H-thiopyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2002:906238 CAPLUS  
DOCUMENT NUMBER: 138:4598  
TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors  
INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yangling, Jonathan Michael; Smith, Edward C. R. Eli Lilly and Company, USA; et al.  
PATENT ASSIGNEE(S):  
SOURCE: PCT Int. Appl., 305 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MV, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2446820	A1	20021128	CA 2002-2446820	20020513
AU 2002339268	A1	20021203	AU 2002-339268	20020513
AU 2002339268	B2	20070531		
EP 1397364	A1	20040317	EP 2002-744115	20020513
EP 1397364	B1	20070725		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002009939	A	20040330	BR 2002-9939	20020513
CN 1511157	A	20040707	CN 2002-810508	20020513
JP 2004535404	T	20041125	JP 2002-591506	20020513
HU 2004000451	A2	20041228	HU 2004-451	20020513
NZ 528525	A	20051028	NZ 2002-528525	20020513
CN 1951939	A	20070425	CN 2006-10094674	20020513
AT 368041	T	20070815	AT 2002-744115	20020513
IN 2003KN01359	A	20060317	IN 2003-KN1359	20031022
ZA 2003008546	A	20050131	ZA 2003-8546	20031031
US 2004106604	A1	20040603	US 2003-477111	20031106
US 7087626	B2	20060808		
MX 2003PA10630	A	20040309	MX 2003-PA10630	20031119
NO 2003005193	A	20031121	NO 2003-5193	20031121
PRIORITY APPLN. INFO.:			US 2001-293464P	P 20010524
			CN 2002-810508	A3 20020513
			WO 2002-US11884	W 20020513


OTHER SOURCE(S): MARPAT 138:4598  
G1




AB Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; R3 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared For instance, 1-[(2-[6-Bromoquinolin-4-yl]-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00  $\mu$ M for the TGF- $\beta$  type I receptor.  
IT 476477-76-6P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]piperidin-7-ol  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors)  
RN 476477-76-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-ol, 2-(2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)



IT 476476-22-9P, 7-Benzyloxy-2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]piperidine 476477-77-7P, 7-Acetoxy-2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]piperidine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors)  
RN 476476-22-9 CAPLUS  
CN Quinoline, 4-[7-(phenylmethoxy)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 476477-77-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-ol, 2-(2-pyridinyl)-3-(4-quinolinyl)-, acetate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 38 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN  
 ACCESSION NUMBER: 2002:849629 CAPLUS  
 DOCUMENT NUMBER: 137:337887  
 TITLE: Pyrazolopyridines as virucides for herpes virus infections  
 INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 150 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088124	A2	20021107	WO 2002-US10687	20020405
WO 2002088124	A3	20030508		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002305143	A1	20021111	AU 2002-305143	20020405
EP 1385847	A2	20040204	EP 2002-733945	20020405
EP 1385847	B1	20050601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004527560	T	20040909	JP 2002-585423	20020405
AT 296826	T	20050615	AT 2002-733945	20020405
ES 2242028	T3	20051101	ES 2002-2733945	20020405
US 2004142941	A1	20040722	US 2003-473751	20031001
US 6962914	B2	20051108		
US 2005192303	A1	20050901	US 2005-95212	20050331
US 7030134	B2	20060418		
US 2005192295	A1	20050901	US 2005-95361	20050331
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 137:337887				
GI				


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Pyrazolopyridines I [Y = N, CH; R = (un)substituted Ph; R1 = halo, aryl, heterocyclic, amino; R2 = halo, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted OH, SH, S(O)H, SO2H, NH2; R3, R4 = H, halo, alkyl, alkenyl, cycloalkyl, aryl, heterocyclic, (un)substituted OH, CO2H, SO2NH2, NH2, alkyl, acyl; R5 = halo, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted alkyl, OH, CO2H, CONH2, CSNH2, c:(NH)NH2, SH, SO2H, SO2NH2, NH2, acyl, CN, NO2, N3; p = 1-3] were prepared for use in treating herpes virus infections. Thus, the pyrazolopyridine II was prepared from 4-FCGH4COMe, 2-chloro-5-


L4 ANSWER 38 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 474303-72-5 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[(5,7-dichloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)




RN 474303-85-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 474303-86-1 CAPLUS  
 CN Phenol, 4-(5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl)- (CA INDEX NAME)

L4 ANSWER 38 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 trifluoromethylpyridine, 1-pyrrolidinescarboximidamide, and cyclopentylamine in 9 steps. II had IC50 against HSV-1 of 5.3 µM.  
 IT 474303-58-7P 474303-59-8P 474303-67-8P  
 474303-72-5P 474303-85-0P 474303-86-1P  
 474303-88-3P 474303-90-7P 474303-91-8P  
 474303-92-9P 474303-93-0P 474303-94-1P  
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazolopyridines as virucides for herpes virus infections)

RN 474303-58-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)




RN 474303-59-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 474303-67-8 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[(5,7-dichloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)


L4 ANSWER 38 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 474303-88-3 CAPLUS  
 CN Phenol, 4-(5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl)- (CA INDEX NAME)




RN 474303-90-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 5,7-dichloro-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 474303-91-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 474303-92-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 474303-93-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 474303-94-1 CAPLUS  
CN Phenol, 4-[5-chloro-7-(cyclopentylamino)-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




IT 474303-56-5P 474303-57-6P 474303-60-1P  
474303-61-2P 474303-62-3P 474303-63-4P  
474303-64-5P 474303-65-6P 474303-66-7P  
474303-68-9P 474303-69-0P 474303-70-3P  
474303-71-4P 474303-73-6P 474303-74-7P  
474303-75-8P 474303-76-9P 474303-77-0P  
474303-78-1P 474303-79-2P 474303-80-5P  
474303-81-6P 474303-82-7P 474303-83-8P  
474303-84-9P 474303-87-2P 474303-89-4P  
474303-95-2P 474303-96-3P 474303-97-4P  
474303-98-5P 474303-99-6P 474304-00-2P  
474304-01-3P 474304-08-0P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyridines as virucides for herpes virus infections)


RN 474303-56-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 474303-57-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(trifluoromethyl)- (CA INDEX NAME)




RN 474303-60-1 CAPLUS  
CN Pyrrolidine, 1-[[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 474303-61-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 474303-62-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-hydroxy- (CA INDEX NAME)




RN 474303-63-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 474303-64-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 474303-65-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (CA INDEX NAME)




RN 474303-66-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-methanol, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-68-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-69-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5,7-diamine, N,N'-dicyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-70-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (CA INDEX NAME)




RN 474303-71-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5,7-diamine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N'-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474303-73-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 474303-74-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (CA INDEX NAME)




RN 474303-75-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(3-methylphenyl)- (CA INDEX NAME)




RN 474303-76-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (CA INDEX NAME)




RN 474303-77-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-78-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 474303-79-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 474303-80-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 474303-81-6 CAPLUS  
CN Guanidine, N-[5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-N'-cyclopentyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 474303-82-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-89-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 474303-95-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 474303-96-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-5-amine, 7-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-83-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[5,7-dichloro-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 474303-84-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-87-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)



RN 474303-97-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 4,6-dibromo-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-98-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 4,6-dibromo-3-[5-bromo-2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 474303-99-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 6-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)







RN 474304-00-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-5-methoxy- (CA INDEX NAME)




RN 474304-01-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-5-(2-methoxyethoxy)- (CA INDEX NAME)




RN 474304-08-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)





RN 468062-87-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 468063-27-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 473711-94-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-85-3P  
468062-87-5P 468063-27-6P 473711-94-3P  
474304-02-4P 474304-03-5P 474304-04-6P  
474304-05-7P 474304-07-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(Preparation of pyrazolopyridines as virucides for herpes virus infections)

RN 468062-79-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-80-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-85-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)


RN 474304-02-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 474304-03-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 474304-04-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 474304-05-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(triethoxymethyl)- (CA INDEX NAME)




RN 474304-07-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-chloro-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)



ACCESSION NUMBER: 2002:814131 CAPLUS  
DOCUMENT NUMBER: 137:325427  
TITLE: Preparation of antiviral 3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridines  
INVENTOR(S): Cheung, Mui; Gudmundsson, Kristjan; Johns, Brian A.  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 145 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083672	A1	20021024	WO 2002-US8793	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002254326	A1	20021028	AU 2002-254326	20020321
EP 1377575	A1	20040107	EP 2002-723554	20020321
EP 1377575	B1	20060705		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR			
JP 2004529926	T	20040930	JP 2002-581427	20020321
AT 332301	T	20060715	AT 2002-723554	20020321
ES 2266487	T3	20070301	ES 2002-2723554	20020321
US 2004167335	A1	20040826	US 2003-473491	20030925
US 7141569	B2	20061128		
US 2006235043	A1	20061019	US 2006-422357	20060606
PRIORITY APPLN. INFO.:			US 2001-282749P	P 20010410
			WO 2002-US8793	W 20020321
			US 2003-473491	A3 20030925
OTHER SOURCE(S):		MARPAT 137:325427		
GI				




AB The title compds. [I; R1 = H; R2 = halo, alkyl, cycloalkyl, etc.; Y = N,


L4 ANSWER 39 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, cycloalkyl, etc.; p = 1-3; R6 = halo, alkyl, cycloalkyl, etc.), useful in treatment of herpes viral infections, were prep. E.g., a 7-step synthesis of I [R1 = H; R2 = cyclopentylamino; Y = N; R3, R4 = H; q = 1; R5 = 4-F; p = 1; R6 = 5-(cyclopentylamino)], starting from 4-chloro-2-picoline and Et 4-fluorobenzoate, which showed IC50 of 0.5 μM against HSV-1, was given.  
IT 468062-85-3P 468062-87-5P 473711-94-3P 473711-95-4P 473711-97-6P 473712-02-6P 473712-09-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of antiviral pyrazolopyridines for treating herpes viral infections)


RN 468062-85-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468062-87-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 473711-94-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 473711-95-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 473711-97-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 473712-02-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




L4 ANSWER 39 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 473712-09-3 CAPLUS  
 CN Phenol, 4-[5-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




IT 473711-96-5P 473711-98-7P 473711-99-8P  
 473712-00-4P 473712-01-5P 473712-03-7P  
 473712-04-8P 473712-05-9P 473712-06-0P  
 473712-07-1P 473712-08-2P 473712-10-6P  
 473712-11-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of antiviral pyrazolopyridines for treating herpes viral infections)  
 RN 473711-96-5 CAPLUS  
 CN Methanesulfonamide, N-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]- (CA INDEX NAME)




RN 473711-98-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-6-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




L4 ANSWER 39 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 473712-04-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, 4-bromo-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 473712-05-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, 4-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 473712-06-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, 4-bromo-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)


L4 ANSWER 39 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 473711-99-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (CA INDEX NAME)



RN 473712-00-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 473712-01-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (CA INDEX NAME)




RN 473712-03-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-(1-methylethyl)- (CA INDEX NAME)


L4 ANSWER 39 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 473712-07-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, 4-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 473712-08-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-4-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 473712-10-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (CA INDEX NAME)




RN 473712-11-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




IT	468062-79-5P 468062-80-8P 468062-81-9P
	473712-17-3P 473712-18-4P
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
	(preparation of antiviral pyrazolopyridines for treating herpes viral infections)
RN	468062-79-5 CAPIUS
CN	2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-. (CA INDEX NAME)




RN 468062-80-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 468062-81-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473712-17-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473712-18-4 CAPLUS  
CN Carbamic acid, [3-{2-(cyclopentylamino)-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)

ACCESSION NUMBER: 2002:777725 CAPLUS  
 DOCUMENT NUMBER: 137:288973  
 TITLE: Preparation and use of pyrazolopyridines for treatment  
 or prophylaxis of herpes viral infections  
 INVENTOR(S): Boyd, F. Leslie; Gudmundsson, Kristjan; Johns, Brian  
 A.  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 172 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078701	A1	20021010	WO 2002-058621	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CO, CQ, CZ, DE, DK, DM, DZ, EK, EE, ES, FI, FG, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RU, RO, SD, SE, SG, SI, SK, SL, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BY, CF, CG, CI, CM, GN, GW, GU, GW, ML, MR, NE, SN, TD, TG				
AE 2002254310	A1	20021015	AO 2002-254310	20020320
EP 1372642	A1	20040402	EP 2002-723538	20020320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, HK, CY, AL, TR				
JP 2002545150	T	20040419	JP 2002-576967	20020320
US 2005107400	A1	20050519	US 2003-473197	20030924
PRIORITY APPLN. INFO.:			US 2001-280047P	P 20010330
			US 2001-307189P	P 20010723
			WO 2002-058621	W 20020320

OTHER SOURCE(S): MARPAT 137:288973  
GI



AB The present invention provides methods using I (e.g. 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyrrolidinamine) for the treatment or prophylaxis of viral infections such as herpes viral infections. IC50 values are reported for about 70 of the claimed compds. against HSV-1 (e.g. 0.2 µM for N-cyclopropyl-4-(6-cyano-


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine). In 1, Z is CH or N; a is 1 or 2; b is 1, 2 or 3; c is 1, 2 or 3; each R1 is independently selected from -(X)d-(CH2)e-R5 wherein d is 0 or 1; e is 0 to 6; X is selected from O, NR6 and S(O)f where f is 0, 1 or 2. R5 is selected from H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, cyano, nitro, trihalomethyl, NR7R8, C6H4(CR2)NR7R8, C(O)R7, C(O)NR7R8, OC(O)R7, OC(O)NR7R8, CO2R7, OCO2R7, SO2R7, SO2NR7R8, C(=NR7)NR7R8, N(R7)[C(=NR7)NR7R8], NHC(O)R7 and N(C1-3alkyl)C(O)R7. Each R2 is independently selected from H, cyano, halo, trihalomethyl, OC1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, S(O)gC1-6alkyl where g is 0, 1 or 2, NC1-6alkyl(C1-6alkyl), hydroxy and nitro. Each R4 is independently selected from -(Y)d-(CH2)e-R3 wherein d is 0 or 1; e is 0 to 6; Y is O or S(O)f where f is 0, 1 or 2. R3 is selected from H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, cyano, nitro, trihalomethyl, phthalimido, C6H4(CR2)NR7R8, C(O)R7, C(O)NR7R8, OC(O)R7, OC(O)NR7R8, CO2R7, OCO2R7, SO2R7, SO2NR7R8 and C(=NR7)NR7R8. R6 is selected from H, C1-6alkyl, C2-6alkenyl, heteroaryl, cycloalkyl, and heterocyclyl. R7 and R8 are each independently selected from H, C1-8alkyl, C2-6alkenyl, SO2C1-6alkyl, (CH2)m-cycloalkyl, (CH2)m-aryl, (CH2)m-heterocyclyl and (CH2)m-heteroaryl, wherein m is 0, 1 or 2, or R7 and R8 together with the N atom to which they are bound, form a heterocyclyl group. Addnl. conditions for I are stated in the claims. Although neither the methods of prepn. nor the compds. are claimed, approx. 100 example preps. are included.

IT 401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 437612-52-7P, 7-Chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468062-75-1P, [3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)]pyrazolo[1,5-a]pyridine-6-yl]methanol 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-95-5P, 2-(4-Fluorophenyl)-7-methylthio-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-97-7P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-00-5P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-02-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-04-9P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-13-0P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(ethylsulfinyl)pyrazolo[1,5-a]pyridine 468063-14-1P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(ethylthio)pyrazolo[1,5-a]pyridine 468063-15-2P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-21-0P 468063-25-4P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylate 468063-29-8P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylic acid 468063-49-2P, N-Cyclopentyl-4-[2-(2,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine


RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate; preparation and use of pyrazolopyridines for treatment or


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 prophylaxis of herpes viral infections)  
 RN 401815-63-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 401816-32-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 401816-34-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 401816-35-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437612-52-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 468062-75-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 468062-85-3 CAPLUS  
 CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 468062-95-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 468062-97-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-00-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-02-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 468063-04-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 468063-13-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-(ethylsulfinyl)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)





RN 468063-25-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (CA INDEX NAME)




RN 468063-29-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 468063-49-2 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 468063-14-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-(ethylthio)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)



RN 468063-15-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)- (CA INDEX NAME)




RN 468063-21-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-7-methoxy- (CA INDEX NAME)


IT 401815-97-2P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-15-7P, 3-(2,6-Difluoro-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-18-0P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-24-8P, 6-Bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-55-5P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methoxybenzyl)propyl]-2-pyrimidinamine 437612-75-4P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 437613-05-3P, N-Butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-79-5P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-80-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-81-9P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468062-83-1P, 4-[6-(Bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-98-8P, 7-Chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-17-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 468063-27-6P, 4-[7-Chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-28-7P, Ethyl 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Intermediate: preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)


RN 401815-97-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)




RN 401815-15-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)- (CA INDEX NAME)





RN 401816-18-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-(trifluoromethyl)- (CA INDEX NAME)




RN 401816-24-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)




RN 401816-55-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[(4-methoxyphenyl)methoxy]propyl]- (CA INDEX NAME)




RN 468062-81-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)




RN 468062-83-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[6-(bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468062-98-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-75-4 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (CA INDEX NAME)



RN 437613-05-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-79-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-80-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)

RN 468063-17-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 468063-27-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 468063-28-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)




IT 468063-31-2P, N-Butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation and use of pyrazolopyridines for treatment or prophylaxis of

L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
herpes viral infections)

RN 468063-31-2 CAPLUS

CN 2-Pyrimidinamine, N-butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



IT 401815-99-4P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyrimidinamine 401816-00-0P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-01-1P, 3-[[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]-1-propanol 401816-03-3P, N'-[[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]-1,3-propanediamine 401816-04-4P, 3-(2-Butoxypropylidene-4-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-05-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl-2-pyrimidinamine 401816-06-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxybenzyl)-2-pyrimidinamine 401816-07-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl-2-pyrimidinamine 401816-08-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyrimidinamine 401816-09-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-2-pyrimidinamine 401816-12-4P, 2-[[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]-1-ethanol 401816-13-5P, N-Benzyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-14-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl-2-pyrimidinamine 401816-17-9P, N-Benzyl-6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-19-1P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-isopropyl-2-pyrimidinamine 401816-22-6P, 3-[[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]-1-propanol 401816-25-9P, N-(3-Aminopropyl)-4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-37-3P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-40-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyrimidinamine 401816-41-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-44-2P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-48-6P, N-Butyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-49-7P, N-Benzyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-50-0P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-53-3P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)-2-pyrimidinamine 401816-54-4P, 3-[[4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]-1-propanol 401816-57-7P, N-Cyclopropyl-4-[6-cyano-2-(4-

L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
468063-36-7P, 1-[3-[[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]propyl]-2-pyrrolidinone 468063-37-8P, 6-Fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-methyl-2-pyrimidinamine 468063-38-9P, 4-[4-Fluoro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl-2-pyrimidinamine 468063-39-0P, N-Allyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-40-3P, 5-[6-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 468063-41-4P, 3-[[5-Bromo-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]-1-propanol 468063-42-5P, Methyl 3-[2-[[4-(acetoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468063-43-6P, 3-[2-(Cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylic acid 468063-44-7P, 3-[2-(Cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-45-8P, N-Cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxamide 468063-46-9P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-2-pyrimidinamine 468063-48-1P 468063-50-5P, 5-Bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentylpyrimidin-2-amine 468063-51-6P, N-Cyclopentyl-6-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468063-52-7P, N-Cyclopropyl-4-[2-(4-methoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-53-8P, N-Cyclopropyl-4-[2-(4-methoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-54-9P, Ethyl 3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468063-55-0P, 3-[2-(Cyclopropylamino)pyrimidin-4-yl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-6-carboxamide 468063-56-1P, 4-[5-Chloro-2-(4-cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 468063-57-2P, 4-[7-Butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-58-3P, 4-[5-Chloro-2-(3-chlorophenyl)-7-(methanesulfonyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-59-4P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(methythio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-60-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(isopropylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. and use of pyrazolopyrimidines for treatment or prophylaxis of herpes viral infections)


RN 401815-99-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-62-4P, 2-(4-Fluorophenyl)-3-[2-[[3-(3-hydroxypropyl)amino]-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinecarboxamide 401816-68-0P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]amine 401816-71-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyrimidinamine 401816-72-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyrimidinamine 401816-73-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)-2-pyrimidinamine 401816-74-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)-2-pyrimidinamine 401816-79-3P, N1-[4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N3,N3-dimethylpropane-1,3-diamine 437612-79-8P, N-Cyclopentyl-6-[2-(4-Fluorophenyl)-7-(methythio)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468062-82-0P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-84-2P, N-Cyclopentyl-4-[6-[[cyclopentylamino]methyl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-86-4P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-5-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-87-5P, 4-[5-Chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-94-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-96-6P, 2-(4-Fluorophenyl)-7-methylsulfinyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-99-9P, N-Butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-01-6P, N-Benzyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-03-8P, N-Butyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-05-0P, N-Benzyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-06-1P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-07-2P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-08-3P, N-Cyclohexyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-09-4P, 3-[[4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]-1-propanol 468063-10-7P, 2-(4-Fluorophenyl)-3-(2-methoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-11-8P, 2-(4-Fluorophenyl)-3-(2-phenyloxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-12-9P, 2-(4-Fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-20-9P, 2-(4-Fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-23-2P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-24-3P, N-[4-[5-Chloro-7-(ethylsulfonyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N-cyclopentylamine 468063-30-1P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-32-3P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-33-4P, N-Butyl-4-[2-(4-Fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-34-5P, N-Cyclopropyl-4-[7-ethyl-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-35-6P, N,N-Dimethyl 2-(4-Fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-7-pyrazolo[1,5-a]pyridinecarboxamide

L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 401816-00-0 CAPLUS

CN 2-Pyrimidinamine, N-butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-01-1 CAPLUS

CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (CA INDEX NAME)



RN 401816-03-3 CAPLUS


CN 1,3-Propanediamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)






L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 401816-04-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-butoxy-4-pyridinyl)-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 401816-05-5 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl- (CA INDEX NAME)




RN 401816-06-6 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxyphenyl)methyl- (CA INDEX NAME)




RN 401816-07-7 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl- (CA INDEX NAME)

L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 401816-13-5 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 401816-14-6 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 401816-17-9 CAPLUS  
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 401816-19-1 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-08-8 CAPLUS  
CN 3-Pyridinemethanamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 401816-09-9 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl- (CA INDEX NAME)




RN 401816-12-4 CAPLUS  
CN Ethanol, 2-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (CA INDEX NAME)




L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-22-6 CAPLUS  
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (CA INDEX NAME)




RN 401816-25-9 CAPLUS  
CN 1,3-Propanediamine, N-[4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-37-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 401816-40-8 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 401816-41-9 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-44-2 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-48-6 CAPLUS  
 CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 401816-54-4 CAPLUS  
 CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 401816-57-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 401816-62-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 401816-68-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-49-7 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 401816-50-0 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-53-3 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-71-5 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 401816-72-6 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 401816-73-7 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 401816-74-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 401816-79-3 CAPLUS  
CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 437612-79-8 CAPLUS  
CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 468062-87-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468062-94-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 468062-96-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylsulfinyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 468062-99-9 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-82-0 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-84-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-methanamine, N-cyclopentyl-3-[2-(4-fluorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 468062-86-4 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 468063-01-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 468063-03-8 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-05-0 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 468063-06-1 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 468063-07-2 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-08-3 CAPLUS  
CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-09-4 CAPLUS  
CN 1-Propanol, 3-([4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino)- (CA INDEX NAME)


L4 ANSWER 40 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 468063-20-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)- (CA INDEX NAME)




RN 468063-23-2 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-24-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468063-30-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 468063-10-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-methoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)





RN 468063-11-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-phenoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 468063-12-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-32-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-33-4 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-34-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-35-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 468063-36-7 CAPLUS  
CN 2-Pyrrolidinone, 1-[3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]propyl]- (CA INDEX NAME)




RN 468063-37-8 CAPLUS  
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-methyl- (CA INDEX NAME)




RN 468063-38-9 CAPLUS  
CN 2-Pyridinamine, 4-[4-fluoro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (CA INDEX NAME)





RN 468063-42-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-[[3-(acetyloxy)propyl]amino]-4-pyridinyl]-2-(4-fluorophenyl)-, methyl ester (CA INDEX NAME)




RN 468063-43-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 468063-44-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 468063-39-0 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 468063-40-3 CAPLUS  
CN 2-Pyridinamine, 5-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (CA INDEX NAME)




RN 468063-41-4 CAPLUS  
CN 1-Propanol, 3-[[5-bromo-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (CA INDEX NAME)




RN 468063-45-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 468063-46-9 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl- (CA INDEX NAME)




RN 468063-48-1 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-50-5 CAPLUS  
CN 2-Pyrimidinamine, 5-bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)







RN 468063-51-6 CAPLUS  
CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-52-7 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-53-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-57-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[(7-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl]- (CA INDEX NAME)




RN 468063-58-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[(5-chloro-2-(3-(4-chlorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl]- (CA INDEX NAME)




RN 468063-59-4 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-54-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopropylamino)-4-pyridinyl]-2-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 468063-55-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyridinyl]-N-(2-methoxyphenyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 468063-56-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-(cyclopropylmethoxy)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 468063-60-7 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-[(1-methylethylthio)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN  
ACCESSION NUMBER: 2002:777724 CAPLUS  
DOCUMENT NUMBER: 137:294953  
TITLE: Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections  
INVENTOR(S): Alberti, Michael John; Chamberlain, Stanley D.; Chueng, Mui; Gudmundsson, Kristjan; Harris, Philip Anthony; Johns, Brian A.; Jung, David Kendall; Peel, Michael Robert; Stanford, Jennifer Badiang  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 155 pp.  
CODEN: P1XXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078700	A1	20021010	WO 2002-US8524	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002305067	A1	20021015	AU 2002-305067	20020320
EP 1372643	A1	20040102	EP 2002-733866	20020320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525149	T	20040819	JP 2002-576966	20020320
US 2005059677	A1	20050317	US 2003-473196	20030924
US 7034030	B2	20060425		
US 2006058319	A1	20060316	US 2005-245972	20051007
US 7109209	B2	20060919		
PRIORITY APPL. INFO.:				
US 2001-280047P F 20010330				
US 2001-307189P P 20010723				
US 2001-307786P P 20010725				
US 2001-315090P P 20010827				
WO 2002-US8524 W 20020320				
US 2003-473196 A3 20030924				

OTHER SOURCE(S): MARPAT 137:294953  
GI


L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
-R10NR7R8, -R10NR7Ay, -R10C(O)R9, -C(O)R9, -C(O)Ay, -C(O)Het, -CO2R9, -R10CO2R9, -C(O)NR7R8, -C(O)NR7Ay, -C(O)NR9R11, -R10C(O)NR9R11, -C(S)NR9R11, -R10C(S)NR9R11, -R10NHC(NH)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ay, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7Ay, -R10SO2NHCOR9, -R10SO2NR9R11, -R10SO2R9, -S(O)NR9, cyano, azido and nitro; or two adjacent R5 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or aryl. P is 0-3; and each R6 is the same or different and is independently halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10Cycloalkyl, Ay, Het, -R10Ay, -R10Het, -OR7, -OAY, -OR9, -OR10Ay, -OR10Het, -R10NR7R8, -R10NR7Ay, -R10C(O)R9, -C(O)R9, -C(O)Ay, -C(O)Het, -CO2R9, -R10CO2R9, -C(O)NR7R8, -C(O)NR7Ay, -C(O)NR9R11, -R10C(O)NR9R11, -C(S)NR9R11, -R10NHC(NH)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ay, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7Ay, -R10SO2NHCOR9, -R10SO2NR9R11, -R10SO2R9, -S(O)NR9, cyano, azido and nitro; or two adjacent R6 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or a 5- or 6-membered heterocyclic group contg. 1 or 2 heteroatoms; wherein when Y is CH, R3 is not -NR7Ay;. appr.45 Example preps. are included. Several methods of prep. are claimed, e.g. reaction of II (R1a = H, halo, etc. as specified in the claims) with H2NC(=NH)R2 to give I (R1a in place of R1 and other variables are subsets of those defined for I above) and when R1a = H, halo, converting this compd. to a subset of I. For example, to a soln. of 1-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-butyne-1-one (2.0 mmol) in DMF was added cyclopentylguanidine hydrochloride (4.1 mmol) followed by anhyd. K carbonate (4.1 mmol). The resulting mixt. was heated at 80° for 12 hr upon cooling to room temp., H2O was added, the mixt. was extd. with EtOAc, the EtOAc phase was washed with brine, dried (Mg sulfate), filtered and concd. in vacuo; the resulting residue was purified by flash chromatog. (1:1 EtOAc-hexane) to give, after recrystn. from MeCN, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (744) as a white solid. To a soln. of 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (0.37 mmol) in anhyd. THF (5 mL) at -78° was added BuLi (1.1 mmol of 1.6M soln. in hexane); the resulting soln. was stirred for 10 min at -78°, followed by addn. of di-Et disulfide (1.1 mmol). The reaction was stirred at -78° for 20 min and then allowed to warm to room temp. H2O and EtOAc were added to the reaction mixt., the phases were sepd., the aq. phase washed with EtOAc and the combined org. phase dried (Mg sulfate), filtered and concd. in vacuo; the resulting solid was purified by flash chromatog. (1:1 EtOAc-hexane) to give, after recrystn. from EtOAc, N-(4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(ethylsulfonyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)-N-cyclopentylamine (524) as a solid.  
IT 401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-15-2P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(intermediate: preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)  
RN 401815-63-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)

L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




AB The present invention provides I (variables defined below: e.g. 4-[7-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (Example 41)), methods for their preparation and their use for the treatment or prophylaxis of viral infections such as herpes viral infections. IC50 values are reported for about 20 of the claimed compds. against HSV-1, e.g. 0.28 µM for Example 41. In I, R1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10Cycloalkyl, -R10Ay, -R10Het, -OR7, -OAY, -OR9, -OR10Het, -R10OR9, -R10NR7R8, -R10NR7Ay, -R10C(O)R9, -C(O)R9, -C(O)Ay, -C(O)Het, -R10OC(O)R9, -R10OC(O)Ay, -R10OC(O)Het, -CO2R9, -R10CO2R9, -C(O)NR7R8, -C(O)NR7Ay, -C(O)NR10Ay, -R10C(O)NR9R11, -C(S)NR9R11, -R10C(S)NR9R11, -R10NHC(NH)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ay, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7Ay, -R10SO2NHCOR9, -R10SO2NR9R11, -R10SO2R9, -R10SO2R9, -S(O)NR9, -S(O)Nay, -S(O)Nhet, cyano, azido and nitro. Each R7 and R8 are the same or different and are independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -R10Cycloalkyl, -OR9, -R10OR9, -R10NR9R11, -R10C(O)R9, -C(O)R9, -CO2R9, -R10CO2R9, -C(O)NR9R11, -R10C(O)NR9R11, -C(S)NR9R11, -R10C(S)NR9R11, -R10NHC(NH)NR9R11, -R10C(NH)NR9R11, -C(NH)NR9R11, -SO2NR9R11, -R10SO2NR9R11, -R10NHCOR9, -SO2R10, -R10SO2R10, -R10NHCOR9 and -R10SO2NHCOR9. Each R9 and R11 are the same or different and are independently selected from H, alkyl, cycloalkyl, -R10Cycloalkyl, -R10OH, -R10(OR10)w where w is 1-10, and -R10NR10R10. Each R10 is the same or different and is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl; Ay is an aryl; Het is a 5- or 6-membered heterocyclic or heteroaryl group; n is 0-2. R2 is H, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -NR7R8, Ay, -NHR10Ay, -OR7, -OAY, -S(O)NR9, -S(O)Nay, -R10NR7R8, -R10NR7Ay, Het, -NHHet, -NHR10Het, -OHet and -OR10Het. Y is N or CH; R3 and R4 are the same or different and are each independently H, halo, alkyl, cycloalkyl, alkenyl, Ay, -OR7, -OAY, -R10OR7, -R10OR9, -NR7R8, -NR7Ay, -R10NR7R8, -R10NR7Ay, -C(O)R7, C(O)Ay, -CO2R9, -CO2Ay, -SO2NR9R11, Het, -NHHet and -NHR10Het; q is 0-5. Each R5 is the same or different and is independently halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10Cycloalkyl, Ay, -NHR10Ay, -NR7Ay, Het, -NHHet, -NHR10Het, -OR7, -OAY, -OHet, -R10OR9, -NR7R8,


L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 468063-15-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)- (CA INDEX NAME)




IT 437612-75-4P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 437613-05-3P, N-Butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-79-5P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-80-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-98-8P, 7-Chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-17-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 468063-27-6P, 4-[7-Chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-28-7P, Ethyl 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate: preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)  
RN 437612-75-4 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)





RN 437613-05-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-79-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 468062-80-8 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-28-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)




IT 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 437612-52-7P, 7-Chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468062-95-5P, 2-(4-Fluorophenyl)-7-methylthio-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-97-7P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-00-5P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-02-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-04-9P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-13-0P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(ethylsulfinyl)pyrazolo[1,5-a]pyridine 468063-14-1P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(ethylthio)pyrazolo[1,5-a]pyridine 468063-21-0P, 2-(4-Fluorophenyl)-3-[2-(fluoro-4-pyridinyl)-7-methoxypyrazolo[1,5-a]pyridine 468063-25-4P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylate 468063-29-8P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylic acid  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)  
RN 401816-32-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)


RN 468062-85-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 468062-98-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-17-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 468063-27-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 401816-34-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 401816-35-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-52-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)







RN 468062-95-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 468062-97-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-00-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-14-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-(ethylthio)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-21-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-7-methoxy- (CA INDEX NAME)




RN 468063-25-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (CA INDEX NAME)




RN 468063-02-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 468063-04-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)



RN 468063-13-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-(ethylsulfinyl)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 468063-29-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)




IT 401816-37-3P, N-Butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 437612-79-8P, N-Cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468062-94-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-96-6P, 2-(4-Fluorophenyl)-7-methylsulfinyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-99-9P, N-Butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-01-6P, N-Benzyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-03-8P, N-Butyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-05-0P, N-Benzyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-06-1P, N-Cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-07-2P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-08-3P, N-Cyclohexyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-09-4P, 3-[4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinylamino]-1-propanol 468063-10-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-11-8P, 2-(4-Fluorophenyl)-3-[2-(phenyloxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-12-9P, 2-(4-Fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-20-9P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-23-2P, N-Butyl-4-[2-(4-fluorophenyl)-7-methoxy]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-24-3P, N-[4-[5-Chloro-7-(ethylsulfinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-

L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

3-yl]-2-pyrimidinyl]-N-cyclopentylamine 468063-30-1P,  
 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-31-2P,  
 N-Butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-32-3P, N-Butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-33-4P,  
 N-Butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-34-5P, N-Cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-35-6P, N,N-Dimethyl-2-(4-fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-7-pyrazolo[1,5-a]pyridinylcarboxamide 468063-57-2P, 4-[7-Butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-58-3P,  
 4-[5-Chloro-2-(3-chlorophenyl)-7-(methylsulfonyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-59-4P,  
 N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-60-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(isopropylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)  
 RN 401816-37-3 CAPLUS  
 CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437612-79-8 CAPLUS  
 CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468062-94-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)- (CA INDEX NAME)


L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 468063-03-8 CAPLUS  
 CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-05-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 468063-06-1 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 468062-96-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylsulfinyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 468062-99-9 CAPLUS  
 CN 2-Pyrimidinamine, N-butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-01-6 CAPLUS  
 CN 2-Pyrimidinamine, 4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 41 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 468063-07-2 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-08-3 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-09-4 CAPLUS  
 CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 468063-10-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-methoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)





RN 468063-11-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-phenoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 468063-12-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)-3-(2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl)- (CA INDEX NAME)




RN 468063-20-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)- (CA INDEX NAME)




RN 468063-32-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-33-4 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-34-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 468063-23-2 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 468063-24-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468063-30-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 468063-31-2 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


RN 468063-35-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 468063-57-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 468063-58-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[5-chloro-2-(3-chlorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 468063-59-4 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 468063-60-7 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-[(1-methylethyl)thio]-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:720128 CAPLUS  
DOCUMENT NUMBER: 137:379680  
TITLE: Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists  
AUTHOR(S): Bondavalli, Francesco; Botta, Maurizio; Bruno, Olga; Ciacci, Andrea; Corelli, Federico; Fossa, Paola; Lucacchini, Antonio; Manetti, Fabrizio; Martini, Claudia; Menozzi, Giulia; Mosti, Luisa; Ranise, Angelo; Schenone, Silvia; Tafi, Andrea; Trincavelli, Maria Letizia  
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Genova, I-16132, Italy  
SOURCE: Journal of Medicinal Chemistry (2002), 45(22), 4875-4887  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 137:379680

AB We present a combined computational study aimed at identifying the three-dimensional structural properties required for different classes of compounds to show antagonistic activity toward the A1 adenosine receptor (AR). Particularly, an approach combining pharmacophore mapping, mol. alignment, and pseudoreceptor generation was applied to derive a hypothesis of the interaction pathway between a set of A1 AR antagonists taken from the literature and a model of the putative A1 receptor. The pharmacophore model consists of seven features and represents an improvement of the N6-C8 model, generally reported as the most probable pharmacophore model for A1 AR agonists and antagonists. It was used to build up a pseudoreceptor model able to rationalize the relationships between structural properties and biol. data of, and external to, the training set. In fact, to further assess its statistical significance and predictive power, the pseudoreceptor was employed to predict the free energy of binding associated with compounds constituting a test set. While part of these mols. was also taken from the literature, the remaining compounds were designed and synthesized by our research group. All of the new compounds were tested for their affinity toward A1, A2a, and A3 AR, showing interesting antagonistic activity and A1 selectivity.

IT RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (synthesis, mol. modeling studies, and pharmacol. activity of selective A1 receptor antagonists)  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:716277 CAPLUS  
DOCUMENT NUMBER: 137:247709  
TITLE: Preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amine for treating herpes viral infections  
INVENTOR(S): Boyd, P. Leslie; Gudmundsson, Kristjan; Johns, Brian A.  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 191 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072581	A2	20020919	WO 2002-US6552	20020305
WO 2002072581	A3	20030501		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002248531	A1	20020924	AU 2002-248531	20020305
EP 1366048	A2	20031203	EP 2002-717537	20020305
EP 1366048	B1	20040825		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
AT 274515	T	20040915	AT 2002-717537	20020305
JP 2004529119	T	20040924	JP 2002-571497	20020305
ES 2227451	T3	20050401	ES 2002-2717537	20020305
US 2005049260	A1	20050303	US 2003-468729	20030822
US 7153855	B2	20061226		
US 2006293344	A1	20061228	US 2006-468319	20060830
PRIORITY APPLN. INFO.:			US 2001-274297P	P 20010308
			WO 2002-US6552	W 20020305
			US 2003-468729	A3 20030822

OTHER SOURCE(S): MARPAT 137:247709  
GI



AB The title compds. [I; R1 = halo, NR7R8, aryl, etc. (wherein R7, R8 = H, alkyl, cycloalkyl, etc.); R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, alkenyl, etc.; when q = 1 and R5 is in the para position, R5 is not halo; when Y = CH, R3 is not NR7(aryl)], useful for the prophylaxis or treatment of herpes viral infections, were prepared. E.g., a multi-step synthesis of 1 [R1, R2 = cyclopentylamino; R3, R4 = H; Y = N; R5 = 4-MeO], starting with 6-chloro-2-picoline, which showed IC50 of 0.3  $\mu$ M against HSV-1, was given.

IT 437611-98-8P 460078-20-0P 460078-24-4P

460078-25-5P 460078-26-6P 460078-37-9P

460078-46-0P 460078-47-1P 460078-55-1P

460078-60-8P 460078-67-5P 460078-70-0P

460078-71-1P 460078-74-4P 460078-78-8P

460078-80-2P 460078-86-8P 460078-87-9P

460078-88-0P 460078-89-1P 460079-01-0P


460079-04-3P 460079-10-1P 460079-11-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Preparation of  
3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amine  
for treating herpes viral infections)


RN 437611-98-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-20-0 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460078-24-4 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 460078-46-0 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-47-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 460078-55-1 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-aminophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-25-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-methoxyphenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 460078-26-6 CAPLUS

CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-37-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-aminophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-60-8 CAPLUS

CN Benzonitrile, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-67-5 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5,6-dimethyl- (CA INDEX NAME)




RN 460078-70-0 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 460078-71-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 460078-74-4 CAPLUS  
CN Phenol, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-78-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460078-80-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460078-86-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460078-87-9 CAPLUS  
CN Phenol, 4-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-88-0 CAPLUS  
CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-89-1 CAPLUS  
CN Phenol, 4-[7-(cyclopropylamino)-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460079-01-0 CAPLUS  
CN 1,4-Butanediolamine, N-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 460079-04-3 CAPLUS  
CN Carbamic acid, [[4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 460079-10-1 CAPLUS  
CN 1-Butanol, 4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]- (CA INDEX NAME)



RN 460079-11-2 CAPLUS  
CN Phosphoric acid, 4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl bis(phenylmethyl) ester (CA INDEX NAME)




IT 437613-19-9P 460078-27-7P 460078-28-8P  
 460078-29-9P 460078-30-2P 460078-31-3P  
 460078-32-4P 460078-33-5P 460078-34-6P  
 460078-35-7P 460078-36-8P 460078-38-0P  
 460078-39-1P 460078-40-4P 460078-41-5P  
 460078-42-6P 460078-43-7P 460078-44-8P  
 460078-45-9P 460078-48-2P 460078-49-3P  
 460078-50-6P 460078-51-7P 460078-52-8P  
 460078-53-9P 460078-54-0P 460078-56-2P  
 460078-57-3P 460078-58-4P 460078-59-5P  
 460078-61-9P 460078-62-0P 460078-63-1P  
 460078-64-2P 460078-65-3P 460078-66-4P  
 460078-68-6P 460078-69-7P 460078-72-2P  
 460078-73-3P 460078-75-5P 460078-76-6P  
 460078-77-7P 460078-79-9P 460078-81-3P  
 460078-82-4P 460078-83-5P 460078-84-6P  
 460078-85-7P 460078-90-4P 460078-91-5P  
 460078-92-6P 460078-93-7P 460078-94-8P  
 460078-95-9P 460078-96-0P 460078-97-1P  
 460078-98-2P 460078-99-3P 460079-00-9P  
 460079-02-1P 460079-03-2P 460079-05-4P  
 460079-06-5P 460079-07-6P 460079-08-7P  
 460079-09-8P 460079-14-5P 460079-17-8P  
 460079-19-0P 460079-21-4P 460079-22-5P  
 460079-23-6P 460079-24-7P 460079-25-8P  
 460079-26-9P 460079-27-0P 460079-28-1P  
 460079-29-2P 460079-30-5P 460079-31-6P  
 460079-32-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  
 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amines  
 for treating herpes viral infections)


RN 437613-19-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-27-7 CAPLUS  
 CN Phenol, 4-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-28-8 CAPLUS  
 CN Phenol, 4-[3-(2-amino-4-pyrimidinyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-29-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-30-2 CAPLUS  
 CN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460078-31-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-32-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (CA INDEX NAME)




RN 460078-33-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 460078-34-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-(cyclobutylmethoxy)phenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-35-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 460078-36-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[1,1'-biphenyl]-4-yl-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-38-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(cyclohexylamino)phenyl]- (CA INDEX NAME)




RN 460078-39-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(1-methylethenyl)phenyl]- (CA INDEX NAME)




RN 460078-43-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-((cyclopropylmethyl)amino)phenyl]- (CA INDEX NAME)




RN 460078-44-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 460078-45-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(2-bromophenyl)-N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)- (CA INDEX NAME)




RN 460078-40-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(phenylamino)phenyl]- (CA INDEX NAME)




RN 460078-41-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-N-phenyl-2-[4-(phenylamino)phenyl]- (CA INDEX NAME)




RN 460078-42-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-(bis(cyclopropylmethyl)amino)phenyl]-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 460078-48-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-2-(3-bromophenyl)-N-cyclopentyl- (CA INDEX NAME)




RN 460078-49-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)







RN 460078-50-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[1,1'-biphenyl]-3-yl-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-51-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-[1,1'-biphenyl]-3-yl-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 460078-52-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 460078-53-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 460078-58-4 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 460078-59-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (CA INDEX NAME)




RN 460078-61-9 CAPLUS  
CN Benzamide, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-54-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(2-thienyl)phenyl]- (CA INDEX NAME)




RN 460078-56-2 CAPLUS  
CN Acetamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 460078-57-3 CAPLUS  
CN Methanesulfonamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)




RN 460078-62-0 CAPLUS  
CN Benzoic acid, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 460078-63-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-methoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-64-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-amino-4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-65-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[(4-[(phenylmethyl)amino]phenyl)- (CA INDEX NAME)




RN 460078-66-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (CA INDEX NAME)




RN 460078-68-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5,6-dimethyl-4-pyrimidinyl]-2-(3-methylphenyl)- (CA INDEX NAME)




RN 460078-75-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 460078-76-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 460078-77-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-69-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-(3-methylphenyl)- (CA INDEX NAME)




RN 460078-72-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)- (CA INDEX NAME)




RN 460078-73-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 460078-79-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 460078-81-3 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 460078-82-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460078-83-5 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-methoxyphenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 460078-84-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460078-85-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 460078-90-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 460078-91-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-92-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (CA INDEX NAME)




RN 460078-93-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-94-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-((4-methoxyphenyl)methyl)amino]phenyl]- (CA INDEX NAME)




RN 460078-95-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 460078-96-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-97-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl- (CA INDEX NAME)



RN 460078-98-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460078-99-3 CAPLUS  
CN Glycine, N-[3-{2-[(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (CA INDEX NAME)




RN 460079-00-9 CAPLUS  
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[4-{7-(butylamino)-3-[2-(butylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 460079-02-1 CAPLUS  
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[4-{3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 460079-07-6 CAPLUS  
CN Benzenesulfonamide, N-[4-{3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]amino]carbonyl]-4-methyl- (CA INDEX NAME)


PAGE 1-A




RN 460079-08-7 CAPLUS  
CN Butanoic acid, 4-[[4-{3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]amino]-4-oxo- (CA INDEX NAME)




PAGE 2-A




RN 460079-03-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 460079-05-4 CAPLUS  
CN Guanidine, [4-{3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 460079-06-5 CAPLUS  
CN Methanesulfonamide, N-[4-{3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]- (CA INDEX NAME)



RN 460079-09-8 CAPLUS  
CN Phosphoramidic acid, [4-{3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 460079-14-5 CAPLUS  
CN 1-Butanol, 4-[[4-{3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]amino]-, dihydrogen phosphate (ester), diammonium salt (9CI) (CA INDEX NAME)




● 2 NH3


RN 460079-17-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-azidophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460079-19-0 CAPLUS  
CN Pyrrolidine, 1-[[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 460079-21-4 CAPLUS  
CN Methanesulfonamide, N-[2-[[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]ethyl]- (CA INDEX NAME)




RN 460079-22-5 CAPLUS  
CN 1,2-Ethanediamine, N-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 460079-26-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl- (CA INDEX NAME)




RN 460079-27-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460079-28-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 460079-23-6 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(3-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 460079-24-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 460079-25-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 460079-29-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)




RN 460079-30-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 460079-31-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 460079-32-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




IT 460079-83-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of  
3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amine  
for treating herpes viral infections)  
RN 460079-83-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-chloro-3-  
[(diphenylmethylene)amino]phenyl]-N-cyclopentyl-3-[2-(cyclopentylamino)-4-  
pyrimidinyl]- (CA INDEX NAME)




IT 460079-35-0P 460079-50-9P 460079-51-0P  
460079-65-6P 460079-73-6P 460079-74-7P  
460079-80-5P 460079-81-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of  
3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amine  
for treating herpes viral infections)  
RN 460079-35-0 CAPLUS





RN 460079-73-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-  
yl]-N-cyclopentyl- (CA INDEX NAME)




RN 460079-74-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-  
yl]-N-cyclopropyl- (CA INDEX NAME)




RN 460079-80-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-  
yl]-N-cyclopentyl- (CA INDEX NAME)



RN 460079-50-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-  
pyrimidinyl]-2-[3-[(diphenylmethylene)amino]phenyl]- (CA INDEX NAME)




RN 460079-51-0 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-[3-[(diphenylmethylene)amino]phenyl]-  
7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 460079-65-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-  
yl]-N-cyclopentyl- (CA INDEX NAME)

RN 460079-81-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-  
yl]-N-cyclopropyl- (CA INDEX NAME)



L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:466008 CAPLUS

DOCUMENT NUMBER: 137:33325

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048148	A2	20020620	WO 2001-US44231	20011126
WO 2002048148	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 200239348	A	20020624	AU 2002-39348	20011126
EP 1377573	A2	20040107	EP 2001-987099	20011126
EP 1377573	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515550	T	20040527	JP 2002-549679	20011126
AT 300541	T	20050815	AT 2001-987099	20011126
ES 2243579	T3	20051201	ES 2001-1987099	20011126
US 2005049259	A1	20050303	US 2003-433881	20030605
US 7163940	B2	20070116		
PRIORITY APPL. INFO.:				
US 2000-255763P P 20001215				
US 2001-274284P P 20010308				
WO 2001-US44231 W 20011126				

OTHER SOURCE(S): MARPAT 137:33325

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [1: R1 = cyclopentylamino, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>NH, Cl, NHNH<sub>2</sub>, H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, NH<sub>2</sub>, 4-methylpiperiziny, 4-CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>NH, Br, CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>, HO<sub>2</sub>CCH<sub>2</sub>NH, cyclopropylamino, (CH<sub>3</sub>)<sub>2</sub>N, 4-morpholinyl; R2 = NH<sub>2</sub>, cyclopentylamino, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>NH, CH<sub>3</sub>S=O, HO(CH<sub>2</sub>)<sub>3</sub>NH, CH<sub>2</sub>:CHCH<sub>2</sub>NH, 4-morpholinyl, cyclopropylamino, pyrrolidinyl, (CH<sub>3</sub>)<sub>2</sub>N, 3-(4-morpholinyl)propylamino, CH<sub>3</sub>(HOOCCH<sub>2</sub>)N; R3 = H, CH<sub>3</sub>, (CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>, (tetrahydro-2H-pyran-2-yl)omethyl, HOCH<sub>2</sub>, C<sub>6</sub>H<sub>5</sub>, COOH, 4-pyridinyl; R4 = H, CH<sub>3</sub>; R5 = F, Br, Cl, X = N, CH<sub>3</sub>, salts, and pharmaceutical compns. containing the same are prepared as antiviral agents. Title compds. I are

L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 437612-13-0 CAPLUS

CN 4-Pyrimidinmethanol, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)- (CA INDEX NAME)




RN 437612-20-9 CAPLUS

CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (CA INDEX NAME)



RN 437612-22-1 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (CA INDEX NAME)



RN 437612-23-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)- (CA INDEX NAME)

L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

tested for HSV-1 inhibition and the results demonstrate that title compds. I are useful for the treatment and prophylaxis of herpes viral infections. Thus, the title compd. II was prep. from 6-chloro-2-picoline, Et 4-fluorobenzoate, and cyclopentylamine via cyclization.


IT

437612-03-8P 437612-12-9P 437612-13-0P  
437612-20-9P 437612-22-1P 437612-23-2P  
437612-33-4P 437612-46-9P 437612-48-1P  
437612-50-5P 437612-52-7P 437612-57-2P  
437612-60-7P 437612-70-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)


RN

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl- (CA INDEX NAME)



RN 437612-12-9 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 437612-33-4 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-46-9 CAPLUS


CN 4-Pyrimidinmethanamine, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)-N,N-dimethyl- (CA INDEX NAME)




RN 437612-48-1 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl- (CA INDEX NAME)






RN 437612-50-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 437612-52-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 437612-57-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-bromo-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)


437612-27-6P 437612-28-7P 437612-29-8P  
437612-30-1P 437612-31-2P 437612-32-3P  
437612-34-5P 437612-35-6P 437612-36-7P  
437612-37-8P 437612-38-9P 437612-39-0P  
437612-40-3P 437612-41-4P 437612-42-5P  
437612-43-6P 437612-44-7P 437612-45-8P  
437612-47-0P 437612-49-2P 437612-51-6P  
437612-53-8P 437612-54-9P 437612-55-0P  
437612-56-1P 437612-58-3P 437612-59-4P  
437612-61-8P 437612-62-9P 437612-63-0P  
437612-64-1P 437612-65-2P 437612-66-3P  
437612-67-4P 437612-68-5P 437612-69-6P  
437612-71-0P 437612-72-1P 437612-73-2P  
437612-74-3P 437612-75-4P 437612-76-5P  
437612-77-6P 437612-78-7P 437612-79-8P  
437612-80-1P 437612-80-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)


RN 437611-97-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437611-98-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437611-99-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-60-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3,7-bis(2-fluoro-4-pyridinyl)- (CA INDEX NAME)




RN 437612-70-9 CAPLUS  
CN 4-Pyrimidinecarboxamide, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-(cyclopentylamino)- (CA INDEX NAME)




IT 437611-97-7P 437611-98-8P 437611-99-9P  
437612-00-5P 437612-01-6P 437612-02-7P  
437612-04-9P 437612-05-0P 437612-06-1P  
437612-07-2P 437612-08-3P 437612-09-4P  
437612-10-7P 437612-11-8P 437612-14-1P  
437612-15-2P 437612-16-3P 437612-17-4P  
437612-18-5P 437612-19-6P 437612-21-0P  
437612-24-3P 437612-25-4P 437612-26-5P




RN 437612-00-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 437612-01-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-02-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)







L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 437612-04-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 437612-05-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-06-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-07-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437612-11-8 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (CA INDEX NAME)




RN 437612-14-1 CAPLUS  
 CN Glycine, N-[4-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N-methyl- (CA INDEX NAME)




RN 437612-15-2 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437612-08-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-09-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(3-(4-morpholinyl)propyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-10-7 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 437612-16-3 CAPLUS  
 CN 1,2-Ethanediamine, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 437612-17-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-18-5 CAPLUS  
 CN 4-Pyrimidinemethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
fluorophenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437612-19-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 437612-21-0 CAPLUS  
CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (CA INDEX NAME)




L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 437612-28-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 437612-29-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-30-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 437612-31-2 CAPLUS


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 437612-24-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 437612-25-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-26-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-hydrazinyl-4-pyridinyl)- (CA INDEX NAME)




RN 437612-27-6 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437612-32-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437612-34-5 CAPLUS  
CN 1-Propanol, 3-[4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinylamino]- (CA INDEX NAME)




RN 437612-35-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(2-propenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)





RN 437612-36-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-37-8 CAPLUS  
CN 1-Piperazineethanol, 4-[4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)




RN 437612-38-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-methoxyethyl)-1-piperazinyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 437612-43-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-(4-morpholinylethyl)]- (CA INDEX NAME)




RN 437612-44-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 437612-45-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)


RN 437612-39-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-40-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-41-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-(4-morpholinylethyl)amino)]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-42-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[2-(4-morpholinylethoxy)-4-pyrimidinyl]- (CA INDEX NAME)



RN 437612-47-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-[(dimethylamino)methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-49-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-51-6 CAPLUS


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-propyl- (CA INDEX NAME)



RN 437612-53-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-fluorophenyl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 437612-54-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-fluorophenyl)-N-methyl-3-(4-pyridinyl)- (CA INDEX NAME)




RN 437612-55-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N,N-diethyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437612-61-8 CAPLUS  
 CN 1,3-Propanediamine, N,N'-bis-([2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3,7-diyl]di-4,2-pyridinediyl)bis- (9CI) (CA INDEX NAME)




RN 437612-62-9 CAPLUS  
 CN 2-Pyridinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl- (CA INDEX NAME)




RN 437612-63-0 CAPLUS  
 CN 2-Pyridinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437612-56-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-iodo-3-(4-pyridinyl)- (CA INDEX NAME)




RN 437612-58-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 437612-59-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(1H-imidazol-1-yl)-3-(4-pyridinyl)- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 437612-64-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-65-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(1-pyrrolidinyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-66-3 CAPLUS  
 CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-7-((2-hydroxyethyl)methylamino)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 437612-67-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclohexyl-3-[2-(cyclohexylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 437612-68-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-69-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(2-phenyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 437612-71-0 CAPLUS  
 CN 4-Pyrimidinecarboxamide, N-cyclopentyl-2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437612-75-4 CAPLUS  
 CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (CA INDEX NAME)




RN 437612-76-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-77-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437612-72-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-chloro-3-(2-cyclopropyl-4-pyrimidinyl)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-73-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(1-methylethyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437612-74-3 CAPLUS  
 CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 44 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 437612-78-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437612-79-8 CAPLUS  
 CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 437612-80-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[6-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 437613-20-2 CAPLUS  
CN 4-Pyrimidinemethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrochloride (9C1) (CA INDEX NAME)




•x HCl


IT 401815-63-2P 437612-94-7P 437612-97-0P  
437613-02-0P 437613-05-3P 437613-07-5P  
437613-08-6P 437613-09-7P 437613-12-2P  
437613-19-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)  
RN 401815-63-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)





RN 437613-05-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437613-07-5 CAPLUS  
CN 2(1H)-Pyrimidinethione, 4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 437613-08-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (CA INDEX NAME)



RN 437612-94-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[[tetrahydro-2H-pyran-2-yl]oxy]methyl]- (CA INDEX NAME)




RN 437612-97-0 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl- (CA INDEX NAME)




RN 437613-02-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)


RN 437613-09-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-(iodomethyl)- (CA INDEX NAME)



RN 437613-12-2 CAPLUS  
CN 4-Pyrimidinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)-, methyl ester (CA INDEX NAME)



RN 437613-19-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-amine, 2-(3-bromo-4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (CA INDEX NAME)



ACCESSION NUMBER: 2002:466007 CAPLUS


DOCUMENT NUMBER: 137:33316

TITLE: Preparation of pyrazolopyridinamine derivatives as antiviral agents  
 INVENTOR(S): Chamberlain, Stanley D.; Gudmundsson, Kristjan; Johns, Brian A.  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIKXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048147	A2	20020620	WO 2001-US44210	20011126
WO 2002048147	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 200239344	A	20020624	AU 2002-39344	20011126
EP 1341788	A1	20030910	EP 2001-987095	20011126
EP 1341788	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518651	T	20040624	JP 2002-549678	20011126
AT 301653	T	20050815	AT 2001-987095	20011126
ES 2245380	T3	20060101	ES 2001-1987095	20011126
US 2004072853	A1	20040415	US 2003-433884	20030605
US 6919352	B2	20050719		
US 2005182080	A1	20050818	US 2005-82466	20050317
US 7087618	B2	20060808		
US 2005171133	A1	20050804	US 2005-84410	20050318
US 7160897	B2	20070109		
PRIORITY APPLN. INFO.:				
US 2000-255763P P 20001215				
US 2001-274284P P 20010308				
US 2001-315089P P 20010827				
WO 2001-US44210 W 20011126				
US 2003-433884 A3 20030605				

OTHER SOURCE(S): MARPAT 137:33316  
 GI




AB Title compds. [I; R = F, OCH<sub>3</sub>; R<sub>1</sub> = 3-N<sub>3</sub>, 3-NH<sub>2</sub>, 3-CH<sub>2</sub>OH, 3-NO<sub>2</sub>, H, 3-COC<sub>6</sub>H<sub>5</sub>, 4-F, 4-OCH<sub>3</sub>, 3,4,5-(OCH<sub>3</sub>)<sub>3</sub>; R<sub>2</sub> = 7-cyclopentylamino, H, SCH<sub>2</sub>CH<sub>3</sub>; R<sub>3</sub> = Cl, cyclopentylamino, H] are prepared from condensation of picolines and alkyl benzoates followed by cyclization and addition reaction. Title compds. I, pharmaceutically acceptable salt, solvate, or physiol. functional derivative are useful in the prophylaxis or treatment of conditions or diseases associated with herpes viral infections in an animal.


IT 437384-04-8P 437384-11-7P 437384-12-8P  
 437384-13-9P 437384-14-0P 437384-23-1P  
 437384-32-2P 437384-33-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazolopyridinamine derivs. as antiviral agents)


RN 437384-04-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437384-11-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437384-12-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437384-13-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437384-14-0 CAPLUS  
 CN Methanone, [3-[[4-(7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)amino]phenyl]phenyl- (CA INDEX NAME)




RN 437384-23-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (CA INDEX NAME)




RN 437384-32-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 437384-33-3 CAPLUS  
 CN Benzenemethanol, 3-[[4-(7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



IT 437384-29-7P 437384-30-0P 437384-31-1P  
 437384-36-6P 437384-37-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazolopyridine derivs. as antiviral agents)  
 RN 437384-29-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 437384-30-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 437384-31-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (CA INDEX NAME)


## L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:171898 CAPLUS  
 DOCUMENT NUMBER: 136:232298  
 TITLE: Pyrazolopyridine compounds and pharmaceutical use thereof as adenosine receptor antagonists  
 INVENTOR(S): Akahane, Atsushi; Tanaka, Akira; Minagawa, Masatoshi; Itani, Hiromichi; Ohtake, Hiroaki  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 149 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018382	A1	20020307	WO 2001-JP7322	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TH, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080188	A5	20020313	AU 2001-80188	20010827
EP 1313733	A1	20030528	EP 2001-958521	20010827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507542	T	20040311	JP 2002-523897	20010827
US 2004110763	A1	20040610	US 2003-344894	20030226
PRIORITY APPLN. INFO.:			AU 2000-9698	A 20000828
			WO 2001-JP7322	W 20010827
OTHER SOURCE(S):		MARPAT 136:232298		
GI				





RN 437384-36-6 CAPLUS  
 CN 1,3-Benzenediamine, N-[4-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 437384-37-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-[(3-azidophenyl)amino]-4-pyrimidinyl]-N-cyclopentyl-2-(4-methoxyphenyl)- (CA INDEX NAME)



## L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Pyrazolopyridines I are disclosed [wherein: R1 = H, (un)substituted lower alkyl or cycloalkyl which may be interrupted by an O or N; R2 = H, halo, or lower alkoxy; R3 = independent substituent(s); and n = 1 to 4; or a salt thereof]. The compds. are adenosine antagonists, and are thus useful for the prevention and/or treatment of a wide variety of medical conditions, e.g., depression, dementia (e.g., Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.) Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. In particular, treatment of Parkinson's disease and/or associated symptoms is specifically claimed.

Over 330 example compds. are described. For instance, cyclization of 1-amino-4-methoxypyridinium iodide with 3-(benzenesulfonyl)-6-(phenylethynyl)pyridazine, gave 3-(3-phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine. This compound was hydrolyzed at the phenylsulfinyl group, and the resultant pyridazinone was N-alkylated with NaH/DMP and iso-PrI to give title compound II. In radioligand binding assays, II had Ki values of 0.15 nM for human A1 receptors and 1.38 nM for human A2A receptors. In an antileptospire test in mice, 6 tested example compds. I at 3.2 mg/kg orally completely suppressed the cataleptic effects of haloperidol at 0.32 mg/kg i.p.


IT 403490-01-7P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-03-9P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-05-1P, 5-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-24-4P, 2-[2-[(3-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]ethyl]-1H-isindole-1,3(2H)-dione 403490-59-5P, tert-Butyl 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-1-piperidinecarboxylate 403490-61-9P, 5-(4-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride 403490-77-7P, Ethyl [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetate 403490-79-9P, [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetic acid 403490-87-9P,



L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 5-[2-Oxo-2-(1-piperazinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride 403491-38-3P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl trifluoromethanesulfonate 403491-41-8P, Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylate 403491-43-0P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylic acid 403492-02-4P, 5-(4-Hydroxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-07-9P, tert-Butyl 4-(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)-1-piperazinecarboxylate 403492-13-7P, 5-(1-Piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-89-7P, tert-Butyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl carbamate 403492-91-1P, 5-Amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-06-1P, 5-(4-Bromobutanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-91-4P, 4-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; prepn. of pyrazolopyridines as adenosine receptor antagonists)  
 RN 403490-01-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 403490-03-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-05-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(5-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




•x HCl

RN 403490-77-7 CAPLUS  
 CN Acetic acid, [[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403490-79-9 CAPLUS  
 CN Acetic acid, [[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403490-87-9 CAPLUS  
 CN Piperazine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 403490-24-4 CAPLUS  
 CN 1H-Indole-1,3(2H)-dione, 2-[2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl]- (CA INDEX NAME)




RN 403490-59-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 403490-61-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-piperidin-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




•x HCl


RN 403491-38-3 CAPLUS  
 CN Methanesulfonic acid, trifluoro-, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX NAME)




RN 403491-41-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, methyl ester (CA INDEX NAME)




RN 403491-43-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, (CA INDEX NAME)





RN 403492-02-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-(4-hydroxy-1-piperidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)



RN 403492-07-9 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 403492-13-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




IT 403490-07-3P, 5-[2-(Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-10-8P, 5-[2-(4-Morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-13-1P, 5-[4-(4-Methoxyphenylsulfonyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-15-3P, 5-Benzyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-16-4P, 5-Phenethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-18-6P, 5-Isopropoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-20-0P, 5-[3-((2R)-2-(Methoxymethyl)-4-morpholinyl)propoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-22-2P, 5-(2-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-26-6P, 5-(2-Aminoethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-28-8P, 5-[3-Dimethylaminopropoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-30-2P, 5-[2-(1-Piperidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-32-4P, 5-[2-(1-Pyrrolidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-34-6P, 5-[2-((3R,5S)-3,5-Dimethyl-4-morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-36-8P, 5-(4-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-38-0P, 5-(3-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-40-4P, 5-Propoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-42-6P, 5-Isopentyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-47-1P, 5-(2-Cyclohexylethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-49-3P, 5-[2-((2R,6S)-2,6-Dimethyl-4-morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-51-7P, 5-[2-(Diethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-53-9P, 5-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-55-1P, 5-(2-Oxopropoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-57-3P, 5-[2-(2-Oxo-1-pyrrolidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-63-1P, 5-(2-Pyridinyl)ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
403490-65-3P, Benzyl [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-


RN 403492-89-7 CAPLUS  
CN Carbamic acid, [3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 403492-91-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)



RN 403493-06-1 CAPLUS  
CN Butanamide, 4-bromo-N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (CA INDEX NAME)



RN 403493-91-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(4-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetate 403490-67-5P  
5-(2-Cyclopentylethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-69-7P  
5-[2-(1-Aziridinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-71-1P  
5-(4-Pyridinyl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-73-3P, N-[3-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]phenyl]acetamide 403490-75-5P, 5-Phenoxo-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-81-3P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethylacetamide 403490-83-5P, N,N-Diethyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403490-85-7P, tert-Butyl 4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]phenyl]acetate 403490-89-1P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-phenylacetamide 403490-91-5P, N-Isobutyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403490-93-7P, 5-(Tetrahydropyran-4-yl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-95-9P, 5-(5-Methoxy-2-pyridinyl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-97-1P, 5-[[5-Nitro-2-pyridinyl]oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-99-3P, Methyl [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetate 403491-01-0P, 5-[2-(4-Methyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-03-2P, 5-[2-(4-Morpholinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-05-4P, N,N-Bis-(2-ethoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-07-6P, 5-[2-(4-Benzyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-09-8P, 5-[2-(4-Acetyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-11-2P, N,N-Dimethyl-4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-1-piperazinecarboxamide 403491-13-4P, N,N-Dimethyl-4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-1-piperidinecarboxamide 403491-15-6P, 5-[[1-Acetyl-4-piperidinyl]oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-17-8P, N-[2-(Dimethylamino)ethyl]-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-19-0P, 2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(3-methoxybenzyl)acetamide 403491-21-4P, 2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-[2-(2-pyridinyl)ethyl]acetamide 403491-23-6P, N-Cyclopropyl-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-25-8P, N-Cyclopentyl-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-27-0P, N-Cyclohexyl-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-29-2P, N-(4-Hydroxycyclohexyl)-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-31-6P

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
N-Butyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-33-8P,  
N-(2-Methoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-36-1P,  
N-(2-Ethoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-45-2P,  
3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-47-8P, N,N-Dimethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-49-6P, 5-[(1-Pyrrolidinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-51-0P, 5-[(4-Methyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-53-2P, N-(2-Hydroxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-55-4P, N-[2-(Dimethylamino)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-56-5P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenyl-N-[(15)-1-phenylethyl]pyrazolo[1,5-a]pyridine-5-carboxamide 403491-58-7P, N-(2-Ethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-60-1P, N-Methyl-N-[2-(pyridin-2-yl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-62-3P, 5-[(4-Acetyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-64-5P, 5-[(cis-2,6-Dimethyl-4-morpholinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-66-7P, N-Benzyl-N-methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-68-9P, N-(tert-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-70-3P, 5-[(4-Phenyl-1-piperidinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-72-5P, N,N-Dimethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-74-7P, N-(2-Isopropoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-76-9P, N-(3-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-78-1P, N-Methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-80-5P, 5-(1-Piperidinylcarbonyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-82-7P, N-[2-(1-Pyrrolidinyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-84-9P, N-(5-Methyl-1,3-thiazol-2-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-86-1P, N-(2-Phenoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-88-3P, N,N-Bis(2-methoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-90-7P, N-(1-Methyl-1-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-92-9P, N-Isopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-93-0P, 5-(4-Methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-96-3P, 5-(4-Morpholinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-98-5P, 5-(4-Phenyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-69-3P, 4-Bromo-5-methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-71-7P, 5-(3-Hydroxy-3-methyl-1-butenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-73-9P, 5-[(1-Hydroxycyclohexyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-75-1P, 5-(1-Cyclohexylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-77-3P, N-Cyclopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-79-5P, N-Cycloheptyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-81-9P, 5-[(Hexahydro-1H-azepin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-83-1P, 5-[(2-Pyridinyl)-1-piperazinyl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-85-3P, N-(n-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-87-5P, N-(2-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-93-3P, 5-Acetylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-95-5P, 5-Benzoylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-97-7P, 5-(2-Methylpropanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-99-9P, 5-(Methylsulfonylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-04-9P, Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl carbamate 403493-08-3P, 5-(2-Oxo-1-pyrrolidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-10-7P, 5-[Bis(methoxymethyl)amino]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-12-9P, 5-[(1-Methyl-4-piperidinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride 403493-14-1P, 1,1-Dibenzyl-4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]piperidinium bromide 403493-16-3P, 5-[(4-Methoxybenzyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-18-5P, 5-[(4-Fluorobenzyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-20-9P, 5-(Nicotinamid-6-oxyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-22-1P, 5-(2-Oxo-2-(1-piperidinyl)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-24-3P, N-(tert-Butyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403493-26-5P, N-Cyclohexyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403493-28-7P, 3-(2,3-Dihydropyridazin-6-yl)-6-methoxy-2-phenylpyrazolo[1,5-a]pyridine 403493-30-1P, 6-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-32-3P, 6-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-34-5P, 6-[2-(N,N-Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-36-7P, 6-[2-(2R,6S)-2,6-Dimethyl-4-morpholinyl]ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
phenylpyrazolo[1,5-a]pyridine 403492-00-2P, 5-(cis-2,6-Dimethyl-4-morpholinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-04-6P, 5-[4-(2-Pyridinyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-09-1P, 5-(4-Benzyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-11-5P, 5-(4-Methoxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-15-9P, Methyl 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-1-piperazinecarboxylate 403492-17-1P, 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-N,N-dimethyl-1-piperazinecarboxamide 403492-19-3P, 5-[4-(Methylsulfonyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-21-7P, 5-[4-(Phenylsulfonyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-23-9P, 5-(4-Benzoyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-25-1P, 5-(4-Acetyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-27-3P, 5-[4-[(Dimethylamino)acetyl]-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-29-5P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-31-9P, 5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-33-1P, 5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-35-3P, 5-Methoxy-3-(3-oxo-2-(tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-37-5P, 5-Methoxy-3-(3-oxo-2-((3R)-tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-39-7P, 5-Methoxy-3-(3-oxo-2-((3S)-tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-41-1P, 5-Methoxy-3-(3-oxo-2-(1-methoxy-2-propyl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-43-3P, 5-Methoxy-3-(3-oxo-2-(1-methylpiperidin-4-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-45-5P, 5-Methoxy-3-(3-oxo-2-(1-methylpiperidin-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-47-7P, 5-Methoxy-3-(3-oxo-2-(tetrahydropyran-4-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-49-9P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-51-3P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-53-5P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-55-7P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-57-9P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-59-1P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-61-5P, 5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-63-7P, 5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-65-9P, 7-Amino-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-67-1P, 7-Amino-3-(3-oxo-2-isopropyl-2,3-

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
403493-38-9P, 6-(2-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-40-3P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetic acid 403493-42-5P, Ethyl 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetate 403493-44-7P, N,N-Dimethyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetate 403493-46-9P, 5-(2-(1-Pyrrolidinyl)-2-oxoethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-48-1P, 6-[2-(4-Methyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-50-5P, 6-[2-(2R,6S)-2,6-Dimethyl-4-morpholinyl]-2-oxoethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-52-7P, N-Cyclopentyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetamide 403493-54-9P, N-Isopropyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetamide 403493-56-1P, N-Isobutyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetamide 403493-58-3P, 6-[(Trifluoromethanesulfonyl)oxy]pyridin-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-60-7P, 6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-62-9P, 6-(4-Methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-64-1P, Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxylate 403493-66-3P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxylic acid 403493-68-5P, N,N-Dimethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxamide 403493-70-9P, 6-[(4-Methyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-72-1P, 6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-74-3P, N-Isobutyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxamide 403493-76-5P, 7-Acetylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-78-7P, 7-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-80-1P, 7-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-82-3P, 7-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-84-5P, 7-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-85-6P, 7-Methoxy-3-(3-oxo-2-n-propyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-87-8P, 4-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-89-0P, 4-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-91-6P, 4-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-93-8P, 4-(n-Propoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-97-0P, 4-[(2-Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-99-2P, 4-[2-(4-Morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-01-9P, 5-[1-(4-Diazabicyclo[4.3.0]non-4-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

403494-03-1P, 5-[(Morpholin-4-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

403494-05-3P, N-Allyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-07-5P, (R)-N-(1-Phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-09-7P, N-(4-Methoxyphenethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-11-1P, N-(2-(Hydroxymethyl)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-15-5P, N-(3-Methoxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-17-7P, N-(1-Phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-19-9P, N-(2-Methoxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-21-3P, 5-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-23-5P, N-(2-Methoxyethyl)-N-methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-25-7P, N-(4-Hydroxybutyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-27-9P, N-[2-(2-Pyridinyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-29-1P, N-[2-(4-Chlorophenyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-31-5P, N-(5-Methylisoxazol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-33-7P, N-(6-Methoxy-3-pyridinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-35-9P 403494-37-1P, N-[4-(Difluoromethoxy)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-39-3P, (S)-5-[(2-(Hydroxymethyl)pyrrolidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-41-7P, N-(4-Phenoxypheyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-43-9P, N-Cyclooctyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-45-1P, N-(1-Naphthylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-47-3P, N-(5-Hydroxy-1-naphthyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-49-5P, 5-[(4-(Methanesulfonylamino)piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-51-9P, 5-[(3-Hydroxypiperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-53-1P, N-(2-Oxohomopiperidin-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of pyrazolopyridines as adenosine receptor antagonists)


RN 403490-07-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[5-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 403490-16-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-phenylethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 403490-18-6 CAPLUS


CN 3(2H)-Pyridazinone, 6-[5-(1-methylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)



RN 403490-20-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[5-[3-[(2R)-2-(methoxymethyl)-4-morpholinyl]propoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 403490-22-2 CAPLUS


CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 403490-10-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-[2-(4-morpholinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403490-13-1 CAPLUS

CN Benzenesulfonic acid, 4-methoxy-, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (CA INDEX NAME)




RN 403490-15-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(phenylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 403490-26-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[5-(2-aminoethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-28-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[5-[3-(dimethylamino)propoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-30-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-[2-(1-piperidinyl)ethoxy]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 403490-32-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-[2-(1-pyrrolidinyl)ethoxy]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403490-34-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-[5-[2-[(3R,5S)-3,5-dimethyl-4-morpholinyl]ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 403490-36-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403490-38-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(3-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3(2H)-Pyridazinone, 6-[5-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 403490-51-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-[5-[2-(diethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-53-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-[5-(5-ethoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-55-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(2-oxopropoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 403490-40-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-5-propoxypyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 403490-42-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-[5-(3-methylbutoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-47-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-[5-(2-cyclohexylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-49-3 CAPLUS


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 403490-57-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(2-(2-oxo-1-pyrrolidinyl)ethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403490-63-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403490-65-3 CAPLUS  
 CN Acetic acid, [[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 403490-67-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-(2-cyclopentylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-69-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-[2-(1-aziridinylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-71-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)


RN 403490-83-5 CAPLUS  
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 403490-85-7 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403490-89-1 CAPLUS  
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-phenyl- (CA INDEX NAME)




RN 403490-91-5 CAPLUS  
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 403490-73-3 CAPLUS  
CN Acetamide, N-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]phenyl]- (CA INDEX NAME)




RN 403490-75-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 403490-81-3 CAPLUS  
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 403490-93-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 403490-93-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-diethyl- (CA INDEX NAME)



RN 403490-95-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-[[5-methoxy-2-pyridinyl]oxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403490-97-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-methylpropyl)- (CA INDEX NAME)




L4. ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 403490-99-3 CAPLUS  
CN Acetic acid, [[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 403491-01-0 CAPLUS  
CN Piperazine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 403491-03-2 CAPLUS  
CN Morpholine, 4-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403491-05-4 CAPLUS  
CN Acetamide, 2-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-bis(2-ethoxyethyl)- (CA INDEX NAME)

L4. ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 403491-13-4 CAPLUS  
CN 1-Piperidinecarboxamide, 4-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 403491-15-6 CAPLUS  
CN Piperidine, 1-acetyl-4-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-17-8 CAPLUS  
CN Acetamide, 2-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-(dimethylamino)ethyl)- (CA INDEX NAME)


L4. ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 403491-07-6 CAPLUS  
CN Piperazine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-4- (9CI) (CA INDEX NAME)




RN 403491-09-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403491-11-2 CAPLUS  
CN 1-Piperazinecarboxamide, 4-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)


L4. ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 403491-19-0 CAPLUS  
CN Acetamide, 2-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(3-methoxyphenyl)methyl- (CA INDEX NAME)




RN 403491-21-4 CAPLUS  
CN Acetamide, 2-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-(2-pyridinyl)ethyl)- (CA INDEX NAME)




RN 403491-23-6 CAPLUS  
CN Acetamide, N-cyclopropyl-2-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (CA INDEX NAME)




RN 403491-25-8 CAPLUS  
CN Acetamide, N-cyclopentyl-2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (CA INDEX NAME)




RN 403491-27-0 CAPLUS  
CN Acetamide, N-cyclohexyl-2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (CA INDEX NAME)




RN 403491-29-2 CAPLUS  
CN Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(4-hydroxycyclohexyl)- (CA INDEX NAME)





RN 403491-45-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carbonitrile, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403491-47-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 403491-49-6 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 403491-31-6 CAPLUS  
CN Acetamide, N-butyl-2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (CA INDEX NAME)




RN 403491-33-8 CAPLUS  
CN Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 403491-36-1 CAPLUS  
CN Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-ethoxyethyl)- (CA INDEX NAME)


RN 403491-51-0 CAPLUS  
CN Piperazine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 403491-53-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxyethyl)-2-phenyl- (CA INDEX NAME)




RN 403491-55-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-(dimethylamino)ethyl)-2-phenyl- (CA INDEX NAME)




RN 403491-56-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.







RN 403491-58-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(2-ethoxyethyl)-2-phenyl]- (CA INDEX NAME)




RN 403491-60-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-methyl-2-phenyl-N-(2-(2-pyridinyl)ethyl)]- (CA INDEX NAME)




RN 403491-62-3 CAPLUS  
CN Piperazine, 1-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403491-70-3 CAPLUS  
CN Piperidine, 1-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-phenyl]- (9CI) (CA INDEX NAME)



RN 403491-72-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N,N-diethyl-2-phenyl]- (CA INDEX NAME)




RN 403491-74-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(2-(1-methylethoxy)ethyl)-2-phenyl]- (CA INDEX NAME)




RN 403491-64-5 CAPLUS  
CN Morpholine, 4-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403491-66-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-methyl-2-phenyl-N-(phenylmethyl)]- (CA INDEX NAME)




RN 403491-68-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(1,1-dimethylethyl)-2-phenyl]- (CA INDEX NAME)




RN 403491-76-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl-N-(3-pyridinylmethyl)]- (CA INDEX NAME)




RN 403491-78-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-methyl-2-phenyl]- (CA INDEX NAME)




RN 403491-80-5 CAPLUS  
CN Piperidine, 1-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 403491-82-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-(1-pyrrolidinyl)ethyl)- (CA INDEX NAME)




RN 403491-84-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(5-methyl-2-thiazolyl)-2-phenyl- (CA INDEX NAME)




RN 403491-86-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-phenoxyethyl)-2-phenyl- (CA INDEX NAME)


RN 403491-93-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(4-methyl-1-piperazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 403491-96-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(4-morpholinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403491-98-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-phenyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403492-00-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.





RN 403491-88-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-bis(2-methoxyethyl)-2-phenyl- (CA INDEX NAME)




RN 403491-90-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-methyl-1-phenylethyl)-2-phenyl- (CA INDEX NAME)




RN 403491-92-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-methylethyl)-2-phenyl- (CA INDEX NAME)




RN 403492-04-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-(2-pyridinyl)-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403492-09-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-(phenylmethyl)-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403492-11-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-(4-methoxy-1-piperidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403492-15-9 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, methyl ester (CA INDEX NAME)




RN 403492-17-1 CAPLUS  
CN 1-Piperazinecarboxamide, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 403492-19-3 CAPLUS  
CN Piperazine, 1-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 403492-21-7 CAPLUS  
CN Piperazine, 1-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 403492-23-9 CAPLUS  
CN Piperazine, 1-benzoyl-4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 403492-25-1 CAPLUS  
CN Piperazine, 1-acetyl-4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 403492-27-3 CAPLUS  
CN Piperazine, 1-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)




RN 403492-29-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-methyl- (CA INDEX NAME)




RN 403492-31-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-ethyl-6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 403492-33-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (CA INDEX NAME)




RN 403492-35-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 403492-37-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(3R)-tetrahydro-3-furanyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 403492-39-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(3S)-tetrahydro-3-furanyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 403492-41-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-methoxy-1-methylethyl)-6-(5-methoxy-2-


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 403492-43-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 403492-45-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methyl-3-piperidinyl)- (CA INDEX NAME)




RN 403492-47-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 403492-49-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 403492-57-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403492-59-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 403492-61-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-ethyl-6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
3-yl)- (CA INDEX NAME)



RN 403492-51-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 403492-53-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403492-55-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 403492-63-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-propyl- (CA INDEX NAME)




RN 403492-65-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(7-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 403492-67-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(7-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403492-69-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(4-bromo-5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-71-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-(3-hydroxy-3-methyl-1-butanyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-73-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-[(1-hydroxycyclohexyl)ethynyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-81-9 CAPLUS  
CN 1H-Azepine, 1-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]hexahydro- (9CI) (CA INDEX NAME)




RN 403492-83-1 CAPLUS  
CN Piperazine, 1-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 403492-85-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-butyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403492-75-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-(2-phenyl-5-(phenylethynyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 403492-77-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclopropyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403492-79-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cycloheptyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403492-87-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 403492-93-3 CAPLUS  
CN Acetamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (CA INDEX NAME)




RN 403492-95-5 CAPLUS  
CN Benzamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (CA INDEX NAME)




RN 403492-97-7 CAPLUS  
CN Propanamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-2-methyl- (CA INDEX NAME)




RN 403492-99-9 CAPLUS  
CN Methanesulfonamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (CA INDEX NAME)



RN 403493-04-9 CAPLUS  
CN Carbamic acid, [3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 403493-08-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-[5-[(2-oxo-1-pyrrolidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]oxy]-1,1-bis(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)




• Br<sup>-</sup>


RN 403493-16-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-[(4-methoxyphenyl)methoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403493-18-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-[2-phenyl-5-[[4-(trifluoromethyl)-2-pyridinyl]oxy]pyrazolo[1,5-a]pyridin-3-yl]oxy]- (CA INDEX NAME)




RN 403493-20-9 CAPLUS  
CN 3-Pyridinecarboxamide, 6-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (CA INDEX NAME)



RN 403493-10-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[5-[[bis(methoxymethyl)amino]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 403493-12-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-[5-[(1-methyl-4-piperidinyl)oxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]oxy]-, hydrochloride (9CI) (CA INDEX NAME)




• x HCl


RN 403493-14-1 CAPLUS  
CN Piperidinium, 4-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-1,1-bis(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)




RN 403493-22-1 CAPLUS  
CN Piperidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403493-24-3 CAPLUS  
CN Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 403493-26-5 CAPLUS  
CN Acetamide, N-cycloheptyl-2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (CA INDEX NAME)




RN 403493-28-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(1,6-dihydro-3-pyridazinyl)-6-methoxy-2-phenyl- (CA INDEX NAME)




RN 403493-30-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(6-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403493-32-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(6-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403493-34-5 CAPLUS




RN 403493-42-5 CAPLUS  
CN Acetic acid, [[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403493-44-7 CAPLUS  
CN Acetamide, 2-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 403493-46-9 CAPLUS  
CN Pyrrolidine, 1-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403493-36-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[6-[2-(2R,6S)-2,6-dimethyl-4-morpholinyl]ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 403493-38-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-6-(2-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 403493-40-3 CAPLUS  
CN Acetic acid, [[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403493-48-1 CAPLUS  
CN Piperazine, 1-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 403493-50-5 CAPLUS  
CN Morpholine, 4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403493-52-7 CAPLUS  
CN Acetamide, N-cyclopentyl-2-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 403493-54-9 CAPLUS  
CN Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 403493-56-1 CAPLUS  
CN Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 403493-58-3 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl ester (9CI) (CA INDEX NAME)




RN 403493-66-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)



RN 403493-68-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 403493-70-9 CAPLUS  
CN Piperazine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 403493-60-7 CAPLUS  
CN 3-(2H)-Pyridazinone, 6-[6-[[2,6-dimethyl-4-morpholinyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 403493-62-9 CAPLUS  
CN 3-(2H)-Pyridazinone, 2-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403493-64-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, methyl ester (CA INDEX NAME)




RN 403493-72-1 CAPLUS  
CN Morpholine, 4-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]carbonyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 403493-74-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methylpropyl)-2-phenyl- (CA INDEX NAME)




RN 403493-76-5 CAPLUS  
CN Acetamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]-4-methyl- (9CI) (CA INDEX NAME)







RN 403493-78-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 403493-80-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403493-82-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-methyl- (CA INDEX NAME)




RN 403493-89-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(4-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403493-93-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(4-ethoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 403493-95-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-4-propoxy-pyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 403493-97-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[4-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 403493-84-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-ethyl-6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 403493-85-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (CA INDEX NAME)




RN 403493-87-8 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(4-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 403493-99-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-([3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl)octahydro- (9CI)




RN 403494-01-9 CAPLUS  
CN Pyrrolo[1,2-a]pyrazine, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]octahydro- (9CI)



RN 403494-03-1 CAPLUS  
CN Morpholine, 4-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403494-05-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 403494-07-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 403494-09-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(4-methoxyphenyl)ethyl]-2-phenyl- (CA INDEX NAME)




RN 403494-11-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(hydroxymethyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 403494-15-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-methoxypropyl)-2-phenyl- (CA INDEX NAME)




RN 403494-17-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(1-phenylethyl)- (CA INDEX NAME)




RN 403494-19-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 403494-21-3 CAPLUS  
CN 4-Piperidinol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403494-23-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyethyl)-N-methyl-2-phenyl- (CA INDEX NAME)




RN 403494-25-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxybutyl)-2-phenyl- (CA INDEX NAME)




RN 403494-27-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 403494-29-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2-(4-chlorophenyl)ethyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403494-31-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(5-methyl-3-isoxazolyl)-2-phenyl- (CA INDEX NAME)




RN 403494-33-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(6-methoxy-3-pyridinyl)-2-phenyl- (CA INDEX NAME)




RN 403494-35-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-chloro-4-methylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403494-43-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclooctyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403494-45-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-naphthalenylmethyl)-2-phenyl- (CA INDEX NAME)



RN 403494-47-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(5-hydroxy-1-naphthalenyl)-2-phenyl- (CA INDEX NAME)




RN 403494-37-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(4-(difluoromethoxy)phenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403494-39-3 CAPLUS  
CN 2-Pyrrolidinemethanol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403494-41-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-phenoxypiperidin-1-yl)-2-phenyl- (CA INDEX NAME)




RN 403494-49-5 CAPLUS  
CN 4-Piperidinamine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 403494-51-9 CAPLUS  
CN 3-Piperidinol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 403494-53-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(hexahydro-2-oxo-1H-azepin-3-yl)-2-phenyl- (CA INDEX NAME)



IT 403494-55-3P, N-(5-Phenyl-1H-pyrazol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-57-5P, (S)-5-[(2-(Methoxymethyl)pyrrolidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-59-7P, N-(2,3-Dihydroxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-61-1P, N-(2-Hydroxy-5-chlorophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-63-3P, (R)-5-[(2-(Methoxymethyl)pyrrolidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-66-6P, N-(2-Furylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-68-8P, N-(2-Morpholinoethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-70-2P, N-[(1S,2S)-2-Hydroxy-1-(hydroxymethyl)-2-phenylethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-72-4P, N-(4-Methylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-77-9P, N-Isobutyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-79-1P, N-Cyclohexyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-81-5P, N-(2,2-Diethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-83-7P, (S)-5-[(3-(Methylaminocarbonyl)-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-85-9P, 5-[(2,3-Dihydro-1H-Indol-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-86-0P, N-Hexyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-88-2P, N-(3-Phenylpropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-90-6P, N-(3,4-Dimethoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-92-8P, N-1-(2-Hydroxyethyl)-4-(ethoxycarbonyl)-1H-pyrazol-5-yl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-94-0P, N-(2-Hydroxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-95-1P, N-(2-Hydroxy-2-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-97-3P, N-[1-(Naphthyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-99-5P, N-[4-(Acetylamino)phenyl]-3-(3-oxo-2-isopropyl-2,3-

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued) dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-00-1P, 5-[(4-(2-Hydroxyethyl)piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-01-2P, N-(2-Methoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-03-4P, N-[3-(Dimethylamino)propyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-05-6P, N-(2-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-07-8P, N-(1H-Indol-5-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-09-0P, N-Methyl-N-phenethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-11-4P, (S)-N-[1-(Hydroxymethyl)-2-methylpropyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-13-6P, N-(3-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-15-8P, (R)-N-[1-(Naphthyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-17-0P, 5-[(4-[(4-Fluorophenyl)carbonyl]amino)piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-19-2P, N-(3-Ethoxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-20-5P, N-(4-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-21-6P, N-(3-Hydroxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-23-8P, N-(1H-Indazol-6-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-25-0P, N-[4-(Diethylamino)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-27-2P, 5-[(4-[(Ethoxycarbonyl)phenyl]piperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-29-4P, 5-[(4-(Ethoxycarbonyl)piperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-30-7P, N-Cyclopentyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-31-8P, N-(2,2-Dimethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-32-9P, N-(4-Hydroxyphenethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-33-0P, N-(3-Acetylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-34-1P, 5-[(4-Phenylpiperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-35-2P, N-[3-(Methylthio)propyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-36-3P, N-[2-Hydroxy-1-phenylethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-37-4P, N-(3,4-Dichlorobenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-38-5P, N-(4-Fluorophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-39-6P, N-Isopentyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-40-8P, N-Benzyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-41-0P, N-(3-Chlorobenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-


L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued) phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-42-1P, N-(3,4-Dimethoxyphenethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-43-2P, 5-[(6-Nitroindolin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-44-3P, N-Pentyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-45-4P, N-(2-Chlorobenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-46-5P, N-(4-Isopropylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-47-6P, N-Benzyl-N-(1-hydroxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-48-7P, 5-[(4-Cyclohexylpiperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-49-8P, N-(4-Chlorobenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-50-1P, N-(Diphenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-51-2P, N-(3-Cyanophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-52-3P, 5-[(1,2,3,4-Tetrahydro-9H-pyrido[3,4-b]indol-2-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-53-4P, N-(1-Benzylpiperidin-4-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-54-5P, N-(2,4-Dimethylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-55-6P, N-[4-(2-Hydroxyethyl)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-56-7P, 5-[(4-(2-Methoxyphenyl)piperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-57-8P, N-(3,4-Dimethylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-58-9P, N-(4-Methoxy-2-methylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-59-0P, N-(4-Hydroxy-3-nitrophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-60-3P, N-(5-Chloro-2-nitrophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-61-4P, N-(6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-62-5P, trans-N-(4-(Hydroxycyclohexyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-63-6P, N-[2-(Diisopropylamino)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-64-7P, N-(4-Hydroxy-2-nitrophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-66-9P, (R)-N-[2-(tert-Butoxycarbonyl)amino]-3-(1H-Indol-3-yl)propyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-67-0P, 5-[(4-(2-Oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-68-1P, N-(2-Hydroxy-1,1-dimethylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-69-2P, N-[2-(Diethylamino)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-70-5P, N-(1,2,3,4-Tetrahydro-9H-pyrido[3,4-b]indol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-

L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued) carboxamide 403495-71-6P, (S)-N-[1-(tert-Butoxycarbonyl)methyl]-2-oxo-3,4,5-tetrahydro-1H-benz[b]azepin-3-yl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-72-7P, 5-[(4-Benzhydryl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-73-8P, N-Phenethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-74-9P, N-(4-Fluorobenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-75-0P, 5-[(4-Benzhydryloxy)piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-76-1P, N-(4-Methylbenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-77-2P, N-(3,4-Methyleneedioxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-78-3P, N-(4-Anilino)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-79-4P, N-(3-Phenoxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-80-7P, N-(4-Bromo-3-methylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-81-8P, N-(3-Bromo-4-methylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-82-9P, N-(5-(4-Chlorophenyl)-1H-pyrazol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-83-0P, N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-84-1P, N-(3-Benzoylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-85-2P, N-(4-(4-Methylphenoxy)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-86-3P, N-(3-Iodo)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-87-4P, N-[2-(Methoxycarbonyl)-4,5-dihydro-3-thienyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-88-5P, N-[4-(4-Fluorophenoxy)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-89-6P, (S)-N-(4-Hydroxy-2,3,4-dichlorophenyl)butyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-90-9P, N'-Bis[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of pyrazolopyridines as adenosine receptor antagonists)

RN 403494-55-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 403494-57-5 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403494-59-7 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)




RN 403494-61-1 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)




RN 403494-70-2 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403494-72-4 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)




RN 403494-77-9 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)




RN 403494-63-3 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403494-66-6 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)




RN 403494-68-8 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)



RN 403494-79-1 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)




RN 403494-81-5 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)




RN 403494-83-7 CAPLUS  
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403494-85-9 CAPLUS  
CN 1H-Indole, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 403494-86-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-hexyl-2-phenyl- (CA INDEX NAME)




RN 403494-88-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 403494-95-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxy-2-phenylethyl)-2-phenyl- (CA INDEX NAME)




RN 403494-97-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[1-(1-naphthalenyl)ethyl]-2-phenyl- (CA INDEX NAME)




RN 403494-99-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(acetylamino)phenyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403494-90-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 403494-92-8 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid, 5-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-1-(2-hydroxyethyl)-, ethyl ester (CA INDEX NAME)




RN 403494-94-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxypropyl)-2-phenyl- (CA INDEX NAME)




RN 403495-00-1 CAPLUS  
CN 4-Piperidineethanol, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403495-01-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyethyl)-2-phenyl- (CA INDEX NAME)




RN 403495-03-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[3-(dimethylamino)propyl]-2-phenyl- (CA INDEX NAME)




RN 403495-05-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(2-methoxyphenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 403495-07-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-1H-indol-5-yl-2-phenyl- (CA INDEX NAME)




RN 403495-09-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl-N-(2-phenylethyl)- (CA INDEX NAME)




L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Benzamide, N-[1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-piperidinyl]-4-fluoro- (CA INDEX NAME)



RN 403495-19-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-ethoxypropyl)-2-phenyl- (CA INDEX NAME)




RN 403495-20-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(4-methoxyphenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 403495-21-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-hydroxyphenyl)-2-phenyl- (CA INDEX NAME)

RN 403495-11-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-2-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 403495-13-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(3-methoxyphenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 403495-15-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1R)-1-(1-naphthalenyl)ethyl]-2-phenyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-17-0 CAPLUS




RN 403495-23-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-1H-indazol-6-yl-2-phenyl- (CA INDEX NAME)




RN 403495-25-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(diethylamino)phenyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-27-2 CAPLUS  
CN Benzoic acid, 4-[4-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-1-piperazinyl]-, ethyl ester (CA INDEX NAME)




RN 403495-29-4 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 403495-30-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclopentyl-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)



RN 403495-31-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2,2-dimethoxyethyl)-2-phenyl- (CA INDEX NAME)




RN 403495-35-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-(methylthio)propyl)-2-phenyl- (CA INDEX NAME)




RN 403495-36-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]-2-phenyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-37-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-32-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-(4-hydroxyphenyl)ethyl)-2-phenyl- (CA INDEX NAME)




RN 403495-33-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-acetylphenyl)-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-34-1 CAPLUS  
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 403495-38-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-fluorophenyl)-2-phenyl- (CA INDEX NAME)




RN 403495-39-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-methylbutyl)-2-phenyl- (CA INDEX NAME)




RN 403495-40-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]-N-(phenylmethyl)- (CA INDEX NAME)







RN 403495-41-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(3-chlorophenyl)methyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-42-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-phenyl- (CA INDEX NAME)




RN 403495-43-2 CAPLUS  
CN 1H-Indole, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3-dihydro-6-nitro- (9CI) (CA INDEX NAME)




RN 403495-44-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-pentyl-2-phenyl- (CA INDEX NAME)




RN 403495-45-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(2-chlorophenyl)methyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-46-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-(1-methylethyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 403495-47-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(phenylmethyl)-N-(6,7,8,9-tetrahydro-1-hydroxy-5H-benzocyclohepten-6-yl)- (CA INDEX NAME)




RN 403495-48-7 CAPLUS  
CN Piperidine, 4-cyclohexyl-1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403495-49-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-50-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(diphenylmethyl)-2-phenyl- (CA INDEX NAME)




RN 403495-51-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-cyanophenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-52-3 CAPLUS  
CN 1H-Pyrido[3,4-b]indole, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 403495-53-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 403495-54-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2,4-dimethylphenyl)-2-phenyl- (CA INDEX NAME)




RN 403495-55-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-(2-hydroxyethyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 403495-59-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxy-3-nitrophenyl)-2-phenyl- (CA INDEX NAME)




RN 403495-60-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(5-chloro-2-nitrophenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-61-4 CAPLUS  
CN 1H-Pyrido[3,4-b]indole, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3,4,9-tetrahydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 403495-56-7 CAPLUS  
 CN Piperazine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(2-methoxyphenyl)- (9CT)  
 (CA INDEX NAME)



RN 403495-57-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3,4-dimethylphenyl)-2-phenyl- (CA INDEX NAME)




RN 403495-58-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-methoxy-2-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 403495-62-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(trans-4-hydroxycyclohexyl)-2-phenyl- (CA INDEX NAME)


Relative stereochemistry.




RN 403495-63-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)



RN 403495-64-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1,2-diphenylethyl)-2-phenyl- (CA INDEX NAME)




RN 403495-65-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxy-2-nitrophenyl)-2-phenyl- (CA INDEX NAME)




RN 403495-66-9 CAPLUS  
CN Carbamic acid, [(1R)-2-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403495-67-0 CAPLUS  
CN Piperidine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 403495-71-6 CAPLUS  
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-72-7 CAPLUS  
CN Piperazine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)




RN 403495-73-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 403495-68-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxy-1,1-dimethylethyl)-2-phenyl- (CA INDEX NAME)




RN 403495-69-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2-(diethylamino)ethyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-70-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)




RN 403495-74-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 403495-75-0 CAPLUS  
CN Piperidine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-4-(diphenylmethoxy)- (9CI) (CA INDEX NAME)




RN 403495-76-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(4-methylphenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 403495-77-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-78-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[4-(phenylamino)phenyl]- (CA INDEX NAME)




RN 403495-79-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-phenoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 403495-83-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-84-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-benzoylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-85-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-(4-methylphenoxy)phenyl]-2-phenyl- (CA INDEX NAME)




RN 403495-80-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(4-bromo-3-methylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-81-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-bromo-4-methylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-82-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)




RN 403495-86-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-iodophenyl)-2-phenyl- (CA INDEX NAME)



RN 403495-87-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-4,5-dihydro-, methyl ester (CA INDEX NAME)




RN 403495-88-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-(4-fluorophenoxy)phenyl]-2-phenyl- (CA INDEX NAME)




RN 403495-89-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(2S)-2-(3,4-dichlorophenyl)-4-hydroxybutyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 403496-05-9 CAPLUS  
CN Urea, N,N'-bis[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (CA INDEX NAME)




IT 403495-90-9P, 3-(3-Phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine 403495-95-4P, 5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403495-96-5P, 5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403495-97-6P, 3-(6-Methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine-7-carboxylic acid 403495-98-7P, tert-Butyl [3-(3-methoxy-6-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-yl]carbamate 403495-99-8P, 7-Amino-3-(3-methoxy-6-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine 403496-03-7P, 7-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-


RN 403495-97-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-carboxylic acid, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (CA INDEX NAME)



RN 403495-98-7 CAPLUS  
CN Carbamic acid, [3-(6-methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403495-99-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (CA INDEX NAME)




RN 403496-03-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (CA INDEX NAME)



L4 ANSWER 46 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
phenylpyrazolo[1,5-a]pyridine 403496-04-8P, 4-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate) prepn. of pyrazolopyridines as adenosine receptor antagonists  
RN 403495-90-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (CA INDEX NAME)




RN 403495-95-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluorophenyl)-5-methoxy-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (CA INDEX NAME)



RN 403495-96-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methoxy-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (CA INDEX NAME)




RN 403496-04-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 4-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (CA INDEX NAME)



IT 131185-62-1, 3-(6-Methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(precursor) preparation of pyrazolopyridines as adenosine receptor antagonists

RN 131185-62-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:15771 CAPLUS

DOCUMENT NUMBER: 136:200184

TITLE: Preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases

INVENTOR(S): Alberti, Michael John; Baldwin, Ian Robert; Cheung, Mui; Cockerill, Stuart; Flack, Stephen; Harris, Philip; Anthony, Jung; David Kendall; Peckham, Gregory; Peel, Michael Robert; Stanford, Jennifer Badiang; Stevens, Kirk; Veal, James Marvin

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 173 pp.

CODEN: PIXX2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:





PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016359	A1	20020228	WO 2001-GB3783	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420024	A1	20020228	CA 2001-2420024	20010822
AU 200182318	A	20020304	AU 2001-82318	20010822
EP 1311507	A1	20030521	EP 2001-960928	20010822
EP 1311507	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013448	A	20030617	BR 2001-13448	20010822
JP 2004506736	T	20040304	JP 2002-521460	20010822
AU 2004000757	A2	20040728	HU 2004-757	20010822
AT 318814	T	20060315	AT 2001-960928	20010822
CN 1798747	A	20060705	CN 2001-817742	20010822
ES 2259331	T3	20061001	ES 2001-1960928	20010822
IN 2003KN00168	A	20050311	IN 2003-KN168	20030211
ZA 2003001318	A	20040622	ZA 2003-1318	20030218
NO 2003000779	A	20030407	NO 2003-779	20030219
MX 2003PA01593	A	20030604	MX 2003-PA1593	20030221
US 2004053942	A1	20040318	US 2003-362146	20030707
US 7166597	B2	20070123		

PRIORITY APPL. INFO.:

OTHER SOURCE(S): MARPAT 136:200184

GI

CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl)-N-[3-[(4-methoxyphenyl)methoxy]propyl]- (CA INDEX NAME)

RN 401816-63-5 CAPLUS  
CN 1-Propanol, 3-[[4-(2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)RN 401816-64-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]-, ethyl ester (CA INDEX NAME)RN 401816-70-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(4-fluorophenyl)-3-[2-[(3-(4-methyl-1-piperazinyl)propyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)


AB Title compds. I [wherein Z = CH or N; m = 1-2; n = 1-3; p = 1-3; R1 = independently Xd(CH2)eR5; d = 0-1; e = 0-6; X = O, NR6, or SO2; R3 = H, halo, OH, CN, NO2, trihalomethyl, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, (hetero)aryl, phthalimido, aminophenyl, aminobenzyl, acyl(oxy), carbamoyl(oxy), carboxylate, sulfamoyl, carbamidamido, etc.; R4 = independently Yd(CH2)eR3; R5 = H, halo, OH, CN, NO2, trihalomethyl, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, (hetero)aryl, amino, aminophenyl, aminobenzyl, acyl(oxy), carbamoyl(oxy), carbamidamido, acylamino, sulfamoyl, etc.; R6 = H, (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or their salts, solvates, or physiol. functional derivs. thereof] were prepared as p38 and JNK3 protein kinase inhibitors. For example, cycloaddn. of Me 3-(4-fluorophenyl)propiolate (2-step preparation given) and 1-aminopyridinium iodide in AcCN in the presence of 1,8-diazabicyclo[6.4.0]undec-7-ene gave Me 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxylate (701), which was hydrolyzed to the acid (1001). Reaction with sodium bicarbonate, followed by N-bromosuccinimide, in DMF afforded the bromo derivative (801).

Reductive addition of 4-(tributylstannyl)pyridine using Pd(PPh3)4 in toluene gave II (801). The latter inhibited p38 kinase and tumor necrosis factor (TNF) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 values of < 0.5 μM. I are useful for the treatment of inflammatory and autoimmune diseases, cancer, and a variety of other conditions related to regulation of p38 kinase and/or JNK kinase.


IT 401816-55-5P, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[(4-methoxybenzyl)oxy]propyl]-2-pyrimidinamine 401816-63-5P 401816-64-6P 401816-70-4P 401816-83-9P, Methyl 4-[6-(trifluoromethyl)-2-[(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfide 401816-84-0P, Methyl 4-[6-(trifluoromethyl)-2-[(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfone 401816-87-3P, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl methyl sulfide 401816-88-4P, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl methyl sulfone 401816-91-9P, Methyl 4-[6-(trifluoromethyl)-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfide 401816-92-0P, Methyl 4-[6-(trifluoromethyl)-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfone  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)

RN 401816-55-5 CAPLUS


RN 401816-83-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 401816-84-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 401816-87-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 401816-88-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 401816-91-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 401816-92-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 401815-73-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-methanol, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 401815-85-8 CAPLUS  
CN Benzoic acid, 3-(aminosulfonyl)-4-chloro-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-90-5 CAPLUS  
CN 1H-isoindole-1,3(2H)-dione, 2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




IT 401815-65-4P, 2-(4-Fluorophenyl)-6-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-73-4P, 2-(4-Fluorophenyl)-5-hydroxymethyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-85-8P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-(aminosulfonyl)-4-chlorobenzoate 401815-90-5P, 2-[[2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]-1H-isoindole-1,3(2H)-dione hydrochloride 401815-97-2P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-15-7P, 3-(2,6-Difluoro-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-18-0P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-24-8P, 6-Bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-26-0P, 6-Cyano-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-29-3P, 6-Cyano-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 401816-50-0P, N-Cyclopropyl-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-65-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-66-8P, 2-(4-Fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-68-0P, N-[3-(4-Methylpiperazin-1-yl)propyl]-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(protein kinase inhibitors; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)

RN 401815-65-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-6-methyl-3-(4-pyridinyl)- (CA INDEX NAME)




● HCl


RN 401815-97-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)




RN 401816-15-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 401816-18-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-(trifluoromethyl)- (CA INDEX NAME)





RN 401816-24-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)




RN 401816-26-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 401816-29-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (CA INDEX NAME)




RN 401816-66-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylsulfonyl)-4-pyridinyl)-6-(trifluoromethyl)- (CA INDEX NAME)




RN 401816-68-0 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




IT 401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 401815-68-7P, 2-(4-Fluorophenyl)-6-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-69-8P, 2-(4-Fluorophenyl)-5-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-70-1P, 2-(4-Fluorophenyl)-4-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-72-3P, 2-(4-Fluorophenyl)-5-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-74-5P, 2-(4-Fluorophenyl)-4-hydroxymethyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-76-7P, 6-Fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-77-8P, 4-Fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-78-9P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-methylbenzoate 401815-79-0P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 1-isonicotinate 401815-80-3P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl nicotinate 401815-81-4P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-bromo-2-thiophenecarboxylate 401815-82-5P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2,3-dichlorobenzoate 401815-83-6P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 5-(methylsulfonyl)-2-thiophenecarboxylate 401815-84-7P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-aminonicotinate 401815-86-9P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-methyl-2-thiophenecarboxylate 401815-87-0P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-methoxybenzoate 401815-88-1P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 1,3-dihydro-1H-imidazole-1,3-dione 401815-91-6P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methanamine 401815-92-7P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401815-94-9P, 5-(n-Butoxy)-2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-96-1P, 5-(Benzyloxy)-2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-99-4P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyridinamine 401816-00-0P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-01-1P, 3-[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-propanol 401816-02-2P, N-(4-Chlorobenzyl)-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-03-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,3-propanediamine 401816-04-4P, 3-(2-Butoxy-4-pyridinyl)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine 401816-05-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl-2-pyridinamine 401816-06-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxybenzyl)-2-pyridinamine 401816-07-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl-2-pyridinamine 401816-08-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyridinamine 401816-09-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-2-pyridinamine 401816-10-2P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-2-pyridinamine 401816-11-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,4-butanediamine 401816-12-4P, 2-[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-ethanol 401816-13-5P, N-Benzyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-14-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl-2-pyridinamine 401816-17-9P, N-Benzyl-6-fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-19-1P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-isopropyl-2-pyridinamine 401816-20-4P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-22-6P, 3-[4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-propanol 401816-25-9P, N-(3-Aminopropyl)-4-[6-bromo-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-28-2P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine-6-carboxamide 401816-31-7P, 6-Cyano-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyridinamine 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridinylpyrazolo[1,5-a]pyridine



RN 401816-35-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 401816-50-0 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 401816-65-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)


pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 1-isonicotinate 401815-80-3P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl nicotinate 401815-81-4P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-bromo-2-thiophenecarboxylate 401815-82-5P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2,3-dichlorobenzoate 401815-83-6P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 5-(methylsulfonyl)-2-thiophenecarboxylate 401815-84-7P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-aminonicotinate 401815-86-9P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-methyl-2-thiophenecarboxylate 401815-87-0P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-methoxybenzoate 401815-88-1P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 1,3-dihydro-1H-imidazole-1,3-dione 401815-91-6P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methanamine 401815-92-7P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401815-94-9P, 5-(n-Butoxy)-2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-96-1P, 5-(Benzyloxy)-2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-99-4P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyridinamine 401816-00-0P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-01-1P, 3-[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-propanol 401816-02-2P, N-(4-Chlorobenzyl)-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-03-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,3-propanediamine 401816-04-4P, 3-(2-Butoxy-4-pyridinyl)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine 401816-05-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl-2-pyridinamine 401816-06-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxybenzyl)-2-pyridinamine 401816-07-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl-2-pyridinamine 401816-08-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyridinamine 401816-09-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-2-pyridinamine 401816-10-2P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-2-pyridinamine 401816-11-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,4-butanediamine 401816-12-4P, 2-[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-ethanol 401816-13-5P, N-Benzyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-14-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl-2-pyridinamine 401816-17-9P, N-Benzyl-6-fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-19-1P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-isopropyl-2-pyridinamine 401816-20-4P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-22-6P, 3-[4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-propanol 401816-25-9P, N-(3-Aminopropyl)-4-[6-bromo-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-28-2P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine-6-carboxamide 401816-31-7P, 6-Cyano-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyridinamine 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridinylpyrazolo[1,5-a]pyridine




L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 a)pyridine 401816-36-2P, 2-(4-Fluorophenyl)-3-[2-(methylsulfonyl)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 401816-37-3P, N-Butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-38-4P, N-Cyclopropyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-39-5P, N-Benzyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-40-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyrimidinamine 401816-41-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-44-2P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-48-6P, N-Butyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-49-7P, N-Benzyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-51-1P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyrimidinamine 401816-52-2P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propenyl)-2-pyrimidinamine 401816-53-3P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)-2-pyrimidinamine 401816-54-4P, 3-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethylamino)-1-propanol 401816-57-7P, N-Cyclopropyl-4-[6-cyano-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-61-3P, 2-(4-Fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinylcarboxamide 401816-62-4P, 2-(4-Fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinylcarboxamide 401816-67-9P, 2-(4-Fluorophenyl)-3-[2-[(3-(4-methylpiperazin-1-yl)propyl)amino]-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinylcarboxamide 401816-71-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyrimidinamine 401816-72-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyrimidinamine 401816-73-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)-2-pyrimidinamine 401816-74-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)-2-pyrimidinamine 401816-76-0P, 2-(4-Fluorophenyl)-3-(2-phenoxy)pyrimidin-4-yl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401816-77-1P, 3-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]oxy)-N,N-dimethylaniline 401816-78-2P, 3-[2-(2,5-Dimethylphenoxy)pyrimidin-4-yl]-2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401816-79-3P, N-[3-(Dimethylamino)propyl]-N-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-80-6P, N-[3-(Dimethylamino)propyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-85-1P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[3-(dimethylamino)propyl]amine 401816-89-5P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[3-(dimethylamino)propyl]amine 401816-93-1P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(dimethylamino)ethyl]amine 401816-95-3P, N-[4-(Diethylamino)butyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-96-4P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[4-(diethylamino)butyl]amine 401816-97-5P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[4-

L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 (diethylamino)butyl]amine 401816-98-6P, N-[2-(Diethylamino)ethyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-99-7P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diethylamino)ethyl]amine 401817-00-3P, N-[2-(Diisopropylamino)ethyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-01-4P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diisopropylamino)ethyl]amine 401817-02-5P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diisopropylamino)ethyl]amine 401817-03-6P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diisopropylamino)ethyl]amine 401817-04-7P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diisopropylamino)ethyl]amine 401817-05-8P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(pyrrolidin-1-ylethyl)amine 401817-06-9P, N-[2-(Pyrrolidin-1-ylethyl)-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-07-0P 401817-08-1P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-pyrrolidin-1-ylethyl)amine 401817-09-2P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(4-pyrrolidin-1-ylbutyl)amine 401817-10-5P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-11-6P, N-(2-Piperidin-1-ylethyl)-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-12-7P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-13-8P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-14-9P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-15-0P, N-(3-Piperidin-1-ylpropyl)-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-16-1P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-17-2P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-18-3P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-19-4P, N-(2-Azepan-1-ylethyl)-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-20-7P, N-(2-Azepan-1-ylethyl)-N-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-21-8P, N-(2-Azepan-1-ylethyl)-N-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-22-9P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-morpholin-4-ylethyl)amine 401817-23-0P, N-(2-Morpholin-4-ylethyl)-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-24-1P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-morpholin-4-ylethyl)amine 401817-25-2P, N-(3-Morpholin-4-ylpropyl)-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-

L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 yl]amine 401817-26-3P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-morpholin-4-ylpropyl)amine 401817-27-4P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-morpholin-4-ylpropyl)amine 401817-28-5P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]amine 401817-29-6P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]amine 401817-31-0P, N-[2-(4-Ethylpiperazin-1-yl)ethyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-32-1P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(4-propylpiperazin-1-yl)ethyl]amine 401817-33-2P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(4-propylpiperazin-1-yl)ethyl]amine  
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOB (Biological study); PREP (Preparation); USES (Uses)  
 (protein kinase inhibitor; prepn. of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)  
 RN 401815-63-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 401815-68-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-6-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl  
 RN 401815-69-8 CAPLUS


L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methoxy-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl  
 RN 401815-70-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-4-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 401815-72-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methoxy-3-(4-pyridinyl)- (CA INDEX NAME)



RN 401815-74-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-4-methanol, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 401815-76-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 6-fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 401815-77-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 4-fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 401815-78-9 CAPLUS  
CN Benzoic acid, 2-methyl-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)





RN 401815-83-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(methylsulfonyl)-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-84-7 CAPLUS  
CN 3-Pyridinecarboxylic acid, 2-amino-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-86-9 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-methyl-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-79-0 CAPLUS  
CN 4-Pyridinecarboxylic acid, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)



RN 401815-80-3 CAPLUS  
CN 3-Pyridinecarboxylic acid, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-81-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-bromo-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-82-5 CAPLUS  
CN 3-Pyridinecarboxylic acid, 6-amino-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)


RN 401815-87-0 CAPLUS  
CN Benzoic acid, 2-methoxy-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-88-1 CAPLUS  
CN Benzoic acid, 2,3-dichloro-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (CA INDEX NAME)




RN 401815-89-2 CAPLUS  
CN 1H-Indole-1,3(2H)-dione, 2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]- (CA INDEX NAME)




RN 401815-91-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-methanamine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)





RN 401815-92-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-6-(trifluoromethyl)- (CA INDEX NAME)




RN 401815-94-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-butoxy-2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 401815-96-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-(phenylmethoxy)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 401816-03-3 CAPLUS  
CN 1,3-Propanediamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-04-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-butoxy-4-pyridinyl)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 401816-05-5 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl- (CA INDEX NAME)




RN 401815-99-4 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 401816-00-0 CAPLUS  
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-01-1 CAPLUS  
CN 1-Propanol, 3-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (CA INDEX NAME)




RN 401816-02-2 CAPLUS  
CN 2-Pyridinamine, N-[(4-chlorophenyl)methyl]-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


RN 401816-06-6 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 401816-07-7 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl- (CA INDEX NAME)




RN 401816-08-8 CAPLUS  
CN 3-Pyridinemethanamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 401816-09-9 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl- (CA INDEX NAME)





RN 401816-10-2 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (CA INDEX NAME)




RN 401816-11-3 CAPLUS  
CN 1,4-Butanediamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-12-4 CAPLUS  
CN Ethanol, 2-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (CA INDEX NAME)




RN 401816-20-4 CAPLUS  
CN 2-Pyridinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-22-6 CAPLUS  
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (CA INDEX NAME)




RN 401816-25-9 CAPLUS  
CN 1,3-Propanediamine, N-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-13-5 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 401816-14-6 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 401816-17-9 CAPLUS  
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 401816-19-1 CAPLUS  
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)


RN 401816-28-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 401816-31-7 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-(cyclopropylamino)-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-32-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 401816-36-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 401816-37-3 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-38-4 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-39-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)


RN 401816-48-6 CAPLUS  
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-49-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 401816-51-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 401816-52-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 401816-40-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)





RN 401816-41-9 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-44-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401816-53-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 401816-54-4 CAPLUS  
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 401816-57-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 401816-61-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 401816-62-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 401816-67-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-(4-methyl-1-piperazinyl)propyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 401816-71-5 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 401816-72-6 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 401816-73-7 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 401816-74-8 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)- (CA INDEX NAME)


L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 401816-76-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(2-phenoxy-4-pyrimidinyl)-6-(trifluoromethyl)]- (CA INDEX NAME)




RN 401816-77-1 CAPLUS  
 CN Benzenamine, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 401816-78-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[2-(2,5-dimethylphenoxy)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(trifluoromethyl)- (CA INDEX NAME)


L4 ANSWER 47 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401816-79-3 CAPLUS  
 CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-80-6 CAPLUS  
 CN 1,3-Propanediamine, N,N-dimethyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-85-1 CAPLUS  
 CN 1,3-Propanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-89-5 CAPLUS  
CN 1,3-Propanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-93-1 CAPLUS  
CN 1,2-Ethanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-95-3 CAPLUS  
CN 1,4-Butanediamine, N,N-diethyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-99-7 CAPLUS  
CN 1,2-Ethanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 401817-00-3 CAPLUS  
CN 1,2-Ethanediamine, N,N-dipropyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-01-4 CAPLUS  
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 401816-96-4 CAPLUS  
CN 1,4-Butanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 401816-97-5 CAPLUS  
CN 1,4-Butanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 401816-98-6 CAPLUS  
CN 1,2-Ethanediamine, N,N-diethyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-02-5 CAPLUS  
CN 1,2-Ethanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 401817-03-6 CAPLUS  
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401817-04-7 CAPLUS  
CN 1,2-Ethanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 401817-05-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 401817-06-9 CAPLUS  
CN 2-Pyrimidinamine, N-[2-(1-pyrrolidinyl)ethyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401817-07-0 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)


RN 401817-11-6 CAPLUS  
CN 2-Pyrimidinamine, N-[2-(1-piperidinyl)ethyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401817-12-7 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 401817-13-8 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 401817-14-9 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)





RN 401817-08-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 401817-09-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)




RN 401817-10-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 401817-15-0 CAPLUS  
CN 2-Pyrimidinamine, N-[3-(1-piperidinyl)propyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 401817-16-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 401817-18-3 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)







RN 401817-19-4 CAPLUS  
CN 1H-Azepine-1-ethanamine, hexahydro-N-[4-{6-(trifluoromethyl)-2-{4-(trifluoromethyl)phenyl}pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (CA INDEX NAME)




RN 401817-20-7 CAPLUS  
CN 1H-Azepine-1-ethanamine, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]hexahydro- (CA INDEX NAME)




RN 401817-21-8 CAPLUS  
CN 1H-Azepine-1-ethanamine, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]hexahydro- (CA INDEX NAME)




RN 401817-22-9 CAPLUS  
CN 4-Morpholineethanamine, N-[4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (CA INDEX NAME)




RN 401817-23-0 CAPLUS  
CN 4-Morpholineethanamine, N-[4-{6-(trifluoromethyl)-2-{4-(trifluoromethyl)phenyl}pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (CA INDEX NAME)




RN 401817-24-1 CAPLUS  
CN 4-Morpholineethanamine, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (CA INDEX NAME)




RN 401817-25-2 CAPLUS  
CN 4-Morpholinepropanamine, N-[4-{6-(trifluoromethyl)-2-{4-(trifluoromethyl)phenyl}pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (CA INDEX NAME)




RN 401817-26-3 CAPLUS  
CN 4-Morpholinepropanamine, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (CA INDEX NAME)




RN 401817-27-4 CAPLUS  
CN 4-Morpholinepropanamine, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (CA INDEX NAME)




RN 401817-28-5 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 401817-29-6 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 401817-31-0 CAPLUS  
CN 2-Pyrimidinamine, N-[2-(4-propyl-1-piperazinyl)ethyl]-4-[6-(trifluoromethyl)-2-{4-(trifluoromethyl)phenyl}pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 401817-32-1 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-propyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 401817-33-2 CAPLUS  
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-propyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




IT 401815-95-0, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-ol  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant: preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)  
RN 401815-95-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridin-5-ol, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2001:816663 CAPLUS  
DOCUMENT NUMBER: 135:357918  
TITLE: Process for the preparation of pyrazolo[1,5-a]pyridines  
INVENTOR(S): Fitzgerald, Russ N.; Jung, David Kendall; Eaddy, John F.  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: Patent  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083479	A2	20011108	WO 2001-US13801	20010427
WO 2001083479	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001059242	A5	20011112	AU 2001-59242	20010427
EP 1276742	A2	20030122	EP 2001-932738	20010427
EP 1276742	B1	20040609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531906	T	20031028	JP 2001-580907	20010427
AT 268771	T	20040615	AT 2001-932738	20010427
ES 2222372	T3	20050201	ES 2001-1932738	20010427
US 2003212275	A1	20031113	US 2002-258679	20021025
US 6756498	B2	20040629		
PRIORITY APPLN. INFO.: US 2000-200400P P 20000428 WO 2001-US13801 W 20010427				
OTHER SOURCE(S): CASREACT 135:357918; MARPAT 135:357918				
GI				




AB The title compds. (I; R0, R1 = H, halo, alkyl, etc.; R2 = H, alkyl, alkyl substituted by one or more fluorine atoms, etc.; R3 = H, Ph substituted by SO2(alkyl) or SO2NH2) were prepared by rearrangement of an azirine II or a protected derivative thereof, in the presence of a catalyst and a solvent.

ACCESSION NUMBER: 2001:915602 CAPLUS  
DOCUMENT NUMBER: 136:303408  
TITLE: New developments in A1 and A2 adenosine receptor antagonists  
AUTHOR(S): Kiec-Kononowicz, K.; Drabczynska, A.; Pekala, E.; Michalak, B.; Miller, C. E.; Schumacher, B.; Karolak-Wojciechowska, J.; Duddeck, H.; Rockitt, S.; Wartchow, R.  
CORPORATE SOURCE: IUPAC Commission, Medical College, Department of Chemical Technology of Drugs, Jagiellonian University, Krakow, PL 30-688, Pol.  
SOURCE: Pure and Applied Chemistry (2001), 73(9), 1411-1420  
CODEN: PACHAS; ISSN: 0033-4545  
PUBLISHER: International Union of Pure and Applied Chemistry  
DOCUMENT TYPE: Journal: General Review  
LANGUAGE: English  
AB A review with refs. The aim of this article is to briefly present progress in the development of the potent adenosine receptor (AR) antagonists with high selectivity for either A1, A2A or A2B ARs. The structural requirements for each AR subtype were discussed as well as their potential therapeutic use. In the search for new AR antagonists, series of imidazo-, pyrimido-, and diazepino-purindione derivs. as well as oxazolo-, oxazino-, and oxazepino-purindione derivs. were designed, synthesized, and preliminarily evaluated in pharmacol. studies. Oxygen-containing tricyclic derivs. were shown to be moderately potent AR antagonists exhibiting selectivity either for A1 or A2A ARs. Tricyclic purindiones with nitrogen in the third ring were generally more A2A AR selective. The compds. tested in vivo according to the Antiepileptic Drug Development Program of the National Institutes of Health (USA) were generally active as anticonvulsants in chemical induced seizures.  
IT 131185-37-OP, Fk 838  
RL: FRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(new developments in A1 and A2 adenosine receptor antagonists)  
RN 131185-37-0 CAPLUS  
CN 1-(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Thus, treating a soln. of 1-(3-fluorophenyl)-2-(5-trifluoromethyl-2-pyridinyl)ethanone oxime (prepn. given) and Et3N in CH2Cl2 with TFAA followed by rearrangement of the resulting azirine II (R0 = 3-F; R1, R3 = H; R2 = 5-CF3) in the presence of FeCl2 in DME afforded I (R0 = 3-F; R1, R3 = H; R2 = 6-CF3).  
IT 267235-56-3P  
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
(process for the preparation of pyrazolo[1,5-a]pyridines)  
RN 267235-56-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



L4 ANSWER 50 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2001:584502 CAPLUS

DOCUMENT NUMBER: 135:352333

TITLE: Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability  
AUTHOR(S): Kuroda, Satoru; Takamura, Fujiko; Tenda, Yoshiyuki; Itani, Hiromichi; Tomishima, Yasuyori; Akahane, Atsushi; Sakane, Kazuo

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(8), 988-998

CODEN: CPBTAL; ISSN: 0009-2363  
Pharmaceutical Society of Japan


PUBLISHER: Journal

DOCUMENT TYPE: English

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:352333

GI




1

AB A novel series of 3-(2-substituted-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines were synthesized and evaluated for their in vitro adenosine A1 and A2A receptor binding activities, and in vitro metabolism by rat liver in order to search for orally active compds. Most of


the test compds. were potent adenosine A1 receptor antagonists with high A1 selectivity and the A1 affinity and A1 selectivity of carbonyl deriva. was particularly high. In particular, 1 was an extremely potent and selective adenosine A1 antagonist with high A1 selectivity (Ki=0.026 nM, A2A/A1=5400). In terms of metabolic stability, 2-oxopropyl, 2-hydroxypropyl, N-methylacetamide, 2-(piperidin-1-yl)ethyl and 1-methylpiperidin-4-yl (FR194921) deriva. were the most stable compds. in this series of analogs. Further in vivo evaluation indicated that several of the compds., including FR194921 were detected in both plasma and brain after oral administration in rats. In particular, FR194921 displayed good plasma and brain concns. As a result, we could show that FR194921 is a good candidate for an orally active adenosine A1 receptor antagonist with high blood-brain barrier permeability and good bioavailability (Ki=6.6 nM, A2A/A1=820, BA=60.6±4.9% (32 mg/kg)).

IT 141060-39-1P 202646-80-8P, FR 194921  
202646-91-1P 202646-92-2P 202646-94-4P  
202646-96-6P 202646-98-8P 202646-99-9P  
210879-61-1P 210879-63-3P 210879-64-4P  
210879-67-7P 210879-68-8P 210879-69-9P  
210879-71-3P 210880-05-0P 210880-07-2P


L4 ANSWER 50 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 202646-94-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-pentyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202646-96-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[1-(1-methylethyl)-4-piperidinyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202646-98-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[1-(phenylmethyl)-4-piperidinyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202646-99-9 CAPLUS  
CN Piperidine, 1-acetyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 50 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

210880-09-4P 210880-11-8P 210880-20-9P  
210880-21-0P 210880-23-2P 210880-25-4P  
210880-27-6P 210880-28-7P 210880-29-8P  
210880-31-2P 222722-65-8P 222722-71-6P  
222722-94-3P 222722-96-5P 372492-23-4P  
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)  
(Synthesis of adenosine A1 receptor antagonists with high blood-brain barrier permeability)

RN 141060-39-1 CAPLUS


CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202646-80-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202646-91-1 CAPLUS


CN 3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202646-92-2 CAPLUS


CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-propyl-4-piperidinyl)- (CA INDEX NAME)

L4 ANSWER 50 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 210879-61-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-63-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-64-4 CAPLUS


CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-67-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-68-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210879-69-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-71-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-11-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-20-9 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-21-0 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-(1,1-dimethylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-05-0 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-07-2 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-09-4 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-23-2 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-25-4 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-27-6 CAPLUS  
CN Pyrrolidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS  
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS  
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS  
CN Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 222722-65-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 222722-71-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 222722-94-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 222722-96-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-((2R,6S)-2,6-dimethyl-1-piperidinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl


RN 372492-23-4 CAPLUS  
CN 1(6H)-Pyridazineacetamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 131185-06-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis of adenosine A1 receptor antagonists with high blood-brain barrier permeability)  
RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (CA INDEX NAME)




IT 202646-90-0P 210880-36-7P 726182-36-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of adenosine A1 receptor antagonists with high blood-brain barrier permeability)  
RN 202646-90-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (CA INDEX NAME)



RN 210880-36-7 CAPLUS  
CN 1(6H)-Pyridazineacetamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 726182-36-1 CAPLUS  
CN 1(6H)-Pyridazineacetamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 51 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2001:581708 CAPLUS  
DOCUMENT NUMBER: 135:147440  
TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors as  
gastroprokinetic agents  
INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan  
PATENT ASSIGNEE(S): GlaxoSmithKline, UK  
SOURCE: PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056573	A1	20010809	WO 2001-GB423	20010201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 200130395	A	20010814	AU 2001-30395	20010201
EP 1259239	A2	20021127	EP 2001-902541	20010201
EP 1259239	B1	20070328		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003521516	T	20030715	JP 2001-556472	20010201
AT 357918	T	20070415	AT 2001-902541	20010201
US 2003022897	A1	20030130	US 2002-182080	20020725
US 6759413	B2	20040706		
US 2004192694	A1	20040930	US 2004-786423	20040225
PRIORITY APPLN. INFO.:			GB 2000-2336	A 20000201
			WO 2001-GB423	W 20010201
			US 2002-182080	A1 20020725

AB The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of a disorder ameliorated by a gastroprokinetic agent.


IT 267235-56-3 267235-56-30, derivs.  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cyclooxygenase-2 inhibitors as gastroprokinetic agents)

RN 267235-56-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)

L4 ANSWER 51 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 267235-56-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2001:581693 CAPLUS  
DOCUMENT NUMBER: 135:147439  
TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors for  
constipation  
INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 21 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056555	A2	20010809	WO 2001-GB416	20010201
WO 2001056555	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1251839	A2	20021030	EP 2001-948935	20010201
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003521511	T	20030715	JP 2001-556247	20010201
US 2003013717	A1	20030116	US 2002-182169	20020725
PRIORITY APPLN. INFO.:			GB 2000-2312	A 20000201
			WO 2001-GB416	W 20010201



AB The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of constipation.

IT 267235-56-3 267235-56-30, derivs.  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cyclooxygenase-2 inhibitors for treatment of constipation)

RN 267235-56-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)


L4 ANSWER 52 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 267235-56-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




L4 ANSWER 53 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:517649 CAPLUS  
 DOCUMENT NUMBER: 135:107325  
 TITLE: Preparation of pyrazolopyridines as adenosine antagonists and their use for treatment of various diseases  
 INVENTOR(S): Akabane, Atsushi; Kuroda, Satoshi; Itani, Hiromichi  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.  
 CODEN: JKKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001192384	A	20010717	JP 2000-378350	20001213
PRIORITY APPLN. INFO.:			AU 1999-4622	A 19991213
OTHER SOURCE(S):	MARPAT	135:107325		




AB Pyrazolopyridines I [R = lower alkenyl- or aryl-substituted lower alkyl (linked by O), ARI: R1 = substituted oxadiazolyl, thiazolyl, oxazolyl, imidazolyl; A = lower alkylene] or their salts are prepared by N-substitution of I (R = H), cyclocondensation of I [R = AC(NH2):NOH; A = same as above] with R2COX2 (R2 = lower alkyl; X2 = leaving group), etc. Thus, 2.88 g I (R = H) was treated with NaH and allyl bromide at room temperature for 2 h in DMF to give 2.04 g I (R = allyl), which inhibited binding of [3H]DPCPX to A1 receptor, and [3H]OGS21680 to A2a receptor with Ki values of 0.04 and 2.69 nM, resp.  
 IT 141060-46-0P 350227-04-2P 350227-07-5P  
 350227-09-7P 350227-11-1P 350227-13-3P  
 350227-15-5P 350227-17-7P 350227-19-9P  
 350227-21-3P 350227-22-4P 350227-24-6P  
 350227-26-8P 350227-28-0P 350227-30-4P  
 350227-32-6P 350227-34-8P 350227-36-0P  
 350227-38-2P 350227-40-6P 350227-42-8P  
 350227-44-0P 350227-46-2P 350227-48-4P  
 350227-50-8P 350227-52-0P 350227-54-2P  
 350227-56-4P 350227-58-6P 350227-59-7P  
 350227-61-1P 350227-63-3P 350227-65-5P  
 350227-67-7P 350227-69-9P 350227-71-3P  
 350227-73-5P 350227-88-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological


L4 ANSWER 53 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of pyrazolopyridines as adenosine antagonists for treatment of various diseases)  
 RN 141060-46-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 350227-04-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 350227-07-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[3-(phenylmethoxy)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-09-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 53 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 350227-11-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(4-methyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 350227-13-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(5-acetyl-4-methyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-15-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(4-phenyl-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 350227-17-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(4-(3,4,5-trimethoxyphenyl)-2-thiazolyl)methyl]- (CA INDEX NAME)


L4 ANSWER 53 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 350227-19-9 CAPLUS  
 CN 4-Thiazolecarboxylic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 350227-21-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(4,5-dimethyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-22-4 CAPLUS  
 CN 4-Thiazolecarboxylic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (CA INDEX NAME)




RN 350227-24-6 CAPLUS  
 CN Piperidine, 1-[[2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]-4-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 350227-26-8 CAPLUS  
CN 4-Thiazolecarboxamide, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 350227-28-0 CAPLUS  
CN 4-Thiazolecarboxamide, N,N-dimethyl-2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (CA INDEX NAME)




RN 350227-30-4 CAPLUS  
CN 4-Thiazolecarboxamide, N-2-(dimethylamino)ethyl-2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (CA INDEX NAME)




RN 350227-32-6 CAPLUS  
CN 4-Thiazolecarboxamide, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (CA INDEX NAME)




RN 350227-42-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(2,5-dimethoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-44-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[[4-(3-pyridinyl)-2-thiazolyl]methyl]- (CA INDEX NAME)




RN 350227-46-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(4-nitrophenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-48-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(4-ethyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-34-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(hydroxymethyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-36-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(4-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-38-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(2-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-40-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(3-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-50-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(4-methylphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 350227-52-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(4-chlorophenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-54-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(2,4-dimethoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-56-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[4-(4-ethyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)







RN 350227-58-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(4-(trifluoromethyl)-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 350227-59-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4-methyl-5-phenyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-61-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(5-propyl-1,2,4-oxadiazol-3-yl)methyl]- (CA INDEX NAME)




RN 350227-63-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4-phenyl-1H-imidazol-1-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-73-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4-phenyl-1H-imidazol-1-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-88-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methyl-5-phenyl-1H-imidazol-2-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 131185-06-3 141060-69-7 202647-16-3  
210880-36-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrazolopyridines as adenosine antagonists for treatment of various diseases)  
RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-69-7 CAPLUS  
CN 1(6H)-Pyridazineacetone, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-65-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-67-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4,5-dimethyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-69-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4,5-diphenyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 350227-71-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4-phenyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202647-16-3 CAPLUS  
CN 1(6H)-Pyridazineethanethioamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-36-7 CAPLUS  
CN 1(6H)-Pyridazineethanethioamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 350227-76-8P 350227-79-1P 350227-81-5P  
350227-84-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrazolopyridines as adenosine antagonists for treatment of various diseases)  
RN 350227-76-8 CAPLUS  
CN 1(6H)-Pyridazineethanethioamide, N-hydroxy-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 350227-79-1 CAPLUS  
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, 1-methyl-2-oxopropyl ester (CA INDEX NAME)



RN 350227-81-5 CAPLUS  
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, 1,2-diphenylethyl ester (CA INDEX NAME)





RN 350227-84-8 CAPLUS  
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, 2-oxo-2-phenylethyl ester (CA INDEX NAME)


## L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:371567 CAPLUS  
DOCUMENT NUMBER: 135:5612  
TITLE: Preparation of new pyrazolo terpyridines as remedies for inflammation, autoimmune diseases  
INVENTOR(S): Yamamoto, Hirofumi; Takahashi, Fumie; Kato, Takeshi; Nakamura, Katsuya; Manabe, Koji  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.  
CODEN: JKKXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001139575	A	20010522	JP 1999-323692	19991115
PRIORITY APPL. INFO.:			JP 1999-323692	19991115
OTHER SOURCE(S):		MARPAT 135:5612		




AB The pyrazolo terpyridine or that salt which is cyclooxygenase - 2 (COX-II) inhibitors, those production methods, the medicine composition, and the person or the animal which contain those inflammation condition, u painfully, prevention of the autoimmune disease and / or the method of treating is offered. Below-mentioned general formula (I) [ in the formula, the R1 and the R2, the resp. hydrogen, the hydrogen, the low-grade alkyl group and the halogen et cetera, mean, R3 such as low-grade alkyl group and the cyclo (low grade) alkyl group resp. ] So the chemical compound which is




## L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 340321-35-9P 340321-41-7P 340321-70-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of new pyrazolo terpyridines as remedies for inflammation autoimmune diseases)  
RN 340321-35-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-41-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-70-2 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 IT 340322-61-4 340322-64-7 340322-66-9  
 340322-74-9 340322-75-0 340322-76-1  
 340322-80-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of new pyrazolo terpyridines as remedies for inflammation  
 autoimmune diseases)  
 RN 340322-61-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(4-methylphenyl)-2-phenyl-  
 (CA INDEX NAME)



RN 340322-64-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[4-(methylthio)phenyl]-2-  
 phenyl- (CA INDEX NAME)




RN 340322-66-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-7-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-  
 phenyl-, ethyl ester (CA INDEX NAME)




RN 340322-74-9 CAPLUS  
 CN 1H-Pyrrole, 2,5-dimethyl-1-[[4-[2-[4-(methylamino)phenyl]pyrazolo[1,5-  
 a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 340322-75-0 CAPLUS  
 CN 1H-Pyrrole, 2,5-dimethyl-1-[[4-[2-[4-(phenylmethoxy)phenyl]pyrazolo[1,5-  
 a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)






RN 340322-76-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-bromophenyl)-3-[4-(methylsulfonyl)phenyl]-  
 (CA INDEX NAME)




RN 340322-80-7 CAPLUS  
 CN 1H-Pyrrole, 1-[[[4-(methylphenyl)ethynyl]sulfonyl]-3-[3-[4-  
 (methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX  
 NAME)

L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 291743-98-1P 340323-05-9P 340323-06-0P  
 340323-08-2P 340323-09-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of new pyrazolo terpyridines as remedies for inflammation  
 autoimmune diseases)  
 RN 291743-98-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylthio)phenyl]- (CA  
 INDEX NAME)




RN 340323-05-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[4-(methylthio)phenyl]- (CA  
 INDEX NAME)


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 340323-06-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylthio)phenyl]-2-phenyl-6-  
 (trifluoromethyl)- (CA INDEX NAME)



RN 340323-08-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-cyclohexyl-3-[4-(methylthio)phenyl]- (CA INDEX  
 NAME)




RN 340323-09-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(3-methoxyphenyl)-3-[4-(methylthio)phenyl]-  
 (CA INDEX NAME)



IT 267235-61-0P 267235-62-1P 267235-87-0P  
 291743-97-0P 340321-37-1P 340321-38-2P


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

340321-39-3P 340321-40-6P 340321-42-8P  
 340321-43-9P 340321-44-0P 340321-45-1P  
 340321-46-2P 340321-47-3P 340321-49-5P  
 340321-50-8P 340321-51-9P 340321-52-0P  
 340321-53-1P 340321-55-3P 340321-56-4P  
 340321-57-5P 340321-58-6P 340321-59-7P  
 340321-60-0P 340321-61-1P 340321-62-2P  
 340321-63-3P 340321-64-4P 340321-65-5P  
 340321-66-6P 340321-67-7P 340321-68-8P  
 340321-69-9P 340321-71-3P 340321-72-4P  
 340321-73-5P 340321-74-6P 340321-75-7P  
 340321-76-8P 340321-77-9P 340321-78-0P  
 340321-79-1P 340321-80-4P 340321-81-5P  
 340321-82-6P 340321-83-7P 340321-84-8P  
 340321-85-9P 340321-86-0P 340321-87-1P  
 340321-88-2P 340321-89-3P 340321-90-6P  
 340321-91-7P 340321-92-8P 340321-93-9P  
 340321-94-0P 340321-95-1P 340321-96-2P  
 340321-97-3P 340321-98-4P 340321-99-5P  
 340322-00-1P 340322-01-2P 340322-02-3P  
 340322-03-4P 340322-04-5P 340322-05-6P  
 340322-06-7P 340322-07-8P 340322-08-9P  
 340322-09-0P 340322-10-3P 340322-11-4P  
 340322-12-5P 340322-13-6P 340322-14-7P  
 340322-15-8P 340322-16-9P 340322-17-0P  
 340322-18-1P 340322-19-2P 340322-20-5P  
 340322-21-6P 340322-22-7P 340322-24-9P  
 340322-25-0P 340322-26-1P 340322-27-2P  
 340322-28-3P 340322-30-7P 340322-31-8P  
 340322-32-9P 340322-33-0P 340322-34-1P  
 340322-35-2P 340322-38-5P 340322-39-6P  
 340322-40-9P 340322-41-0P 340322-42-1P  
 340322-43-2P 340322-44-3P 340322-45-4P  
 340322-46-5P 340322-47-6P 340322-48-7P  
 340322-49-8P 340322-50-1P 340322-51-2P  
 340322-52-3P 340322-53-4P 340322-54-5P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of new pyrazolo terpyridines as remedies for inflammation autoimmune diseases)  
 RN 267235-61-0 CAPLUS  
 CN Benzenesulfonamide, 4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 267235-62-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 340321-39-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(3-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-40-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-42-8 CAPLUS  
 CN Benzonitrile, 4-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 267235-87-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 6-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)



RN 291743-97-0 CAPLUS  
 CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340321-37-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-cyclohexyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-38-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)

L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 340321-43-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 340321-44-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)



RN 340321-45-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 340321-46-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 340321-47-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(5-methyl-2-pyridinyl)-3-[4-


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 (methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-49-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-  
 (CA INDEX NAME)




RN 340321-50-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-[4-(1-methylethyl)phenyl]-3-[4-(methylsulfonyl)phenyl]-  
 (CA INDEX NAME)




RN 340321-51-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(2-pyridinyl)-  
 (CA INDEX NAME)




L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 (trifluoromethyl)- (CA INDEX NAME)



RN 340321-58-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-  
 (CA INDEX NAME)




RN 340321-59-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-  
 (CA INDEX NAME)




RN 340321-60-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 5-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl-  
 (CA INDEX NAME)


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 340321-52-0 CAPLUS  
 CN Benzenesulfonamide, 4-[2-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340321-53-1 CAPLUS  
 CN Benzenesulfonamide, 4-[2-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 340321-55-3 CAPLUS  
 CN Benzenesulfonamide, 4-[3-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-2-yl]-  
 (CA INDEX NAME)




RN 340321-56-4 CAPLUS  
 CN Benzenesulfonamide, 4-[3-phenylpyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 340321-57-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-4-  
 (CA INDEX NAME)


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 340321-61-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 340321-62-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-5-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-  
 (CA INDEX NAME)




RN 340321-63-3 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 4-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl-  
 (CA INDEX NAME)




RN 340321-64-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 340321-65-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-7-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-66-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-67-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 340321-68-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(2-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-74-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-75-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-76-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-77-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-69-9 CAPLUS  
CN Benzenesulfonamide, 4-(2-cyclohexylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 340321-71-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-methoxyphenyl)-2-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-72-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-[4-(methylsulfonyl)phenyl]-3-phenyl- (CA INDEX NAME)




RN 340321-73-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-78-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-79-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 6-(methoxymethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)



RN 340321-80-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 6-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-81-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-5-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 340321-82-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 5-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-83-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-4-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)



RN 340321-84-8 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-4-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-85-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 4-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-86-0 CAPLUS

L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
phenyl-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl


RN 340321-91-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 7-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-92-8 CAPLUS  
CN Benzenamine, 4-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 340321-93-9 CAPLUS  
CN Benzenamine, N,N-dimethyl-4-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Pyrazolo[1,5-a]pyridine-7-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-87-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 340321-88-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 6-bromo-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 340321-89-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-amine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl

RN 340321-90-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-6-amine, N-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl-


L4 ANSWER 54 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 340321-94-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(2,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-95-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-[4-(methoxymethoxy)phenyl]-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 340321-96-2 CAPLUS  
CN Benzenesulfonamide, 4-[3-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 340321-97-3 CAPLUS  
CN Benzenesulfonamide, 4-[3-[4-(chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)





RN 340321-98-4 CAPLUS  
CN Benzenesulfonamide, 4-[3-(2-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]-  
(CA INDEX NAME)




RN 340321-99-5 CAPLUS  
CN Benzenesulfonamide, 4-[3-(4-methylphenyl)pyrazolo[1,5-a]pyridin-2-yl]-  
(CA INDEX NAME)




RN 340322-00-1 CAPLUS  
CN Benzenesulfonamide, 4-[3-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]-  
(CA INDEX NAME)




RN 340322-05-6 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-06-7 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-07-8 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-01-2 CAPLUS  
CN Benzenesulfonamide, 4-[3-(3-(phenylmethoxy)phenyl)pyrazolo[1,5-a]pyridin-2-yl]-  
(CA INDEX NAME)



RN 340322-02-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-03-4 CAPLUS  
CN Benzenesulfonamide, 4-[2-(6-methyl-3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-04-5 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)


RN 340322-08-9 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-(difluoromethoxy)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)



RN 340322-09-0 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-10-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-chloro-4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-11-4 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-fluoro-4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)







RN 340322-12-5 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-chloro-4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-13-6 CAPLUS  
CN Benzenesulfonamide, 4-[2-(2,3-dihydro-1H-inden-5-yl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-14-7 CAPLUS  
CN Benzenesulfonamide, 4-[3-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 340322-18-1 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-acetylphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-19-2 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-propoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-20-5 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-(2-chloroethoxy)phenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-15-8 CAPLUS  
CN Benzenesulfonamide, 4-[3-[4-(aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)






RN 340322-16-9 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-17-0 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-[(methylsulfonyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-21-6 CAPLUS  
CN Benzenesulfonamide, 4-[2-(2-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-22-7 CAPLUS  
CN Benzenesulfonamide, 4-[2-(2-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-24-9 CAPLUS  
CN Benzenesulfonamide, 4-[2-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-25-0 CAPLUS  
CN Benzenesulfonamide, 4-[2-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)





RN 340322-26-1 CAPLUS  
CN Benzenesulfonamide, 4-[2-[5-(trimethylsilyl)-3-isoxazolyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-30-7 CAPLUS  
CN Benzenesulfonamide, 4-[2-(2-oxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-31-8 CAPLUS  
CN Benzenesulfonamide, 4-[2-(5-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-32-9 CAPLUS  
CN Benzenesulfonamide, 4-[2-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)






RN 340322-27-2 CAPLUS  
CN Benzenesulfonamide, 4-[2-(5-ethoxy-3-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-28-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-33-0 CAPLUS  
CN Benzenesulfonamide, 4-[2-(2-amino-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-34-1 CAPLUS  
CN Benzenesulfonamide, 4-[2-(2-chloro-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-  
(CA INDEX NAME)




RN 340322-35-2 CAPLUS  
CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)






RN 340322-38-5 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-(1-methylethenyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-39-6 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-(dimethylamino)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-43-2 CAPLUS  
CN Benzenesulfonamide, 4-[2-(1-methyl-1H-pyrrol-3-yl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-44-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-cyanophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-45-4 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-ethenylphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-40-9 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-41-0 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-[methyl(methylsulfonyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-42-1 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-(2-propenyloxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 340322-46-5 CAPLUS  
CN Benzenesulfonamide, 4-[2-(6-chloro-3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-47-6 CAPLUS  
CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-N-methyl- (CA INDEX NAME)




RN 340322-48-7 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)







RN 340322-49-8 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-(ethenyloxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-50-1 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-(1-azetidiny)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 340322-51-2 CAPLUS  
CN Benzenesulfonamide, 4-[2-[3-(furyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)



RN 340322-52-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-[4-(methylamino)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)






RN 340322-53-4 CAPLUS  
CN Benzenesulfonamide, 4-[3-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (CA INDEX NAME)




RN 340322-54-5 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)

ACCESSION NUMBER: 2000:824128 CAPLUS  
DOCUMENT NUMBER: 134:533  
TITLE: Novel use of adenosine A1A2a receptor dual antagonists  
INVENTOR(S): Matsuoka, Nobuya; Moriguchi, Akira; Tada, Miho; Mihara, Takuma  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 61 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069464	A1	20001123	WO 2000-JP3015	20000511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1177797	A1	20020206	EP 2000-925617	20000511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2004152659	A1	20040805	US 2003-716865	20031120
PRIORITY APPLN. INFO.:				
			JP 1999-131108	A 19990512
			WO 2000-JP3015	W 20000511
			US 2001-926469	B1 20011108
OTHER SOURCE(S):		MARPAT 134:533		
GI				



L4 ANSWER 55 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 therewith such as anxiety, depression and/or memory disorder which contain  
 as the active ingredient an adenosine A1A2a receptor dual antagonists or  
 salts thereof. Markush's structures of pyrazolopyridine derivs. (I),  
 pyrazolopyrazine derivs. (II), and xanthine derivs. (III) were given.  
 IT 202646-79-5  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (novel use of adenosine A1A2a receptor dual antagonists in psychiatry)  
 RN 202646-79-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-  
 thiazolylmethyl)- (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 56 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:628138 CAPLUS  
 DOCUMENT NUMBER: 133:222726  
 TITLE: Preparation of pyrazolopyridines as selective  
 inhibitors of COX-2  
 INVENTOR(S): Campbell, Ian Baxter; Lambeth, Paul Francis; Naylor,  
 Alan; Pegg, Neil Anthony  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: FIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052008	A1	20000908	WO 1999-EP10263	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1157025	A1	20011128	EP 1999-968808	19991222
EP 1157025	B1	20040310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002538157	T	20021112	JP 2000-602234	19991222
AT 261444	T	20040315	AT 1999-968808	19991222
ES 2216631	T3	20041016	ES 1999-968808	19991222
US 6498166	B1	20021224	US 2001-890925	20010830
PRIORITY APPLN. INFO.:			GB 1999-4506	A 19990227
			GB 1999-20904	A 19990903
			WO 1999-EP10263	W 19991222

OTHER SOURCE(S): MARPAT 133:222726  
 GI




AB The title compds. [I; R0, R1 = H, halo, alkyl, etc.; R2 = halo, CN, CONRR5, etc.; R3 = alkyl, NH2; R4, R5 = H, alkyl, (un)substituted Ph; NR4R5 = saturated 4-8 membered ring] which are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation


L4 ANSWER 56 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 of a variety of conditions and diseases, were prepd. and formulated.  
 E.g., a multi-step synthesis of 1 [R0 = 4-F; R1 = H; R2 = 6-CN; R3 = NH2]  
 which showed IC50 of 21 nM against COX-2 vs. IC50 of 20,950 nM against  
 COX-1, was given.  
 IT 291743-84-5P 291743-85-6P 291743-86-7P  
 291743-87-8P 291743-88-9P 291743-89-0P  
 291743-90-3P 291743-91-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazolopyridines as selective inhibitors of COX-2)  
 RN 291743-84-5 CAPLUS  
 CN Benzenesulfonamide, 4-[6-cyano-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-  
 yl]- (CA INDEX NAME)



RN 291743-85-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 291743-86-7 CAPLUS  
 CN Benzenesulfonamide, 4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-  
 yl]- (CA INDEX NAME)




RN 291743-87-8 CAPLUS


L4 ANSWER 56 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 291743-88-9 CAPLUS  
 CN Benzenesulfonamide, 4-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-  
 yl]- (CA INDEX NAME)




RN 291743-89-0 CAPLUS  
 CN Benzenesulfonamide, 4-[6-chloro-2-(4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-  
 yl]- (CA INDEX NAME)




RN 291743-90-3 CAPLUS  
 CN Benzenesulfonamide, 4-[6-chloro-2-(3-fluorophenyl)pyrazolo[1,5-a]pyridin-3-  
 yl]- (CA INDEX NAME)



RN 291743-91-4 CAPLUS  
CN Benzenesulfonamide, 4-(6-chloro-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 291743-97-0P 291743-98-1P 291743-99-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrazolopyridines as selective inhibitors of COX-2)  
RN 291743-97-0 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 291743-98-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylthio)phenyl]- (CA INDEX NAME)


ACCESSION NUMBER: 2000:416645 CAPLUS  
DOCUMENT NUMBER: 133:38215  
TITLE: Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives  
INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.  
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
SOURCE: U.S., 15 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:  
PATENT NO. KIND DATE APPLICATION NO. DATE  
US 6077842 A 20000620 US 1998-200376 19981124 19981124  
PRIORITY APPLN. INFO.: MARPAT 133:38215  
OTHER SOURCE(S):  
AB A method is provided for inhibiting neoplasia, particularly cancerous and precancerous lesions, by exposing the affected cells to pyrazolopyridylpyridazinone deriva. Preparation of compds. of the invention is included.  
IT 204504-56-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(pyrazolopyridylpyridazinone derivative preparation for inhibition of neoplastic cells)  
RN 204504-56-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-4,5-dihydro-5-methyl- (CA INDEX NAME)



REFERENCE COUNT: 164  
THERE ARE 164 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 291743-99-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-[4-(methylthio)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2  
THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:314697 CAPLUS  
DOCUMENT NUMBER: 132:321858  
TITLE: Preparation of pyrazolopyridines as selective COX-2 inhibitors  
INVENTOR(S): Campbell, Ian Baxter; Naylor, Alan  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 46 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:  
PATENT NO. KIND DATE APPLICATION NO. DATE  
WO 2000026216 A1 20000511 WO 1999-EP8186 19991101  
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
CA 2349567 A1 20000511 CA 1999-2349567 19991101  
BR 9915011 A 20010807 BR 1999-15011 19991101  
EP 1127058 A1 20010829 EP 1999-955897 19991101  
EP 1127058 B1 20040501  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO  
TR 200101208 T2 20011022 TR 2001-1208 19991101  
HU 2001004204 A2 20020429 HU 2001-4204 19991101  
HU 2001004204 A3 20020628  
JP 2002528547 T 20020903 JP 2000-579604 19991101  
JP 3420751 B2 20030630  
NZ 511349 A 20031031 NZ 1999-511349 19991101  
AU 767464 B2 20031113 AU 2000-12667 19991101  
AT 275148 T 20040915 AT 1999-955897 19991101  
ES 2228127 T3 20050401 ES 1999-955897 19991101  
TW 542836 B 20030721 TW 1999-88119040 19991102  
IN 2001KN00463 A 20050311 IN 2001-KN463 20010124  
ZA 2001003344 A 20020724 ZA 2001-3344 20010424  
US 7223772 B1 20070529 US 2001-830836 20010501  
NO 2001002156 A 20010702 NO 2001-2156 20010502  
NO 318884 B1 20050518  
MX 2001PA04401 A 20010731 MX 2001-PA4401 20010502  
PRIORITY APPLN. INFO.: GB 1998-24062 A 19981103  
GB 1999-20909 A 19990903  
WO 1999-EP8186 W 19991101  
OTHER SOURCE(S): MARPAT 132:321858  
GI




AB The title compds. [I; R0, R1 = H, halo, alkyl, etc.; R2 = H, alkyl, alkyl substituted by one or more fluorine atoms, etc.; R3 = alkyl, NH2] which are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases, were prepared and formulated. E.g., a multi-step synthesis of I [R0 = 3-F; R1 = H; R2 = 6-CF3; R3 = NH2] which showed IC50 of 34 nM against COX-2, was given.


IT 267235-24-5P 267235-56-3P 267235-57-4P  
267235-58-5P 267235-59-6P 267235-60-9P  
267235-61-0P 267235-62-1P 267235-63-2P  
267235-64-3P 267235-65-4P 267235-66-5P  
267235-67-6P 267235-68-7P 267235-69-8P  
267235-70-1P 267235-72-3P 267235-73-4P  
267235-74-5P 267235-75-6P 267235-76-7P  
267235-77-8P 267235-78-9P 267235-79-0P  
267235-80-3P 267235-81-4P 267235-82-5P  
267235-83-6P 267235-84-7P 267235-85-8P  
267235-86-9P 267235-87-0P 267235-88-1P  
267235-89-2P 267235-90-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrazolopyridines as selective COX-2 inhibitors)


RN 267235-24-5 CAPLUS  
CN Acetamide, N-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 267235-56-3 CAPLUS  
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 267235-60-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 267235-61-0 CAPLUS  
CN Benzenesulfonamide, 4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 267235-62-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)




RN 267235-63-2 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-methylphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 267235-57-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 267235-58-5 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 267235-59-6 CAPLUS  
CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 267235-64-3 CAPLUS  
CN Acetamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 267235-65-4 CAPLUS  
CN Acetamide, N-[[4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 267235-66-5 CAPLUS  
CN Acetamide, N-[[4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)



L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 267235-67-6 CAPLUS


CN Acetamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, sodium salt (9CI) (CA INDEX NAME)



• Na

RN 267235-68-7 CAPLUS

CN Acetamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-2-methoxy- (CA INDEX NAME)




RN 267235-69-8 CAPLUS

CN Propanamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 267235-70-1 CAPLUS

CN Propanamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-2-methyl- (CA INDEX NAME)



RN 267235-72-3 CAPLUS


CN Benzamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 267235-73-4 CAPLUS


CN Butanoic acid, 4-[[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)

L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 267235-74-5 CAPLUS

CN Butanoic acid, 4-[[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]amino]-4-oxo- (CA INDEX NAME)



RN 267235-75-6 CAPLUS


CN Pentanamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 267235-76-7 CAPLUS


CN Acetamide, 2-(acetyloxy)-N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 267235-77-8 CAPLUS

CN Acetamide, 2-chloro-N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 267235-78-9 CAPLUS

CN Acetamide, 2-(diethylamino)-N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)







L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 267235-79-0 CAPLUS  
 CN Carbamic acid, [[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 267235-80-3 CAPLUS  
 CN Carbamic acid, [[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 267235-81-4 CAPLUS  
 CN Benzenesulfonamide, 4-[2-(6-chloro-2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)




L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 267235-86-9 CAPLUS  
 CN Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)



RN 267235-87-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 6-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 267235-88-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 267235-82-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 6-chloro-2-(3-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 267235-83-6 CAPLUS  
 CN Benzenesulfonamide, 4-(6-methyl-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 267235-84-7 CAPLUS  
 CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)




RN 267235-85-8 CAPLUS  
 CN Benzenesulfonamide, 4-[2-(3-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)




L4 ANSWER 58 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 267235-89-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(3-ethoxyphenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 267235-90-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-(4-ethoxyphenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 59 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:291038 CAPLUS

DOCUMENT NUMBER: 132:308348

TITLE: Preparation of pyridazinylpyrazolopyridines as adenosine antagonists  
INVENTOR(S): Akahane, Atsushi; Kuroda, Satoru; Itani, Hiromichi  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 55 pp.  
CODEN: PIXKD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024742	A1	20000504	WO 1999-JP5696	19991014
W: BR, CA, CN, JP, KR, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2002528453	T	20020903	JP 2000-578312	19991014
PRIORITY APPLN. INFO.:			AU 1998-6721	A 19981023
			WO 1999-JP5696	W 19991014

OTHER SOURCE(S): MARPAT 132:308348  
AB R12122R2 [Z1 = pyrazolo[1,5-a]pyridine-2,3-diyl; Z2 = 3-oxo-2,3-dihydropyridazine-6,2-diyl] (I; R1 = substituted Ph; R2 = H or alkyl) were prepared. Thus, 2-(MeO)C6H4I was alkylated by HC.tplbond.CSiMe3 and the product deprotected to give HC.tplbond.CC6H4(OMe)-2 which was treated with EtNHBr/Ac2O to give MeOCC.tplbond.CC6H4(OMe)-2. The latter was cyclized with 1-aminopyridinium iodide to give I [R1 = C6H4(OMe)-2, R2 = H]. Data for biol. activity of I were given.


IT 265660-54-6P 265660-55-7P 265660-56-8P  
265660-57-9P 265660-58-0P 265660-59-1P  
265660-60-4P 265660-61-5P 265660-62-6P  
265660-63-7P 265660-64-8P 265660-65-9P  
265660-66-0P 265660-67-1P 265660-68-2P  
265660-69-3P 265660-71-7P 265660-72-8P  
265660-73-9P 265660-74-0P 265660-75-1P  
265660-76-2P 265660-77-3P 265660-78-4P  
265660-79-5P 265660-80-8P 265660-81-9P  
265660-82-0P 265660-83-1P 265660-84-2P  
265660-85-3P 265660-86-4P 265660-87-5P  
265660-88-6P 265660-89-7P 265660-90-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyridazinylpyrazolopyridines as adenosine antagonists)


RN 265660-54-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




L4 ANSWER 59 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 265660-59-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-60-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-61-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)

L4 ANSWER 59 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 265660-55-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)



RN 265660-56-8 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-57-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-58-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)


L4 ANSWER 59 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 265660-62-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-63-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-64-8 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-65-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-66-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-67-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-72-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 265660-73-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 265660-74-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-68-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-69-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-71-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 265660-75-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 265660-76-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 265660-77-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 265660-78-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-79-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(1-methylethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 265660-80-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(1-pentyloxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 265660-84-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-85-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 265660-86-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 265660-81-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME)




RN 265660-82-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-83-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (CA INDEX NAME)




RN 265660-87-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 265660-88-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)



RN 265660-89-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)



RN 265660-90-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2000:125853 CAPLUS  
DOCUMENT NUMBER: 132:245853  
TITLE: Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines  
AUTHOR(S): Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi; Nishimura, Shintaro; Durkin, Kieran; Tenda, Yoshiyuki; Sakane, Kazuo  
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan  
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(1), 55-64  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines was synthesized and evaluated for in vitro adenosine A1 and A2A receptor binding activities. Most of the cyclohexenyl derivs. (7a-e, 8a-s) were found to be potent adenosine A1 receptor antagonists. In a series of analogs of FR166124 (3a), alc. 7c, nitrile 7e and amide derivs. (7d, 8c, 8r) were found to be more potent A1 antagonists with higher A2A/A1 selectivity than FR166124. Amongst them, 8r showed considerable water solubility (33.3 mg/mL), but lower than that of the sodium salt of FR166124 (> 200 mg/mL). Addnl., FR166124 had strong diuretic activity by both p.o. and iv administration in rats (min. ED<sub>0.1</sub> and 0.032 mg/kg, resp.).


IT 171050-45-6, FR166124 171051-35-7  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(Synthesis and structure-activity of novel 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)

RN 171050-45-6 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-35-7 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 171050-95-6P 171051-04-0P 171051-07-3P  
171051-08-4P 171051-11-9P 171051-12-0P  
171051-14-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(Synthesis and structure-activity of novel 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


RN 171050-95-6 CAPLUS  
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-04-0 CAPLUS  
CN Glycine, N-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-07-3 CAPLUS  
CN Glycine, N-methyl-N-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-08-4 CAPLUS  
CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



RN 171051-11-9 CAPLUS  
CN β-Alanine, N-methyl-N-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-12-0 CAPLUS  
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 171051-14-2 CAPLUS  
CN β-Alanine, N-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 60 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



IT 171050-85-4P 171050-87-6P 171050-88-7P  
171050-96-7P 171050-97-8P 171050-98-9P  
171050-99-0P 171051-01-7P 171051-02-8P  
171051-10-8P 171051-13-1P 171051-15-3P  
171051-19-7P 171051-22-2P 171051-23-3P  
171051-24-4P 171051-47-1P 171051-52-8P  
171051-55-1P 262358-35-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(Synthesis and structure-activity of novel 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)  
RN 171050-95-4 CAPLUS  
CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-87-6 CAPLUS  
CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-88-7 CAPLUS  
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 60 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-01-7 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-02-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-10-8 CAPLUS  
CN 1-Cyclohexene-1-acetamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-13-1 CAPLUS

L4 ANSWER 60 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 171050-96-7 CAPLUS  
CN 1-Cyclohexene-1-butanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-97-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171050-98-9 CAPLUS  
CN Glycine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-99-0 CAPLUS  
CN β-Alanine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 60 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
1-Cyclohexene-1-acetamide, N-(2-hydroxyethyl)-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-15-3 CAPLUS  
CN 1-Cyclohexene-1-acetamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171051-19-7 CAPLUS  
CN Thiomorpholine, 4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-22-2 CAPLUS  
CN Morpholine, 4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-23-3 CAPLUS


L4 ANSWER 60 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 171051-55-1 CAPLUS  
 CN Pyridazine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-24-4 CAPLUS  
 CN Piperidine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171051-47-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[2-(2-hydroxyethyl)-1-cyclohexen-1-yl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-52-8 CAPLUS  
 CN 1-Cyclohexene-1-acetonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




L4 ANSWER 60 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 171051-40-4 CAPLUS  
 CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 60 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 171051-55-1 CAPLUS  
 CN Piperazine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 262358-35-0 CAPLUS  
 CN Piperazine, 1-methyl-4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 171051-36-8 171051-40-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Synthesis and structure-activity of novel 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)  
 RN 171051-36-8 CAPLUS  
 CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 61 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:34554 CAPLUS  
 DOCUMENT NUMBER: 132:83673  
 TITLE: Combination of loop diuretics with adenosine A1-receptor antagonists for treatment of hypertension and related diseases  
 INVENTOR(S): Hropot, Max  
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 10 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 970696	A1	20000112	EP 1998-108127	19980505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPL. INFO.: EP 1998-108127 19980505				
AB The invention relates to a pharmaceutical composition containing combination of a loop diuretic and an adenosine A1 receptor antagonist. This composition is useful for the treatment of and/or prophylaxis of hypertension, renal failure or disorders with increased proximal tubular reabsorption, e.g., congestive heart failure, liver cirrhosis or nephrotic syndrome. KW-3902 (30 g) was dissolved in a mixed solvent of EtOH (350 g) and CH2Cl2 (350 g), and Eudragit L 100 (90 g) was added to the solution. The resulting solution was sprayed on the mixture of furosemide (120 g) and lactose (760 g), and granulated at 60° with a fluidized bed granulator. After drying, the granules were sieved (24 mesh) and mixed uniformly and homogeneously with magnesium stearate in a blender. The resulting granules were filled into hard gelatin capsules. The capsules containing 5 mg KW-3902 and 20 mg of furosemide were obtained. Results of salidiuretic expts. show that KW-3902 at 0.01 and 0.1 mg/kg and furosemide at 10, 20 and 30 mg/kg body weight in male Wistar rats orally caused a significant increase in urine volume, sodium and chloride excretion as compared to the control. The combinations of KW-3902 at 0.1 mg/kg with furosemide at 10 mg/kg exerted significant additive or even synergistic effects with respect to urine volume, sodium and chloride excretion in the collection periods 1-4 h as compared with single compds.				
IT 131185-37-0, FK-838 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of loop diuretics with adenosine A1-receptor antagonists for treatment of hypertension and related diseases) RN 131185-37-0 CAPLUS CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)				



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:819369 CAPLUS  
DOCUMENT NUMBER: 132:49958  
TITLE: Preparation of pyrazolopyridine derivatives as adenosine antagonists  
INVENTOR(S): Akahane, Atsushi; Nishimura, Shintaro; Kuroda, Satoru; Itani, Hiromichi  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 92 pp.  
CODEN: PIXXDZ  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967239	AI	19991229	WO 1998-JP2794	19980622
W: CA, CN, JP, KR, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			WO 1998-JP2794	19980622
OTHER SOURCE(S):			MARPAT 132:49958	
GI				




AB The title compds. I [R = alkanoylalkyl, etc.] are prepared. These compds. are adenosine antagonists and useful as recognition augmenters, nootropic drugs, mental stimulants, analgesic agents, cardiac protective drugs, antidepressive drugs, cerebral vasodilators, tranquilizers, remedies for cardiac failure, cardiac tonics, hypotensive drugs, drugs for renal insufficiency, remedies for nephrotoxicity, renal protective agents, renal function improving drugs, diuretic agents, remedies for edema, antihypertensive drugs, antispasmodics, bronchodilators, remedies for apnea, remedies for gout, remedies for hyperuricemia, remedies for sudden infant death syndrome (SIDS), drugs for improving immunosuppression by adenosine, antidiabetic drugs, antiulcer drugs, remedies for pancreatitis, remedies for Meniere syndrome, antianemic agents, remedies for thrombosis, remedies for heart infarction, remedies for embolism, remedies for arteriosclerosis obliterans, remedies for thrombotic phlebitis, remedies for brain infarction, remedies for transient cerebral ischemia, remedies for angina pectoris, etc. In an in vitro test for adenosine A1 antagonism, 3-[2-(1-methyl-2-oxopropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine at 3.2 X 10<sup>-7</sup> M showed > 90% inhibition of binding of [3H]-N6-cyclohexyladenosine.

IT 210879-61-1P 210879-62-2P 210879-63-3P  
210879-64-4P 210879-65-5P 210879-66-6P  
210879-67-7P 210879-68-8P 210879-69-9P  
210879-70-2P 210879-71-3P 210879-72-4P  
210879-73-5P 210879-74-6P 210879-75-7P


210879-76-8P 210879-77-9P 210879-78-0P  
210879-79-1P 210879-80-4P 210879-81-5P  
210879-82-6P 210879-83-7P 210879-84-8P  
210879-85-9P 210879-86-2P 210879-87-3P  
210879-88-2P 210879-89-2P 210879-90-4P  
210879-91-5P 210879-92-6P 210879-93-7P  
210879-94-8P 210879-95-9P 210879-96-2P  
210879-97-3P 210879-98-4P 210879-99-5P  
210880-01-6P 210880-02-7P 210880-03-8P  
210880-04-9P 210880-05-0P 210880-06-1P  
210880-07-2P 210880-08-3P 210880-09-4P  
210880-10-5P 210880-11-6P 210880-12-7P  
210880-13-8P 210880-14-9P 210880-15-0P  
210880-16-1P 210880-17-2P 210880-18-3P  
210880-19-4P 210880-20-5P 210880-21-6P  
210880-22-7P 210880-23-8P 210880-24-9P  
210880-25-0P 210880-26-1P 210880-27-2P  
210880-28-3P 210880-29-4P 210880-30-5P  
210880-31-6P 210880-32-7P 210880-33-8P  
210880-34-9P 210880-35-0P 252953-71-2P  
252953-72-3P 252953-73-4P 252953-74-5P  
252953-75-6P 252953-76-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of pyrazolopyridine derivs. as adenosine antagonists)


RN 210879-61-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-62-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-63-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210879-64-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-65-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-acetyl-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-66-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-methyl-2-oxopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)







RN 210879-67-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-68-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-69-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-70-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210879-74-6 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, alpha, alpha-dimethyl-beta, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 210879-75-7 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, alpha, alpha-diethyl-beta, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 210879-76-8 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, alpha-(ethoxymino)-beta, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester, (αZ)- (CA INDEX NAME)


Double bond geometry as shown.




RN 210879-71-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-72-4 CAPLUS  
CN 1(6H)-Pyridazinepentanoic acid, gamma, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 210879-73-5 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, beta, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 210879-77-9 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, alpha, alpha-dimethyl-beta, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, phenylmethyl ester (CA INDEX NAME)




RN 210879-78-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-phenylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-79-1 CAPLUS  
CN Benzoic acid, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-80-4 CAPLUS  
CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 210879-81-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-82-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-83-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-oxo-2-(3-pyridinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

RN 210879-96-2 CAPLUS  
CN 2-Piperidineacetic acid, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210879-99-5 CAPLUS  
CN Benzoic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-03-8 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, α,α-dimethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-04-9 CAPLUS  
CN Benzoic acid, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 210879-84-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-tricyclo[3.3.1.1.3,7]dec-1-ylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-85-9 CAPLUS  
CN Glycine, N-[2,2-dimethyl-1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]-, methyl ester (CA INDEX NAME)




RN 210879-88-2 CAPLUS  
CN 2-Piperidineacetic acid, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210880-07-2 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-09-4 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-11-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-13-0 CAPLUS  
CN 1(6H)-Pyridazinebutanamide, N,N,α,α-tetramethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-14-1 CAPLUS  
CN 1(6H)-Pyridazinepentanamide, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-15-2 CAPLUS  
CN 1(6H)-Pyridazineacetanamide, N-methyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-23-2 CAPLUS  
CN 1(6H)-Pyridazineacetanamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-25-4 CAPLUS  
CN 1(6H)-Pyridazineacetanamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-27-6 CAPLUS  
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-16-3 CAPLUS  
CN 1(6H)-Pyridazinepentanamide, N,N-dimethyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-18-5 CAPLUS  
CN Piperidine, 1-[[1,4-dioxo-5-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl]- (9CI) (CA INDEX NAME)




RN 210880-20-9 CAPLUS  
CN 1(6H)-Pyridazineacetanamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-28-7 CAPLUS  
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS  
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-30-1 CAPLUS  
CN Piperazine, 1-methyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS  
CN Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-33-4 CAPLUS  
CN 1(6H)-Pyridazinebutanamide, N,N-dimethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210880-34-5 CAPLUS  
CN Piperidine, 1-[[1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 210880-35-6 CAPLUS  
CN 3-Pyrrolidinone, 1-[[[1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 252953-71-2 CAPLUS  
CN Benzeneacetic acid, α-[[[1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]amino]-, methyl ester, (αR)- (CA INDEX NAME)


L4 ANSWER 62 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
a]pyridin-3-yl)- (CA INDEX NAME)



RN 252953-75-6 CAPLUS  
CN 1(6H)-Pyridazinebutanenitrile, β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 252953-76-7 CAPLUS  
CN Azetidine, 1-[[1,4-dioxo-5-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl]- (9CI) (CA INDEX NAME)




IT 131185-06-3 131185-08-5 210880-36-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrazolopyridine derivs. as adenosine antagonists)  
RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 252953-72-3 CAPLUS  
CN Glycine, N-[[1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]-, methyl ester (CA INDEX NAME)




RN 252953-73-4 CAPLUS  
CN Benzeneacetic acid, α-[[[1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 252953-74-5 CAPLUS  
CN 1(6H)-Pyridazinepentanoic acid, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 62 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 131185-08-5 CAPLUS  
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210880-36-7 CAPLUS  
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:652945 CAPLUS

DOCUMENT NUMBER: 132:49932

TITLE: Process Improvements in the Production of a Novel Non-Xanthine Adenosine A1 Receptor Antagonist. A "One-Pot" Horner-Emmons Isomerization Reaction  
 Zanka, Atsuhiko; Itoh, Norihumi; Kuroda, Satoru  
 Technological Development Laboratories, Fujisawa Pharmaceutical Co. Ltd., Osaka, 532-8514, Japan  
 Organic Process Research & Development (1999), 3(6), 394-399

CODEN: OPDFK; ISSN: 1083-6160


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 132:49932

GI



I

AB Pilot plant scale synthesis of 2-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazin-6-one]-1-cyclohexen-1-yl] acetic acid (FR166124) (I) is described. The process involved efficient isomerization of regioisomers produced in a Horner-Emmons reaction and employed ester exchange and hydrolysis with NaOH in MeOH. Challenges encountered in the final purification stage to afford high quality drug substance in pure crystalline form are also

described. Process improvements and optimization of each step permitted elimination of column chromatog., resulting in a straightforward, practical, and cost-effective synthesis of I. These methods were successfully scaled up in a pilot plant to give bulk drug suitable for pharmacol. and toxicol. evaluation.

IT 252765-35-8P 252765-36-9P 252765-37-0P


RL: BYP (Byproduct); PREP (Preparation)  
 (manuf of adenosine A1 receptor antagonist  
 phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FR166124)  
 via successive Horner Emmons reaction, isomerization, and hydrolysis of  
 phenylpyrazolopyridinylpyridazine)

RN 252765-35-8 CAPLUS

CN Cyclohexanol, 2-[[6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl]oxy]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.

(Continued)




IT 171050-40-1P 171050-43-4P 171051-34-6P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
 (manuf of adenosine A1 receptor antagonist  
 phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FR166124)  
 via successive Horner Emmons reaction, isomerization, and hydrolysis of  
 phenylpyrazolopyridinylpyridazine)

RN 171050-40-1 CAPLUS


CN 3(2H)-Pyridazinone, 2-[(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)



RN 171050-43-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-[(1R,2R)-2-hydroxycyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 171051-34-6 CAPLUS


CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

(Continued)




RN 252765-36-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(sulfoxy)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 252765-37-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-[2-[(methylthio)methoxy]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 171050-45-6P

RL: IMF (Industrial manufacture); PREP (Preparation)  
 (manuf of adenosine A1 receptor antagonist  
 phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FR166124)  
 via successive Horner Emmons reaction, isomerization, and hydrolysis of  
 phenylpyrazolopyridinylpyridazine)

RN 171050-45-6 CAPLUS

CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)

(Continued)




IT 131185-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (manuf of adenosine A1 receptor antagonist  
 phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FR166124)  
 via successive Horner Emmons reaction, isomerization, and hydrolysis of  
 phenylpyrazolopyridinylpyridazine)

RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 171051-36-8P 171051-40-4P

RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)


[optimization of conditions for double bond isomerization of tert-Bu phenylpyrazolopyridinylpyridazinonecyclohexylmethylenecarboxylate)  
 RN 171051-36-8 CAPLUS  
 CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-40-4 CAPLUS

CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 64 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1999:548679 CAPLUS  
DOCUMENT NUMBER: 131:299420  
TITLE: Synthesis of the water-soluble adenosine A1 receptor antagonist FR166124 through a novel sequential Horner-Emmons / isomerization reaction  
AUTHOR(S): Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi; Nishimura, Shintaro; Durkin, Kieran; Kinoshita, Takayoshi; Nakanishi, Isao; Sakane, Kazuo  
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan  
SOURCE: Tetrahedron (1999), 55(34), 10351-10364  
CODEN: TETRA; ISSN: 0040-4020  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 131:299420  
GI




AB An efficient synthesis of FR166124 I (R = H) was achieved through a novel sequential Horner-Emmons - isomerization reaction of cyclohexanone II with tert-Bu diethylphosphonoacetate as the key process. E.g., cyclohexanone was treated with a phenylpyrazolo[1,5-a]pyridazinone in a toluene/water mixture in the presence of sodium hydroxide and triethylbenzylammonium chloride to give a cyclohexanol derivative in 80% yield which undergoes Swern oxidation with DMSO, oxalyl chloride, and triethylamine in methylene chloride to give II in 88% yield. E.g., II is added to a mixture of sodium hydride and tert-Bu diethylphosphonoacetate in toluene at 4° and allowed to warm to room temperature over 24h to give I (R = Me3C) in 80% yield, along with three isomers, formed by incomplete or undesired isomerization of the double bond, which were separated by chromatog. addition of F3CCO2H to a solution of I (R = Me3C) in methylene chloride provides I (R = H) (FR166124) in 75% yield. Extensive studies of the olefination/isomerization reaction indicated that temperature, base and conformation of the Horner-Emmons products were important factors in the isomerization reaction, leading to a proposed mechanism for this unusual Horner-Emmons reaction.  
IT 131185-06-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of the adenosine A1 antagonist FR166124 with a novel Horner-Emmons olefination/isomerization as the key step)  
RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX




IT 171050-40-1P 171051-34-6P 247110-27-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of the adenosine A1 antagonist FR166124 with a novel Horner-Emmons olefination/isomerization as the key step)  
RN 171050-40-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-34-6 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247110-27-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



IT 171050-45-6P, FR166124  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of the adenosine A1 antagonist FR166124 with a novel Horner-Emmons olefination/isomerization as the key step)  
RN 171050-45-6 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




IT 171051-35-7P 171051-36-8P 171051-40-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(the regio- and stereoselectivity, product analyses and energies of isomers formed in a novel Horner-Emmons olefination/isomerization reaction)  
RN 171051-35-7 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 171051-36-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 171051-40-4 CAPLUS


L4 ANSWER 64 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 65 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1999:504267 CAPLUS  
 DOCUMENT NUMBER: 131:266565  
 TITLE: Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist  
 AUTHOR(S): Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi; Nishimura, Shintaro; Durkin, Kieran; Kinoshita, Takayoshi; Tenda, Yoshiyuki; Sakane, Kazuo  
 CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(14), 1979-1984  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Novel 3-(2-cycloalkyl and cycloalkenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines were synthesized and evaluated for their adenosine A1 receptor binding activities. In this series, FR166124 was found to be the most potent and selective adenosine A1 receptor antagonist, and the double bond of the cyclohexenyl acetic acid group was essential for selectivity of A1 receptor binding. Furthermore, the solubility in water of the sodium salt of FR166124 was high.  
 IT 131185-37-0, FK838 171050-45-6, FR 166124  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 [preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist]  
 RN 131185-37-0 CAPLUS  
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-45-6 CAPLUS  
 CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




IT 171050-53-6P 171050-59-2P 171050-80-9P

L4 ANSWER 65 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 171050-81-0P  
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)  
 [prepn. of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist]  
 RN 171050-53-6 CAPLUS  
 CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-59-2 CAPLUS  
 CN 1-Cycloheptene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



RN 171050-80-9 CAPLUS  
 CN Cyclohexanecetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 171050-81-0 CAPLUS  
 CN Cyclohexanecetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 65 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 171051-03-9P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 [preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist]


RN 171051-03-9 CAPLUS  
 CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

IT 131185-06-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 [preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist]


RN 131185-06-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 171050-40-1P 171050-41-2P 171050-49-0P  
 171050-73-0P 171050-74-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 [preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist]

L4 ANSWER 65 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
antagonist)


RN 171050-40-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171050-41-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxocyclopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-49-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxocycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171050-73-0 CAPLUS  
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1999:206896 CAPLUS

DOCUMENT NUMBER: 130:282079  
TITLE: Preparation of pyridazinylpyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them  
INVENTOR(S): Akabane, Atsushi; Kuroda, Satoshi; Itani, Hiromichi  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.  
CODEN: JKKXAF

DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11080157	A	19990326	JP 1997-252751	19970901
PRIORITY APPL. INFO.:			JP 1997-252751	19970901
OTHER SOURCE(S):		MARPAT 130:282079		




AB The title compds. I [R1 = aryl; R2 = CH2CHMeOH, CH2CHMe2OH, lower alkanoylaminoalkyl, N-alkanoyl-N-alkylaminoalkyl, lower alkenyloxy-carbonylaminoalkyl, 2-N,N-dialkylamino-2-methylpropyl, lower alkylaminoalkyl, aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, perhydroazepinylalkyl, perhydroazocinylalkyl, lower alkylpiperidinylalkyl, 2-, or 3-pyridylalkyl, (un)substituted pyrazolylalkyl, (un)substituted imidazolylalkyl] (II) or their salts are prepared II or their salts are prepared, e.g. by treatment of I (R2 = H) or their salts with R2OH (R2 = amino-protected aralkylaminoalkyl, pyrazolylalkyl having protected amino, amino-protected imidazolylalkyl, amino-protected lower alkylaminoalkyl) or their salts. II are useful as recognition enhancers, antideementia agents, psychostimulants, analgesics, cardioprotectants, antidepressants, cerebral circulation improvers, tranquilizers, antihypertensives, diuretics, bronchodilators, etc. 3-[2-(imidazol-4-yl)methyl-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine hydrochloride (preparation given) at 10-7M showed >90% inhibition against ligand binding


by human A1 receptors.  
IT 222722-75-0P 222722-77-2P 222722-79-4P  
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyridazinylpyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them)

L4 ANSWER 65 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 171050-74-1 CAPLUS  
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2R)-rel- (CA INDEX NAME)




IT 171051-72-2P  
RI: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)  
RN 171051-72-2 CAPLUS  
CN Cyclohexanone, 2-[[6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl]oxy]- (CA INDEX NAME)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 222722-75-0 CAPLUS  
CN Carbamic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 222722-77-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 222722-79-4 CAPLUS  
CN Acetamide, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (CA INDEX NAME)



IT 222722-39-6P 222722-40-9P 222722-41-0P  
222722-42-1P 222722-46-5P 222722-50-1P  
222722-52-3P 222722-55-6P 222722-58-9P  
222722-60-3P 222722-61-4P 222722-62-5P  
222722-63-6P 222722-64-7P 222722-65-8P  
222722-66-9P 222722-67-0P 222722-69-2P  
222722-71-6P 222722-81-8P 222722-83-0P  
222722-85-2P 222722-87-4P 222722-89-6P




L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

222722-92-1P 222722-94-3P 222722-96-5P  
222722-98-7P 222723-65-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of pyridazinyldiazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals contg. them)

RN 222722-39-6 CAPLUS


CN 3(2H)-Pyridazinone, 2-(1H-imidazol-2-ylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 222722-40-9 CAPLUS


CN 3(2H)-Pyridazinone, 2-(1H-imidazol-4-ylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 222722-41-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-[[2-(1H-imidazol-4-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-42-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-[[2-(1H-imidazol-4-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 1H-Imidazole-1-acetic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (CA INDEX NAME)



RN 222722-58-9 CAPLUS


CN 3(2H)-Pyridazinone, 2-[[1-methyl-1H-imidazol-2-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 222722-60-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-61-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl


RN 222722-46-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[[1-(triphenylmethyl)-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 222722-50-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1H-imidazol-2-ylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 222722-52-3 CAPLUS

CN 1H-Imidazole-1-acetic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 222722-55-6 CAPLUS


L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 222722-62-5 CAPLUS


CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 222722-63-6 CAPLUS


CN 3(2H)-Pyridazinone, 2-[[1-methyl-1H-imidazol-5-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 222722-64-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-[[2-(5-amino-1H-pyrazol-1-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl



RN 222722-65-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 222722-66-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methyl-1H-imidazol-4-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 222722-67-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]- (CA INDEX NAME)




● HCl

RN 222722-85-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-methyl-2-[methyl(phenylmethyl)amino]propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 222722-87-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(methylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 222722-69-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-[(triphenylmethyl)-1H-imidazol-4-yl]ethyl]- (CA INDEX NAME)



RN 222722-71-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 222722-81-8 CAPLUS  
CN Acetamide, N-methyl-N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (CA INDEX NAME)




RN 222722-83-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[dimethylamino]-2-methylpropyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 222722-89-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[(phenylmethyl)amino]propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-92-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[methyl(phenylmethyl)amino]propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 222722-94-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 222722-96-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[(2R,6S)-2,6-dimethyl-1-piperidiny]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
INDEX NAME)

Relative stereochemistry.




● HCl

RN 222722-98-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1(2H)-azocinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9C1) (CA INDEX NAME)



● HCl

RN 222723-65-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-(1H-pyrazol-4-yl)ethyl)-, monohydrochloride (9C1) (CA INDEX NAME)



● HCl

IT 131185-06-3 210879-61-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyridazinylpyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them)  
RN 131185-06-3 CAPLUS


L4 ANSWER 67 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1999:120305 CAPLUS  
DOCUMENT NUMBER: 130:320362  
TITLE: Discovery of 6-Oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic Acid (FK 838): A Novel Non-Xanthine Adenosine A1 Receptor Antagonist with Potent Diuretic Activity  
AUTHOR(S): Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi; Kato, Takeshi; Kinoshita, Takayoshi; Kita, Yasuhiro; Kusunoki, Takahiro; Terai, Takao; Yoshida, Keizo; Shikawa, Youtchi  
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Company Ltd., Yodogawa-ku Osaka, 532-8514, Japan  
SOURCE: Journal of Medicinal Chemistry (1999), 42(5), 779-783  
CODEN: JMCMAH; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Based on an X-ray crystal structure of FK 453, the authors designed and synthesized a new series of pyrazolo[1,5-a]pyridines, in which heterocyclic groups were introduced instead of the acryloylamide of FK 453. 6-Oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic Acid (FK 838) displayed the most potent diuretic activity and was a potent and selective adenosine A1 receptor antagonist with good oral availability and solubility in water. FK 838 can be

classified as the first of a new generation of adenosine A1 receptor antagonists, which are useful for the treatment of diseases such as hypertension and renal failure.


IT 131185-37-0, FK 838  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)

RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 131185-06-3P 131185-30-3P 131185-31-4P  
131185-32-5P 131754-91-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPW (Synthetic preparation); BIOL (Biological study); PRP (Preparation); RACT (Reactant or reagent)  
(adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)  
RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 66 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-61-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 67 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 131185-30-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-31-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (CA INDEX NAME)




RN 131185-32-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131754-91-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 131185-04-1P 131185-05-2P 131185-08-5P  
131185-40-5P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)  
RN 131185-04-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridazinyl)- (CA INDEX NAME)




RN 131185-05-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridinyl)- (CA INDEX NAME)




RN 131185-08-5 CAPLUS  
CN 1(6H)-Pyridazinedipentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-40-5 CAPLUS  
CN 1(6H)-Pyridazinedipentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-39-2 CAPLUS  
CN 1(6H)-Pyridazinedipentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 223753-60-4 CAPLUS  
CN 1(4H)-Pyridinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



IT 131185-02-9P 131185-07-4P 131185-28-9P  
131185-39-2P 223753-60-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)  
RN 131185-02-9 CAPLUS  
CN 1(4H)-Pyridinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 131185-07-4 CAPLUS  
CN 1(6H)-Pyridazinedipentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)



RN 131185-28-9 CAPLUS  
CN 1(6H)-Pyridazinedipentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)

ACCESSION NUMBER: 1999:45448 CAPLUS  
DOCUMENT NUMBER: 130:246861  
TITLE: Pyrazolopyridine derivatives act as competitive antagonists of brain adenosine A1 receptors: [35S]GTPyS binding studies  
AUTHOR(S): Ito, Harunobu; Maemoto, Takuya; Akahane, Atsushi; Butcher, Steven P.; Olverman, Henry J.; Finlayson, Keith  
CORPORATE SOURCE: Fujisawa Institute of Neuroscience, Japan  
SOURCE: European Journal of Pharmacology (1999), 365(2/3), 309-315  
CODEN: EJPHAZ; ISSN: 0014-2999  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The effects of adenosine receptor ligands and three novel pyrazolopyridine derivs. on guanosine-5'-O-(3-[(35S)]thio)triphosphate ([35S]GTPyS) binding to rat cerebral cortical membranes were examined. [35S]GTPyS binding was stimulated in a concentration dependent manner by several adenosine receptor agonists. The adenosine A2a receptor selective agonist, 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), was ineffective confirming specificity for adenosine A1 receptor activation. 2-Chloro-N6-cyclopentyladenosine (CCPA; 10-7 M)-stimulated [35S]GTPyS binding was inhibited by xanthine and pyrazolopyridine based adenosine receptor antagonists. The concentration-response curve for CCPA-stimulated [35S]GTPyS binding was shifted to the right with increasing concns. of antagonist without significant changes in maximal response. Schild analyses determined pKB values of 8.97, 8.88, 8.21, 8.16, 7.79 and 7.65 for 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine ethanol (FK453), 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinedipentanoic acid (FK838), 9-chloro-2-(2-furyl)[1,2,4]triazolo-[1,5-c]quinazolin-5-amine (CGS 15943), 8-cyclopentyl-1,3-methylxanthine (CPT) and (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-piperidine-2-yl acetic acid (FK352), resp. Schild slopes were close to unity, confirming that these novel pyrazolopyridine derivs. act as competitive antagonists at rat brain adenosine A1 receptors. Also, [35S]GTPyS binding provides a convenient pharmacol. assay for the functional activity of adenosine A1 receptors in rat cortical membranes.  
IT 131185-37-0, FK838  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(pyrazolopyridine derivs. act as competitive antagonists of brain adenosine A1 receptors in [35S]GTPyS binding studies in relation to effect of other ligands in rat cerebral cortical membranes)  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinedipentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 68 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 69 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1998:635675 CAPLUS  
 DOCUMENT NUMBER: 129:239894  
 TITLE: Preventives and remedies for hyperphosphatemia  
 INVENTOR(S): Nomura, Kazuhiko; Sasaki, Emiko; Nakazi, Kazumi;  
 Kajihio, Tokuaki  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841237	A1	19980924	WO 1998-JP933	19980305
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 972525	A1	20000119	EP 1998-905796	19980305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6303624	B1	20011016	US 1999-380617	19991104
PRIORITY APPLN. INFO.:			JP 1997-64034	A 19970318
			WO 1998-JP933	W 19980305

OTHER SOURCE(S): MARPAT 129:239894  
 AB The invention relates to efficacious preventives and/or remedies for hyperphosphatemia or secondary accessory thyroid hyperfunction and concomitant symptoms thereof which contain adenosine antagonists as the active ingredient.  
 IT 131185-37-0 171050-45-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preventives and remedies for hyperphosphatemia)  
 RN 131185-37-0 CAPLUS  
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-45-6 CAPLUS  
 CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)

L4 ANSWER 69 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 70 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1998:499463 CAPLUS  
 DOCUMENT NUMBER: 129:216575  
 TITLE: Pilot-Scale Synthesis of a Novel Non-Xanthine Adenosine A1 Receptor Antagonist. 1,3-Dipolar Cycloaddition of Pyridine N-Imine to an Acetylene  
 Zanka, Atsuhiko; Hashimoto, Norio; Uematsu, Ryoichi; Okamoto, Takumi  
 CORPORATE SOURCE: Technological Development Laboratories, Fujisawa Pharmaceutical Co. Ltd., Yodogawa-ku Osaka, 532, Japan  
 SOURCE: Organic Process Research & Development (1998), 2(5), 320-324  
 CODEN: OPRDFK; ISSN: 1083-6160  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Adenosine A1 receptor antagonist, FK838, has been synthesized in 44% overall yield by a five-step sequence which is operationally straightforward and readily carried out on a large scale. Investigations into the 1,3-dipolar cycloaddn. process that afforded a pyrazolo[1,5-a]pyridine derivative are also described. Process improvements and optimization of each step permitted elimination of column chromatog., resulting in a practical and cost-effective synthesis of FK838. These methods were successfully scaled up in a pharmaceutical pilot plant to give bulk drug used in clin. trials.  
 IT 131185-06-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (pilot-scale preparation of FK838)  
 RN 131185-06-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 131185-37-0P, FK838  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (pilot-scale preparation of FK838)  
 RN 131185-37-0 CAPLUS  
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 71 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1998:430761 CAPLUS  
DOCUMENT NUMBER: 129:144876  
TITLE: Pyrazolopyridines as adenosine antagonists and pharmaceuticals containing them  
INVENTOR(S): AkaBne, Atsushi; Nishimura, Shintaro; Kurota, Satoshi; Itani, Hiromichi  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.  
CODEN: JGXAXF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10182643	A	19980707	JP 1996-357706	19961226
PRIORITY APPL. INFO.: JP 1996-357706 19961226				
OTHER SOURCE(S): MARPAT 129:144876				




AB Pharmaceuticals contain pyrazolopyridines I [R = (substituted) lower alkanoyl(lower)alkyl, N-[(substituted) lower alkyl]carbamoyl(lower)alkyl, etc.] or their salts as adenosine, especially A1, antagonists with cognition-enhancing, analgesic, and locomotor-stimulant effects, and other pharmacol. actions. 3-[2-(1-Methyl-2-oxopropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine (preparation given)  
(at 3.2 + 10<sup>-7</sup>M) showed >90% inhibition of [3H]-N6-cyclohexyladenosine binding to rat A1 receptors  
IT 210879-77-9P 210879-80-4P 210879-85-9P  
210880-03-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)  
RN 210879-77-9 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, α,α-dimethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, phenylmethyl ester (CA INDEX NAME)




RN 210879-80-4 CAPLUS  
CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210879-85-9 CAPLUS  
CN Glycine, N-[2,2-dimethyl-1,3-dioxo-4-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)butyl]-, methyl ester (CA INDEX NAME)




RN 210880-03-8 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, α,α-dimethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 210879-61-1P 210879-62-2P 210879-63-3P  
210879-64-4P 210879-65-5P 210879-66-6P  
210879-67-7P 210879-68-8P 210879-69-9P  
210879-70-2P 210879-71-3P 210879-72-4P  
210879-73-5P 210879-74-6P 210879-75-7P  
210879-76-8P 210879-78-0P 210879-79-1P  
210879-81-5P 210879-82-6P 210879-83-7P  
210879-84-8P 210879-87-1P 210879-88-2P  
210879-91-7P 210879-94-0P 210879-96-2P  
210879-99-5P 210880-04-9P 210880-05-0P  
210880-07-2P 210880-09-4P 210880-11-8P  
210880-13-0P 210880-14-1P 210880-15-2P  
210880-16-3P 210880-18-5P 210880-20-9P  
210880-21-0P 210880-23-2P 210880-25-4P  
210880-27-6P 210880-28-7P 210880-29-8P  
210880-30-1P 210880-31-2P 210880-32-3P  
210880-33-4P 210880-34-5P 210880-35-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)  
RN 210879-61-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-62-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210879-63-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-64-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-65-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-acetyl-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


RN 210879-69-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-70-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-71-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-72-4 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, gamma,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)





RN 210879-66-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-methyl-2-oxopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-67-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-68-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-73-5 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, beta,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)



RN 210879-74-6 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, alpha,6-dimethyl-beta,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 210879-75-7 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, alpha,6-diethyl-beta,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 210879-76-8 CAPLUS  
CN 1(6H)-Pyridazinone, 2-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)-, ethyl ester, (αZ)- (CA INDEX NAME)


Double bond geometry as shown.



RN 210879-78-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-79-1 CAPLUS  
CN Benzoic acid, 2-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-87-1 CAPLUS  
CN Benzoic acid, 2-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210879-88-2 CAPLUS  
CN 2-Piperidineacetic acid, 1-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)-, methyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210879-91-7 CAPLUS  
CN Glycine, N-[2,2-dimethyl-1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]- (CA INDEX NAME)




RN 210879-81-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-([2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-82-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-([2-oxo-2-(3-pyridinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210879-83-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-([2-oxo-2-(3-pyridinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-84-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-([2-oxo-2-(3-pyridinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210879-94-0 CAPLUS  
CN Benzoic acid, 2-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210879-96-2 CAPLUS  
CN 2-Piperidineacetic acid, 1-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210879-99-5 CAPLUS  
CN Benzoic acid, 2-([6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl)- (9CI) (CA INDEX NAME)








RN 210880-04-9 CAPLUS  
CN Benzoic acid, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-05-0 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-07-2 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210880-15-2 CAPLUS  
CN 1(6H)-Pyridazinepentanamide, N-methyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-16-3 CAPLUS  
CN 1(6H)-Pyridazinepentanamide, N,N-dimethyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-18-5 CAPLUS  
CN Piperidine, 1-[1,4-dioxo-5-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl]- (9CI) (CA INDEX NAME)

RN 210880-09-4 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-11-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-13-0 CAPLUS  
CN 1(6H)-Pyridazinebutanamide, N,N,α,α-tetramethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-14-1 CAPLUS  
CN 1(6H)-Pyridazinepentanamide, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-20-9 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-21-0 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-(1,1-dimethylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-23-2 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)





RN 210880-25-4 CAPLUS  
CN 1(6H)-Pyridazineacetamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 210880-27-6 CAPLUS  
CN Pyrrolidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS  
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 210880-34-5 CAPLUS  
CN Piperidine, 1-[[1,3-dioxo-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 210880-35-6 CAPLUS  
CN 3-Pyrrolidinone, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




IT 131185-06-3 131185-08-5 210880-36-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)  
RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


RN 210880-29-8 CAPLUS  
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-30-1 CAPLUS  
CN Piperazine, 1-methyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS  
CN Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-32-3 CAPLUS  
CN 3-Acetidinol, 1-[[1,4-dioxo-5-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl]- (9CI) (CA INDEX NAME)




RN 210880-33-4 CAPLUS  
CN 1(6H)-Pyridazinebutanamide, N,N-dimethyl-6,6-dioxo-3-(2-



RN 131185-09-5 CAPLUS  
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 210880-36-7 CAPLUS  
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



L4 ANSWER 72 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:219808 CAPLUS

DOCUMENT NUMBER: 128:230381

TITLE: Preparation of pyrazolopyridylpyridazinone derivatives as phosphodiesterase inhibitors  
 INVENTOR(S): Kouno, Yasushi; Ogata, Takenobu; Awano, Katsuya; Matsuzawa, Kayoko; Tooru, Taroh  
 PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814448	A1	19980409	WO 1997-JP3436	19970926
W: AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2267103	A1	19980409	CA 1997-2267103	19970926
CA 2267103	C	20060530		
AU 9743213	A	19980424	AU 1997-43213	19970926
AU 733316	B2	20010510		
CN 1232463	A	19991020	CN 1997-198468	19970926
CN 1083841	B	20020501		
HU 9903018	A2	20000328	HU 1999-3018	19970926
EP 989129	A1	20000329	EP 1997-941255	19970926
EP 989129	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 229527	T	20021215	AT 1997-941255	19970926
ES 2187814	T3	20030616	ES 1997-941255	19970926
TW 494100	B	20020711	TW 1997-86114443	19971003
KR 2000048874	A	20000725	KR 1999-702884	19990402
US 6265577	B1	20010724	US 1999-269734	19990405
PRIORITY APPLN. INFO.:			JP 1996-283148	A 19961004
OTHER SOURCE(S):		MARPAT 128:230381	WO 1997-JP3436	W 19970926
GI				

L4 ANSWER 72 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



AB Novel pyrazolopyridylpyridazinone derivs. (I; R1 = C1-4 alkyl or C3-6 cycloalkyl; R2-R5 = H, C1-4 alkyl, Ph, or alternatively R3 and R5 may be united to form a double bond) are prepared. I possess phosphodiesterase inhibiting activity and have a selective potent bronchodilating effect on the respiratory tract. Thus, compound (II; preparation given) was refluxed with NH2NH2.H2O in EtOH to give I (R1 = R2 = Me, R3-R5 = H). One of I was tested and showed bronchodilating effect on the respiratory tract.  
 IT 204504-56-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolopyridylpyridazinone derivs. as phosphodiesterase inhibitors)  
 RN 204504-56-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-4,5-dihydro-5-methyl- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 73 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:219808 CAPLUS

DOCUMENT NUMBER: 128:230381

TITLE: Preparation of pyrazolopyridine compounds as adenosine antagonists  
 INVENTOR(S): Akahane, Atsushi; Kuroda, Satoru; Itani, Hiromichi; Shimizu, Yasuyo  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 92 pp.  
 CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803507	A1	19980129	WO 1997-JP2493	19970717
W: AU, CA, CN, HU, IL, JP, KR, NO, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2260990	A1	19980129	CA 1997-2260990	19970717
AU 9734621	A	19980210	AU 1997-34621	19970717
AU 733034	B2	20010503		
EP 925299	A1	19990630	EP 1997-930832	19970717
EP 925299	B1	20020925		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1230186	A	19990929	CN 1997-197819	19970717
HU 9903527	A2	20000328	HU 1999-3527	19970717
JP 2000514821	T	20001107	JP 1998-506791	19970717
AT 224893	T	20021015	AT 1997-930832	19970717
ES 2179352	T3	20030116	ES 1997-930832	19970717
US 6124456	A	20000926	US 1999-147543	19990119
PRIORITY APPLN. INFO.:			AU 1996-1110	A 19960718
OTHER SOURCE(S):		MARPAT 128:154090	WO 1997-JP2493	W 19970717
GI				



AB The title compds. [I; R1 = aryl; R2 = lower alkyl (un)substituted with unsatd. 3 to 8-membered heteromonocyclic group, etc.] are prepared. I are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. Thus, 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

L4 ANSWER 73 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)


(prepn. given) was reacted with 4-chloro-1-methyl-piperidine.HCl in the presence of NaH to give I (R1 = Ph, R2 = Me), which was tested and showed adenosine antagonistic activity.

IT 202646-79-5P 202646-80-8P 202646-82-0P  
 202646-84-2P 202646-85-3P 202646-87-5P  
 202646-89-7P 202646-90-0P 202646-91-1P  
 202646-92-2P 202646-93-3P 202646-94-4P  
 202646-95-5P 202646-96-6P 202646-97-7P  
 202646-98-8P 202646-99-9P 202647-00-5P  
 202647-01-6P 202647-02-7P 202647-03-8P  
 202647-04-9P 202647-05-0P 202647-06-1P  
 202647-07-2P 202647-08-3P 202647-09-4P  
 202647-10-7P 202647-11-8P 202647-12-9P  
 202647-13-0P 202647-14-1P 202647-15-2P  
 202647-23-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolopyridine compds. as adenosine antagonists)


RN 202646-79-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 202646-80-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202646-82-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202646-84-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 202646-85-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyrrolidinyl)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 202646-87-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202646-93-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-butyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202646-94-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-pentyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202646-95-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-hexyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202646-96-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-(1-methylethyl)-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




● HCl

RN 202646-89-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyrrolidinyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202646-90-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (CA INDEX NAME)




RN 202646-91-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202646-92-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 202646-97-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-methyl-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202646-98-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-phenylmethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202646-99-9 CAPLUS  
CN Piperidine, 1-acetyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 202647-00-5 CAPLUS  
CN Piperidinium, 1,1-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, iodide (9CI) (CA INDEX NAME)


● I<sup>-</sup>

RN 202647-01-6 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 202647-02-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-azabicyclo[2.2.2]oct-3-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (CA INDEX NAME)




RN 202647-03-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methyl-3-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




● HCl

RN 202647-09-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 202647-10-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-piperidinylmethyl)- (CA INDEX NAME)




RN 202647-11-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-pyrrolidinylmethyl)]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202647-12-9 CAPLUS


RN 202647-04-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methyl-2-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202647-05-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(1-methyl-2-piperidinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202647-06-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-(2-piperidinyl)ethyl)- (CA INDEX NAME)




RN 202647-07-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methyl-4-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202647-08-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(1-methyl-4-piperidinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 73 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN 1-Piperidinecarboxylic acid, 4-hydroxy-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]-, phenylmethyl ester (CA INDEX NAME)




RN 202647-13-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4-hydroxy-4-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 202647-14-1 CAPLUS  
CN 4-Piperidinol, 1-acetyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 202647-15-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(2-methyl-4-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 202647-23-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(1-methyl-2-pyrrolidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (S)- (9CI) (CA INDEX NAME)

L4 ANSWER 73 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



IT 141060-69-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrazolopyridine compds. as adenosine antagonists)  
RN 141060-69-7 CAPLUS  
CN 1(6H)-Pyridazineacetoneitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



IT 202647-16-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of pyrazolopyridine compds. as adenosine antagonists)  
RN 202647-16-3 CAPLUS  
CN 1(6H)-Pyridazineethanethioamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 75 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:751670 CAPLUS  
DOCUMENT NUMBER: 128:97575  
TITLE: Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists  
AUTHOR(S): Maemoto, Takuya; Finlayson, Keith; Olverman, Henry J.; Akahane, Atsushi; Horton, Roger W.; Butcher, Steven P.  
CORPORATE SOURCE: Fujisawa Institute of Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ, UK  
SOURCE: British Journal of Pharmacology (1997), 122(6), 1202-1208  
CODEN: BJPCBM; ISSN: 0007-1188  
PUBLISHER: Stockton Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB The pharmacol. profile of adenosine A1 receptors in human, guinea-pig, rat and mouse brain membranes was characterized in a radioligand binding assay by use of the receptor selective antagonist, [3H]-8-cyclopentyl-1,3-dipropylxanthine ([3H]-DPCPX). The affinity of [3H]-DPCPX binding sites in rat cortical and hippocampal membranes was similar. Binding site affinity was higher in rat cortical membranes than in membranes prepared from guinea-pig cortex and hippocampus, mouse cortex and human cortex. PKD values (M) were 9.55, 9.44, 8.85, 8.94, 8.67, 9.39 and 8.67, resp. The binding site d. (Bmax) was lower in rat cortical membranes than in guinea-pig or human cortical membranes. The rank order of potency of seven adenosine receptor agonists was identical in each species. With the exception of 5'-N-ethylcarboxamidoadenosine (NECA), agonist affinity was 3.5-26.2 fold higher in rat cortical membranes than in human and guinea-pig brain membranes; affinity in rat and mouse brain membranes was similar. While NECA exhibited 9.3 fold higher affinity in rat compared to human cortical membranes, affinity in other species was comparable. The stable GTP analog, Gpp(NH)p (100 μM) reduced 2-chloro-N6-cyclopentyladenosine (CCPA) affinity 7-13.9 fold, whereas the affinity of DPCPX was unaffected. The affinity of six xanthine-based adenosine receptor antagonists was 2.2-15.9 fold higher in rat cortical membranes compared with human or guinea-pig membranes. The rank order of potency was species-independent. In contrast, three pyrazolopyridine derivs., (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine ethanol (FK453), (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-piperidin-2-yl acetic acid (FK352) and 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutyric acid (FK838) exhibited similar affinity in human, guinea-pig, rat and mouse brain membranes. PKi values (M) for [3H]-DPCPX binding sites in human cortical membranes were 9.31, 7.52 and 7.92, resp. Drug affinity for adenosine A2A receptors was determined in a

[3H]-2-[4-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine ([3H]-CGS 21680) binding assay in rat striatal membranes. The pyrazolopyridine derivs., FK453, FK838 and FK352 exhibited pKi values (M) of 5.90, 5.92 and 4.31, resp., compared with pKi values of 9.31, 8.18 and 7.57 determined in the [3H]-DPCPX binding assay in rat cortical membranes. These novel pyrazolopyridine derivs. therefore represent high affinity, adenosine A1 receptor selective drugs that, in contrast to xanthine based antagonists, exhibit similar affinity for [3H]-DPCPX binding sites in human, rat, mouse and guinea-pig brain membranes.

IT 131185-37-0, FK838  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(species differences in human and laboratory animal brain adenosine A1 receptor pharmacol. revealed by use of xanthine and pyrazolopyridine

L4 ANSWER 74 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1998:16460 CAPLUS  
DOCUMENT NUMBER: 128:24224  
TITLE: Efficient large-scale synthesis of 4-phenyl-3-butyne-2-one, a key intermediate for a novel potent adenosine antagonist  
AUTHOR(S): Zanka, Atsuhiko  
CORPORATE SOURCE: Technological Development Laboratories, Fujisawa Pharmaceutical Co. Ltd., Osaka, 532, Japan  
SOURCE: Organic Process Research & Development (1998), 2(1), 60-62  
CODEN: OPRDFK; ISSN: 1083-6160  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Phenylacetylenic bromide Grignard reagent reacts with acetic anhydride under mild conditions to give 4-phenyl-3-butyne-2-one in high yield. This method was applicable to a large-scale synthesis, and optimized reaction conditions have been investigated.  
IT 131185-37-0P, FK 838  
RL: IMF (Industrial manufacture); PREP (Preparation)  
(large-scale synthesis of phenylbutynone intermediate for)  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 75 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


based antagonists)  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 76 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1997:717919 CAPLUS  
 DOCUMENT NUMBER: 128:10318  
 TITLE: Preventives and remedies for ischemic intestinal lesion and ileus  
 INVENTOR(S): Kadowaki, Makoto; Tomoi, Masaaki  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Kadowaki, Makoto; Tomoi, Masaaki  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740047	A1	19971030	WO 1997-JP1417	19970424
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9724056	A	19971112	AU 1997-24056	19970424
EP 900796	A1	19990310	EP 1997-919667	19970424
EP 900796	B1	20041215		
R: CH, DE, ES, FR, GB, IT, LI				
US 6214843	B1	20010410	US 1999-147169	19990127
PRIORITY APPLN. INFO.:			JP 1996-105020	A 19960425
			WO 1997-JP1417	W 19970424
OTHER SOURCE(S):	MARPAT 128:10318			
GI				



I



II


AB Preventives and/or remedies for ischemic intestinal lesions and/or ileus which contain as the active ingredient pyrazolopyridine compds. represented by general formula (I) or salts thereof wherein R1 represents lower alkyl, etc.; R2 represents a group represented by general formula (II), etc. (wherein R4 represents protected amino, etc.; and R5 represents hydrogen, etc.); and R3 represents hydrogen, etc. The effects of I on intestinal transport and contractility were tested in rat models.

IT 131185-37-0 171050-45-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preventives and remedies for ischemic intestinal lesion and ileus)


RN 131185-37-0 CAPLUS  
 CN 1-(6H)-pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

L4 ANSWER 77 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1997:558055 CAPLUS  
 DOCUMENT NUMBER: 127:262667  
 TITLE: Preparation of pyrazolo[1,5-a]pyridine derivatives as adenosine antagonists and their pharmaceutical uses  
 INVENTOR(S): Kuroda, Satoshi; Itani, Hiromichi; Akabane, Atsushi  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.  
 CODEN: JKOXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09216883	A	19970819	JP 1996-24146	19960209
PRIORITY APPLN. INFO.:			JP 1996-24146	19960209
OTHER SOURCE(S):	MARPAT 127:262667			
GI				



I



Q




Q2


AB The deriva. I (R1 = aryl; R2 = oxodihydropyridazinyl Q [R3 = H, lower alkyl, acyl-lower alkyl, acyl-lower alkanoyl-lower alkyl, (un)substituted heterocyclyl, (un)substituted lower aralkyl; R4 = H, acyl, cyano, heterocyclyl, lower hydroxyalkyl, (unprotected) amino; R5 = H, lower alkyl; R6 and/or R5 = substituent], pyridazinyl Q1 [R6 = halo, lower alkoxy, (un)substituted arylamino; R7 = acyl, lower hydroxyalkyl]) or their pharmaceutically acceptable salts are claimed. Also claimed are pharmaceuticals containing I or their salts and carriers. I show cognition-enhancing, analgesic, antidepressant, vasodilating, diuretic, cardiostimulant, renal circulation-increasing, lipolysis-promoting, antiasthmatic, insulin secretion-promoting, platelet aggregation-inhibiting effects, etc., and are especially useful as cardiac infarction inhibitors, antihypertensives, renal failure inhibitors, and diuretics.

IT 195826-94-9P 195826-95-0P 195826-96-1P  
 195826-97-2P 195826-98-3P 195826-99-4P  
 195827-00-0P 195827-01-1P 195827-02-2P  
 195827-03-3P 195827-04-4P 195827-05-5P  
 195827-07-7P 195827-08-8P 195827-09-9P  
 195827-10-2P 195827-12-4P 195827-13-5P  
 195827-14-6P 195827-15-7P 195827-16-8P  
 195827-17-9P 195827-18-0P 195827-19-1P  
 195827-20-4P 195827-21-5P 195827-22-6P  
 195827-23-7P 195827-24-8P 195827-25-9P  
 195827-26-0P 195827-27-1P 195827-28-2P

L4 ANSWER 76 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 171050-45-6 CAPLUS  
 CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




L4 ANSWER 77 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 195827-29-3P 195827-30-6P 195827-31-7P  
 195827-32-8P 195827-33-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of pyrazolo[1,5-a]pyridine derivs. as adenosine antagonists and their pharmaceutical uses)


RN 195826-94-9 CAPLUS  
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-5-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)



RN 195826-95-0 CAPLUS  
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-5-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195826-96-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195826-97-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-methyl-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 77 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 195826-99-3 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, hydrazide (CA INDEX NAME)




RN 195826-99-4 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195827-00-0 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (CA INDEX NAME)




L4 ANSWER 77 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 195827-05-5 CAPLUS  
CN 4-Pyridazinecarbonitrile, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 195827-07-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 195827-08-8 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




L4 ANSWER 77 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 195827-01-1 CAPLUS  
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 195827-02-2 CAPLUS  
CN Glycine, N-[[2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 195827-03-3 CAPLUS  
CN Glycine, N-[[2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl]- (CA INDEX NAME)




RN 195827-04-4 CAPLUS  
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

L4 ANSWER 77 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 195827-09-9 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)



RN 195827-10-2 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195827-12-4 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 195827-13-5 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)







RN 195827-14-6 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 195827-15-7 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195827-16-8 CAPLUS  
CN 1(6H)-Pyridazinepentanoic acid, 5-(ethoxycarbonyl)-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 195827-17-9 CAPLUS  
CN (1(6H),3'-Bipyridazine]-5-carboxylic acid, 1',4',5',6'-tetrahydro-6,6'-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)




RN 195827-18-0 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-[(4-methoxyphenyl)methyl]-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 195827-19-1 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-[(4-methoxyphenyl)methyl]-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195827-20-4 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 3-chloro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 195827-21-5 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-[(3,4,5-trimethoxyphenyl)amino]-, ethyl ester (CA INDEX NAME)




RN 195827-22-6 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-[(3,4,5-trimethoxyphenyl)amino]- (CA INDEX NAME)




RN 195827-23-7 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 3-ethoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 195827-24-8 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 195827-25-9 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 3-chloro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)



RN 195827-26-0 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 195827-27-1 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)





RN 195827-28-2 CAPLUS  
CN 4-Pyridazinecarboxylic acid, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


RN 195827-32-8 CAPLUS  
CN Carbamic acid, [2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 195827-33-9 CAPLUS  
CN 3(2H)-Pyridazinone, 4-amino-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195827-29-3 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(hydroxymethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 195827-30-6 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 195827-31-7 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(2-hydroxyethyl)-2-[(3-hydroxyphenyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



ACCESSION NUMBER: 1997:262220 CAPLUS  
DOCUMENT NUMBER: 126:272373  
TITLE: Pyrazolopyridine derivatives for prevention and treatment of constipation and allergic intestinal diseases  
INVENTOR(S): Takeda, Masahiro; Ise, Masayuki; Kadowaki, Makoto; Hori, Haruo; Tomoi, Masaaki  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.  
CODEN: JKOXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09059157	A	19970304	JP 1995-208815	19950816
PRIORITY APPLN. INFO:			JP 1995-208815	19950816
OTHER SOURCE(S):				




I


AB Pyrazolopyridine derivs. (I; R1 = allyl, heterocyclic; R2 = protected amino, amido-carboxyl, cyano, -C(R5)=NR4, -A-R6, unsatd. heterocyclic; R3 = H, halogen, low alkyl, low alkoxy; R4 = protected amino, OH; R5 = H, low alkyl; R6 = amino; A = low fatty carbohydrate) are claimed for prevention and treatment of constipation and allergic intestinal diseases. I can be formulated into oral and parenteral dosage forms. I (3-[2-(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine) given orally promoted defecation in normal and constipated mice.

IT 131185-37-0  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (pyrazolopyridine derivs. for prevention and treatment of constipation and allergic intestinal diseases)

RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




ACCESSION NUMBER: 1996:521818 CAPLUS  
 DOCUMENT NUMBER: 125:191894  
 TITLE: Effects of selective adenosine A1 receptor antagonism on glomerular microcirculation and tubuloglomerular feedback  
 AUTHOR(S): Han, Wen-Hua  
 CORPORATE SOURCE: Department of Internal Medicine (I), Kanazawa University, Kanazawa, 920, Japan  
 SOURCE: Kanazawa Daigaku Juzen Igakkai Zasshi (1996), 105(2), 239-248  
 CODEN: JUZIAG; ISSN: 0022-7226  
 PUBLISHER: Juzen Igakkai  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Japanese  
 AB Renal clearance and micropuncture studies were carried out in anesthetized Sprague-Dawley rats to examine the effects of a selective adenosine A1 receptor antagonist, FK 838 on the glomerular microcirculation and tubuloglomerular feedback (TGF) mechanism. A low dose (1 µg/min/kg) and a high dose (10 µg/min/kg) infusion of FK 838 increased urine volume by 2.2 and 3.8 times and fractional excretion of sodium by 25 and 59 times, resp. while the mean blood pressure and renal plasma flow remained unaltered. The glomerular filtration rate showed a transient minimal increase during the high dose infusion. TGF responsiveness was estimated by measuring changes in the early proximal flow rate (EPFR) when the loop of Henle was perfused orthogradely with Ringer's solution at 40 nl/min. Loop perfusion decreased EPFR by 46.8% from 31.5 to 17.1 nl/min/g kidney weight. The reduction of EPFR in response to loop perfusion was 31.9% at the low and 9.8% at the high dose of FK 838 infusion, showing a suppression of TGF response. To determine the proximal tubule transport of FK 838, probenecid (100 mg/kg + 30 mg/h/kg) was administered i.v. before infusing the high dose of FK 838. The plasma concentration of FK 838 was increased by 2.8 approx. 3.4-fold and natriuresis was enhanced by probenecid, although its urinary excretion was unaltered. EPFR reduction was 6.1% after probenecid and comparable with the high dose of FK 838 alone. The effect of FK 838 from the tubular lumen was also studied by perfusing FK 838 (10<sup>-7</sup>, 10<sup>-6</sup>, and 10<sup>-5</sup> M) in Ringer's solution into the loop at 40 nl/min. TGF-mediated reduction of EPFR was decreased to 34.8, 21.8 and 6.8%, resp. in a dose dependent manner. In conclusion, FK 838 induces marked natriuresis and diuresis through the direct tubular effect. Intravascular and intratubular FK 838, after gaining access to the juxtaglomerular apparatus, blocks the sensing mechanism of macula densa cells and antagonizes afferent arteriolar vasoconstriction induced by endogenous adenosine, and thus inhibits TGF. This study demonstrates a crucial role of A1 receptor activation by endogenous adenosine in the control of glomerular microcirculation and tubular sodium handling.  
 IT 131185-37-0, FK 838  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (adenosine A1 receptor antagonism effect on glomerular microcirculation and tubuloglomerular feedback in rats)  
 RN 131185-37-0 CAPLUS  
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




ACCESSION NUMBER: 1996:440609 CAPLUS  
 DOCUMENT NUMBER: 125:86637  
 TITLE: Preparation of novel pyrazolopyridine derivatives as adenosine antagonists  
 INVENTOR(S): Shiokawa, Yoichi; Akaha, Atsushi; Katayama, Hirohito; Mitsuunaga, Takafumi  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKOXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08099976	A	19960416	JP 1994-237543	19940930
PRIORITY APPLM. INFO.:			JP 1994-237543	19940930
OTHER SOURCE(S): MARPAT 125:86637				


 GI




AB Pyrazolopyridine compds. I [R1 = aryl; R2 = acylalkyl, N-monoalkylcarbamoylalkyl, substituted aralkyl] and their pharmaceutically acceptable salts as adenosine antagonists are prepared. Thus, 3-[3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine was treated with NaH, then reacted with Et 8-bromooctanoate to give 3-[2-(7-ethoxycarbonylheptyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine (II). II was then hydrolyzed to give 3-[2-(7-carboxyheptyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine, 10<sup>-6</sup> M solution of which showed 96.7% adenosine antagonism in guinea pig.  
 IT 131185-08-5P 178878-89-2P 178878-90-5P  
 178878-91-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate for adenosine antagonistic dihydropyridazinylpyrazolopyridine derivs.)  
 RN 131185-08-5 CAPLUS  
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 178878-89-2 CAPLUS  
CN 1(6H)-Pyridazino[1,5-a]pyridin-3-yl-, ethyl ester (CA INDEX NAME)




RN 178878-90-5 CAPLUS  
CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (CA INDEX NAME)




RN 178878-91-6 CAPLUS  
CN 1(6H)-Pyridazino[1,5-a]pyridin-3-yl-, ethyl ester (CA INDEX NAME)




IT 131185-06-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of adenosine antagonistic dihydropyridazinylpyrazolopyridine derivs.)




RN 178878-87-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1-phenylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 178878-88-1 CAPLUS  
CN 1(6H)-Pyridazino[1,5-a]pyridin-3-yl-, ethyl ester (CA INDEX NAME)




RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



IT 178878-84-7P 178878-85-8P 178878-86-9P  
178878-87-0P 178878-88-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrazolopyridine derivs. as adenosine antagonist)  
RN 178878-84-7 CAPLUS  
CN 1(6H)-Pyridazino[1,5-a]pyridin-3-yl-, ethyl ester (CA INDEX NAME)



RN 178878-85-8 CAPLUS  
CN Benzanide, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (CA INDEX NAME)



RN 178878-86-9 CAPLUS  
CN 1(6H)-Pyridazino[1,5-a]pyridin-3-yl-, ethyl ester (CA INDEX NAME)

ACCESSION NUMBER: 1996:227103 CAPLUS  
DOCUMENT NUMBER: 124:306972  
TITLE: The effects of adenosine subtype-1 receptor antagonist (FK-838) on salt-induced hypertension in Dahl salt-sensitive rats  
AUTHOR(S): Kaneko, Hiroshi; Numabe, Atsushi; Doumoto, Maho; Uehara, Yoshio; Yagi, Shigeru  
CORPORATE SOURCE: Sch. Med., Dokkyo Univ., Japan  
SOURCE: Dokkyo Igakkai Zasshi (1995), 10(2), 235-44  
CODEN: DIZABG; ISSN: 0911-5900  
PUBLISHER: Dokkyo Igakkai  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese


AB The authors investigated the effects of an adenosine type-1 (A1) receptor antagonist (FK-838) on salt-induced hypertension in Dahl-Sea salt-sensitive (Dahl S) rats. Alterations in kidney function and morphol. changes were assessed in Dahl S rats treated for 4-wk with FK-838 (1.0 mg/kg, 10.6 mg/kg) or hydrochlorothiazide (HCTZ, 9.7 mg/kg), a thiazide diuretic. All prolonged treatments decreased systolic blood pressure in Dahl S rats fed a high-salt (2% NaCl) diet. There was a trend toward increased urinary excretion and fractional excretion of sodium with FK-838 treatment. The blood pressure reduction by FK-838 was associated with the partial resolution of glomerular and arterial injury in the kidney. The renal protective effect of FK-838 treatment was associated with the reduction of plasma renin activity and plasma aldosterone concentration. In contrast,

HCTZ which produced almost the same blood pressure reduction as FK-838, did not attenuate renal damage. These data indicate that A1 receptor antagonism ameliorates salt-induced hypertension and the consequent renal injury. The protective effects of FK-838 may be mediated in part by a decrease in the activity of the renin-angiotensin system.


IT 131185-37-0, FK-838  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of adenosine subtype-1 receptor antagonist (FK-838) on salt-induced hypertension in Dahl salt-sensitive rats in relation to diuretic activity and kidney protection and effect on renin-angiotensin system)

RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazino[1,5-a]pyridin-3-yl-, ethyl ester (CA INDEX NAME)




L4 ANSWER 82 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1995:94563 CAPLUS  
 DOCUMENT NUMBER: 124:164769  
 TITLE: A new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats  
 AUTHOR(S): Uehara, Yoshio; Numabe, Atsushi; Hirawa, Nobuhito; Kawabata, Yukari; Nagoshi, Hiroshi; Kaneko, Hiroshi; Gomi, Tomoko; Goto, Atsuo; Toyo-oka, Teruhiko; Omata, Masao  
 CORPORATE SOURCE: Dep. Medicine, Univ. Tokyo, Tokyo, Japan  
 SOURCE: American Journal of Hypertension (1995), 8(12, Pt. 1), 1189-99  
 CODEN: AJHYEG; ISSN: 0895-7061  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The authors investigated the effects of the adenosine type-1 receptor antagonist FK-838 on salt-induced hypertension in Dahl-S salt-sensitive (Dahl S) rats. Dahl S rats fed a high-salt (4% NaCl) diet for 4 wk were treated with FK-838 or hydrochlorothiazide for 4 wk and alterations in kidney function and morphol. changes were assessed. FK-838 attenuated the development of hypertension in Dahl S rats, and caused a decrease in aortic weight in a dose-dependent fashion. The adenosine antagonist did not produce any detectable metabolic disturbance. The blood pressure reduction by FK-838 was associated with attenuation of glomerular and arterial injury in the kidney. The renal protective effect of FK-838 treatment was associated with a reduction of plasma renin activity and plasma aldosterone concentration. In contrast, the thiazide diuretic, which produced almost the same blood pressure reduction as FK-838, did not attenuate renal damage. These data indicate that adenosine A1 receptor antagonism reduces salt-induced hypertension and the consequent renal injuries.  
 IT 131185-37-0, FK 838  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (a new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats)  
 RN 131185-37-0 CAPLUS  
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1995:960198 CAPLUS  
 DOCUMENT NUMBER: 124:8834  
 TITLE: Preparation of (oxypyridazinyl)pyrazolopyridines as adenosine antagonists  
 INVENTOR(S): Akahane, Atsushi; Nishimura, Shintaro; Itani, Hiromichi; Durkin, Kieran P. M.  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 167 pp.  
 CODEN: PIXK02  
 Patent  
 DOCUMENT TYPE: English  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518128	A1	19950706	WO 1994-JP2230	19941226
W: AU, CA, CN, FI, HU, JP, KR, NO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2180253	A1	19950706	CA 1994-2180253	19941226
AU 9512817	A	19950717	AU 1995-12817	19941226
AU 694157	B2	19980716		
EP 737193	A1	19961016	EP 1995-903969	19941226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1139928	A	19970108	CN 1994-194724	19941226
CN 1046724	B	19991124		
HU 76280	A2	19970728	HU 1996-1789	19941226
JP 09507485	T	19970729	JP 1995-517911	19941226
JP 3572617	B2	20041006		
ZA 9410409	A	19950926	ZA 1994-10409	19941229
IL 112193	A	20001031	IL 1994-112193	19941229
BR 9500905	A	19951024	BR 1995-905	19950306
IN 1995MA00292	A	20050225	IN 1995-MA292	19950310
US 5737330	A	19980630	US 1996-663119	19960913
US 6355640	B1	20020312	US 1998-72696	19980506
PRIORITY APPLN. INFO.:			GB 1993-26524	A 19931229
			GB 1994-4323	A 19940304
			WO 1994-JP2230	W 19941226
			US 1996-663119	A1 19960913


OTHER SOURCE(S): MARPAT 124:8834  
 GI




AB Title compds. [I: R1 = aryl; R2 = (un)substituted cycloalkyl] were prepared

L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 Thus, I (R1 = Ph, R2 = H) was alkylated by 2-chlorocyclohexanone and the product condensed with (EtO)2P(O)CH2CO2Et to give, after sapon., title compd. II and the exo-unsatd. product. II gave redn. of serum creatinine from 3.60 (control) to 1.10mg/dL i.v. in rats experiencing cisplatin-induced renal failure.  
 IT 171050-39-8P 171050-40-1P 171050-41-2P  
 171050-42-3P 171050-43-4P 171050-44-5P  
 171050-45-6P 171050-46-7P 171050-47-8P  
 171050-48-9P 171050-49-0P 171050-50-3P  
 171050-51-4P 171050-52-5P 171050-53-6P  
 171050-54-7P 171050-55-8P 171050-56-9P  
 171050-57-0P 171050-58-1P 171050-59-2P  
 171050-60-3P 171050-61-4P 171050-62-7P  
 171050-63-8P 171050-64-9P 171050-65-0P  
 171050-66-1P 171050-67-2P 171050-68-3P  
 171050-69-4P 171050-70-7P 171050-71-8P  
 171050-72-9P 171050-73-0P 171050-74-1P  
 171050-75-2P 171050-76-3P 171050-77-4P  
 171050-78-5P 171050-79-6P 171050-80-9P  
 171050-81-0P 171050-82-1P 171050-83-2P  
 171050-84-3P 171050-85-4P 171050-86-5P  
 171050-87-6P 171050-88-7P 171050-89-8P  
 171050-90-1P 171050-91-2P 171050-92-3P  
 171050-93-4P 171050-94-5P 171050-95-6P  
 171050-96-7P 171050-97-8P 171050-98-9P  
 171050-99-0P 171051-00-6P 171051-01-7P  
 171051-02-8P 171051-03-9P 171051-04-0P  
 171051-05-1P 171051-06-2P 171051-07-3P  
 171051-08-4P 171051-09-5P 171051-10-8P  
 171051-11-9P 171051-12-0P 171051-13-1P  
 171051-14-2P 171051-15-3P 171051-16-4P  
 171051-17-5P 171051-18-6P 171051-19-7P  
 171051-20-0P 171051-21-1P 171051-22-2P  
 171051-23-3P 171051-24-4P 171051-25-5P  
 171051-26-6P 171051-27-7P 171051-28-8P  
 171051-29-9P 171051-30-2P 171051-31-3P  
 171051-32-4P 171051-33-5P 171051-34-6P  
 171051-35-7P 171051-36-8P 171051-37-9P  
 171051-38-0P 171051-39-1P 171051-40-4P  
 171051-41-5P 171051-42-6P 171051-43-7P  
 171051-44-8P 171051-45-9P 171051-46-0P  
 171051-47-1P 171051-48-2P 171051-49-3P  
 171051-50-6P 171051-51-7P 171051-52-8P  
 171051-53-9P 171051-54-0P 171051-55-1P  
 171051-56-2P 171051-57-3P 171051-58-4P  
 171051-59-5P 171051-60-6P 171051-61-9P  
 171051-62-0P 171051-63-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of (oxypyridazinyl)pyrazolopyridines as adenosine antagonists)  
 RN 171050-39-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-cyclohexyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 171050-40-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-41-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171050-42-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-43-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(1R,2R)-2-hydroxycyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 171050-44-5 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-46-7 CAPLUS  
CN Cyclohexanecarboxylic acid, 3-hydroxy-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, [1S-(1 $\alpha$ ,3 $\beta$ ,4 $\alpha$ )]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171050-47-8 CAPLUS

L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 171050-51-4 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclopentylidene]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171050-52-5 CAPLUS  
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-53-6 CAPLUS  
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



RN 171050-54-7 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclopentylidene]- (9CI) (CA INDEX NAME)


L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN 3(2H)-Pyridazinone, 2-(2-hydroxycycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-48-9 CAPLUS  
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-49-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxocycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-50-3 CAPLUS  
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (CA INDEX NAME)

L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 171050-55-8 CAPLUS  
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-56-9 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-57-0 CAPLUS  
CN 1-Cycloheptene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 171050-58-1 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cycloheptylidene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171050-59-2 CAPLUS  
CN 1-Cycloheptene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-60-5 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (CA INDEX NAME)




RN 171050-65-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2-oxo-3-furanyl)- (CA INDEX NAME)




RN 171050-66-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxo-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-67-2 CAPLUS  
CN 2,4-(1H,3H)-Pyrimidinedione, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1,3-dipropyl- (CA INDEX NAME)



RN 171050-68-3 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-2,4-dioxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl-, methyl ester (CA INDEX NAME)




RN 171050-61-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(1,4-dioxaspiro[4.5]dec-8-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-62-7 CAPLUS  
CN Cyclohexanecarboxylic acid, 3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-63-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-oxo-3-pyrrolidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171050-64-9 CAPLUS  
CN 1,3-Cyclohexanedione, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



RN 171050-69-4 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 3,6-dihydro-2,6-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl-, methyl ester (CA INDEX NAME)




RN 171050-70-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1,2,3,4-tetrahydro-2-hydroxy-6-methoxy-1-naphthalenyl)- (CA INDEX NAME)



RN 171050-71-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 171050-72-9 CAPLUS

CN Cyclopentaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171050-73-0 CAPLUS

CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 171050-74-1 CAPLUS


CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
a]pyridin-3-yl]-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 171050-79-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 171050-80-9 CAPLUS

CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2R)-rel- (CA INDEX NAME)



Relative stereochemistry.



RN 171050-81-0 CAPLUS


CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 171050-75-2 CAPLUS


CN 3(2H)-Pyridazinone, 2-[3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171050-76-3 CAPLUS


CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylcyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171050-77-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-(octahydro-2-oxo-7-benzofuranyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171050-78-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)

L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 171050-82-1 CAPLUS

CN Cyclopentaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171050-83-2 CAPLUS


CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171050-84-3 CAPLUS


CN 1-Pyrrolidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-85-4 CAPLUS

CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)







RN 171050-86-5 CAPLUS  
CN Glycine, N-[1-oxo-4-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]butyl]- (CA INDEX NAME)




RN 171050-87-6 CAPLUS  
CN beta-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171050-88-7 CAPLUS  
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 171050-89-8 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (CA INDEX NAME)




RN 171050-93-4 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-hydroxy-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-94-5 CAPLUS  
CN Acetic acid, [4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)



RN 171050-95-6 CAPLUS  
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-96-7 CAPLUS  
CN 1-Cyclohexene-1-butanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171050-90-1 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 171050-91-2 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 3,6-dihydro-2,6-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl- (CA INDEX NAME)




RN 171050-92-3 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-2,4-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl- (CA INDEX NAME)




RN 171050-97-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171050-98-9 CAPLUS  
CN Glycine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-99-0 CAPLUS  
CN beta-Alanine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171051-00-6 CAPLUS  
CN Acetic acid, [[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]amino]oxy]- (9CI) (CA INDEX NAME)




RN 171051-01-7 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-02-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-03-9 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, sodium salt (9CI) (CA INDEX NAME)


RN 171051-07-3 CAPLUS  
CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-08-4 CAPLUS  
CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)



RN 171051-09-5 CAPLUS  
CN 1-Cyclohexene-1-butanamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-10-8 CAPLUS  
CN 1-Cyclohexene-1-acetamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




• Na


RN 171051-04-0 CAPLUS  
CN Glycine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-05-1 CAPLUS  
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, phenylmethyl ester (CA INDEX NAME)




RN 171051-06-2 CAPLUS  
CN 1-Cyclohexene-1-butanonic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, phenylmethyl ester (CA INDEX NAME)




RN 171051-11-9 CAPLUS  
CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 171051-12-0 CAPLUS  
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 171051-13-1 CAPLUS  
CN 1-Cyclohexene-1-acetamide, N-(2-hydroxyethyl)-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-14-2 CAPLUS  
CN β-Alanine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-


L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)




RN 171051-15-3 CAPLUS  
 CN 1-Cyclohexene-1-acetamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)



RN 171051-16-4 CAPLUS  
 CN 1-Cyclohexene-1-butanamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-17-5 CAPLUS  
 CN 1-Cyclohexene-1-butanamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-18-6 CAPLUS


L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 171051-22-2 CAPLUS  
 CN Morpholine, 4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-23-3 CAPLUS  
 CN Pyrrolidine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-24-4 CAPLUS  
 CN Piperidine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 CN Glycine, N-[1-oxo-4-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]butyl]-, ethyl ester (CA INDEX NAME)



RN 171051-19-7 CAPLUS  
 CN Thiomorpholine, 4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-20-0 CAPLUS  
 CN Piperazine, 1-methyl-4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-21-1 CAPLUS  
 CN Piperazine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-4-(triphenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 RN 171051-25-5 CAPLUS  
 CN 4-Piperidinamine, N-methyl-1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-26-6 CAPLUS  
 CN Hydrazinecarboxamide, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (CA INDEX NAME)



RN 171051-27-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(2-hydrazonocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-28-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[2-(hydroxyimino)cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 171051-29-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(methoxyimino)cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-30-2 CAPLUS  
CN Acetic acid, [[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]amino]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-31-3 CAPLUS  
CN Hydroxylamine-O-sulfonic acid, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)



RN 171051-32-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-methylenecyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 171051-37-9 CAPLUS  
CN Acetonitrile, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 171051-38-0 CAPLUS  
CN Acetonitrile, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-39-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[(5,6-dihydro-4,4,6-trimethyl-4H-1,3-oxazin-2-yl)methylene]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 171051-33-5 CAPLUS  
CN Acetic acid, [4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, ethyl ester (9CI) (CA INDEX NAME)



RN 171051-34-6 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 171051-35-7 CAPLUS  
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 171051-36-8 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 171051-40-4 CAPLUS  
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-41-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-phenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-42-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-methoxyphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-43-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-methoxyphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 171051-44-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-45-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-46-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Cyclohexanecarbonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-51-7 CAPLUS  
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-52-8 CAPLUS  
CN 1-Cyclohexene-1-acetonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-53-9 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[1H-tetrazol-5-ylmethylene]cyclohexyl)- (9CI) (CA INDEX NAME)



RN 171051-47-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(2-hydroxyethyl)-1-cyclohexen-1-yl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-48-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(2-oxopropyl)-1-cyclohexen-1-yl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-49-3 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-hydroxy-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171051-50-6 CAPLUS




RN 171051-54-0 CAPLUS  
CN Piperazine, 1-acetyl-4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-55-1 CAPLUS  
CN Piperazine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-56-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-oxo-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 171051-57-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-oxo-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 171051-58-4 CAPLUS  
 CN 1-Pyrrolidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (CA INDEX NAME)




RN 171051-59-5 CAPLUS  
 CN 1-Piperidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-60-8 CAPLUS  
 CN Acetic acid, [[5,6,7,8-tetrahydro-5-oxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 171051-61-9 CAPLUS  
 CN Acetic acid, [[5,6,7,8-tetrahydro-5-oxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 IT 131185-06-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)  
 RN 131185-06-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



IT 131185-57-4P 171051-64-2P 171051-73-3P  
 171051-74-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)  
 RN 131185-57-4 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylethynyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-64-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylethynyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-73-3 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-hydroxy-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 a[pyridin-3-yl]-1(6H)-pyridazinyl]-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)




RN 171051-62-0 CAPLUS  
 CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 171051-63-1 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




IT 171051-72-2P  
 RL: BYP (Byproduct); PREP (Preparation)  
 (preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)  
 RN 171051-72-2 CAPLUS  
 CN Cyclohexanone, 2-[[6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl]oxy]- (CA INDEX NAME)



L4 ANSWER 83 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 171051-74-4 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 3-hydroxy-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




L4 ANSWER 84 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM  
 ACCESSION NUMBER: 1995:652344 CAPLUS  
 DOCUMENT NUMBER: 123:55871  
 TITLE: Preparation of pyrazolopyridine derivatives as allergy inhibitors  
 INVENTOR(S): Ogata, Takenobu; Amada, Junichiro; Ohashi, Mitsuo; Matsuzawa, Kayoko  
 PATENT ASSIGNEE(S): Kyorin Seiyaku Kk, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
 CODEN: JKKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07033769	A	19950203	JP 1993-203566	19930726
PRIORITY APPLN. INFO.: JP 1993-203566 19930726				
OTHER SOURCE(S): MARPAT 123:55871				
GI				



AB The title compds. I [R = H, alkyl, etc.; m = 0 - 2; n = 0 or 1] are prepared  
 The title compound II (preparation given) showed min. ED of 3 mg/Kg p.o.  
 against

anaphylactic airway constriction in guinea pigs.  
 IT 164391-26-8P 164391-27-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazolopyridine derivs. as allergy inhibitors)  
 RN 164391-26-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-cyclopropyl-3-(3,6-dihydro-2H-thiopyran-4-yl)-  
 (CA INDEX NAME)




RN 164391-27-9 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-cyclopentyl-3-(3,6-dihydro-2H-thiopyran-4-yl)-  
 (CA INDEX NAME)

L4 ANSWER 85 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM  
 ACCESSION NUMBER: 1995:117558 CAPLUS  
 DOCUMENT NUMBER: 122:123153  
 TITLE: Pyrazolopyridine derivatives for prevention and treatment of Meniere's disease  
 INVENTOR(S): Robaato, Geiburieru Petorera  
 PATENT ASSIGNEE(S): Air Products and Chemicals, Inc., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.  
 CODEN: JKKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06192092	A	19940712	JP 1993-247703	19931004
PRIORITY APPLN. INFO.: GB 1992-20894 A 19921005				
OTHER SOURCE(S): MARPAT 122:123153				

AB Pyrazolopyridine derivs. such as (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(2-hydroxyethyl)pyrrolidine are therapeutics for prevention and treatment of Meniere's disease.  
 IT 131185-08-5  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pyrazolopyridine derivs. for prevention and treatment of Meniere's disease)

RN 131185-08-5 CAPLUS  
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-  
 (CA INDEX NAME)




L4 ANSWER 84 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)




L4 ANSWER 86 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM  
 ACCESSION NUMBER: 1994:435602 CAPLUS  
 DOCUMENT NUMBER: 121:35602  
 TITLE: Preparation of pyrazolopyridines as intermediates for pharmaceutical dihydropyridazinylpyrazolopyridines  
 INVENTOR(S): Nakamura, Hitoshi; Kawakami, Ryoichi; Yamazaki, Hiroshi; Hashimoto, Norio; Taki, Isao  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
 CODEN: JKKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06009631	A	19940118	JP 1993-120928	19930423
PRIORITY APPLN. INFO.: JP 1992-107289 19920427				
OTHER SOURCE(S): CASREACT 121:35602; MARPAT 121:35602				
GI				




AB Pyrazolopyridines I (R1 = lower alkyl; R2, R3 = H, substituting group; X- = anion) are prepared by treatment of R2C6H4C.tplbond.CCOR1 (R1, R2 = same as above) with aminopyridines II (R3, X- = same as above). Treatment of 5.00 g I (R1 = Me, R2 = H) with 11.55 g II (R3 = H, X- = iodide) and K2CO3 in DMF at 33-37° for 1 h gave 6.66 g I (R1 = Me, R2 = R3 = H).



IT 131185-06-3P 131185-07-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of)  
 RN 131185-06-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 131185-07-4 CAPLUS  
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




IT 131185-08-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, acetylphenylpyrazolopyridine as intermediate for)  
 RN 131185-08-5 CAPLUS  
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



ACCESSION NUMBER: 1994:153722 CAPLUS  
DOCUMENT NUMBER: 120:153722  
TITLE: Pyrazolopyridine compounds for the treatment of anemia  
INVENTOR(S): Kohnno, Yutaka; Nagatomi, Itsuo; Hanaoka, Kaori  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 61 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 932505	A1	19931223	WO 1993-JP762	19930607
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 644762	A1	19950329	JP 1993-913487	19930607
EP 644762	B1	19971217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08500338	T	19960116	JP 1993-501330	19930607
AT 161178	T	19980115	AT 1993-913487	19930607
JP 326908	B2	20020325	JP 1994-501330	19930607
US 5643938	A	19970701	US 1994-08539	19941208
PRIORITY APPLN. INFO.:				
			GB 1992-12264	A 19920610
			GB 1992-15794	A 19920724
			WO 1993-JP762	W 19930607

OTHER SOURCE(S) : MARPAT 120:153722  
GI



AB Pyrazolopyridin compds. [I: R1=lower alkyl, R2=Q (R4= protected amino, R5=H), R3=H], all other groups are as usual. The pyrazolopyridin was administered to 10 monkeys. Monkeys were injected with 1.25% saline solution of phenylhydrazine.HCl on days 1 and 3 followed by oral administration of 3.2 mg 3-[2-(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]12-phenylpyrazolo[1,5-a]pyridine/kg twice a day for 5 days. The hematocrit value and erythropoietin level on day 5 was 24 and 272.2 resp., as compared to 19% and 250.8 mIU/mL for controls.

IT	131185-37-0P	RL: SPN (Synthetic preparation) PREP (Preparation) (preparation of, for treatment of anemia)
RN	131185-37-0	CAPLUS
CN	1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-	(CA INDEX NAME)

ACCESSION NUMBER: 1992:605214 CAPLUS  
DOCUMENT NUMBER: 117:205214  
TITLE: Preparation and use of adenosine antagonists for the prevention and treatment of pancreaticitis and ulcer  
INVENTOR(S): Shioikawa, Youichi; Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 45 pp.  
CODEN: EPFXKD  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 497258	A2	19920805	EP 1992-101308	19920128
EP 497258	A3	19931013		
EP 497258	B1	20020102		
US R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
US 5155114	A	19921013	US 1991-715460	19910614
CA 2060138	A1	19920710	CZ 1992-2060138	19920128
AT 211384	T	20020115	AT 1992-101308	19920128
JP 05058913	A	19930309	JP 1992-13506	19920129
PRIORITY APPLN. INFO.:			US 1991-648320	A 19910129
			US 1991-715460	A 19910614
			PH 1991-42760	A 19910709
			GB 1989-1423	A 19890123
			US 1990-466829	A2 19900118
			US 1990-626009	B2 19900118


OTHER SOURCE(S):                    MARPAT 117:205214

AB Adenosine antagonists are disclosed for preparation of medicaments for prevention and/or treatment of pancreatitis and/or ulcers. Preparation of a large number of pyrazolopyridine derivative adenosine antagonists is included.

The trans isomer of (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(carboxymethyl)piperidine (I) (preparation given) inhibited gastric ulcer induced by N6-cyclohexyladenosine by 99.8%. I also inhibited (as reflected by serum amylase level reduction) N6-cyclohexyladenosine-induced pancreatitis.

IT 131185-06-3P 131185-32-5P 141060-80-2P  
141060-81-3P 141060-82-4P 143881-06-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(preparation and reaction of, for adenosine antagonist preparation for  
 pancreatitis treatment)  
 RN 131185-06-3 CAPIUS  
 CN 3(2H)-Pyridazinone, 6-[2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX  
 NAME)






L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 131185-32-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-80-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (CA INDEX NAME)



RN 141060-81-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[4-(acetyloxy)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-82-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-hydroxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 143881-06-5 CAPLUS


L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 141060-40-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(dimethylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-41-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[3-(dimethylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141060-42-6 CAPLUS  
CN 1H-Indole-1,3(2H)-dione, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (CA INDEX NAME)



RN 141060-43-7 CAPLUS  
CN 1(6H)-Pyridazinepropanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 3(2H)-Pyridazinone, 2-(5-bromopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



IT 141060-38-0P 141060-39-1P 141060-40-4P  
141060-41-5P 141060-42-6P 141060-43-7P  
141060-44-8P 141060-45-9P 141060-46-0P  
141060-48-2P 141060-49-3P 141060-50-6P  
141060-51-7P 141060-52-8P 141060-53-9P  
141060-54-0P 141060-55-1P 141060-56-2P  
141060-57-3P 141060-58-4P 141060-59-5P  
141060-60-8P 141060-61-9P 141072-32-4P  
143881-04-3P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as adenosine antagonist for ulcer and pancreatitis treatment)

RN 141060-38-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(4-morpholinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 141060-39-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl


L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 141060-44-8 CAPLUS


CN 1(6H)-Pyridazinebutanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-45-9 CAPLUS  
CN 1(6H)-Pyridazinepentanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-46-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-48-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 141060-49-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-50-6 CAPLUS  
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]-, ethyl ester (CA INDEX NAME)



RN 141060-51-7 CAPLUS  
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (CA INDEX NAME)




RN 141060-52-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[[2-hydroxy-3-(1-naphthalenyl)propyl]amino]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




● 2 HCl


RN 141060-56-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-57-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 141060-58-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[3-(1H-tetrazol-5-yl)propyl]- (9CI) (CA INDEX NAME)



RN 141060-59-5 CAPLUS




RN 141060-53-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[[2-hydroxy-3-(1-naphthalenyl)propyl]amino]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-54-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[4-(dimethylamino)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 141060-55-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 141060-60-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-ethenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-61-9 CAPLUS  
CN 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 141072-32-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 143881-04-3 CAPLUS


L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3(2H)-Pyridazinone, 2-((2,3-dihydro-2-oxo-5-oxazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



IT 141060-62-0P 141060-63-1P 141060-64-2P  
 141060-65-3P 141060-66-4P 141060-67-5P  
 141060-68-6P 141060-69-7P 141060-70-0P  
 141060-71-1P 141060-72-2P 141060-73-3P  
 141060-74-4P 141060-75-5P 141060-76-6P  
 141060-77-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, for adenosine antagonist for ulcer and pancreatitis treatment)  
 RN 141060-62-0 CAPLUS  
 CN 1(6H)-Pyridazinehexanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-63-1 CAPLUS  
 CN 1(6H)-Pyridazineheptanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-64-2 CAPLUS  
 CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 141060-69-7 CAPLUS  
 CN 1(6H)-Pyridazineacetoneitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-70-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 141060-71-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[5-(1H-tetrazol-5-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 141060-72-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 141060-65-3 CAPLUS  
 CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-66-4 CAPLUS  
 CN 1(6H)-Pyridazineundecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-67-5 CAPLUS  
 CN 1(6H)-Pyridazineundecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-68-6 CAPLUS  
 CN 1(6H)-Pyridazinetridecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 141060-73-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(7-(1H-tetrazol-5-yl)heptyl)- (9CI) (CA INDEX NAME)




RN 141060-74-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(8-(1H-tetrazol-5-yl)octyl)- (9CI) (CA INDEX NAME)




RN 141060-75-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[9-(1H-tetrazol-5-yl)nonyl]- (9CI) (CA INDEX NAME)




RN 141060-76-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[10-(1H-tetrazol-5-yl)decyl]- (9CI) (CA INDEX NAME)




RN 141060-77-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[12-(1H-tetrazol-5-yl)dodecyl]- (9CI) (CA INDEX NAME)



IT 141060-83-5P 141060-84-6P 141060-85-7P  
141060-86-8P 141060-87-9P 141060-88-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, for adenosine antagonist preparation for ulcer and pancreatitis treatment)  
RN 141060-83-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(6-bromohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-84-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(7-bromoheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)





RN 141060-85-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(8-bromooctyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 88 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)  
CN 3(2H)-Pyridazinone, 2-[4-(dimethylamino)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 131185-37-0  
RL: BIOL (Biological study)  
(ulcer and pancreatitis inhibition by, adenosine antagonist in relation to)  
RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-86-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(9-bromononyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-87-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(10-bromodecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-88-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(12-bromododecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



IT 143881-05-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, in adenosine antagonist preparation for ulcer and pancreatitis treatment)  
RN 143881-05-4 CAPLUS

L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STM  
ACCESSION NUMBER: 1992:214520 CAPLUS  
DOCUMENT NUMBER: 116:214520  
TITLE: Preparation of oxopyridazinylpyrazolopyridines as adenosine antagonists  
INVENTOR(S): Shiokawa, Youichi; Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 44 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 467248	A2	19920122	EP 1991-111715	19910713
EP 467248	A3	19920311		
EP 467248	B1	19981028		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 9105376	A	19920429	ZA 1991-5376	19910710
AT 172731	T	19981115	AT 1991-111715	19910713
ES 2121760	T3	19981216	ES 1991-111715	19910713
US 5204346	A	19930420	US 1991-729688	19910715
AU 9180468	A	19920123	AU 1991-80468	19910716
AU 651353	B2	19940721		
JP 04253978	A	19920909	JP 1991-268125	19910716
JP 3123562	B2	20010115		
CA 2047283	A1	19920119	CA 1991-2047283	19910717
CA 2047283	C	20020702		
FI 9103446	A	19920119	FI 1991-3446	19910717
FI 96688	B	19960430		
FI 96688	C	19960812		
NO 9102805	A	19920120	NO 1991-2805	19910717
NO 178697	B	19960205		
NO 178697	C	19960515		
CN 1059143	A	19920304	CN 1991-105592	19910717
CN 1042730	B	19990331		
HU 58735	A2	19920330	HU 1991-2397	19910717
HU 218666	B	20001028		
IL 98872	A	19961205	IL 1991-98872	19910717
KR 219957	B1	19990901	KR 1991-12195	19910718
PRIORITY APPL. INFO.: GB 1990-15764			GB 1990-15764	A 19900718
OTHER SOURCE(S):				
GI				




L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. (I; R1 = aryl; R2 = aralkyl, heterocyclylalkyl, substituted alkyl, etc.) were prepared. Thus, 6-(2-phenylethynyl)-3-phenylsulfonylpyridazine (preparation given) was cyclocondensed with 1-aminopyridinium iodide and the product hydrolyzed to give I (R1 = Ph) (II; R2 = H) which was condensed with 4-(2-chloroethyl)morpholine to give II.HCl (R2 = 2-morpholinoethyl). II.HCl (R2 = CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>) gave 26.0% increase in renal blood flow in anesthetized beagle dogs at 0.32 mg/kg, i.v.


IT 131185-06-3P 131185-32-5P 141060-80-2P  
141060-81-3P 141060-82-4P 141060-83-5P  
141060-84-6P 141060-85-7P 141060-86-8P  
141060-87-9P 141060-88-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, in preparation of adenosine antagonists)  
RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-32-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-80-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (CA INDEX NAME)




L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 141060-86-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(9-bromononyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-87-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(10-bromodecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-88-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(12-bromododecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




IT 141060-38-0P 141060-39-1P 141060-40-4P  
141060-41-5P 141060-42-6P 141060-43-7P  
141060-44-8P 141060-45-9P 141060-46-0P  
141060-47-1P 141060-48-2P 141060-49-3P  
141060-50-6P 141060-51-7P 141060-52-8P  
141060-53-9P 141060-54-0P 141060-55-1P  
141060-56-2P 141060-57-3P 141060-58-4P  
141060-59-5P 141060-60-8P 141060-61-9P

L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 141060-81-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[4-(acetyloxy)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-82-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-hydroxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-83-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(6-bromohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-84-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(7-bromoheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-85-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(8-bromooctyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)

L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


141060-62-0P 141060-63-1P 141060-64-2P  
141060-65-3P 141060-66-4P 141060-67-5P  
141060-68-6P 141060-69-7P 141060-70-0P  
141060-71-1P 141060-72-2P 141060-73-3P  
141060-74-4P 141060-75-5P 141060-76-6P  
141060-77-7P 141072-32-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as adenosine antagonist)

RN 141060-38-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(4-morpholinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-39-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-40-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-(dimethylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-41-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[3-(dimethylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl


RN 141060-42-6 CAPLUS  
CN 1H-Isindole-1,3(2H)-dione, 2-[2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)ethyl]- (CA INDEX NAME)




RN 141060-43-7 CAPLUS  
CN 1(6H)-Pyridazinepropanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-49-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-50-6 CAPLUS  
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]-, ethyl ester (CA INDEX NAME)




RN 141060-51-7 CAPLUS  
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (CA INDEX NAME)




RN 141060-52-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


RN 141060-44-8 CAPLUS  
CN 1(6H)-Pyridazinebutanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-45-9 CAPLUS  
CN 1(6H)-Pyridazinebutanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-46-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-47-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(2-oxo-5-oxazolidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-48-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 141060-53-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141060-54-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[4-(dimethylamino)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141060-55-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
NAME)




● 2 HCl


RN 141060-56-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-57-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 141060-58-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[3-(1H-tetrazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




RN 141060-59-5 CAPLUS


L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN 1(6H)-Pyridazineheptanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-64-2 CAPLUS  
CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-65-3 CAPLUS  
CN 1(6H)-Pyridazineononanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-66-4 CAPLUS  
CN 1(6H)-Pyridazinedecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-67-5 CAPLUS  
CN 1(6H)-Pyridazineundecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[4-(1H-tetrazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 141060-60-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-ethenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 141060-61-9 CAPLUS  
CN 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (CA INDEX NAME)




RN 141060-62-0 CAPLUS  
CN 1(6H)-Pyridazinehexanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-63-1 CAPLUS


L4 ANSWER 89 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 141060-68-6 CAPLUS  
CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-69-7 CAPLUS  
CN 1(6H)-Pyridazineacetoneitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 141060-70-0 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 141060-71-1 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[5-(1H-tetrazol-5-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 141060-72-2 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)



RN 141060-73-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[7-(1H-tetrazol-5-yl)heptyl]- (9CI) (CA INDEX NAME)



RN 141060-74-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[8-(1H-tetrazol-5-yl)octyl]- (9CI) (CA INDEX NAME)




RN 141060-75-5 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[9-(1H-tetrazol-5-yl)nonyl]- (9CI) (CA INDEX NAME)


ACCESSION NUMBER: 1991:62080 CAPLUS  
DOCUMENT NUMBER: 114:62080  
TITLE: Preparation of 3-heterocyclyl-a-phenylpyrazolo[1,5-a]pyridines as adenosine antagonists  
INVENTOR(S): Shiokawa, Youichi; Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 86 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 379979	A1	19900801	EP 1990-101042	19900119
EP 379979	B1	19970319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				
ZA 9000200	A	19901031	ZA 1990-200	19900111
IL 93050	A	19950526	IL 1990-93050	19900114
US 4985444	A	19910115	US 1990-466929	19900118
FI 96205	B	19960215	FI 1990-307	19900119
FI 96205	C	19960527		
AT 150462	T	19970415	AT 1990-101042	19900119
ES 2098229	T3	19970501	ES 1990-101042	19800119
CA 2008263	A1	19900723	CA 1990-2008263	19900122
CA 2008263	C	20000314		
NO 9000306	A	19900724	NO 1990-306	19900122
NO 176356	B	19941212		
NO 176356	C	19950322		
JP 02243689	A	19900927	JP 1990-12995	19900122
JP 07094454	B	19951011		
HU 53368	A2	19901028	HU 1990-228	19900122
RU 2007403	C1	19940215	RU 1990-4742944	19900122
KR 159502	B1	19981201	KR 1990-690	19900122
AU 9048696	A	19900726	AU 1990-48696	19900123
AU 628913	B2	19920924		
CN 1044656	A	19900815	CN 1990-100900	19900123
CN 1031570	B	19960417		
JP 08081465	A	19960326	JP 1995-64422	19950323
			GB 1989-1423	A 19890123


PRIORITY APPLN. INFO.: CASREACT 114:62080; MARPAT 114:62080  
OTHER SOURCE(S): GI




II




RN 141060-76-6 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[10-(1H-tetrazol-5-yl)decyl]- (9CI) (CA INDEX NAME)



RN 141060-77-7 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[12-(1H-tetrazol-5-yl)dodecyl]- (9CI) (CA INDEX NAME)



RN 141072-32-4 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[4-pyridinylmethyl]- (CA INDEX NAME)




AB The title compds. [I; R1 = aryl; R2 = (substituted) unsatd. heterocyclyl], were prepared. Thus, 3-acetyl-2-phenylpyrazolo[1,5-a]pyridine and glyoxylic acid hydrate were stirred 205 h at 100° to give a product which was refluxed with N2H4 in aqueous NH3 to give

3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine. The latter was stirred 2 days with Br(CH2)3CO2Et and triton B in CHCl3 and the product was saponified to give title compound II. II had an ED100 of ~.31 mg/kg orally in rats for diuretic activity.

IT 131185-02-9P 131185-03-0P 131185-04-1P  
131185-05-2P 131185-06-3P 131185-07-4P  
131185-08-5P 131185-09-6P 131185-10-9P  
131185-11-0P 131185-12-1P 131185-13-2P  
131185-14-3P 131185-15-4P 131185-16-5P  
131185-17-6P 131185-18-7P 131185-19-8P  
131185-20-1P 131185-21-2P 131185-22-3P  
131185-23-4P 131185-24-5P 131185-25-6P  
131185-26-7P 131185-27-8P 131185-28-9P  
131185-29-0P 131185-30-3P 131185-31-4P  
131185-32-5P 131185-33-6P 131185-34-7P  
131185-35-8P 131185-36-9P 131185-37-0P  
131185-38-1P 131185-39-2P 131185-40-5P  
131185-41-6P 131185-42-7P 131185-43-8P  
131185-44-9P 131185-45-0P 131185-46-1P  
131185-47-2P 131185-48-3P 131185-49-4P  
131185-50-7P 131185-51-8P 131185-52-9P  
131185-53-0P 131185-54-1P 131185-55-2P  
131185-56-3P 131185-57-4P 131185-58-5P  
131185-59-6P 131185-60-9P 131185-61-0P  
131185-62-1P 131185-63-2P 131185-64-3P  
131185-65-4P 131185-66-5P 131185-67-6P  
131185-68-7P 131185-69-8P 131185-70-1P  
131185-71-2P 131185-72-3P 131185-73-4P  
131185-74-5P 131185-75-6P 131185-76-7P  
131185-77-8P 131754-91-1P


RI: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as adenosine antagonists)

RN 131185-02-9 CAPLUS  
CN 1(4H)-Pyridazinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 131185-03-0 CAPLUS  
CN 1(6H)-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)







RN 131185-04-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridazinyl)- (CA INDEX NAME)



RN 131185-05-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridinyl)- (CA INDEX NAME)




RN 131185-06-3 CAPLUS  
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-07-4 CAPLUS  
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)


RN 131185-11-0 CAPLUS  
CN 1(4H)-Pyridinecarboxylic acid, 3-acetyl-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 131185-12-1 CAPLUS  
CN 1(4H)-Pyridinecarboxylic acid, 3-cyano-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 131185-13-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3-methyl-4-pyridazinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-14-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(5-methyl-4-pyridazinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-15-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyrimidinyl)- (CA INDEX NAME)



RN 131185-08-5 CAPLUS  
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)





RN 131185-09-6 CAPLUS  
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




• Na


RN 131185-10-9 CAPLUS  
CN 1(4H)-Pyridazinecarboxylic acid, 3-chloro-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 131185-16-5 CAPLUS  
CN 2(1H)-Pyridinone, 5,6-dihydro-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-17-6 CAPLUS  
CN 2-Pyrimidinamine, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-18-7 CAPLUS  
CN 2(1H)-Pyridinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-19-8 CAPLUS  
CN 3(2H)-Pyridazinone, 4,5-dihydro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-20-1 CAPLUS  
CN 3H-Pyrazol-3-one, 1,2-dihydro-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)





RN 131185-21-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-methylimidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2-phenyl- (CA INDEX NAME)




RN 131185-22-3 CAPLUS  
CN 3-Pyridinecarbonitrile, 1,2-dihydro-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-23-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 131185-29-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)



RN 131185-30-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-31-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (CA INDEX NAME)




RN 131185-32-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


RN 131185-24-5 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(1-methyl-1H-pyrazol-4-yl)-2-phenyl- (CA INDEX NAME)




RN 131185-25-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(5-pyrimidinyl)- (CA INDEX NAME)




RN 131185-26-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-methyl-5-pyrimidinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-27-8 CAPLUS  
CN 2-Pyrimidinamine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-28-9 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




RN 131185-33-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(2-ethoxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-34-7 CAPLUS  
CN 1H-Pyrazole-1-propanoic acid, 5-hydroxy-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 131185-35-8 CAPLUS  
CN 1(4H)-Pyridazinepropanoic acid, 5,6-dihydro-2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 131185-36-9 CAPLUS  
CN 1(4H)-Pyridazinepropanoic acid, 5,6-dihydro-2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)



RN 131185-37-0 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)





RN 131185-38-1 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 131185-39-2 CAPLUS  
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (CA INDEX NAME)




● Na


RN 131185-45-0 CAPLUS  
CN 1H-Pyrazole-1-propanoic acid, 5-hydroxy-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 131185-46-1 CAPLUS  
CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-47-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3-chloro-4-pyridazinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-48-3 CAPLUS  
CN Ethanone, 1-[4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridinyl]- (CA INDEX NAME)

RN 131185-40-5 CAPLUS  
CN 1(6H)-Pyridazinepentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-41-6 CAPLUS  
CN 1(6H)-Pyridazinepentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




● Na


RN 131185-42-7 CAPLUS  
CN 3-Pyridinecarboxylic acid, 1,2-dihydro-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-43-8 CAPLUS  
CN 1(2H)-Pyridinepropanoic acid, 5,6-dihydro-2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-44-9 CAPLUS  
CN 1(4H)-Pyridazinepropanoic acid, 5,6-dihydro-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-49-4 CAPLUS  
CN 3-Pyridinecarbonitrile, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-50-7 CAPLUS  
CN 1(6H)-Pyridazinepropanamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-51-8 CAPLUS  
CN 1(6H)-Pyridazinepropanamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-52-9 CAPLUS  
CN Piperidine, 1-[1-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 131185-53-0 CAPLUS  
CN 2(1H)-Pyrimidinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)





RN 131185-54-1 CAPLUS  
CN 2(1H)-Pyrimidinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-55-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-chloro-4-pyridinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-56-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-chloro-4-pyrimidinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-62-1 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (CA INDEX NAME)



RN 131185-63-2 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-64-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3-methyl-4-pyridazinyl)-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 131185-65-4 CAPLUS  
CN 3-Pyridazineethanol, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-α-(trichloromethyl)- (CA INDEX NAME)


RN 131185-57-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(6-chloro-3-pyridazinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-58-5 CAPLUS  
CN 3-Pyridazinamine, N,N-dimethyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-59-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(3-methoxy-4-pyridazinyl)-2-phenyl- (CA INDEX NAME)



RN 131185-60-9 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-methoxy-4-pyridinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-61-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-methoxy-4-pyrimidinyl)-2-phenyl- (CA INDEX NAME)




RN 131185-66-5 CAPLUS  
CN 2-Propenoic acid, 3-[(4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 131185-67-6 CAPLUS  
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 131185-68-7 CAPLUS  
CN 1(2H)-Pyrimidinepropanoic acid, 2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)



L4 ANSWER 90 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 131185-69-8 CAPLUS

CN 1(2H)-Pyridinepropanoic acid, 2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 131185-70-1 CAPLUS

CN 1(2H)-Pyridinepropanoic acid, 3-carboxy-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, α-methyl ester (9CI) (CA INDEX NAME)




RN 131185-71-2 CAPLUS

CN 1(2H)-Pyridinepropanoic acid, 3-cyano-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)




RN 131185-72-3 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-73-4 CAPLUS

L4 ANSWER 90 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 131754-91-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-(3-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




L4 ANSWER 90 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 1(2H)-Pyridinepropanoic acid, 2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-74-5 CAPLUS

CN 1(2H)-Pyridinepropanoic acid, 3-carboxy-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 131185-75-6 CAPLUS

CN 1(2H)-Pyridinepropanoic acid, 3-cyano-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



RN 131185-76-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 1,2-dihydro-1-methyl-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (CA INDEX NAME)



RN 131185-77-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 91 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:95084 CAPLUS

DOCUMENT NUMBER: 110:95084

TITLE: Preparation of new nitrogen-bridged heterocycles. 18. Facile formations of 3-arylpyrazolo[1,5-a]pyridines and 1-arylindolizines

AUTHOR(S): Kakehi, Akikazu; Ito, Suketaka; Kinoshita, Naosumi; Abaka, Yukio

CORPORATE SOURCE: Fac. Eng., Shinshu Univ., Nagano, 380, Japan

SOURCE: Bulletin of the Chemical Society of Japan (1988), 61(6), 2055-61


CODEN: BCSJAB; ISSN: 0009-2673

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:95084

GI



AB The base treatment of [(benzylthio)methyleneamino]pyridinium I (X = N; R, R1 = H, Me; R2 = Ph, substituted Ph, R3 = SMe, Ph, OEt, NMe2) and [(benzylthio)vinyl]pyridinium bromides I (X = CR4; R, R1 = H, Me; R2 = Ph, substituted Ph, R3 = SMe, R4 = CO2Et, cyano, COPh), possessing an electron-withdrawing substituent such as a nitro or cyano group in the presence or absence of a dehydrogenating agent afforded 3-arylpyrazolo[1,5-a]pyridines II (X = N) and 1-arylindolizines II (X = CR4) resp. in moderate to good yields, while the reactions of the parent pyridinium salts and those having an electron-releasing group did not produce any significant products. The mode of the reaction, a ring contraction-desulfurization, is the same as that observed in related monocyclic species.

IT 119093-32-2P 119093-39-9P 119093-44-6P


119093-50-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 119093-32-2 CAPLUS


CN Benzonitrile, 2-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 119093-39-9 CAPLUS

CN Benzonitrile, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)


L4 ANSWER 91 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 119093-44-6 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(2-nitrophenyl)-2-phenyl- (CA INDEX NAME)



RN 119093-50-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 3-(4-nitrophenyl)-2-phenyl- (CA INDEX NAME)




L4 ANSWER 93 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1969:422062 CAPLUS  
DOCUMENT NUMBER: 71:22062  
ORIGINAL REFERENCE NO.: 71:4069a,4072a  
TITLE: A novel heterocyclic rearrangement. Extrusion of carbon dioxide from non-adjacent carbonyl groups  
AUTHOR(S): Rees, Charles W.; Yelland, M.  
CORPORATE SOURCE: Univ. Leicester, Leicester, UK  
SOURCE: Journal of the Chemical Society [Section] D: Chemical Communications (1969), (8), 377-8  
CODEN: CCJDAO; ISSN: 0577-6171  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI For diagram(s), see printed CA Issue.  
AB Oxidation of 4-substituted-3-phenyl-2-pyrazolin-5-ones with Pb(OAc)<sub>4</sub> in CH<sub>2</sub>Cl<sub>2</sub> containing tetraphenylcyclopentadienone (I) gave good yields of the Diels-Alder adducts (II). Thermolyses of I at 210°/1 mm. 16 hrs. caused extrusion of CO<sub>2</sub> and formation of 30-45% III. The proposed mechanism for this unusual rearrangement involved N-C bond fission (1st part of stepwise retro-Diels-Alder) to give a zwitterion, formation of a lactone produced by attack of the pyrazolone O at the cyclopentenone carbonyl group, and subsequent loss of CO<sub>2</sub> with formation of III. The thermolyses also produced 35-40% I, the stable product of the normal retro-Diels-Alder reaction.  
IT 22889-10-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 22889-10-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, hexaphenyl- (8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 92 OF 93 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1973:71992 CAPLUS  
DOCUMENT NUMBER: 78:71992  
ORIGINAL REFERENCE NO.: 78:11445a,11448a  
TITLE: Reactive intermediates. XXI. Thermal decarboxylation of 2,6-diazatricyclo[5.2.1.0<sup>2,6</sup>]deca-4,8-diene-3,10-diones to pyrazolo[1,5-a]pyridines  
AUTHOR(S): Rees, C. W.; Yelland, M.  
CORPORATE SOURCE: Chem. Dep., Univ. Leicester, Leicester, UK  
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1973), (3), 221-5  
CODEN: JCPRB4; ISSN: 0300-922X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 78:71992  
GI For diagram(s), see printed CA Issue.  
AB Oxidation of pyrazolin-5-ones (I; R = H, Ph, or CH<sub>2</sub>Ph) in the presence of tetracyclone gave the corresponding adducts (II), which on heating lost CO<sub>2</sub> and rearranged to the pyrazolo[1,5-a]pyridines (III).  
IT 22889-10-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 22889-10-7 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, hexaphenyl- (8CI, 9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 07:36:15 ON 28 NOV 2007)

FILE 'REGISTRY' ENTERED AT 07:36:29 ON 28 NOV 2007

L1 STRUCTURE UPLOADED  
L2 50 S L1  
L3 2354 S L1 FULL

FILE 'CAPLUS' ENTERED AT 07:36:53 ON 28 NOV 2007

L4 93 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

497.63

669.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-72.54

-72.54

STN INTERNATIONAL LOGOFF AT 07:46:44 ON 28 NOV 2007